

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Apr 2020 01:35:00 +0000
To: (b) (6)
Subject: RE: We Believe in You

(b) (6):

Many thanks for your e-mail. Stay well and safe.
Best regards,
Tony

From: (b) (6)
Sent: Thursday, April 9, 2020 8:07 PM
To: Fauci, Anthony (NIH/NIAID) [E]; (b) (6)
Subject: Re: We Believe in You

Tony,
I would only hope that one of your staff see my email and are prudent to know that this is being sent to him by one of his kin and passes it along to you.

Sincerely,

(b) (6)

On Thursday, April 9, 2020, 05:54:17 PM EDT, Fauci, Anthony (NIH/NIAID) [E]; (b) (6) wrote:

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 9 Apr 2020 21:24:50 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: COVID 19 Briefing Document and COVID Vaccine Overview
Attachments: Overview of COVID-19 Vaccine Development_April9.pdf, Briefing Document NIAID Involvement with Pharma in COVID19_April 9_with table.pdf

The email below is from Larry Corey.


Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Corey MD, Larry (b) (6) >
Sent: Thursday, April 9, 2020 3:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Cc: Mascola, John (NIH/VRC) [E] (b) (6) >; Erbeling, Emily (NIH/NIAID) [E] (b) (6) >; Dieffenbach, Carl (NIH/NIAID) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: COVID 19 Briefing Document and COVID Vaccine Overview

Tony,

We are sending you two documents relating to our strategy for COVID vaccine development . The





Larry

From: (b) (6)
Sent: Thu, 9 Apr 2020 17:18:14 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: INTERVIEW REQUEST with Dr Anthony Fauci - Radio-Canada News Program 24h/60min

Let us discuss

Begin forwarded message:

From: NATHALIE LEMIEUX <nathalie.lemieux@radio-canada.ca>
Date: April 9, 2020 at 5:02:20 PM EDT
To: "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: INTERVIEW REQUEST with Dr Anthony Fauci - Radio-Canada News Program 24h/60min

Hello

My name is Nathalie Lemieux and I am a research journalist for 24h in 60min, an information and public affairs program hosted by Anne-Marie Dussault and broadcast on the CBC/Radio-Canada's French national news network. <https://ici.radio-canada.ca/tele/24-60/site> We are based in Montréal and the broadcast is aired across Canada weekdays on prime time (between 7pm and 8PM ET)

As we are also living through this Covid-19 pandemia, we would be delighted to do an interview with Dr Anthony Fauci

*Of course, host Anne-Marie Dussault can do the interview in English

When: subject to Dr Fauci's availability ...

How: Skype or Facetime (in respect of containment obligations)

How long: 7-8 min

Could this proposal be of interest to Dr Fauci?

Thank you for letting me know the possibilities... we are aware of Dr Fauci's tight

schedule

You can reach me at any time via this email nathalie.lemieux@radio-canada.ca or on my cell phone: [REDACTED] (b) (6)

--

Nathalie Lemieux

Journaliste à la recherche

Émission 24 heures en 60 minutes

RDI/Radio-Canada

Cell: [REDACTED] (b) (6)



From: (b) (6)
Sent: Thu, 9 Apr 2020 16:51:32 -0400
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 serosurvey study launch

Looks fine! Thanks

On Apr 9, 2020, at 1:48 PM, Stover, Kathy (NIH/NIAID) [E]

(b) (6) wrote:

Hi Dr. Fauci,

Please find attached for your review a draft press release announcing the launch of Dr. Memoli's serostudy to detect previously undiagnosed coronavirus infections. Your draft quote is as follows:

"This study will give us a clearer picture of the true magnitude of the COVID-19 pandemic in the United States by telling us how many people in different communities have been infected without knowing it, because they had a very mild, undocumented illness or did not access testing while they were sick," said Anthony S. Fauci, M.D., NIAID director. "These crucial data will help us measure the impact of our public health efforts now and guide our COVID-19 response moving forward."

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b) (6)
E-mail: (b) (6)

NIAID Media Line: (301) 402-1663

<SARSCoV2 serosurvey Release FOG cleared.docx>

<SARSCoV2 serosurvey NSWB Clearance Form.doc>

<SARS_COV2_SERUM_SAMPLING_Clean Changes_Copy_4.2.2020.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 9 Apr 2020 16:40:28 +0000
To: [REDACTED] (b) (6) [E]
Subject: FW: New Yorker: Fauci Urges Trump to Attack the Coronavirus as if It Were an Inspector General

This Borowitz guy is something else....

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Thursday, April 9, 2020 12:33 PM
To: NIAID COG CORE <COG CORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: New Yorker: Fauci Urges Trump to Attack the Coronavirus as if It Were an Inspector General

Satire from The Borowitz Report

Fauci Urges Trump to Attack the Coronavirus as if It Were an Inspector General



By Andy Borowitz
April 8, 2020



Photograph by Lo Scalzo / Bloomberg / Getty

WASHINGTON (The Borowitz Report)—In what he described as a “potentially major breakthrough,” Dr. Anthony Fauci has convinced [Donald Trump](#) to attack [COVID-19](#) as if it were an inspector general. Fauci, who has been frustrated in his efforts to get through to Trump, compared the global pandemic to an inspector general while in a closed-door meeting with the President on Wednesday.

“What do you hate more than anything, Mr. President?” Fauci asked.

“Jim Acosta,” Trump immediately replied.

“O.K., fine. But, besides Jim Acosta,” Fauci said, “it would be an inspector general, right?”

“You’re right, Tony,” Trump agreed. “I hate those losers.”

“Well, think of *COVID-19* as the worst inspector general in the world,” Fauci continued. “It’s overseeing everything you do and making you follow the law. It’s keeping you from spending taxpayer money on anything you want. You wouldn’t stand for that, would you?”

Reportedly, Trump appeared shaken by Fauci’s analogy. “Damn it, Tony, when you put it that way, we’ve got to do something about *COVID-19*,” he said.

Speaking to reporters, Fauci said that he was “cautiously optimistic” that his inspector-general analogy would finally spur Trump to action, but added, “Jared could still screw this up.”

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 9 Apr 2020 10:17:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Mediaset, Italian television broadcast, interview request

FYI

From: Alessandro Matarante <alessandro.matarante@outlook.it>
Sent: Thursday, April 9, 2020 5:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>
Subject: Mediaset, Italian television broadcast, interview request

Hello Dr. Anthony Fauci,

I'm Alessandro Matarante, an Italian reporter, currently working for Mediaset, Italy's most important television broadcast. Specifically, I work for Quarta Repubblica, a program aired every Monday in prime-time, led by reporter Nicola Porro.

I'm writing this e-mail because it would be a pleasure and an honor for us to interview you about the coronavirus emergency and the way the United States are facing it.

Clearly, we are available to consider any kind of day and hour to make the interview, and so we are to consider together the contents of the interview.

Hoping for a positive answer,
I wish you a pleasant day.

Alessandro - [REDACTED] (b) (6)

https://www.mediasetplay.mediaset.it/programmi-tv/quartarepubblica_b100002038

From: (b) (6)
Sent: Wed, 8 Apr 2020 17:17:42 -0400
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: Re: Research Day organized by the Italian Embassy

Paolo:

I am very, very sorry, but I just cannot do this right now. I am swamped and my time is not my own. I hope that they understand.

Best,
Tony

On Apr 8, 2020, at 4:00 PM, Lusso, Paolo (NIH/NIAID) [E]
(b) (6) wrote:

Dear Tony:

I am sorry to bother you with another request during this period. The Italian Embassy is organizing its yearly Research Day (Giornata della Ricerca) that this year will be held strictly online (via Zoom or other e-meeting tool) and centered entirely on the Coronavirus pandemic.

The Italian Ambassador, Mr. Varricchio, would be delighted if you accept to be his guest of honor at the event and asked me to informally enquire with you, before sending an official invitation, if there is any chance you could participate. He understands how crazy your schedule is during this crisis. They would like you to deliver a 30 min lecture on a theme of your choice, preferably related to the state of the art of the pandemic management. The tentative date for the event is between April 20 and April 30, but they are waiting to finalize the date based on your preference, if you are able to accept (even in early May).

Please, let me know if you can accommodate this additional engagement. You will make them very very happy!

All the best,

Paolo

Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of Immunoregulation
Bldg. 10, Rm. 6A11
NIAID, NIH
Bethesda, MD 20892

Phone: [REDACTED] (b) (6) (personal)

[REDACTED] (b) (6) (lab)

Fax: (301) 480-5291

E-mail [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Wed, 8 Apr 2020 16:58:55 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: request of interview by Giuseppe Sarcina, corriere della Sera

Let us discuss

Begin forwarded message:

From: Sarcina Giuseppe <gsarcina@res.it>
Date: April 8, 2020 at 4:16:32 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: R: request of interview by Giuseppe Sarcina, corriere della Sera

Dear Doc. Fauci,
this is Giuseppe Sarcina, the us correspondent of Corriere della Sera, the main italian newspaper.
I understood that you are looking at the italian case with great attention.
I wonder if you can grant me a short interview.
I have sent an email march 21. But then I saw that you spoke with an other italian newspaper. So I would like to have a chance to have your voice for our Readers as well. Corriere della Sera is a newspaper based in Milano, Lombardy, The region most affected by the coronavirus.
Thank you
Warm Regards
Giuseppe Sarcina
Washington dc

(b) (6)>
Oggetto: request of interview by Giuseppe Sarcina, corriere della Sera

Dear Doc. Fauci,
this is Giuseppe Sarcina, the us correspondent of Corriere della Sera, the main italian newspaper.
I understood that you are looking at the italian case with great attention.
I wonder if you can grant me a short interview.
That would be really helpful for our readers

Thank you
Warm Regards
Giuseppe Sarcina
Washington dc

From: (b) (6)
Sent: Wed, 8 Apr 2020 16:57:55 -0400
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: Global Health Leaders Call, Thursday, 8 April at 14:30 CET
Attachments: image001.png, ATT00001.htm, COVID19 Strategy Update V3.2.docx, ATT00002.htm

Please print out for tomorrow. Thanks

Begin forwarded message:

From: "KABIR, Sophia" (b) (6) >
Date: April 8, 2020 at 4:21:00 PM EDT
To: SHOC <shoc@who.int>, Office of the Director-General <DGOoffice@who.int>, "Redfield, Robert R. (CDC/OD)" (b) (6)
(b) (6)
>, David
Heymann <(b) (6)>, "Felicity Harvey" (b) (6)
(b) (6) "Chris.Elias" (b) (6)
>, "J.Farrar" <(b) (6)>
(b) (6)
"Fauci, Anthony" (b) (6)
(NIH/NIAID) [E]"
(b) (6)
"GREIN, Thomas" (b) (6), "COX, Paul Michael" (b) (6)
"SCHWARTLANDER, Bernhard F." (b) (6) >, "MINHAS, Raman" (b) (6)
"Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >, "MAHJOUR, Jaouad" (b) (6) "FALL, Ibrahima Soce" (b) (6) >, "Thomas R. Frieden" (b) (6)
Lynn Banks <(b) (6)>, President | Resolve to Save Lives <president@resolvetosavelives.org>, (b) (6)
(b) (6) >
"AL-SHORBAJI, Farah" (b) (6)
(b) (6) Robynn Leidig (b) (6)
"DRURY, Patrick Anthony" (b) (6) >, "Dr VAN KERKHOVE, Maria" (b) (6)
(b) (6)

(b) (6) >, "POOLE, Marcia" (b) (6) "GRAAFF, Peter Jan"
(b) (6), Tarik Mohammed
(b) (6), Carlos
Navarro Colorado (b) (6)
, Ryan Morhard < (b) (6),
"BRIAND, Sylvie" (b) (6), "MORGAN, Oliver" (b) (6) >,
"Harries, Jenny" < (b) (6), "Awwad, David (NIH/NIAD)
[C]" (b) (6) >, "SIMONSON, Stewart" (b) (6),
"SINGER, Peter Alexander" (b) (6) >, "Jayatunga, Wikum"
(b) (6)
"Julie.HALL" < (b) (6) >, Amelie
RIOUX (b) (6)
"SHIN, Young-Soo" (b) (6) >,
(b) (6) >, Feng Ding
(b) (6)
<
"SMITH, Ian Michael"
(b) (6) >, "AYLWARD, Raymond Bruce J." (b) (6) >,
(b) (6)

Cc: SHOC <shoc@who.int>, Office of the Director-General <DGOffice@who.int>,
"SCHWARTLANDER, Bernhard F." (b) (6) >, "MAHJOUR,
Jaouad" (b) (6), "FALL, Ibrahima Soce" (b) (6) >, "GREIN,
Thomas" (b) (6) >, "MINHAS, Raman" (b) (6) >, "COX, Paul
Michael" (b) (6) >, "AL-SHORBAJI, Farah" (b) (6) >,
"POOLE, Marcia" < (b) (6) >, "DRURY, Patrick Anthony"
(b) (6) >, "GRAAFF, Peter Jan" (b) (6) >, "Dr VAN
KERKHOVE, Maria" (b) (6) >, "FARES, Christine Youssef"
(b) (6)

Subject: Global Health Leaders Call, Thursday, 8 April at 14:30 CET

Dear colleagues,

On behalf of Mike Ryan, allow me to share with you the draft COVID-19 Strategy Update, which will be subject of discussion at tomorrow's Global Health Leaders Call at 14.30 CET.

The epidemiological update and analysis, as well as the **Zoom connection** will be shared tomorrow morning.

Please find below, the key questions for your consideration and input.

1. What is your view on the latest epidemiology, virus transmission and severity in affected countries ?
2. What are the emerging issues/challenges that you see as important ?
3. What should be the priorities for the 1-2 weeks?
4. Any other issues you see as important?

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: **+41 22 79 15 533**

Kind regards,

Sophia

Sophia Kabir

Executive Officer

Office of the Executive Director

WHO Health Emergencies Programme (WHE)

Tel. (b) (6)

Mobile (b) (6)

Website: [WHO in emergencies](#) | [WHO Facebook](#) | [WHO Twitter](#)



World Health
Organization

HEALTH
EMERGENCIES
programme

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 17:28:01 +0000
To: Awwad, David (NIH/NIAID) [C]
Subject: FW: NIAID Information RE: Update Your PIV Card (HHS ID Badge) Certificates Before They Expire

Do I need to do anything?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: afauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: NIAID News and Information (NIH/NIAID) <niaidnewsinfo@niaid.nih.gov>
Sent: Wednesday, April 8, 2020 10:18 AM
To: NIAID Announcements <NIAID-announce@niaid.nih.gov>
Subject: NIAID Information RE: Update Your PIV Card (HHS ID Badge) Certificates Before They Expire

(b) (2)

-----Original Message-----

From: ORS Information Line <orsinfo@ors.od.nih.gov>
Sent: Tuesday, April 7, 2020 6:23 PM

To: NIH-STAFF@LIST.NIH.GOV

Subject: Update Your PIV Card (HHS ID Badge) Certificates Before They Expire



If you need help, please contact the NIH IT Service Desk: <http://itservicedesk.nih.gov/>
301-496-4357 (HELP), 301-496-8294 (TTY), or 1-866-319-4357 (HELP)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 17:25:25 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Doepel, Laurie (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: PR HHS Treatment Guidelines for COVID-19

We should include in the statement something about [REDACTED] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (5) >
Sent: Wednesday, April 8, 2020 12:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] [REDACTED] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6); Doepel, Laurie (NIH/NIAID) [E] [REDACTED] (b) (6); Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: ASF: PR HHS Treatment Guidelines for COVID-19

This is a press release that we (Laurie) drafted for HHS to announce the HHS treatment guidelines. Cliff has reviewed. I know how slammed you are. In the interest of time, I would like to move this to Bill Hall now, with the understanding that we can catch up with any changes you might have before the release is actually issued.

FYI, the release includes a quote for you as follows:

[REDACTED] (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 16:59:29 +0000
To: Barillas, Carolina (NIH/NIAID) [E]
Cc: Holland, Steven (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: Article - BCG protection from COVID-19 mortality

Thanks, Carolina.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barillas, Carolina (NIH/NIAID) [E] <(b) (6)>
Sent: Wednesday, April 8, 2020 12:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] <(b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] <(b) (6)>
Subject: Article - BCG protection from COVID-19 mortality

Hello everyone,

I found this article that comes to a similar conclusion regarding the protective role of universal BCG vaccination on COVID-19 mortality. I will be working with an epidemiologist from Virginia Tech to see if we can provide stronger quantitative analysis and modelling.
All the best,

Carolina

Carolina Barillas Mury, M.D., Ph.D.
Chief, Mosquito Immunity and Vector Competence Section
Laboratory of Malaria and Vector Research
National Institutes of Health
12735 Twinbrook Parkway, Room 2E-20C

Rockville, MD 20852

Phone: [REDACTED] (b) (6) Fax: (301) 480 0930

E-mail: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 15:09:38 +0000
To: [REDACTED] (b) (6)
Subject: FW: Google Alert - Fauci AND Tony OR Anthony

Click on the "Cuomo Crush" and "Fauci Fever" link below. It will blow your mind. Our society is really totally nuts.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Google Alerts <googlealerts-noreply@google.com>
Sent: Tuesday, April 7, 2020 11:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Google Alert - Fauci AND Tony OR Anthony

Google Alerts

Fauci AND Tony OR Anthony

As-it-happens update - April 8, 2020

NEWS

[Dr. Anthony Fauci, Trump address Iowa's lack of shelter-in-place](#)

Little Village

Speaking at President Trump's press conference late Monday afternoon, Dr. **Anthony Fauci** mentioned Iowa, and a clip of his comments was quickly ...



[Plus as relevant](#)

[Dr. Fauci: 'We need to put our foot on the accelerator' to see an end to COVID-19 pandemic](#)

fox4kc.com

WASHINGTON — Even though he says the worst is yet to come, Dr. **Anthony Fauci**, the nation's top infectious-disease expert, has seen signs of ...



[Flag as irrelevant](#)

[Fauci: African-American Community at Higher Risk for Coronavirus Complications](#)

NBC4 Washington

Dr. **Anthony Fauci**, director of the NIAID, spoke on Tuesday about the impact the coronavirus pandemic is having on the ... [Read More ...](#)



[Flag as irrelevant](#)

[John Calipari Confirms Bill Clinton, Mark Cuban, and Dr. Fauci as Guests on 'Coffee With Cal'](#)

kentuckysportsradio.com

Anthony Fauci. Every Monday for the next 25 weeks, Calipari's show will feature positive messaging and conversation with high-profile guests from the ...



[Flag as irrelevant](#)

['Cuomo Crush' and 'Fauci Fever' — Sexualization Of These Men Is a Real Thing on The Internet](#)

Talent Recap

The coronavirus pandemic has led brothers Andrew and Chris Cuomo and Dr.

Anthony Fauci to the forefront COVID news and updates, but it also ...



[Flag as irrelevant](#)



[Before the White House, Trump called NIH 'terrible,' questioned vaccines](#)

KPQ

President Donald Trump speaks to the press while Director of the National Institute of Allergy and Infectious Diseases **Anthony Fauci** speaks during a ...



[Flag as irrelevant](#)

You have received this email because you have subscribed to **Google Alerts**.

[Unsubscribe](#)

 [Receive this alert as RSS feed](#)

[Send Feedback](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 13:23:07 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: On the record

Yes. Please point him to what I said yesterday.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, April 8, 2020 9:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: On the record

Pls see below....Bob Franken...

-----Original Message-----

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, April 8, 2020 9:03 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6) Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: RE: On the record

I think he probably knows Bob Franken personally so I'm wondering if you might want to flag this for him, as he might decide it warrants a personal response.

Otherwise, he did speak about health disparities at yesterday's WH press conference, and we could certainly point Franken to those comments and then also direct him to NIMHD. (b) (5)
(b) (5)

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, April 8, 2020 8:56 AM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6) Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Cc: NIAID OCGR NSWB <NIAIDOCGRNSWB@mail.nih.gov>
Subject: FW: On the record

Defer to you to decide on this

-----Original Message-----

From: Bob Franken (b) (6) >

Sent: Wednesday, April 8, 2020 5:17 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Subject: On the record

Tony:

For my syndicated column, I want to do a piece on the racial aspect of coronavirus. I'm not seeing any breakdown of deaths in the poorer areas as opposed to the more prosperous ones.

Isn't that the telling statistic here that the economically less well off live in areas where medical services are inadequate and as a result they have more underlying conditions that make them more vulnerable? Isn't it relevant that people of color are predominantly among the poorer in our country for a variety of reasons?

I will appreciate your comments, particularly since you have so little to do these days.

Warmest regards,

Bob

Bob Franken

www.bobfranken.tv

From: (b) (6)
Sent: Wed, 8 Apr 2020 07:18:27 -0400
To: (b) (6)
Subject: Re: last questions, i promise

In first response, I meant to say "I always qualified the statement....." .not "I almost qualified the statement..."

On Apr 8, 2020, at 7:04 AM, Michael Specter (b) (6) >wrote:

Thank you. Will do all this and take out (b) (6)

On Wed, Apr 8, 2020 at 03:59 Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>wrote:

Michael:

See comments below in red.

Thanks,

Tony

From: Michael Specter <(b) (6)>
Sent: Wednesday, April 8, 2020 1:25 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: last questions, i promise

Hi. Mostly these are two second yes or no answers - though I need to understand the b cell issue better.

Thank you for all this. Hang in there:

L.)

Fauci has at times struggled to compel politicians and businesses to attack the problems that he considers most worrisome. Over the years, he has become especially concerned about the possible impact of a lethal strain of influenza." True, but I almost qualified the

statement and said it most likely would be influenza, but I was concerned with any type of novel respiratory virus that efficiently spread from human to human and that had a high degree of morbidity and mortality

2.) Dyker Heights versus Bensonhurst:

-
- What do we say about where he grew up.? He always says Bensonhurst. The apartment was technically in Dyker Heights, though the neighborhood lines shift. And I never see him mention moving neighborhoods. Did he move? Yes. I moved. I was born at [REDACTED] (b)(6) in the middle of the Bensonhurst section of Brooklyn. When I was 9 years old my father opened a Pharmacy on 8302-13th Avenue at the outer edge of the Dyker Heights Section of Brooklyn (only We moved into an apartment over the pharmacy.
-

3.) [the question below is the meaning of hyperactive. Does it mean producing too many B cells or that they were too active, as in working too hard, producing too many antibodies??] Not necessarily too many B cells. It means that the B cells that are there, are aberrantly turned on

He had been investigating B-cells, which are involved in the production of antibodies. In 1983—before H.I.V. was even known by that name—his lab became the first to report that B-cells became hyperactive in patients with AIDS. The virus was somehow leading its hosts to overproduce a defense that normally would keep them healthy. Fauci had identified one of the crucial features of AIDS. “We made that observation without having any idea of what we were dealing with,” he said. “I think that speaks for sound scientific and clinical observation.” The politics of seeking a cure, though, would be far harder to manage.

- 4.). This I asked before you could not speak to me but we can take me out of it. Or do whatever you like: I asked Fauci if he thought that novel coronavirus would force a change in attitude among political leaders and funding agencies. [REDACTED] (b)(6)
[REDACTED] (b)(6)
-

5.). This you have said in more than one place. People kind of became alarmed when you were absent so just want to be sure you don't mind it in here: No problem.

Fauci said that there was nothing meaningful about his absence from the Mar.23 White House briefing, “I was tied up in a task force meeting, and we were trying to work out some difficult policies and the topic of the briefing that day was more related to other members of the Task Force. He also said, “I have no trouble with the President. When I talk to him, he listens.”

Michael Specter
Staff Writer
The New Yorker

Adjunct Professor of Bioengineering

Stanford University

(b) (6)

Phone: (Work, Cell, SMS) + (b) (6)

--

Michael Specter
Staff Writer
The New Yorker
Adjunct Professor of Bioengineering
Stanford University

(b) (6)

Phone: (Work, Cell, SMS) (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 10:42:24 +0000
To: Perez-Stable, Eliseo (NIH/NIMHD) [E]
Subject: RE: WH Briefing

Thanks, Eliseo. Stay safe and well.
Best,
Tony

From: Perez-Stable, Eliseo (NIH/NIMHD) [E] (b) (6) >
Sent: Tuesday, April 7, 2020 11:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: WH Briefing

Hey Tony, you are the man! Best, Eliseo

From: Natasha Williams (b) (6)
Date: Tuesday, April 7, 2020 at 8:42 PM
To: Eliseo Perez Stable (b) (6) >, Courtney Aklin
(b) (6) >
Subject: WH Briefing

Hello Eliseo and Courtney,

During the White House briefing on COVID-19 this evening, there was a discussion on the disproportionate impact of COVID-19 on African Americans, health disparities and data collection. Please see CSPAN Clips below I cued up.

<https://www.c-span.org/video/?c4866877/user-clip-covid-19-african-american-community>

<https://www.c-span.org/video/?c4866892/user-clip-dr-fauci-health-disparities-african-american-community>

<https://www.c-span.org/video/?c4866897/user-clip-data-collection-question-african-american-community>

I know we are not commenting but I would like to recommend that we have some talking points prepared and on hold in case we receive congressional inquiries. These topics are also receiving coverage on the networks.

Thank you,
Natasha

Natasha H. Williams, PhD, JD, LLM, MPH
Legislative Liaison

National Institute on Minority Health and Health Disparities
National Institutes of Health
Bethesda, MD 20892

Email: [REDACTED] (b) (6)

Phone: [REDACTED] (b) (6) | www.nimhd.nih.gov

Connect with us: [Twitter](#) | [Facebook](#) | [YouTube](#) | [Email Updates](#)

NIMHD
National Institute on Minority Health and Health Disparities



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 03:06:30 +0000
To: Grogan, Joseph J. EOP/WHO
Cc: Bonner, Maria K. EOP/WHO; Campana, Alexandra D.
EOP/WHO; (b) (6); Barasch, Kimberly (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [EXTERNAL] RE: Good news

Joe:

I would be happy to speak with him. However, it would have to wait until Thursday since tomorrow is impossible. I believe that we can work this out. Perhaps we can arrange for a call between me, the CEO and some knowledgeable people in my program.

Best regards,
Tony

From: Grogan, Joseph J. EOP/WHO (b) (6) >
Sent: Tuesday, April 7, 2020 10:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Bonner, Maria K. EOP/WHO (b) (6) >; Campana, Alexandra D. EOP/WHO (b) (6) >
Subject: Fwd: [EXTERNAL] RE: Good news

Dr., I would never abuse your personal email, but since the ceo of Lilly wants to speak with you, I thought I would share this request. Just let me know how to respond (b) (6)

Sent from my iPhone

Begin forwarded message:

From: Shawn O'Neil (b) (6)
Date: April 7, 2020 at 10:07:37 PM EDT
To: "Grogan, Joseph J. EOP/WHO" (b) (6) >, "Bonner, Maria K. EOP/WHO" (b) (6)
Subject: [EXTERNAL] RE: Good news

You bet.

Joe – Have an enormous request – for help or counsel.

(b) (6)


My CEO, Dave Ricks, would like to speak with Dr. Fauci in this regard (given his role at the Institute). I know that is a tall order – but underscores the importance.

I did reach out to Dr. Fauci's Chief but received an automated reply indicated he was behind in email – any thoughts in the regard greatly appreciated....

Best, Shawn

=====

Shawn O'Neail
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) (office) | (b) (6) (mobile)
(b) (6) | >www.lilly.com<



CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Grogan, Joseph J. EOP/WHO <(b) (6)>
Sent: Tuesday, April 7, 2020 9:31 AM
To: Shawn O'Neail (b) (6); Bonner, Maria K. EOP/WHO (b) (6)
Subject: [EXTERNAL] RE: Good news

EXTERNAL EMAIL: Use caution before replying, clicking links, and opening attachments.

This is great. Thank you for sharing and everything you are doing. Joe

From: Shawn O'Neail (b) (6) >
Sent: Tuesday, April 7, 2020 9:26 AM
To: Grogan, Joseph J. EOP/WHO <(b) (6)>; Bonner, Maria K. EOP/WHO (b) (6) >
Subject: [EXTERNAL] Good news

Hi Joe and Maria

I want to share an important update about Lilly's efforts to address insulin affordability. In response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance - and those without insurance - to fill their monthly prescription of Lilly insulin for \$35. The program is effective today and

covers most Lilly insulins. Details and more information can be found in the press release here attached.


Lilly has introduced several solutions in recent years to help meet the individual financial circumstances of people living with diabetes that are still in effect during the COVID-19 crisis, including:

- The Lilly Diabetes Solution Center, through which representatives can direct people to the \$35 savings card, as well as affordability options that may reduce their out-of-pocket costs further – such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.
- Three non-branded versions of our insulin options with list prices 50 percent lower than the branded versions.
- In January, the company announced plans to donate at least 200,000 KwikPens® to relief agencies over the next three years.

Hope all is well with you...

Shawn

Shawn O'Neil
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) office | (b) (6) (mobile)
(b) (6) | >>www.lilly.com<<



CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 02:41:56 +0000
To: (b) (6)
Subject: FW: [EXTERNAL] RE: Good news

Cliff:

Let us discuss this. How do you think that I should respond?
Thanks,
Tony

From: Grogan, Joseph J. EOP/WHO (b) (6)
Sent: Tuesday, April 7, 2020 10:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Bonner, Maria K. EOP/WHO (b) (6); Campana, Alexandra D. EOP/WHO (b) (6)
Subject: Fwd: [EXTERNAL] RE: Good news

Dr., I would never abuse your personal email, but since the ceo of Lilly wants to speak with you, I thought I would share this request. Just let me know how to respond, (b) (6)

Sent from my iPhone

Begin forwarded message:

From: Shawn O'Neil (b) (6)
Date: April 7, 2020 at 10:07:37 PM EDT
To: "Grogan, Joseph J. EOP/WHO" <(b) (6)>, "Bonner, Maria K. EOP/WHO" (b) (6)
Subject: [EXTERNAL] RE: Good news

You bet,

Joe – Have an enormous request – for help or counsel.



My CEO, Dave Ricks, would like to speak with Dr. Fauci in this regard (given his role at the Institute). I know that is a tall order – but underscores the importance.

I did reach out to Dr. Fauci's Chief but received an automated reply indicated he was behind in email – any thoughts in the regard greatly appreciated....

Best, Shawn

Shawn O'Neil
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) (office) | (b) (6) (mobile)
(b) (6) | >www.lilly.com<



CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Grogan, Joseph J. EOP/WHO (b) (6)>
Sent: Tuesday, April 7, 2020 9:31 AM
To: Shawn O'Neil (b) (6) Bonner, Maria K. EOP/WHO
(b) (6)>
Subject: [EXTERNAL] RE: Good news

EXTERNAL EMAIL: Use caution before replying, clicking links, and opening attachments.

This is great. Thank you for sharing and everything you are doing. Joe

From: Shawn O'Neil (b) (6)
Sent: Tuesday, April 7, 2020 9:26 AM
To: Grogan, Joseph J. EOP/WHO (b) (6) Bonner, Maria K.
EOP/WHO (b) (6)>
Subject: [EXTERNAL] Good news

Hi Joe and Maria

I want to share an important update about Lilly's efforts to address insulin affordability. In response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance - and those without insurance - to fill their monthly prescription of Lilly insulin for \$35. The program is effective today and covers most Lilly insulins. Details and more information can be found in the press release here attached.

Lilly has introduced several solutions in recent years to help meet the individual financial circumstances of people living with diabetes that are still in effect during the COVID-19 crisis, including:

- The Lilly Diabetes Solution Center, through which representatives can direct people to the \$35 savings card, as well as affordability options that may reduce their out-of-pocket costs further – such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.
- Three non-branded versions of our insulin options with list prices 50 percent lower than the branded versions.
- In January, the company announced plans to donate at least 200,000 KwikPens® to relief agencies over the next three years.

Hope all is well with you....

Shawn

Shawn O'Neil
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) (office) | (b) (6) (mobile)
(b) (6) | >>www.lilly.com<<

The Lilly logo is written in a cursive, script font.

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 22:58:33 +0000
To: Chris Joffe;Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Supporting Schools In Covid-19

Due to the high demand on Dr. Fauci's time during the current outbreak – we must decline your request at this time. Thank you for your understanding.

Best,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health

(b) (6) (office)

(b) (6) (cell)

From: Chris Joffe <Chris@joffeemergencyservices.com>
Sent: Tuesday, April 7, 2020 6:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Supporting Schools In Covid-19

Dr. Fauci -

I'm a safety/security consultant to independent and charter schools. I run a firm supporting ~1,000 of them. What, if anything, would you want them to know? **I'm wondering if there's any chance in the world you'd be willing to join us and a few hundred schools for a 15 - 30-minute webinar one day next week?**

Specifically, schools are looking for information/perspective as it relates to what to expect as we return to a new normal and the like. Beyond that, they've begun to ask questions such as what we can be thinking about for this short period of time between the return to school and the development of a vaccine. What would best practice look like for us to educate, but maintain social distance? I believe we can manage a lot of the operationalizing but would be immensely grateful for some high-level guidance to follow.

I recognize how incredibly busy this time is for you and would be so incredibly grateful for any time you might be willing to spare for this audience.

With immense gratitude,

Chris Joffe

--

Chris Joffe
CEO | Joffe Emergency Services
HQ | Santa Monica, CA
Twitter: [@joffechris](https://twitter.com/joffechris)

(b) (6)

Executive Assistant

E: (b) (6)

P: (b) (6)

*

From: [REDACTED] (b) (6)
Sent: Tue, 7 Apr 2020 13:12:39 -0400
To: Lane, Cliff (NIH/NIAID) [E]
Subject: Fwd: [REDACTED] (b) (4)
[REDACTED]
Attachments: [REDACTED] (b) (4)
[REDACTED]

Here it is

Begin forwarded message:

From: "Gelfand, Jeffrey A.,M.D." [REDACTED] (b) (6)
Date: April 7, 2020 at 9:39:51 AM EDT
To: "Callahan, Michael V.,M.D." [REDACTED] (b) (6), "Fauci,
Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)
Subject: [REDACTED] (b) (4)
[REDACTED]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 15:45:18 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: NFLPA-NFL Task Force

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 7, 2020 11:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: NFLPA-NFL Task Force

Pls see below – (b) (7)

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, April 4, 2020 12:06 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6) >
Subject: RE: NFLPA-NFL Task Force

(b) (5)

From: (b) (6)
Sent: Saturday, April 4, 2020 11:01 AM

To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Cc: Thom Mayer (b) (6)>
Subject: NFLPA-NFL Task Force

Hi Courtney,

1st, I hope you, your family and your loved ones are harboring safely through this storm. 2nd, thanks for your efforts and those of Dr. Fauci-he is truly a national treasure during this crisis and it is deeply appreciated.

I appreciate your help and introductions on how our players can be helpful. As you know Drew and Brittany Brees made a \$5M contribution to the Louisiana coronavirus efforts and they have done a lot of press. Drew's message has been "Hang in there-hang tough! We are in this together."

I've done several webinars with our players and their families, both educating them and pointing out their role both with friends and family as well as on social media to let NFL fans know that whether or not we have an NFL season depends to a large extent upon those fans following the guidelines zealously-as zealously as they follow NFL games!

That message seems to be getting through.

I write now with a request for a little bit of Dr. Fauci's time in about 2 weeks. I requested that we stand up a joint NFLPA-NFL Task Force to scenario plan a pathway to getting NFL Club facilities open, with a view towards if and when we might look towards an NFL season, even if games are played with no fans. My request is to have Dr. Fauci give a telephone briefing to our group on this difficult topic, which would of course be confidential. The floor would be his and I can brief him prior to the call on what we have been working on. If he were willing, we can do the call anytime, probably during the week of April 13, although of course the modeling shows that would be during the peak of the outbreak. We could also do it the week before or after.

Thanks so much for considering this. We are mindful of the psychological toll the virus is taking and the lift NFL games would give to a sports-starved population, but only if it can be done safely for the players and the fans who (ultimately) allow them to play this great game.

Again, thanks!

Best,

Doc

Thom Mayer, MD, FACEP, FAAP, FACHE
Medical Director



NFL Players Association

11150 Sunset Hills Road, Ste 305

Reston, VA 20190

Mobile: [REDACTED] (b) (6)
NFLPA.COM

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 15:24:35 +0000
To: Barillas, Carolina (NIH/NIAID) [E]
Cc: Holland, Steven (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; [REDACTED] (b) (6)
Subject: RE: BCG protection from COVID-19 mortality

Carolina:



Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barillas, Carolina (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Tuesday, April 7, 2020 11:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] [REDACTED] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: BCG protection from COVID-19 mortality

Good morning Tony,

All the best,

Carolina

Carolina Barillas Mury, M.D., Ph.D.
Chief, Mosquito Immunity and Vector Competence Section
Laboratory of Malaria and Vector Research
National Institutes of Health
12735 Twinbrook Parkway, Room 2E-20C
Rockville, MD 20852
Phone: (b) (6) Fax: (301) 480 0930
E-mail: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:51:59 +0000
To: Alison Galvani
Subject: RE: Your PNAS article "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published

Alison:

Thanks for sending this. I hope that all is well with you. Keep up your great work.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alison Galvani (b) (6)
Sent: Friday, April 3, 2020 3:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Singer, Burton H (b) (6); Seyed Moghadas (b) (6)
Subject: Fwd: Your PNAS article "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published

Hi Tony,

Please find attached our second COVID publication. This one focuses on projections of the number of ICU beds that will be needed at the peak of the outbreak.

Please don't hesitate to let me know if we can be of any assistance.

Take care,
Alison

----- Forwarded message -----

From: <journalstaff@pnascentral.org>

Date: Fri, Apr 3, 2020 at 2:06 PM

Subject: Your PNAS article "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published

To: (b) (6)

PNAS is pleased to announce that your paper "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published online at: www.pnas.org. Did you know article-level metrics data and article downloads are now available for all PNAS articles? Article-level metrics provide a new way of measuring the reach and impact of an article by tracking the mentions it receives online. Clicking on the "Authors & Info" tab near the top of each article and scrolling down will reveal a summary of mentions of the article across news sites, blogs, social media, and other online sources- which are visualized in a colorful icon, or "badge." The number in the middle of the badge is the Altmetric score, which is based on the volume, type, and author of the mentions. You can click on the badge or "view more" to explore the individual mentions from each source. Article downloads by month and by article format appear below the badge.

Stay connected to PNAS:

[Follow Us on Twitter](#)

[Find Us on Facebook](#)

--

Alison Galvani, PhD

Director, Yale Center for Infectious Disease Modeling and Analysis (CIDMA)
Burnett and Stender Families Professor of Epidemiology
Yale School of Public Health
Yale School of Medicine
New Haven, CT 06520

(b) (6)

<http://cidma.yale.edu/>

Follow me at [@Alison_Galvani](#)

Follow CIDMA [@YCIDMA](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:47:59 +0000
To: Glass, Roger (NIH/FIC) [E]
Subject: RE: To cheer you up!

Thanks, Roger!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Glass, Roger (NIH/FIC) [E] (b) (6) >
Sent: Friday, April 3, 2020 12:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: To cheer you up!

Tony

Read the last lines and see the photo! Your words from the past are remembered and have changed the careers of our fellows.

No need to respond.

Roger

Sent from my iPad

Begin forwarded message:

From: (b) (6)
Date: April 3, 2020 at 11:30:23 AM CDT
To: "Glass, Roger (NIH/FIC) [E]" (b) (6) >
Subject: Hello

Dr. Glass,

I hope you are well and I wanted to check in to see how you are doing in this scary and traumatic time for our world.

During these times, I'm especially thankful for the training I received from the Fogarty Institute. I remember your wise words at our Fogarty orientation in 2011- on why investing in Global health is so critical. No truer words have been spoken especially at times like these!

I'm currently communicating with my former colleagues in Zambia (Mpanji and Innocent pictured here with

me <https://www.thermofisher.com/blog/behindthebench/using-sanger-sequencing-to-detect-drug-resistance-mutations-in-hiv-in-zambia/>) from CIDRZ to see how testing can be brought up via the public health infrastructure in place currently. Thankfully, the number of cases is very low, although the unreported cases are much higher than likely captured

(<https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>). My friend who is a Lieutenant Physician actually likely contracted COVID-19 in January and wrote that she and others had treated a patient returning from Wuhan who was pregnant of respiratory illness upon coming back to Lusaka to deliver, only to die of pleural effusion later. They subsequently developed flu-like symptoms and resolved, but these are the types of cases that likely go undetected and can potentially contribute to community spread of the disease.

Thank you again for being such a wonderful role model, and I look to leaders like you and Dr. Fauci to help our nation think with prudent but difficult decisions.


Kind regards,
Lillian




Why invest in global health?

- Good for science – the new frontier
- Good for diplomacy – “smart power”
- Good for humanity – correct health disparities
- Good for business & competition
- Good for our war on terrorism
- Good for our own future

Just the right thing to do!



Research to Develop and Optimize Interventions Against Infectious Disease Threats



Implementation: Delivery of Proven Interventions to Patients and Populations



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:44:25 +0000
To: [REDACTED] (b) (6)
Subject: FW: [REDACTED] (b) (4)
[REDACTED]
Attachments: [REDACTED] (b) (4)
[REDACTED]

What do you think of this study?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: afauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gelfand, Jeffrey A., M.D. [REDACTED] (b) (6) >
Sent: Tuesday, April 7, 2020 9:39 AM
To: Callahan, Michael V., M.D. <[REDACTED] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
[REDACTED] (b) (6) >
Subject: FW: [REDACTED] (b) (4)
[REDACTED]
Importance: High

Dear Tony and Michael: [REDACTED] (b) (4)
[REDACTED] (b) (4)

Hang in there –
Jeff Gelfand
Mark Poznansky

Vaccine and Immunotherapy Center
Division of Infectious Diseases
Massachusetts General Hospital

(b) (6) (C)-Jeff
(b) (6) -Mark

From: Chen, Huabiao, M.D. <(b) (6)>
Sent: Monday, April 6, 2020 9:07 PM
To: Gelfand, Jeffrey A., M.D. (b) (6) >; Poznansky, Mark, M.B., Ch.B., Ph.D.
(b) (6)
Subject: Re: (b) (4)

Dear Jeff and Mark,

(b) (4)

Thanks,
Huabiao

From: Chen, Huabiao, M.D. (b) (6) >
Sent: Monday, April 6, 2020 12:41 PM
To: Gelfand, Jeffrey A., M.D. (b) (6) >
Subject: Re: (b) (4)

attached please find the supporting information in PDF

From: Chen, Huabiao, M.D. (b) (6) >
Sent: Monday, April 6, 2020 12:23 PM
To: Gelfand, Jeffrey A., M.D. (b) (6) >
Subject: Re: (b) (4)

If needed please download the supporting information (b) (4)

From: Gelfand, Jeffrey A., M.D. <(b) (6) >
Sent: Monday, April 6, 2020 12:16 PM
To: Chen, Huabiao, M.D. (b) (6) >

Subject: RE: [REDACTED] (b) (4)

Wow! Reading it now...Jeff

From: Chen, Huabiao, M.D. [REDACTED] (b) (6)

Sent: Monday, April 6, 2020 11:46 AM

To: Gelfand, Jeffrey A., M.D. [REDACTED] (b) (6) >

Subject: [REDACTED] (b) (4)

Importance: High

Dear Jeff,

I had a Chance getting this information from [REDACTED] (b) (6) Dr. Danlei Mou who works very diligently and seriously on this clinical study. You may be interested in this primary information. Please keep it confidential.

Best, Huabiao

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at <http://www.partners.org/compliance> . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 23:21:25 +0000
To: Upton, Fred
Subject: RE: GOP lawmakers: Fauci may be doing more harm than good | TheHill

Thanks, Fred. I appreciate your note.
Best regards,
Tony

-----Original Message-----

From: Upton, Fred (b) (6) >
Sent: Saturday, April 11, 2020 6:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: GOP lawmakers: Fauci may be doing more harm than good | TheHill

Update. Biggs and Buck are the only 2 members of Congress that voted agn the first two bills dealing with COVID-19. The first vote had only the 2 of them vote no. NRN

Sent from my iPhone

> On Apr 11, 2020, at 5:45 PM, Upton, Fred (b) (6) > wrote:

>

> It's upton again and no need to respond. U may get asked about this story and u should know that both Buck and Biggs were among the 40 that voted no on the 2nd package which provided assistance and testing (think it was \$13B). It was not a surprise that they voted no as they r joined with Tom Massie in almost everything. Keep being a science truth teller.👍

> <https://thehill.com/homenews/coronavirus-report/492350-gop-lawmakers-fauci-may-be-doing-more-harm-than-good>

>

>

> Sent from my iPhone.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 19:26:02 +0000
To: Upton, Fred
Subject: RE: It's Fred upton

Fred:

Thanks for the note. The answer is almost certainly yes, but there would not be enough of them whereby we can compare the results in those who were receiving Hydroxychloroquine or not for their lupus. Large natural history studies, which we will be initiating could possibly answer that question.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Upton, Fred (b) (6)
Sent: Friday, April 10, 2020 6:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: It's Fred upton

U gave me your email at the Capitol briefing. Question, with all the discussion on hydrox.—have there been any Covid-19 cases that have struck lupus victims? TY

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 22:29:20 +0000
To: Bergmann, Kenneth
Cc: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Thanks, Ken.. Interesting concept. I will run it by our program people.

From: Bergmann, Kenneth [REDACTED] (b) (6) >
Sent: Wednesday, April 15, 2020 4:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Hi, Tony

This is not my field but I had some ideas, so thank you for indulging me in thinking about "why not kids." I attached citations I found useful. Hope you are not sorry you asked... 😊



Best regards,

Ken

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 07, 2020 9:50 AM
To: Bergmann, Kenneth (b) (6)
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Ken:

Thanks for the note. I have thought about the same or similar issues. (b) (5)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bergmann, Kenneth (b) (6) >
Sent: Saturday, April 4, 2020 9:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: a thought on selective vulnerability to SARS-CoV-2

Dear Dr. Fauci

I read with interest your JAMA Viewpoint of February 25.

(b) (6), (b) (7)(C)

Thank you for all you do.

Sincerely

Ken

Kenneth J. Bergmann, MD, FAAN
Senior Medical Officer
Division of Neurology I, Office of Neurosciences
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 22, Room 4143
10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002
Office: (b) (6)
Mobile: (b) (6)
Email: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 22:28:57 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: a thought on selective vulnerability to SARS-CoV-2
Attachments: 1_Mab induced Cytokine Storm NEJM 2006.pdf, 2_Covid_pregnancy.pdf, 3_Neonate_innate_immunity_2018.pdf, 4_nihms832701.pdf, 5_12948_2017_Article_77.pdf

Please check this out with program people. Thanks.

From: Bergmann, Kenneth <(b) (6)>
Sent: Wednesday, April 15, 2020 4:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Hi, Tony

This is not my field but I had some ideas, so thank you for indulging me in thinking about "why not kids." I attached citations I found useful. Hope you are not sorry you asked... 😊





Best regards,

Ken

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 07, 2020 9:50 AM
To: Bergmann, Kenneth <(b) (6)>
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Ken:

Thanks for the note. I have thought about the same or similar issues. (b) (5)



Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not

accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bergmann, Kenneth [REDACTED] (b) (6)
Sent: Saturday, April 4, 2020 9:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: a thought on selective vulnerability to SARS-CoV-2

Dear Dr. Fauci

I read with interest your JAMA Viewpoint of February 25.



Thank you for all you do.

Sincerely

Ken

Kenneth J. Bergmann, MD, FAAN
Senior Medical Officer
Division of Neurology I, Office of Neuroscience
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 22, Room 4143
10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002
Office: [REDACTED] (b) (6)
Mobile: [REDACTED] (b) (6)
Email: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 22:44:30 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Collection of COVID-19 patient data from medical records

Please take a look at this and figure out whether we should do something.

From: Hahn, Stephen <(b) (6)>
Sent: Thursday, March 26, 2020 5:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Redfield, Robert R. (CDC/OD) <(b) (6)>; Debi Birx <(b) (6)>
Cc: Abernethy, Amy (FDA/OC) <(b) (6)>; Lenihan, Keagan (FDA/OC) <(b) (6)>
Subject: Collection of COVID-19 patient: data from medical records

Tony, Bob and Debi,

Amy is working on a pathway to collect data from electronic medical records in selected areas of the country (addressing all of the appropriate privacy concerns). We're looking for data elements to collect and wonder if your teams could give us some insight from a public health perspective. I am copying Amy to see if she has anything else to add. Perhaps you could assign someone to work with Amy.

Thanks

Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 18:55:23 +0000
To: Kamoie, Brian
Subject: RE: Thank You

Thanks, Brian. I appreciate your note.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kamoie, Brian (b) (6) >
Sent: Saturday, April 18, 2020 12:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Thank You


Tony,

Thank you for all that you are doing in the fight against COVID-19. Your steady leadership and grounding in the science, and your ability to communicate complex information clearly to policymakers and the public, are what the world needs during this crisis. I know we will see the other side of this pandemic, and you will have once again saved many lives with your work.

I am one step removed from this response, as I am on a detail assignment from FEMA to the Naval Academy, but have been sharing information with the Superintendent and his senior leadership team so that they can make good decisions to protect the community while meeting the Academy's mission. I have thought back to the H1N1 response in 2009-2010 many times since this began.

Again, thank you for what you're doing. My best wishes to you and your family.

Best,
Brian





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 03:00:26 +0000
To: Collins, Francis (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Lane, Cliff (NIH/NIAID) [E]
Cc: Burklow, John (NIH/OD) [E]; Fine, Amanda (NIH/OD) [E]; Wojtowicz, Emma (NIH/OD) [E]; Fritz, Craig (NIH/OD) [E]; Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: For review tonight: draft Sec. Azar statement on ACTIV

Ditto.

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Wednesday, April 15, 2020 10:57 PM
To: Myles, Renate (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6); Wolinetz, Carrie (NIH/OD) [E] <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Cc: Burklow, John (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6); Wojtowicz, Emma (NIH/OD) [E] (b) (6); Fritz, Craig (NIH/OD) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: RE: For review tonight: draft Sec. Azar statement on ACTIV

Looks generally OK
FC

From: Myles, Renate (NIH/OD) [E] (b) (6)
Sent: Wednesday, April 15, 2020 10:44 PM
To: Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6); Wolinetz, Carrie (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Cc: Burklow, John (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6); Wojtowicz, Emma (NIH/OD) [E] (b) (6); Fritz, Craig (NIH/OD) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: FW: For review tonight: draft Sec. Azar statement on ACTIV
Importance: High

Good evening:

I'm sending this directly to principals given the quick turnaround. I've let ASPA know that the goal is to issue the release sometime tomorrow.

Thanks,
Renate

From: Brennan, Patrick (OS/ASPA) (b) (6)
Sent: Wednesday, April 15, 2020 10:20 PM
To: Burklow, John (NIH/OD) [E] (b) (6); Fritz, Craig (NIH/OD) [E] (b) (6);
Myles, Renate (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E]
(b) (6); Wojtowicz, Emma (NIH/OD) [E] (b) (6); Akinso, Woleola
(NIH/OD) [E] (b) (6); Stimson, Brian (HHS/OGC) (b) (6); Charrow,
Robert (HHS/OGC) (b) (6)
Cc: Murphy, Ryan (OS/ASPA) (b) (6); Pratt, Michael (OS/ASPA)
(b) (6); Oakley, Caitlin B. (OS/ASPA) <(b) (6)>
Subject: For review tonight: draft Sec. Azar statement on ACTIV

NIH and OGC,

Can you let me know if the below and attached statement from the Secretary looks OK? **Assuming it is going tonight from NIH, approval as soon as possible would be great.** Thank you!

- Patrick

Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office: (b) (6) | Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 01:14:17 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Erbeling, Emily (NIH/NIAID) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Pursuant to My Email on Friday
Attachments: Vaccine strategy-200411-v 13.pptx, Secretary Determination Memorandum-Project Warp Speed-041120 1825 draft.doc

John:

Let us briefly discuss this tomorrow AM. [REDACTED] (b) (7)

Best,
Tony

From: Kadlec, Robert (OS/ASPR/IO) [REDACTED] (b) (6)>
Sent: Sunday, April 12, 2020 8:59 PM
To: Hassell, David (Chris) (OS/ASPR/IO) [REDACTED] (b) (6); Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6); Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6); Bright, Rick (OS/ASPR/BARDA) [REDACTED] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Disbrow, Gary (OS/ASPR/BARDA) [REDACTED] (b) (6); Patrick, Vanessa (OS/ASPR/BARDA) (CTR) [REDACTED] (b) (6)>; Moughalian, Jen (HHS/ASFR) [REDACTED] (b) (6); Redfield, Robert R. (CDC/OD) [REDACTED] (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [REDACTED] (b) (6); Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marks, Peter (FDA/CBER) [REDACTED] (b) (6)>; Yeskey, Kevin (OS/ASPR/IO) [REDACTED] (b) (6)
Cc: Harrison, Brian (HHS/IOS) [REDACTED] (b) (6); Dareshori, Zack (HHS/IOS) [REDACTED] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6); Stecker, Judy (OS/IOS) [REDACTED] (b) (6); Shuy, Bryan (OS/ASPR/IO) [REDACTED] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] [REDACTED] (b) (6)>
Subject: Pursuant to My Email on Friday

I want to share with you the product of the BCG team who drafted the attached briefing and Decision Memo drafted for the Secretary's review tomorrow. I want to thank all those who contributed over this holiday weekend to offer their ideas and concepts that is represented in these products. This represents just a first step of many steps that first outlines a concept that will then be operationalized into a historic effort for not only the Department and agencies who will contribute to it, but to our Nation. Again, thank you for your contributions and commitment. Best Bob

✘ ✘

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 00:32:55 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: daily data call from Sec Ofc

This looks really good. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Sunday, April 12, 2020 7:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF: daily data call from Sec Ofc

Per request from the Secretary's office that I sent you this morning, below is what I propose to submit tomorrow morning for the new daily 9am data call. I will plan to submit pretty much the same thing every day. I will not clog your in-box with it unless there is a significant update.

RFI from Staff Sec:

1. For tomorrow's press conference, what information or topics do you recommend be included in the President's remarks? Please provide talking point-level details and support.

Nothing specific from NIAID at this time.

2. For tomorrow's press conference, on what information (if any) do you intend to speak?

Specific topics will depend on questions from reporters. Dr. Fauci has been asked about the effect of social distancing; considerations that would factor into returning the country to normal life; off-label use of treatments such as hydrochloroquine; the status of clinical trials; and the disproportionate impact of COVID-19 on communities of color.

NIAID-specific talking points:

- NIAID has mobilized a rapid research response to quickly develop effective countermeasures for COVID-19, including diagnostics, vaccines to prevent disease and treatments.

- NIAID is supporting a clinical trial of the antiviral remdesivir and is investigating other treatments, including antibody therapies and other antivirals, for their activity against SARS-CoV-2. Well-designed clinical trials are the best way to evaluate potential treatments for safety and efficacy.
- NIAID is supporting an early-stage clinical trial of an investigational vaccine called mRNA-1273, developed by NIAID scientists and the biotechnology company Moderna. The study launched first in Seattle, with a second site recently added in Atlanta. NIAID is researching additional vaccine candidates.
- NIAID has launched a serosurvey study that aims to determine how many adults in the United States without a confirmed history of COVID-19 have antibodies to the virus. Researchers will collect and analyze blood samples from as many as 10,000 adult volunteers without a confirmed history of COVID-19. The results will help illuminate the extent to which the novel coronavirus has spread undetected in the United States and provide insights into which communities and populations are most affected. [NOTE: This serosurvey is for research purposes. It is not meant to be a way for people to access antibody testing for personal knowledge of prior infection history. If it is portrayed as a way for people to "get tested" to understand their own infection history, we can expect that people will inaccurately blame the government for not receiving results in a timely manner. People can request to learn about their results, which will be available only after weeks or months of analysis.]
- NIAID is expanding its portfolio of basic research on coronaviruses and emerging pathogens to characterize SARS-CoV-2 (the virus that causes COVID-19) and understand how it causes disease. NIAID also is using animal models to better understand the infection and to investigate optimal ways to treat and prevent COVID-19.

3. Are there topics or announcements for future press conferences (other than tomorrow's) that you would like to flag for the President's speechwriting team?

For HHS to consider mentioning:

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (5)
Sent: Sunday, April 12, 2020 1:55 PM
To: Billet, Courtney (NIH/NIAID) [E] <(b) (5)>
Subject: RE: Staff Sec POC - NIAID

OK. Sounds fine. Do what you can do.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, April 12, 2020 10:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: FW: Staff Sec POC - NIAID

FYI – per request below, HHS is setting up a daily data call. We need to tell them at 9am what you are going to discuss at the daily press conference at the end of the day. My observation is that this may be hard to predict. However, we can certainly come up with some boilerplate talking points that we re-submit every day, emphasizing the importance of properly designed clinical trials as the best way to identify treatments.

From: Boyse, Natalie (OS/ASPA) (b) (6)
Sent: Saturday, April 11, 2020 7:04 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Cc: Bird, Catherine (OS/OGC) (b) (6)>; Puesan, Cesar (HHS/OS/IOS) (b) (6)>; Agnew, Ann (HHS/IOS) (b) (6)>; Brennan, Patrick (OS/ASPA) <(b) (6)>
Subject: Staff Sec POC - NIAID

Hi Courtney -

I hope you're having a good weekend. Just wanted to touch base because starting tomorrow, we will be receiving requests for information from Staff Sec **each evening** ahead of the next day's press conference - for a turnaround **by 9am the following morning**. Staff Sec is requesting feedback (see the questions below) from task force experts, including Dr. Fauci, on information they recommend be included in the next day's press conference.

Could you please help me identify a primary POC at NIAID that I can work with to get information to Staff Sec?

(b) (6)

Thank you,
Natalie

Natalie Boyse
Special Assistant, Immediate Office of the Secretary
U.S. Department of Health & Human Services
M: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 03:05:04 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/DD) [E]; Lane, Cliff (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]
Subject: RE: COVID-19 Advisory Panel Recommendations Following UP on Secretary Meeting this Am.

I am sorry, but I am way behind on e-mails and I just saw this. What is going on here?

From: Collins, Francis (NIH/OD) [E] (b) (6)>
Sent: Friday, April 10, 2020 11:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Mascola, John (NIH/VRC) [E] (b) (6)
Subject: FW: COVID-19 Advisory Panel Recommendations Following UP on Secretary Meeting this Am.
Importance: High

Just saw this. Huh? (b) (6)
? (b) (6)

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)>
Sent: Friday, April 10, 2020 7:27 PM
To: Hassell, David (Chris) (OS/ASPR/IO) (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Collins, Francis (NIH/OD) [E] (b) (6); 'sh1@fda.hhs.gov' (b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6); Dareshori, Zack (HHS/IOS) <(b) (6)>; Bright, Rick (OS/ASPR/BARDA) (b) (6)>; Disbrow, Gary (OS/ASPR/BARDA) (b) (6)>; Blatner, Gretta (OS/ASPR/BARDA) (b) (6)>; Patrick, Vanessa (OS/ASPR/BARDA) (CTR) (b) (6); Moughalian, Jen (HHS/ASFR) (b) (6)>; Shuy, Bryan (OS/ASPR/IO) (b) (6); Redd, John (OS/ASPR/SPPR) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Strength-McGaughey, Tracie (CDC/DDNID/NCIPC/OD) (b) (6)>; Yeskey, Kevin (OS/ASPR/IO) (b) (6)>; Marks, Peter (FDA/CBER) (b) (6)>; Cochran, Norris (HHS/ASFR) (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Johnson, Robert (OS/ASPR/BARDA) (b) (6)>; Gershman, Lynn E. (CDC/DDPHSIS/OD) (b) (6)>; Lenihan, Keagan (FDA/OC) <(b) (6)>; Mark Hartell (b) (6); Mascola, John (NIH/VRC) [E] (b) (6)

(b) (6); Suhana, Tina (NIH/VRC) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Mango, Paul (HHS/IOS) (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6)
Cc: Harrison, Brian (HHS/IOS) (b) (6); Stecker, Judy (OS/IOS) (b) (6); Ford-Barnes, Arwenthia (OS/ASPR/IO) (b) (6); Tignor, Beth (HHS/IOS) (b) (6); Moreno, Rafael (OS/ASPR) (b) (6); Callahan, Victoria (OS/ASPR/IO) (CTR) (b) (6); Kemp, Micha (OS/ASPR/MFHC) (b) (6); Holland, Tara (OS/ASPR/EMMO) (b) (6)

Subject: RE: COVID-19 Advisory Panel Recommendations Following UP on Secretary Meeting this Am.

Importance: High

First thank you all for participating on Wednesday's evening call and producing the briefing memo for the Secretary's review. As a consequence of that meeting and discussion, he fully endorsed the recommendations of the vaccine portfolio you recommended. He, however, expressed concern about (b) (5)

(b) (5)

(b) (5)

This is an ambitious and challenging undertaking but one driven by the necessity to mitigate the public health, economic and national security threat this virus represents to our citizens, nation and our way of life. The Secretary is confident that together with our private sector partners this is achievable.

Have a restful holiday weekend.

Bob

From: Hassell, David (Chris) (OS/ASPR/IO) (b) (6)
Sent: Thursday, April 9, 2020 3:13 PM
To: Kadlec, Robert (OS/ASPR/IO) (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6);

(b) (6); Dareshori, Zack (HHS/IOS)
(b) (6); Bright, Rick (OS/ASPR/BARDA) (b) (6); Disbrow,
Gary (OS/ASPR/BARDA) (b) (6); Ford-Barnes, Arwenchia (OS/ASPR/IO)
< (b) (6); Blatner, Gretta (OS/ASPR/BARDA)
(b) (6); Patrick, Vanessa (OS/ASPR/BARDA) (CTR)
(b) (6); Moughalian, Jen (HHS/ASFR) (b) (6); Shuy,
Bryan (OS/ASPR/IO) (b) (6) Redd, John (OS/ASPR/SPPR)
(b) (6); Tignor, Beth (HHS/IOS) (b) (6); Redfield, Robert R.
(CDC/OD) (b) (6); Strength-McGaughey, Tracie (CDC/DDNID/NCIPC/OD)
(b) (6); Yeskey, Kevin (OS/ASPR/IO) (b) (6); Callahan, Victoria
(OS/ASPR/IO) (CTR) (b) (6); Moreno, Rafael (OS/ASPR)
(b) (6); Marks, Peter (FDA/CBER) (b) (6); Cochran,
Norris (HHS/ASFR) (b) (6); Messonnier, Nancy (CDC/DDID/NCIRD/OD)
(b) (6); Windom, Robert (OS/ASPR/IO) (b) (6); Lane, Cliff
(NIH/NIAID) [E] (b) (6) Holland, Tara (OS/ASPR/EMMO)
(b) (6); Johnson, Robert (OS/ASPR/BARDA) (b) (6);
Gershman, Lynn E. (CDC/DDPHSIS/OD) (b) (6); Kemp, Micha (OS/ASPR/MFHC)
(b) (6); Lenihan, Keagan (FDA/OC) (b) (6); Mark
Hartell (b) (6); Mascola, John (NIH/VRC)
[E] (b) (6); Suhana, Tina (NIH/VRC) [E] (b) (6); Marston,
Hilary (NIH/NIAID) [E] < (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)

Subject: COVID-19 Advisory Panel Recommendations

Dear Panel members—

Secretary Azar requested a summary paper with a recommendation from the Panel re the BARDA vaccine portfolio. His deadline was 3:30pm today.

Based on the discussion last night and other discussions with the BARDA team, (b) (6)
(b) (6) Please let me know as soon as possible if this is not the case.

Apologies for the fast turn. Thank you again for your participation in the Panel.

Chris

<< File: COVID Vaccines Briefing Memo V.3.docx >>

-----Original Appointment-----

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)

Sent: Monday, April 6, 2020 1:36 PM

To: Kadlec, Robert (OS/ASPR/IO); Conrad, Patricia (NIH/NIAID) [E]; Collins, Francis (NIH/OD) [E]; (b) (6); Dareshori, Zack (HHS/IOS); Bright, Rick (OS/ASPR/BARDA); Disbrow, Gary (OS/ASPR/BARDA); Ford-Barnes, Arwenithia (OS/ASPR/IO); Blatner, Gretta (OS/ASPR/BARDA); Patrick, Vanessa (OS/ASPR/BARDA) (CTR); Moughalian, Jen (HHS/ASFR); Shuy, Bryan (OS/ASPR/IO); Redd, John (OS/ASPR/SPPR); Tignor, Beth (HHS/IOS); Redfield, Robert R. (CDC/OD); Strength-McGaughey, Tracie (CDC/DDNID/NCIPC/OD); Hassell, David (Chris) (OS/ASPR/IO); Yeskey, Kevin (OS/ASPR/IO); Callahan, Victoria (OS/ASPR/IO) (CTR); Moreno, Rafael (OS/ASPR); Marks, Peter (FDA/CBER); Cochran, Norris (HHS/ASFR); Messonnier, Nancy (CDC/DDID/NCIRD/OD); Windom, Robert (OS/ASPR/IO); Lane, Cliff (NIH/NIAID) [E]; Holland, Tara (OS/ASPR/EMMO); Johnson, Robert (OS/ASPR/BARDA); Gershman, Lynn E. (CDC/DDPHSIS/OD); Kemp, Micha (OS/ASPR/MFHC); Lenihan, Keagan (FDA/OC); Mark Hartell (b) (6); Mascola, John (NIH/VRC) [E]; Suhana, Tina (NIH/VRC) [E]; Marston, Hilary (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]

Subject: #2 – COVID-19 Advisory Panel

When: Wednesday, April 8, 2020 5:15 PM-6:30 PM (UTC-05:00) Eastern Time (US & Canada).

Where: WEBEx - (b) (3)

Presentation for Wednesday. **THIS IS THE UPDATED VERSION** 4:26pm

<< File: BARDA COVID Vaccines White Paper 20200405b.docx >>

Meeting Objective:

- (1) Complete review of BARDA vaccine portfolio (to include related NIH and DoD programs), with emphasis on discussion among Panel members;
- (2) Formulate a recommendation to Secretary Azar to either endorse or modify current vaccine strategy, plans, proposed funding and contracts.

Agenda

Brief review of vaccine programs

- BARDA (deeper dive after Sunday overview)
- NIAID
- DoD

Discussion

Recommendation to Secretary Azar

For convenience, below are the presentation and White Paper from last Sunday evening.

<< File: BARDA COVID Portfolio Review 20200405b.pptx >> << File: Vaccine Discussion with S1 and HHS Leadership V2 FINAL - Gary.pdf >>

Hi Arwenithia Ford-Barnes,

You updated this WebEx meeting:

#2 COVID-19 Advisory Panel on behalf of Dr. Robert Kadlec

Host: Arwenhia Ford-Barnes

When it's time, start your meeting from here:

Start the meeting

When: Wednesday, April 8, 2020, 5:15 pm (1 hr 15 mins), Eastern Daylight Time (New York, GMT-04:00).

Access Information

Meeting Number:

(b) (5)

Password:

(This meeting does not require a password.)

Host Key:

(b) (5) (Use this key during the meeting if you ever need to reclaim the host role.)

Audio Connection

(b) (5) (Meeting Server Main Number)

Access Code:

(b) (5)

Delivering the power of collaboration
The meetingserver.hhs.gov team

© 2020 Cisco and/or its affiliates. All rights reserved.

<< File: BARDA COVID Vaccines White Paper 20200405b.docx >> << File: BARDA COVID Portfolio Review 20200405b.pptx >> << File: Vaccine Discussion with S1 and HHS Leadership V2 FINAL - Gary.pdf >>

From: (b) (6)
Sent: Thu, 9 Apr 2020 16:48:20 -0400
To: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Hello

How do we nicely say no to this person?

Begin forwarded message:

From: "Sachdev, Amit (HHS/IOS)" (b) (6)
Date: April 9, 2020 at 2:04:56 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Hello

Hi Dr. Fauci, my name is Amit Sachdev. I am a White House fellow and physician most recently at the Brigham.

I know you are super busy and I would love to partner with you and write a op ed on coronavirus and unite the nation.

If you have a few minutes, I would love to speak. I think (b) (6)

Thank you for your time and consideration.

Sincerely,
Amit

(b) (6)

Sent from my iPhone

From: (b) (6)
Sent: Wed, 8 Apr 2020 20:14:10 -0400
To: Adams, Jerome (HHS/OASH)
Subject: Re: Blacks/ minorities

Please text to me your cell phone number

On Apr 8, 2020, at 7:29 PM, Adams, Jerome (HHS/OASH)

(b) (6)

Also, Deb has the data and knows it better than anyone,

(b) (6)

(b) (6)

VADM Jerome Adams
20th US Surgeon General

On Apr 8, 2020, at 7:13 PM, Adams, Jerome (HHS/OASH)

(b) (6) wrote:

With greatest of respect to the two of you,

(b) (6)

(b) (6)

(b) (5)

Jerome

VADM Jerome Adams
20th US Surgeon General

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 14:38:40 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stecker, Judy (OS/IOS) (b) (6)
Sent: Wednesday, April 8, 2020 9:59 AM
To: Harrison, Brian (HHS/IOS) (b) (6)
Cc: (b) (6) (OS/IOS) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: Re: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

Thank you. Will have Beth connect with Patricia ASAP.

Sent from my iPhone

On Apr 8, 2020, at 9:48 AM, Harrison, Brian (HHS/IOS) (b) (6) wrote:

Sounds good, Dr. Fauci - we greatly appreciate the effort that you/Cliff and your team have put into this.

Look forward to receiving and discussing the guidelines (no need for a separate meeting with me first - we can go straight to the Secretary) and agree that they will not be subjected to additional layers of formal clearance given the circumstances.

Adding Judy to quickly help coordinate a time to meet with the Secretary.

Thanks again,

BH

Brian Harrison
Chief of Staff
U.S. Department of Health and Human Services

(b) (6)

(b) (6)

On Apr 8, 2020, at 7:46 AM, (b) (6) (OS/IOS) (b) (6) > wrote:

Thank you Tony. Obviously we will prioritize time to meet/discuss. I'm at your disposal.

AMA

On Apr 7, 2020, at 11:01 PM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6) > wrote:

Brian:

(b)(5) - PCT



(b) (5)

(b) (5) Happy to

discuss further before I brief the Secretary.

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 13:49:56 +0000
To: Harrison, Brian (HHS/IOS)
Subject: RE: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

Thanks, Brian.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harrison, Brian (HHS/IOS) (b) (6)>
Sent: Wednesday, April 8, 2020 9:49 AM
To: (b) (6) (OS/IOS) (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Stecker, Judy (OS/IOS) (b) (6)
Subject: Re: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

Sounds good, Dr, Fauci - we greatly appreciate the effort that you/Cliff and your team have put into this.

Look forward to receiving and discussing the guidelines (no need for a separate meeting with me first - we can go straight to the Secretary) and agree that they will not be subjected to additional layers of formal clearance given the circumstances.

Adding Judy to quickly help coordinate a time to meet with the Secretary.

Thanks again,

BH

Brian Harrison
Chief of Staff
U.S. Department of Health and Human Services
(b) (6)


(b) (6)

On Apr 8, 2020, at 7:46 AM, (b) (6) (OS/IOS) (b) (6) > wrote:

Thank you Tony. Obviously we will prioritize time to meet/discuss. I'm at your disposal.
AMA

On Apr 7, 2020, at 11:01 PM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6) > wrote:

Brian:



(b) (5). Happy to discuss further before I brief the
Secretary.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:48:49 +0000
To: Becks, Karen (HHS/IOS)
Subject: RE: Crazy COVID-19 face cover idea

Karen:

Thanks for your note.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Becks, Karen (HHS/IOS) (b) (6)
Sent: Friday, April 3, 2020 12:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Crazy COVID-19 face cover idea

Hi, Dr. Fauci.

Thank you so much for keeping things honest and know that I am such a champion of you.

I hope that reaching out is okay. I work at HHS/IOS team. As I sit here at home and have been thinking about the shortage of medical supplies, doggie cones actually can be used as protection for our health care workers. Just a thought that looks and sounds crazy but can help.

Stay safe.

Kindest Regards,

Karen Becks

U.S. Department of Health and Human Services

Immediate Office of the Secretary

200 Independence Avenue, SW

Washington, DC 20201

Desk: (b) (6)

Mobile: (b) (6)

Brian Kamoie

DHS/FEMA

(b) (6) (mobile)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 22:05:53 +0000
To: (b) (6)
Subject: RE: Greetings from your former employee (UNCLASSIFIED)

(b) (6)

Many thanks for your kind note. I hope that all is well with you.
Best regards,
Tony

-----Original Message-----

From: (b) (6) (b) (6)
Sent: Thursday, April 2, 2020 4:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Greetings from your former employee (UNCLASSIFIED)

CLASSIFICATION: UNCLASSIFIED

Dear Dr. Fauci,

I was in touch with (b) (6) back in January and he said you all were underwater there with coronavirus. I can only imagine how much busier you are now, with COVID-19 taking hold across America.

We (myself, husband, and family) have followed the news since the start. In watching, I was reminded of the old sign we had posted on the printer between (b) (6) and my desk for quite some time that read, "Keep Calm and Trust Fauci". I can't recall whether we put that up during the Ebola outbreak or Zika, but never has it been more true. We never cease to be amazed at how well you carry yourself, respond to politically loaded questions, and get the truth out in such a way that any viewer can understand.

You also never seem to frustrate from answering the same questions which I am sure must get old. There has been one question I have yet to hear asked however. Who is cutting your hair? I know you used to have a regular gal but with social distancing, we are speculating that perhaps there is a White House barber you use. Of course we know how busy you are so don't expect a reply, just wanted to throw you a question you may not have had yet. I am also wondering how your office tree is doing. How many bungee cords are supporting it these days?

We have found plenty of reasons to smile with the whole family getting in on what we're dubbing the ASF #1 Fan Club. From memes, to cartoons, to t-shirts, we are all here supporting you and wishing for your continued health and success. I am attaching some of our shenanigans in hopes you get a kick out of it and to provide some comic relief.

You've been thanked over and over but I must say it too. Thank you, Dr. Fauci, for all that you do. And thank you to the staff behind the scenes that makes it happen. (b) (6) is no doubt just as busy as you as always (b) (6), are you reading this email? Hi!). When we see you at all hours from the NIH studio and your office, I think of the media staff support you receive, and especially assistance from (b) (6) for helping the ship run smoothly while you are constantly engaged, (b) (6) and your family, the list goes on. Thank you and thanks to your team.

Best wishes,

(b) (6)

(b) (6)

Directorate of Human Resources
USAG Fort Detrick

CLASSIFICATION: UNCLASSIFIED

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 27 Mar 2020 11:23:56 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Reaching out about partnerships and COVID-19. // confidential

The email below is from Maria Freire.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Freire, Maria (FNIH) [T] (b) (6)
Sent: Friday, March 27, 2020 6:03 AM
To: Collins, Francis (NIH/OD) [E] (b) (6); Wholley, David (FNIH) [T] (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Subject: Re: Reaching out about partnerships and COVID-19. // confidential

Yes, quite a note. It is good to see such willingness to pitch in and the things J&J is doing. Let us know what he says. We stand ready to help. Best, M.

From: "Collins, Francis (NIH/OD) [E]" (b) (6) >
Date: Friday, March 27, 2020 at 4:37:15 AM
To: "Wholley, David (FNIH) [T]" <(b) (6)>
Cc: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>, "Lane, Cliff (NIH/NIAID) [E]" (b) (6) >, "Freire, Maria (FNIH) [T]" (b) (6)
Subject: FW: Reaching out about partnerships and COVID-19. // confidential

Hi David,

Quite a message from Paul below. He seems open to the idea of a virtual meeting, to see what collaborative efforts might be most important. I'll try to speak with him today or tomorrow.

Francis

From: Stoffels, Paul [JJCUS] (b) (6) >
Sent: Friday, March 27, 2020 3:54 AM

To: Collins, Francis (NIH/OD) [E] (b) (6)

Cc: Castilejos, Carlos [JJCUS] (b) (6)

Subject: Re: Reaching out about partnerships and COVID-19. // confidential

Francis,

(b) (4)

Lots to talk about. Happy to find a productive way to contribute in the discussion you are planning to have.

we can talk this afternoon US time or over the weekend.
I'm working (b) (6) at the moment.

Carlos can provide more information on the (b) (6) if you want.

Best regards,

Paul

Sent from my iPad

On Mar 27, 2020, at 1:37 AM, Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6)> wrote:

WARNING: This email originated from outside the company. Do not click on links unless you recognize the sender and have confidence the content is safe. If you have concerns about this email, send it as an attachment to 'SuspiciousEmail@ITS.JNJ.COM'.

Hi again Paul,

One more question – is the pharma collaboration mentioned in the BioCentury story below the same thing as the Gates COVID Therapeutic Accelerator Program? Or is this something different? I'm just trying to understand the landscape.

Best, Francis

Pharmas on one page with action plan to solve COVID-19 together
BIOCENTURY IS PROVIDING THIS STORY FOR FREE GIVEN THE URGENT NEED FOR INFORMATION ABOUT THE COVID-19 CRISIS.
BY C. SIMONE FISHBURN, EDITOR IN CHIEF | MAR 25, 2020 | 9:17 PM EDT
A grand-scale behind-the-scenes effort by the pharmaceutical companies is under way to expedite the creation of therapies and vaccines to treat COVID-19.

According to the participants who spoke with BioCentury under conditions of anonymity, R&D heads from at least 10 companies have been gathering several times a week, setting in motion an action plan to use their top talent in different disciplines to produce an industry-wide response, the likes of which haven't been seen since the private sector's coordinated contribution during World War II.

Regulatory heads and manufacturing heads have been holding meetings as well, coordinating to minimize duplication of effort, streamline work and advance efficient testing of compounds and vaccines.

The R&D group is creating working principles to accelerate new COVID-19 therapies and vaccines agnostic to their market potential, eliminating bureaucratic and technical or scientific barriers, and focusing on filling gaps not adequately filled by other initiatives and which the consortium is uniquely suited to address.

The pharma group's leaders also intend to offer resources to biotechs and academic groups pursuing countermeasures who may not want to join the effort but could benefit from expert guidance.

Flying the plane as they build it, the collaborators intend to create a clearing house of ideas for testing of molecules and vaccines, with working groups to vet the ideas and expedite testing on the most promising via clinical or preclinical testing.

According to the participants who spoke to BioCentury, the structure will probably evolve over time. Currently, the model involves five working groups, for clinical phase repurposing, novel small molecule antivirals, novel antibodies, preventive vaccines and preclinical repurposing. Each will be headed by a pharma R&D executive and will be responsible for prioritizing potential compounds and specifying actions.

Two platform groups will integrate across modalities: a clinical trial acceleration group and a data sharing group.

"This is not a time to think about proprietary information or IP or margins. We need to break down the barriers and solve the problem," said one participant involved in the consortium.

From: Collins, Francis (NIH/OD) [E]
Sent: Thursday, March 26, 2020 4:25 PM
To: Stoffels, Paul [JCUJ] (b) (6)>
Subject: RE: Reaching out about partnerships and COVID-19

Hi Paul,

I have done some work on the idea of an "AMP like" COVID project. As I mentioned, Mikael Dolsten has been quite enthusiastic. For FDA, Peter Marks, Janet Woodcock, and Steve Hahn were all extremely positive about this opportunity for a shared consideration about priorities. Tony Fauci and his team are totally in favor, and the FNIH (David Wholley and Maria Freire) stands ready to serve as convener. I thought the first step would be a 90 to 120-minute virtual meeting – hopefully next week. Attached is a draft precis of what this might look like; I have left out the roster because that is very much a work in progress.

Meanwhile I saw reports that there are related partnership discussions going on amongst pharmas: <https://www.globenewswire.com/news-release/2020/03/26/2006713/0/en/Novartis-and-life-sciences-companies-commit-expertise-and-assets-to-the-fight-against-COVID-19-pandemic-alongside-Bill-Melinda-Gates-Foundation.html>

I am wondering how this might all fit together.

Do you have a few minutes to speak with me about this? I'm at (b) (6), and I'd greatly value your advice. Just let me know when you might be able to call, so that I'm not in the midst of a Zoom meeting.

Best, Francis

From: Stoffels, Paul [JJCUS] (b) (6) >
Sent: Tuesday, March 24, 2020 12:58 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Re: Reaching out about partnerships and COVID-19

Absolutely worthwhile. I will write an email in the next hours.
(b) (4).

Paul

Verstuurd vanaf mijn iPhone

Op 24 mrt. 2020 om 17:55 heeft Collins, Francis (NIH/OD) [E] (b) (6) > het volgende geschreven:

Hey again Paul,

Really hoping to hear your thoughts on this proposal. FDA is highly enthusiastic. Dolsten is in. Other pharma R&D Chiefs that would be most helpful? Jay Bradner? John Reed? Roger Perlmutter?

Thanks, Francis

From: Collins, Francis (NIH/OD) [E]
Sent: Monday, March 23, 2020 5:17 PM
To: Stoffels, Paul (b) (6) >
Subject: Reaching out about partnerships and COVID-19

Dear Paul,

I've been thinking that this is a time where we ought to have the best and brightest minds from industry, NIH, academia, and FDA around the same table to identify ways that we can move the coronavirus agenda forward to life-saving products as quickly as possible. Several pharmas and biotechs have been reaching out to NIH to identify viral assays and animal models that can

be run in a BSL-3 facility. Other similar contacts I've had with pharma and biotech tell me that there is a high degree of interest and willingness to combine forces at this time of crisis.

This isn't exactly a precise recipe for AMP-COVID, but it has some of the same flavor. Would it be useful for FNIH to convene a virtual meeting with a few heads of R&D (hopefully you; Mikael Dolsten has already expressed enthusiasm; and I'd be interested in your suggestions of others), FDA (Marks and Woodcock), leaders from NIAID and a few other NIH Institutes with equity in this space. We might be able to make a short list of catalytic actions that neither sector can do optimally right now, but together we can do rapidly.

The focus would be on therapeutics and vaccines. But I can imagine a separate session on diagnostics.

Does this sound worthwhile to you?

Thanks, I always value your advice and partnership.

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 10:58:08 +0000
To: Mascola, John (NIH/VRC) [E]
Subject: FW: Secretary's Medical Countermeasure Advisory Panel

As per our discussion.

From: Kadlec, Robert (OS/ASPR/IO) (b) (6) >
Sent: Thursday, April 2, 2020 6:46 AM
To: Bright, Rick (OS/ASPR/BARDA) (b) (6); Disbrow, Gary (OS/ASPR/BARDA) <(b) (6)>; Lambert, Linda (OS/ASPR/BARDA) (b) (6)
Cc: Shuy, Bryan (OS/ASPR/IO) (b) (6) >; Harrison, Brian (HHS/IOS) (b) (6); Hassell, David (Chris) (OS/ASPR/IO) (b) (6) >
Subject: Secretary's Medical Countermeasure Advisory Panel
Importance: High

Rick, Gary and Linda:

The Secretary has directed me to establish a HHS Senior Advisory Panel of key HHS Operating Divisions (NIH, CDC & FDA) to include head of agencies or their designees to oversee and provide recommendations to the Secretary concerning the development and procurement medical countermeasures (MCM), (vaccines, therapeutics, diagnostics and devices). In meeting this directive, I have asked Dr. Chris Hassell to organize and serve as the intermediary to schedule and coordinate. It is the intent to hold the first virtual meeting of this panel Sunday, 4 April time TBD. The frequency of further meetings will be determined at the inaugural meeting.

The Agenda should include :

- Overall COVID-19 Strategy & Plan (5 min)
- Activities to Date (e.g. industry outreach, RFP BAA etc.) (5 min)
- High level overview of current MCM portfolio (5 min)
- Detailed briefing of current vaccine technical development efforts, timeline and costs (30 min)
- Discussion by participants (30 min)

I ask that the materials for this meeting be submitted by noon April 3 to the ASPR IO to be reviewed and be distributed to the Panel membership by noon Saturday April 4. Thank you

Bob

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 31 Mar 2020 01:57:13 +0000
To: Kavesh, William
Subject: RE: Medical staff need COVID-19 NIH survival data on N-95 respirators to help alleviate shortage

Dr. Kavesh:

Thanks for your note. This issue is now being actively discussed at the Task Force meetings. No guarantee, but I believe that there will be movement in that direction.

Best regards,

Tony

From: Kavesh, William <(b) (6)>
Sent: Monday, March 30, 2020 5:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Medical staff need COVID-19 NIH survival data on N-95 respirators to help alleviate shortage

Dear Dr. Fauci,

The biggest concern of my hospital colleagues is the shortage of protective masks. If any research is being done that might drive safe reuse of N-95 respirators, no one I know has seen it. These should be simple studies to do.

If the virus is shown to die within a few days and moisture dries up, then the number of masks needing disposal could drop drastically.

In that situation, each provider at risk could be given five N-95 masks, one for each day of the week. The provider would wear the N-95 mask for one working day, say Monday, and then place it into a paper bag in a secure location. The provider would not use that mask again until the following Monday, ie seven days later.

The only question, then, would be: how many times can this be repeated? Will the mask lose any protective qualities over time?

Please assign someone to do these studies soon.

I'm also very pleased that our national leaders now seem to be listening to you more closely.

Thank you for your efforts.

William Kavesh MD, MPH
CMC Philadelphia VA Medical Center

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 15:26:47 +0000
To: Gottlieb, Lawrence A.
Subject: RE: Support

Many thanks!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gottlieb, Lawrence A. (b) (6)
Sent: Tuesday, March 24, 2020 11:19 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Support

Dr. Fauci,

Just want to express my support for your indefatigable efforts to thwart the spread of the Coronavirus. Many, many years ago, I was a lab assistant for Dr. Edward L. Kuff and Dr. Karen Lueders, at NCI in building 37!!! Bravo for all you are doing.

Lawrence Gottlieb, PMP, MBA, COR, FAC/PPM III
Senior IT Project Manager
Enterprise Portfolio Management Division
Office of Information & Technology
US Department of Veterans Affairs
810 Vermont Avenue, NW
Washington, DC 20420

(b) (6)
Office: (b) (6)
Cell: (b) (6)

“Alea iacta est” - Caesar



VA Core Values: Integrity Commitment Advocacy Respect Excellence





U.S. Department of Veterans Affairs

Office of Information and Technology


Enterprise Program Management Office




















From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 13:42:04 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6)
Subject: FW: Keynote Speaker Invitation - 8th International mRNA Health Conference

No!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Tuesday, April 7, 2020 9:33 AM
To: NIAID OD AM (b) (6) >
Subject: FW: Keynote Speaker Invitation - 8th International mRNA Health Conference

From: Pardi, Norbert <pnorbert@pennmedicine.upenn.edu>
Sent: Tuesday, April 7, 2020 9:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Keynote Speaker Invitation - 8th International mRNA Health Conference

Dear Dr. Fauci,

On behalf of the organizing committee, **I am writing to invite you to Keynote the 8th International mRNA Health Conference** (<http://www.mrna-conference.com/>) to be held at the Boston Park Plaza Hotel on Nov 9-10, 2020.

The International mRNA Health Conference is a yearly non-profit event collaboratively organized by Curevac, BioNTech and Moderna. It brings together academic and industry thought leaders in the mRNA design and delivery space to explore the rapidly evolving science, business and regulatory landscape of mRNA medicines. Over the last seven years, this 2-day conference has become the premier destination for industry and academic professionals to network with colleagues, learn about the latest advances in mRNA technology, and to attend scientific presentations given by the most esteemed experts in the field. Notably, it is the only annual conference dedicated solely to mRNA therapeutics.

As a scientist with tremendous experience and the director of NIAID, the organizing committee thought that conference attendees would very much appreciate hearing about your thoughts about mRNA therapeutics, particularly vaccines, and any perspectives you wish to share.

The organizing committee recognizes that your calendar is likely filled years in advance, but we all have our fingers crossed that you might be able to fit this into your busy schedule.

I look forward to hearing from you.

all best wishes,

Norbert

P.S. In the event that the COVID-19 crisis is still curtailing travel in the fall, our backup plan would be to have a completely virtual meeting on the same dates. We plan to make that decision in late August/early September.

Norbert Pardi, Ph.D.

Research Assistant Professor of Medicine

Infectious Disease Division

Perelman School of Medicine

University of Pennsylvania

Philadelphia, PA 19104

PH: 215-746-6552

pnorbert@penmedicine.upenn.edu

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 13:01:12 +0000
To: Mark Feinberg
Subject: RE: Greetings and an Update: VSV-SARS-CoV-2 Vaccine Development

Thanks, Mark. This e-mail is very informative and helpful.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mark Feinberg (b) (6)
Sent: Saturday, April 4, 2020 4:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Greetings and an Update: VSV-SARS-CoV-2 Vaccine Development

Dear Tony,

I hope you doing well despite your heroically busy schedule and the complexity and magnitude of the critically important issues you are working so hard and effectively to address. You are providing such amazing and valuable leadership in the response to COVID-19 and the world is so fortunate to have you in this key role!

(b) (4)

Please let me know if you have any questions or would like any additional information. I will keep you posted [REDACTED] (b) (4).


Be well and hang in there!


Very best,

Mark


Mark Feinberg, MD, PhD


(b) (6)


























From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 17:30:06 +0000
To: Anki Wolf
Subject: RE: Elizabeth Glaser

Anki:

Many thanks for your kind note.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Anki Wolf (b) (6)>
Sent: Sunday, April 5, 2020 5:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Elizabeth Glaser

Hi Dr. Fauci,

I am (b) (6) you diagnosed with AIDS back in the mid 1980's. It was in those early days of the AIDS epidemic that you were instrumental in diagnosing and researching this dreadful disease.

(b) (6)

My family had been associated with the NCI through my uncle, Lou Wasserman, who was a researcher for a period of time. Lou did much research on polycythemia vera and was a hemotologist at Mt. Sinai in NYC. I'm glad that he's no longer around to witness the devastation of Covid-19.

I was impressed with your knowledge at the time of (b) (6) diagnosis and I am even more so in these times of the Covid-19 pandemic. Thanks for being the intelligent and informative face of the facts on the virus. There are many around the country who rely on your wisdom but also on your facts and data.

Stay well, stay healthy, and keep providing the country with what we need to know and do.

Best,

Anki Wolf

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 17:27:18 +0000
To: (b) (6)
Subject: FW: clinical trials of Oral LL-37 on COVID-19
Attachments: LL-37 ethic.pdf, three patients clinical study.pdf, CAS001 Subchronic toxicity experiment.pdf, International research programme(1).pdf, Wanzhu Jin CV.pdf

Any suggestion of what to do with this type of thing? Can you have someone respond to them.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: JINWan-Zhu (b) (6) >
Sent: Sunday, April 5, 2020 11:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; sunok301 (b) (6)
Subject: clinical trials of Oral LL-37 on COVID-19

Dear Dr. Anthony S Fauci:

Thank you very much for your hard work on COVID-19. You are the hero of word!

This is Prof. Wanzhu Jin prof. Institute of Zoology, Chinese Academy of Sciences.

(b) (4)



Many thanks in advances!

Wanzhu Jin & Gang Sun

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 16:41:38 +0000
To: info@marianneorlando.com
Cc: Grady, Christine (NIH/CC/BEP) [E]
Subject: FW: Fauci superhero

Marianne:

Many thanks for doing and sending this.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marianne Orlando <info@marianneorlando.com>
Sent: Friday, April 3, 2020 6:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Thank you, sir

Dear Dr. Fauci,

Being a freelance illustrator, I am trying to keep myself productive during this life-altering pandemic by doing a series of COVID-19 inspired drawings.

This is my latest, that I call: "My Personal Superhero."

I dedicated it to you like this: "In his own, quiet way, he is a BadAss:
Disseminating info about this disease calmly and, always, backed by science."

Here is my drawing:



So, Thank you, Sir. You are the voice of reason in what has been a dangerous, frightening situation. You are a real leader.

Thank you,
Marianne Francesca Orlando

Thank you,
Marianne Orlando
Marianne Orlando Illustrations

(b) (6)

cell: (b) (6)
landline: (b) (6)



MARIANNE
ORLANDO *illustrations*

*home, pet and
people portraits
... and more*

info@marianneorlando.com
www.marianneorlando.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 14:57:23 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Request for your support in promoting new WHO recommendation for emergency response operation to provide universal access to mandatory hand hygiene against COVID-19
Attachments: who-interim-recommendation-on-obligatory-hand-hygiene-against-transmission-of-covid-19.pdf

Let us discuss. I am not sure what I should do with this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: HOYER, Stefan Detlef Leo (b) (6) >
Sent: Monday, April 6, 2020 8:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Emanuele CAPOBIANCO (b) (6) >; GORDON, Bruce Allan (b) (6) >; ROGERS, Paul <(b) (6)>
Subject: Request for your support in promoting new WHO recommendation for emergency response operation to provide universal access to mandatory hand hygiene against COVID-19
Importance: High

Dear Dr. Fauci

Please find enclosed the new WHO recommendation on establishing universal access to hand hygiene stations at thresholds of publicly accessible buildings and means of public transport. It is now officially published at : <https://who.int/who-documents-detail/interim-recommendations-on-obligatory-hand-hygiene-against-transmission-of-covid-19> I attach a pdf copy for easy reference.

I would like to request your support in promoting the recommendation as part of an international emergency response operation providing universal access to mandatory hand hygiene and/or sanitation against COVID-19 infections. Provided it is now made available and made obligatory whenever entering

and leaving a facility to which the general public has access, it could become possible to prevent most smear infections by decontaminating all hands prior *and* after each possible contamination, both active or passive. In addition, the measure should massively reduce transmission of other viruses and bacteria currently burdening differential diagnosis of COVID-pneumonias. Based on the excellent experiences made with the acceptability and adherence during Ebola outbreaks, repeated mandatory hand hygiene or sanitation should thus become an almost unconscious routine of everyday life for any person having to leave his or her private home in Corona-affected countries.

I have been asked by senior WHO emergency management to promote the WHO recommendation for rapid implementation with particular focus on current COVID-19 transmission epicenters such as the USA. Providing a systematic access to hand hygiene stations and making their use obligatory prior to entering and whenever leaving any public facility will also provide a safety net whenever current restrictions on movements and commerce are to be progressively reduced. Given the high resource settings in the current COVID-epicentres, and the negligible cost of implementing this public health emergency measure compared to prolonged mass confinement without safe exit strategy, I do presume that the wherewithal to carry it out will not be limiting factor.

Thank you for considering the collaboration in this emergency measure proposed within the USA at the largest possible scale. WHO has requested IFRC to alert the American Red Cross to support large scale implementation should your Government decide to implement the public health measure proposed.

With best wishes for success in all of your endeavours,

Stefan Hoyer

Dr Stefan Leo Hoyer
Medical Officer
Focal Point for Emergencies
Global Malaria Programme

t: [REDACTED] (b) (6) e: [REDACTED] (b) (6)
m: [REDACTED] w: www.who.int/malaria



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 13:40:45 +0000
To: Jameson, James L
Subject: RE: COVID-19 Rx

Thanks, Larry.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jameson, James L (b) (6) >
Sent: Monday, April 6, 2020 9:35 AM
To: Anthony Fauci (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: COVID-19 Rx

Tony,

I completely understand – we are all thinking about you as you help the country navigate this crisis – thanks so much. Let me know if there is any way that I, or people at Penn, can be helpful. Our scientists, several of whom are Coronavirus experts (Susan Weiss, Paul Bates), have coalesced form a Center to focus on potential treatments and immunology related to the virus. I list few below and you might triage to others to f/u further:



(b) (4)

Best regards,
Larry

From: Anthony Fauci <(b) (6)>

Date: Monday, April 6, 2020 at 8:25 AM

To: "J. Larry Jameson" <(b) (6)>

Cc: Dennis Kasper <(b) (6)>, Joseph Loscalzo

<(b) (6)> James Shanahan <(b) (6)>

Subject: Re: COVID-19 Rx

Larry:

I am so sorry that I have not gotten back to you and others in so long. I am completely swamped (3 to 4 hours sleep per night just does not work very well) and have not been able to even check my non-NIH (b) (6). I will try my best to catch up soon. Thank for your understanding.

Best regards,
Tony

On Fri, Mar 13, 2020 at 9:33 AM Jameson, James L <(b) (6)> wrote:

Dennis and Tony,

(b) (4)

Best regards,
Larry

Anthony S. Fauci, M.D.
Editor, *Harrison's Principles of Internal Medicine*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 02:27:39 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Cc: Conrad, Patricia (NIH/NIAID) [E]; schoofs@usc.edu
Subject: FW: 2nd try: Mark Schoofs reaching out

Kim:
Please have me call Mark tomorrow.
Thanks,
Tony

From: Mark Schoofs <schoofs@usc.edu>
Sent: Sunday, April 5, 2020 7:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: 2nd try: Mark Schoofs reaching out

Hi Tony,

God knows you are doing the world's most important work right now, but if possible, I would love to talk with you for my COVID-19 project. I promised to keep it under 10 minutes, probably just 5.

My cell: (b) (6)

All best,

Mark

From: Mark Schoofs
Sent: Saturday, March 28, 2020 10:04 AM
To: (b) (6)
Subject: Mark Schoofs reaching out

Hi Tony,


I hope you're hanging in there! If you have 5 minutes — 10 max — I'd like to talk with you for a COVID-19 project I'm working on.


My cell is (b) (6).

Thank you.

All best,

Mark Schoofs
Visiting Professor of Journalism
University of Southern California





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 5 Apr 2020 15:59:51 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST
Attachments: Statement on the COVID-19 pandemic and the Extraordinary G20 Leaders' Summit - 1Apr2020 .pdf, GPMB Teleconference 30 March 2020 - Meeting Report 1 Apr 2020.pdf

Please check this out and let me know if there is anything we need to do. Thanks.

From: RIOUX, Amelie (b) (6)
Sent: Sunday, April 5, 2020 11:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6) >; Steven T. Smith (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; SMITH, Ian Michael (b) (6)
Subject: FW: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

Dear Dr Fauci,

Please find attached the meeting report from the GPMB teleconference on 30 March 2020 and the GPMB co-Chairs' *Statement on the COVID-19 pandemic and the Extraordinary G20 Leaders' Summit on COVID-19*. I apologize, your email was deleted by mistake in the last two messages to the GPMB.

With kind regards,

Amélie
GPMB Secretariat

From: RIOUX, Amelie
Sent: Friday, 3 April 2020 14:18
To: 'VDzau@nas.edu' (b) (6) >; J.Farrar (b) (6) >; 'hfore@unicef.org' (b) (6) >; 'Gao Fu' (b) (6) >; 'Gashumba Diane' (b) (6) >; Ilona Kickbusch (b) (6) >; 'Skvortsova Veronika' (b) (6) >; 'Vega Morales Jeanette' (b) (6) >
>
Cc: Gro (b) (6) 'As Sy' (b) (6) >; SMITH, Ian Michael (b) (6) >; SCHWARTLANDER, Bernhard F. (b) (6) >; 'Pate Muhamed' (b) (6)
Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

Dear Board Members,

Please find the link to the GPMB co-Chairs' *Statement on the COVID-19 pandemic and the Extraordinary G20 Leaders' Summit on COVID-19* (also attached):

<https://apps.who.int/gpmb/assets/pdf/Statement%20on%20the%20COVID-19%20pandemic%20and%20the%20Extraordinary%20G20%20Leaders'%20Summit%201Apr2020.pdf>

We encourage you to circulate the Statement through your channels. You may wish to use the original hashtag from our report #AWorldatRisk in social media posts.

With kind regards,

Amélie
GPMB Secretariat

This message is being sent to GPMB members and their designated staff in copy.

From: RIOUX, Amélie
Sent: Wednesday, 1 April 2020 16:42
To: 'VDzau@nas.edu' <(b) (6)>; J.Farrar <(b) (6)>;
(b) (6); 'Gao Fu' <(b) (6)>;
(b) (6); 'Gashumba Diane' <(b) (6)>; Ilona Kickbusch <(b) (6)>;
'Skvortsova Veronika' <(b) (6)>; 'Vega Morales Jeanette' <(b) (6)>;
(b) (6);
(b) (6)
Cc: 'Gro' <(b) (6)>; 'As Sy' <(b) (6)>; SMITH, Ian Michael
(b) (6); SCHWARTLANDER, Bernhard F. <(b) (6)>; 'Pate Muhamed'
(b) (6)>
Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

Dear Board Members,

On behalf of the co-Chairs, please find attached the report from Monday's teleconference.

With kind regards,

Amélie
GPMB Secretariat

This message is being sent to GPMB members and their designated staff in copy.

From: RIOUX, Amélie
Sent: Tuesday, 31 March 2020 09:17
To: 'VDzau@nas.edu' <(b) (6)>; J.Farrar <(b) (6)>;
(b) (6); 'Gao Fu' <(b) (6)>;
(b) (6); 'Gashumba Diane' <(b) (6)>; Ilona Kickbusch <(b) (6)>;
(b) (6)>

'Skvortsova Veronika' (b) (6); 'Vega Morales Jeanette' (b) (6);
(b) (6)

Cc: Gro (b) (6); 'As Sy' <(b) (6)>; SMITH, Ian Michael
(b) (6); SCHWARTLANDER, Bernhard F. <(b) (6)>; RYAN, Michael J.
(b) (6); 'Pate Muhamed' <(b) (6)>; 'Godal, Tore' (b) (6)
'Tore Godal' <(b) (6)>; Alveberg, Benedikte Louise (b) (6);

(b) (6)
Scott Dowell
(b) (6) William
Hall (b) (6) 'Teresa Miller de
Vega' <(b) (6)>

'Marston Hilary'
(b) (6)
Carlos Navarro Colorado <(b) (6)>
>; 'Zacharie Gahungu'
(b) (6)

; 'office-psa@nic.in' <office-psa@nic.in>; Toomas
Palu (b) (6); GPMB Secretariat <gpmbscretariat@who.int>; GABEDAVA, Tsira
(b) (6); 'Steve Landry' (b) (6)

Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30
MARCH 15:00 CEST

MESSAGE ON BEHALF OF THE GPMB CO-CHAIRS DR BRUNDTLAND AND MR SY

Dear GPMB Members,

Many thanks for your contributions to our teleconference, and to Jeremy and Victor for their very helpful report on the GPMB COVID-19 advocacy.

Several of you mentioned that you had additional points that you might wish to make in writing; please do so as soon as possible, copying them to all Board members.

If you have not already nominated a 'sherpa' to represent you in the informal support group that will work with the secretariat, please do so as soon as possible. The secretariat is organizing a teleconference with the informal support group to follow up on the direction given by the Board on the annual report and work plan.

Kind regards,

Gro & As
GPMB Co-chairs

From: RIOUX, Amelie

Sent: Monday, 30 March 2020 12:19

To: 'VDzau@nas.edu' <[redacted]>; J.Farrar <[redacted]>
<[redacted]> 'Gao Fu' <[redacted]>
<[redacted]>, 'Gashumba Diane' <[redacted]>; Ilona Kickbusch <[redacted]>;
'Skvortsova Veronika' <[redacted]>; 'Vega Morales Jeanette' <[redacted]>;
<[redacted]>

Cc: Gro <[redacted]> 'As Sy' <[redacted]>; SMITH, Ian Michael <[redacted]>;
<[redacted]> SCHWARTLANDER, Bernhard F. <[redacted]>; RYAN, Michael J. <[redacted]>;
<[redacted]> 'Pate Muhamed' <[redacted]>; 'Godal, Tore' <[redacted]>;
'Tore Godal' <[redacted]>; Alveberg, Benedikte Louise <[redacted]>;
<[redacted]>
<[redacted]> Scott Dowell <[redacted]> William
<[redacted]> Hall <[redacted]> 'Teresa Miller de
<[redacted]> Vega' <[redacted]>
<[redacted]> 'Marston Hilary' <[redacted]>
<[redacted]> Carlos Navarro Colorado <[redacted]>
<[redacted]> 'Zacharie Gahungu' <[redacted]>
<[redacted]>
<[redacted]>
<[redacted]>
<[redacted]>
<[redacted]> 'office-psa@nic.in' <office-psa@nic.in>; Toomas
<[redacted]> Palu <[redacted]>; GPMB Secretariat <[redacted]>; GABEDAVA, Tsira <[redacted]>;
<[redacted]> 'Steve Landry' <[redacted]>

Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

Dear Board Members and Colleagues,

A kind reminder that Europe has switched to Daylight Saving Time over the weekend.

The call takes place today at 15:00 Geneva time, which is 06:00 Seattle time, 09:00 DC time, 21:00 Beijing time, and 22:00 Tokyo time.

Best,

Amélie

From: SMITH, Ian Michael <[redacted]>
Sent: Friday, 27 March 2020 19:19
To: <[redacted]>; Chris.Elias <[redacted]>; J.Farrar <[redacted]>

< (b) (6) >; 'Anthony Fauci' (b) (6)
(b) (6) 'Gao Fu' (b) (6)
(b) (6); 'Gashumba Diane' (b) (6); Ilona Kickbusch < (b) (6) >;
'Skvortsova Veronika' (b) (6) 'Vega Morales Jeanette' (b) (6)
(b) (6)
Cc: Gro < (b) (6) >; 'As Sy' (b) (6); SCHWARTLANDER, Bernhard F.
< (b) (6) >; RYAN, Michael J. (b) (6); 'Pate Muhamed'
(b) (6); 'Godal, Tore' (b) (6); 'Tore Godal' (b) (6)
Alveberg, Benedikte Louise (b) (6)
(b) (6)
(b) (6); Scott Dowell (b) (6)
(b) (6) William Hall < (b) (6) >
(b) (6) 'Teresa Miller de Vega'
(b) (6)
(b) (6) 'Marston Hilary' (b) (6)
(b) (6); Carlos
Navarro Colorado (b) (6)
(b) (6) 'Zacharie Gahungu' (b) (6);
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6) >; 'office-psa@nic.in' <office-psa@nic.in>; Toomas Palu (b) (6)
GPMB Secretariat <gpmbsecretariat@who.int>; GABEDAVA, Tsira (b) (6); 'Steve Landry'
(b) (6) RIOUX, Amelie (b) (6)

Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

Dear Board members, dear Colleagues,

Thank you very much to those of you who confirmed your participation in the teleconference on Monday from 15.00-16.00 CET. If you have not done so yet, we would be grateful if you could let us know as soon as possible.

If you cannot attend, the co-Chairs would welcome your written comments in advance of the call.

In preparation for the call, please find attached:

1. Agenda
2. Extraordinary G20 Leaders' Summit Statement on COVID-19 (shared with you earlier)
3. Update on the GPMB urgent COVID-19 funding call from the GPMB COVID-19 sub group
4. Overview of Existing Global Appeals and Funding Mechanisms for COVID-19 (for information)

The call-in details are copied below.

Please note that as several of you have nominated an Alternate to attend on your behalf, the co-chairs will invite Board Members to speak first, followed by Alternates speaking on behalf of Board members.

Given the very limited time, the co-Chairs have asked that keep your interventions as short as possible.

We look forward to the call. Please let us know if you have any questions.

With kind regards,

Ian Smith
GPMB Secretariat

Call-in Details:

By clicking on the link [Access via Web](#), you will find local and toll-free call-in numbers.

Participant access



(b) (4)

Security code: For this conference a Security code is not necessary.



Optional dial-in numbers
international
+41 58 262 07 22 (English) +41 58
262 07 44 (Italiano) +41 58 262
07 11 (Deutsch) +41 58 262 07 33
(Français)



Access via [Web](#)

From: RIOUX, Amelie

Sent: Wednesday, 25 March 2020 14:16

To: (b) (6) Jeremy Farrar (b) (6)

Anthony Fauci (b) (6); Gao Fu (b) (6);

(b) (6); Gashumba Diane (b) (6); Ilona Kickbusch

(b) (6); Skvortsova Veronika (b) (6); Vega Morales Jeanette

(b) (6)

Cc: (b) (6); As Sy (b) (6); SMITH, Ian Michael (b) (6);

SCHWARTLANDER, Bernhard F. (b) (6); RYAN, Michael J. (b) (6); Pate

Muhammed (b) (6); Godal, Tore <(b) (6)>; Tore Godal (b) (6);

Alveberg, Benedikte Louise (b) (6)

(b) (6) 'Teresa Miller de Vega'

(b) (6); 'Marston Hilary'

(b) (6)

Zacharie Gahungu

(b) (6)

Toomas Palu (b) (6); GPMB Secretariat (b) (6); GABEDAVA, Tsira (b) (6)>

Subject: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

MESSAGE ON BEHALF OF THE GPMB CO-CHAIRS DR BRUNDTLAND AND MR SY

Dear Board Members,

We would like to propose to hold a Board teleconference on **Monday 30 March 2020, 15:00-16:00 CEST time**. The purpose of the call will be to update you on the GPMB's COVID-19 advocacy and to discuss next steps. A more detailed agenda and call-in details will be shared shortly.

We would appreciate if you could confirm your participation to Amélie Rioux (b) (6)

Thank you for your continued support and engagement.

With kind regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 5 Apr 2020 01:57:37 +0000
To: Teri McPeak
Subject: RE: Association between Proton Pump Inhibitors and increased risk of Covid-19 death

Thanks, Teresa.

From: Teri McPeak <t.mcpeak@live.ca>
Sent: Saturday, April 4, 2020 5:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Association between Proton Pump Inhibitors and increased risk of Covid-19 death

Dr. Fauci,

There is a wealth of medical research papers about the association between Proton Pump Inhibitors (PPI) and increased risk of community acquired pneumonia. Long term use of PPIs reduce the pH of the stomach from 1 to 5. This reduction in stomach acid reduces the body's ability to fight viruses.

In addition, the lower stomach pH reduce the ability to absorb key nutrients that require gastric acid for breakdown and absorption (calcium, vitamin C & B12, iron, magnesium, potassium, zinc). Lack of proper nutrients lead to a compromised immune system.

Seniors and individuals with chronic illnesses are at higher risk of polypharmacology and dying from Covid-19 due to PPIs. The more medications an individual takes, the more likely they will suffer from acid reflux and thus be prescribed a PPI.

Thank you for your commitment and compassion during the pandemic. God bless you.

Regards,

Teresa McPeak
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 5 Apr 2020 01:54:27 +0000
To: Silver, David (NIH/NCI) [C]
Subject: RE: Question

David:

Thanks for the note. Since they both effected adequate quarantine, they are OK with each other....provided that they practice physical distancing with everyone else, i.e. 6 feet apart and masks when out in situations where they cannot guarantee 6ft distance. With regard to your second question, it is not a question of temperature, it is a question of what surface the virus is on – stainless steel versus cloth, versus cardboard. Each of these have differ time frames of survival of replication competent virus from a couple of hours to about 2 days.

Best regards,
Tony

From: Silver, David (NIH/NCI) [C] (b) (6)
Sent: Saturday, April 4, 2020 9:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Question

Dr. Fauci,

You are doing a great job and I am sure that things must be very challenging.

Please let me know your thoughts on this, although I think I know the answer. (b) (6)

(b) (6) Is it safe for them to see each other at this point?

I was also wondering if it has been determined how long COVID-19 can live in a refrigerator or freezer.

Thank you.

Stay Healthy.

David

David Silver - Contractor
(b) (6)

National Institutes of Health, NCI
Center for Biomedical Informatics and Information Technology (CBIIIT)
9609 Medical Center Dr.

Rockville, MD 20850

From: (b) (6)
Sent: Sat, 4 Apr 2020 15:50:32 -0400
To: anthony trocchi
Subject: Re: An acquaintance from the past

Tony:

Thank you for your note. I hear you!

Best regards,

Tony

> On Apr 4, 2020, at 12:25 PM, anthony trocchi (b) (6) > wrote:

>

>

> Hi Tony, You probably don't remember me, I was (b) (6) husband back when she was at NIH, you came to dinner at our house once. We also hung out in Boulder and drank beer together. I am just a working class guy, but keep up with science and politics for what it is worth. I don't know what you hear from the street level, but from here in NY we are pretty concerned with the risk of Covid-19 and the Federal response to the pandemic. You have been the only reasonable voice in the administration. The leadership from the top is utterly lacking and incompetent and dangerous to the American people. You have had a long and venerable career and I am asking you to stand up to power and speak the harsh truth to the people of this country and the without regard to your personal consequences. We need a unified and professional federal response to this unprecedented crisis. I think you may be the only person of repute and status that has the power to change the course of history. I have spoken with a good friend of mine who is a respected epidemiologist and he said that Covid-19 will infect half the population of the world and those numbers are frightening statistically. My dad was born during the first worldwide modern pandemic and I don't really want to see him leave from this current one. I know I am somewhat out of place writing to you, but one can only do what one can do to influence the events that history arises from. With utmost respect. Tony Trocchi

> Sent from my iPhone

From: (b) (6)
Sent: Sat, 4 Apr 2020 15:42:37 -0400
To: Stuart Coulter
Subject: Re: Early Successes in Clinical Trial on COVID-19 Patients with High Dose IV Vitamin C

Thanks, Stuart. I appreciate your sending me this information. I will pass it on to relevant program people.
Best regards,
Tony

On Apr 4, 2020, at 3:38 PM, Stuart Coulter <(b) (6)> wrote:

Dear Dr. Fauci,

Early Successes in Clinical Trial on COVID-19 Patients with High Dose IV Vitamin C

Thank you for the invaluable work that you are doing in guiding the United States through the current COVID-19 pandemic.

I hope that you do not mind me contacting you, but I wanted to bring your attention to a clinical trial that is currently taking place in China on COVID-19 patients with high dose IV Vitamin C.

There are reports of some early successes with this treatment and I wondered if this could be a possible stop gap treatment - that could possibly save many lives - while we await the development of suitable drug treatments and a reliable vaccine.

The trial in China is not due to conclude until September of this year, however, previous trials of IV Vitamin C have shown it to be a very safe treatment with little or no adverse side effects. I have read that the Northwell Hospital Group in New York, which operates 23 hospitals, have already started to give this treatment to many of their COVID-19 patients.

This treatment also appears to meet the normally required criteria for a clinic trial. The treatment has been shown to be:

- 1) Effective (Please see the link below to the promising trial results currently taking place in China).
- 2) Safe (The treatment has been shown to be safe in many previous trials going back well over 40 years).
- 3) Correct dosage is understood (The dosage is fully understood - please see the attached Protocol).
- 4) The correct patients to give this treatment to (Virtually everyone in hospital infected with COVID-19).
- 5) The correct time in the illness to give the treatment (As soon as the infected patient comes into hospital).

I hope that you and your team find the details of this clinical trial of some interest. The hospital protocol for this treatment is attached and here is a link to details of the current trial in China along with some other relevant links:

<http://www.orthomolecular.org/resources/omns/v16n18.shtml>

<http://www.orthomolecular.org/resources/omns/v16n19.shtml>

<http://www.orthomolecular.org/resources/omns/v16n07.shtml>

<http://orthomolecular.org/resources/omns/v16n21.shtml>

<https://www.sciencedirect.com/science/article/pii/S2590098620300154?via%3Dihub>

Kind regards,
Stuart Coulter

<Journal Pre-proof - Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019.pdf>

<Protocol - IVAA-COVID19-Hospital-Use-Anderson-03.24.2020.pdf>

From: (b) (6)
Sent: Sat, 4 Apr 2020 12:42:38 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview Request: #1 Hiking Podcast

FYI

Begin forwarded message:

From: Zach Davis <zach@thetrek.co>
Date: April 4, 2020 at 12:39:25 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Interview Request: #1 Hiking Podcast

Hey Dr. Fauci-

My name is Zach Davis, I'm the founder and editor-in-chief at The Trek, a media company dedicated to long distance backpackers. Thank you for the tremendous service and leadership you've given this country during a time of great need.

I'm reaching out to inquire about the possibility of your doing a short interview for our flagship podcast, Backpacker Radio, the #1 rated hiking podcast on iTunes. We're putting together an episode related to how COVID-19 has impacted this year's class of backpackers, and would love to feature your expert insight on why social distancing is important, and what the future may hold for our community.

The interview would be about 20-25 minutes, though if you're only available for a shorter period, we'll take what we can get!

Thanks for your time and thank you again for your terrific service to this country.

Happy hiking,

--



Zach Davis

founder || editor-in-chief

[hikerlink](#) | [thetrek.co](#) | [backpacker radio](#)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 4 Apr 2020 16:25:36 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: AFRICA CDC: STATEMENT ON MEDICATIONS TO TREAT NOVEL CORONAVIRUS DISEASE

Good for them!!!

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Saturday, April 4, 2020 12:21 PM
Subject: AFRICA CDC: STATEMENT ON MEDICATIONS TO TREAT NOVEL CORONAVIRUS DISEASE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 4 Apr 2020 15:18:14 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Excellent start to COVID PPP
Attachments: COVID PPP April 3 actions.docx, Introductory call short bios - 3 Apr 2020 final.docx

Please print out these attachments and put into a folder labelled "COVID-19 Public Private Partnerships" Thanks.

From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Saturday, April 4, 2020 10:26 AM
To: (b) (6) (OS/IOS) <(b) (6)>
Cc: Harrison, Brian (HHS/IOS) <(b) (6)>; Tabak, Lawrence (NIH/OD) [E]
<(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Excellent start to COVID PPP

Hi Mr. Secretary,

Just wanted to let you know – we had a very productive and significant two-hour virtual meeting with leaders of industry, FDA, and NIH yesterday. I attach the bios of those who attended – which includes the heads of R&D of nine major pharmaceutical companies. There is unanimous support for bringing together all of the sectors to accelerate development of therapeutics and vaccines for COVID-19. Tony compared this to what happened in the early 1990s that led to successful antivirals for HIV.

I attach the action items that came out of this meeting. Working groups for each of the four main topics will be rapidly organized. I will keep you posted.

Best, Francis

From: (b) (6)
Sent: Fri, 3 Apr 2020 16:42:08 -0400
To: Cantor, Harvey I.,M.D.
Cc: NIAID OD AM
Subject: Re: COVID-19

Harvey:

Thank you for your kind note. It is much appreciated. I will let the team know about your willingness to serve on committees and study sections.

Best regards,

Tony

On Apr 3, 2020, at 1:20 PM, Cantor, Harvey I.,M.D.

(b) (6) wrote:

Dear Tony,

In these unsettling times, you are a much-appreciated voice of reason and proponent of rational science.

A great credit to NIH and NIAID...we're all very proud of you.

I know that you have long advocated preparation of viral vaccines against future pandemic threats.

I'm sure that it has been difficult to convince pharmas, charitable agencies and even the government to fund these efforts.

which would include vaccine production and storage for indefinite periods. Perhaps there will be a greater willingness to revisit a cost-benefit analysis of this effort in the near future.

I would be happy to serve on committees, study sections etc. in an effort to increase our ability to identify and fund first-rate

immunology research that might accelerate innovative, safe and effective approaches to improved viral vaccines going forward.

All very best regards, h.

Harvey Cantor, MD
Baruj Benacerraf Professor of Immunology
Department of Immunology,
Harvard Medical School
Dept. of Cancer Immunology & Virology,
Dana-Farber Cancer Institute

Boston MA 02215

(b) (6)

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at <http://www.partners.org/complianceline> . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

From: (b) (6)
Sent: Fri, 3 Apr 2020 16:29:45 -0400
To: Hasenkrug, Kim (NIH/NIAID) [E]
Subject: Re: Thanks from the troops

Kim:
Many thanks for your kind note .
Best regards,
Tony

On Apr 3, 2020, at 1:56 PM, Hasenkrug, Kim (NIH/NIAID) [E]

(b) (6)

Hi Tony, I just want to express my sincere gratitude for all you are doing to get us through this crisis. Everyone I've talked to at RML expresses their deep admiration and appreciation for your strong leadership, and we feel proud to be working for you. We listen to your hoarse voice every day. Personally, I have started two new lines of research to develop and test possible therapeutics for COVID-19. The cooperation and collaboration from everyone I've talked to, both here and around the nation, has been unbelievable. Please take care of yourself and stay strong and healthy for the sake of all of us!

Best regards,

Kim

Kim J Hasenkrug, Ph.D.
Senior Investigator
Chief, Retroviral Immunology Section
Laboratory of Persistent Viral Diseases
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 S. 4th Street
Hamilton, MT 59840
phone (b) (6)

FAX (406)363-9286


(b) (6)


Disclaimer:


The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who

is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other

storage devices. National Institute of Allergy and Infectious Diseases







From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 3 Apr 2020 11:07:58 +0000
To: Ghafoor, Azam (NIH/NCI) [E]
Cc: NIAID DD AM
Subject: RE: Help

Thanks for your note. I will circulate to others in NIAID

From: Ghafoor, Azam (NIH/NCI) [E] (b) (6) >
Sent: Thursday, April 2, 2020 11:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Help

Dear Dr. Fauci,

I am thoracic oncologist at the NCI. I wanted to commend you on your tremendous (and exhausting) job on managing and steering our country with the COVID-19 pandemic. If you need additional any personnel to help with any clinical or non-clinical aspects of the current situation, I am more than happy to help. As you know we have scaled down our clinical operations and trials at the NIH CC and so I have more time.

Best regards,

Azam Ghafoor, MD
Assistant Research Physician & Staff Oncologist
Thoracic Oncology Section
Thoracic and GI Malignancies Branch
National Cancer Institute, National Institutes of Health
10 Center Drive, Building 10, Room: 4G-5330
Bethesda, MD 20892

e: (b) (6)

o: (b) (6)

e: (b) (6)

page ID (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 3 Apr 2020 02:40:47 +0000
To: David Barr
Cc: Giroir, Brett (HHS/OASH); Conrad, Patricia (NIH/NIAID) [E]
Subject: Introduction

David:

I am using this e-mail to introduce you to Adm. Brett Giroir who is the Assistant Secretary for Health at HHS and a key member of the Coronavirus Task Force. I have explained to Brett the issues that you and your colleagues brought up over the phone with me the other night. Brett is willing to get on the phone with the group and go over some of these issues and perhaps help to resolve them. He is waiting to hear from you. Many thanks.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 3 Apr 2020 02:10:12 +0000
To: Stephen Hahn
Cc: (b) (6)
Subject: FDA release

Steve:

My staff just pointed out to me a proposed FDA press release regarding convalescent plasma and hyperimmune globulin. The press release reads as follows:



I just wanted to bring this to your attention for further consideration. Many thanks.

Best regards,

Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 3 Apr 2020 01:53:59 +0000
To: Emilio Emini
Cc: Conrad, Patricia (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]; Erbeding, Emily (NIH/NIAID) [E]; Bright, Rick (OS/ASPR/BARDA); Collins, Francis (NIH/OD) [E] (b) (6); Trevor Mundel
Subject: RE: Connection Request per Bill Gates

Emilio:

Thanks for your note. As I had mentioned to Bill yesterday evening, I am enthusiastic about moving towards a collaborative and hopefully synergistic approach to COVID-19 on the part of NIAID/NIH, BARDA and the BMGF. I will ask John Mascola and Emily Erbeding to connect with you to stay a conversation. Perhaps they can organize a call with you including BARDA. I will try to engage as much as I can given my current circumstances. We look forward to working with you.

Best regards,
Tony

From: Emilio Emini (b) (6)>
Sent: Thursday, April 2, 2020 9:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Connection Request per Bill Gates

Tony—I received a note from Trevor and Bill that they connected with you yesterday and they asked me to reach out. I've taken on the role of coordinating the foundation's contributions to the global COVID vaccine efforts, in particular for those approaches that are (or soon will be) in early development. There's an obvious need for coordination among the various primary funders or the focus we need to have given the state of the pandemic will become lost through uncoordinated activities.

Bill tells me that you will take on a central role in coordinating BARDA's funding to the ongoing efforts. And, of course, there are the NIH/VRC activities. I'm reaching out to ask how we can coordinate and cross-inform each other's activities. I am very sensitive to how busy you are and very grateful for your engagement. I see you on TV almost every day, and although you continue to have considerable energy, I am seriously worried about you. The nation and the world absolutely need your leadership.

As a next step we can connect 1:1 briefly or you can pass this on to an appropriate member of your staff.

If you wish, you can always reach out to me directly at any time though my personal mobile at (b) (6)

Please stay well....Emilio

Emilio A. Emini, Ph.D., FCPP, FAAM
Director

TB and HIV Program
Bill & Melinda Gates Foundation

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 23:50:04 +0000
To: Glass, Roger (NIH/FIC) [E]
Subject: RE: COVID-19 in Africa: Tanzania

Thanks, Roger.

From: Glass, Roger (NIH/FIC) [E] (b) (6)
Sent: Thursday, April 2, 2020 6:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: COVID-19 in Africa: Tanzania

Tony,

You have a fan club in Tanzania—Julie Makani and Lucio with your textbook!

Keep up the heroic work.

Roger

From: Julie Makani <jmakani@blood.ac.tz>
Sent: Wednesday, April 1, 2020 5:46 PM
To: Glass, Roger (NIH/FIC) [E] (b) (6)
Subject: Re: COVID-19 in Africa: Tanzania

Please pass greetings to Dr Fauci

His authorship on Google Scholar including of Harrison's has been under discussion on social media

Lucio has been writing the chapter on hemolytic anemia

He is heading to Italy for 3 months. He has been incredible. He was leaving his copies with the Sickle cell programme as we plan on getting keen scientists to read them

Stay safe

Prof Julie Makani, T: + (b) (6) E: jmakani@blood.ac.tz

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 21:52:30 +0000
To: Lerner, Andrea (NIH/NIAID) [E], NIAID OD AM
Subject: RE: My take on masks

Thanks, Andrea

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Sent: Thursday, April 2, 2020 1:01 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: My take on masks

Given our discussion this AM, just thought I would summarize my take on masks across varying scenarios:



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 21:14:40 +0000
To: Balasundaram, David (NIH/CSR) [E]
Subject: RE: Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study

Thanks, David.

From: Balasundaram, David (NIH/CSR) [E] (b) (6)
Sent: Wednesday, April 1, 2020 7:19 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Balasundaram, David (NIH/CSR) [E] (b) (6)
Subject: Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study
Importance: High

Dear Dr. Fauci,

I thought that you may be interested in reading this paper (Unless you already know about this of course!). This is obviously a data-driven set of correlative observations, but could be worth looking into.

I salute your outspoken efforts to galvanize this country into action in the midst of so many mixed messages and dragging of feet.

Cheers,

David

David Balasundaram, PhD.,

Scientific Review Officer,

Cell Biology Integrated Review Group,

<http://public.csr.nih.gov/StudySections/IntegratedReviewGroups/CBIRG/Pages/default.aspx>

Referral Officer,

Division of Receipt and Referral



6701 Rockledge Drive, Room 5136, Bethesda, MD 20892-7768

Office (b) (6) | Fax: 301-480-1988 | Email: (b) (6)

Integrity matters. Say something! For concerns or questions about possible violations of peer review integrity, please contact your Scientific Review Officer, or the CSR Review Integrity Officer at csrio@mail.nih.gov, or the NIH Review Policy Officer at reviewpolicyofficer@mail.nih.gov. See the [NIH Guide Notice](#) on integrity in review.

From: (b) (6)
Sent: Thu, 2 Apr 2020 13:29:05 -0400
To: Vollmer, Sebastian
Subject: Re: Estimate of undetected COVID-19 infections

Thanks, Sebastian. Very helpful

> On Apr 2, 2020, at 8:43 AM, Vollmer, Sebastian (b) (6) wrote:

>

> Dear Dr. Fauci,

>

> we have used estimates of COVID-19 age specific infection fatality rates and time from onset to death that were recently published in The Lancet Infectious Disease to estimate COVID-19 detection rates and the true number of infected people (in contrast to confirmed cases that are widely reported) for the 40 most affected countries. We estimate a detection rate of on average six percent and number of cases of a few tenth of millions. We thought you might be interested and have attached the note to this email.

>

> Thanks for doing such a great job in such a difficult time. I lived in Boston for a few year when I was a postdoc and later adjunct professor at the Harvard Chan School of Public Health. My thoughts are with my friends in the United States, particularly in New York.

>

> Warmly,

> Sebastian Vollmer

>

>

>

>

> <Bommer & Vollmer (2020) COVID-19 detection April 2nd.docx>

From: (b) (6)
Sent: Thu, 2 Apr 2020 13:02:41 -0400
To: Jim West
Subject: Re: THANK YOU TONY!

Jim:
Thank you for your kind note. It is much appreciated.
Best regards,
Tony

On Apr 2, 2020, at 10:08 AM, Jim West (b) (6) >wrote:

Dear Tony,

My name is Jim West and (b) (6)
(b) (6) Most people did not know (b) (6), except
his immediate family, close friends and of course Jack Whitescarver. I am writing
to congratulate you on the job you are doing with the Coronavirus. There is no
doubt in my mind it has been exceedingly stressful for you and your family, and I
just wanted to offer my support and reassurance that you are indeed doing a great
job. I know (b) (6) could have never handled the stress of all of this, and he would
be most proud of the job you are doing.

Take good care of yourself and keep steadfast in what you are doing. You are
the true *medical advisor* of the United States during this pandemic, and millions of
us are incredibly grateful.

Sincerely yours,

Jim West





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 13:21:29 +0000
To: WAYNE REYNOLDS
Subject: RE: Heads Up - Dr. Fauci Bobblehead with a Cause

Wayne and Catherine:

Thank you for your kind note. Much appreciated. Please stay safe and well so that we can some time soon (I hope) resume our normal lives together.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: WAYNE REYNOLDS (b) (6) >
Sent: Wednesday, April 1, 2020 3:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Grady, Christine (NIH/CC/BEP) [E] (b) (6) >
Subject: Fwd: Heads Up - Dr. Fauci Bobblehead with a Cause

Tony,

You've finally hit the big time. The National Bobblehead Hall of Fame and Museum. Thank you for all you're doing for the country.

Warmest wishes,

Wayne and Catherine

Sent from my iPhone

Begin forwarded message:

From: "Jordan, Mary" <Mary.Jordan@washpost.com>
Date: April 1, 2020 at 3:39:44 PM EDT
To: Wayne Reynolds <(b) (6)>
Subject: Fw: Heads Up - Dr. Fauci Bobblehead with a Cause

Who knew there was a National Bobblehead Hall of Fame and Museum!

From: Phil Sklar <phil.sklar@bobbleheadhall.com>
Sent: Wednesday, April 1, 2020 3:34 PM
To: Jordan, Mary <Mary.Jordan@washpost.com>
Subject: Heads Up - Dr. Fauci Bobblehead with a Cause

CAUTION: EXTERNAL SENDER

Hi Mary,

I hope you are staying well during these unprecedented times! I wanted to give you a heads up that we will be unveiling a bobblehead of Dr. Anthony Fauci this Friday, April 3rd. Dr. Fauci has become America's voice of reason as one of the lead members of the White House Coronavirus Task Force. The National Bobblehead Hall of Fame and Museum will be donating \$5 from every Dr. Fauci Bobblehead sold to the American Hospital Association in support of the 100 Million Mask Challenge [icm-tracking.meltwater.com]. The bobbleheads will be available for pre-order on our website beginning on Friday.

Bobbleheads are the ultimate honor, and we think Dr. Fauci deserves it given what he has done and continues to do for our country and the world in the battle against COVID-19. The bobblehead will join a growing number of items including donuts, socks and t-shirts featuring Dr. Fauci. We received a lot of requests for a bobblehead of Dr. Fauci and are excited to be able to use the bobblehead to raise funds for a vital organization that is helping limit the spread of the Coronavirus while making people smile during these unprecedented times.

Let me know if you would like the press release, pictures and graphics in advance of Friday's release. Please hold off on publicizing anything related to the bobblehead until Friday—any time on Friday is okay. Please also let me know if you would like a sample when they arrive or if you have any questions.

Thank you,

Phil

Phil Sklar

Co-Founder and CEO

National Bobblehead Hall of Fame and Museum

Phil.Sklar@bobbleheadhall.com

414-519-2625

www.bobbleheadhall.com [icm-tracking.meltwater.com]

This email was sent to mary.jordan@washpost.com
National Bobblehead Hall of Fame and Museum, PO Box 0982, Milwaukee, WI
53201-0982, US

[Unsubscribe](#) [icm-tracking.meltwater.com]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 12:59:53 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C]
[REDACTED] (b) (6)
Subject: FW: COVID-19 Planning

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tabak, Lawrence (NIH/OD) [E] [REDACTED] (b) (6)
Sent: Wednesday, April 1, 2020 7:35 PM
To: ICDDIR-L@LIST.NIH.GOV; List DEPDIR-L <DEPDIR-L@list.nih.gov>
Cc: NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>
Subject: Re: COVID-19 Planning
Importance: High

Colleagues,

The momentum behind a 4th COVID supplement seems to be building in the Congress even more quickly than we had expected. We have received a TA request to provide rough numbers for NIH efforts **by Friday afternoon**. With regrets for adding more burdens to the intense efforts you are already engaged in, I ask that you submit a rough estimate of the first year and the five year budget for your (i) IC-specific initiative(s) and/or your (ii) proposals to contribute to economic recovery, no later than *Friday April 3 at noon*. This will be non-binding, and you are free to revise it for the submission that we already asked you for by Friday COE. The only thing we need Friday at noon is the budget – the narrative can come later in the day (or the night).

Please use the second page of the template we sent you yesterday to provide this draft budget. Send to me.

I apologize for the impossible turn-around and appreciate all the hard work that will be needed to get us this information by the Friday noon deadline.

Many thanks,
Larry

From: "Tabak, Lawrence (NIH/OD) [E]" <[REDACTED] (b) (6)>
Date: Tuesday, March 31, 2020 at 4:20 PM
To: "ICDDIR-L@LIST.NIH.GOV" <ICDDIR-L@LIST.NIH.GOV>, List DEPDIR-L <DEPDIR-L@list.nih.gov>
Cc: NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>
Subject: COVID-19 Planning

Colleagues,

Francis is sending out a note shortly to the co-chairs of each of the ten trans-NIH initiatives, asking for their assistance in putting together workplans and budgets for those projects. But in addition to these trans-NIH activities, we invite ICDs to submit a short description of no more than two IC-specific ideas that you believe merit consideration for support in a fourth supplemental bill, should one be put forward. Please use the same template that is being used for the trans-NIH activities, but just check the appropriate tick box. Your submission should include budget estimates for the first year and subsequent outyears (for a total of 5 years). [REDACTED] (b) (5)

[REDACTED]. Please send these to me by COE, Friday, April 3rd.

Finally, if we are asked about technical assistance regarding economic recovery, please send ideas for that option. As part of this, Mike Lauer and Michael Gottesman will submit estimates on what might be needed for extramural institutions and the IRP to "make them whole". However beyond that there are infrastructure, training, and other requests that would help national economic recovery by creating new jobs (construction, IT, biomedical, etc.) and help prepare the nation for COVID-202X. Please use the same template that will be used for the trans-NIH activities (again, checking the correct box) and include budget estimates for the first year and subsequent outyears (for a total of 5 years). Please send these to me by COE, Friday, April 3rd.

Many thanks,
Larry

From: (b) (6)
Sent: Thu, 2 Apr 2020 07:28:32 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: media inquiry on COVID-19

Begin forwarded message:

From: "stefano.valentino@globalreporter.it" <stefano.valentino@globalreporter.it>
Date: April 2, 2020 at 5:54:54 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: media inquiry on COVID-19

Dear Dr. Fauci,

I am a Brussels-based journalist, member of the European Data Journalism Network (EDJNet), a digital news-making platform that affiliates media outlets across Europe.

I found a quote from you in this article which seems to be quite prophetic: <https://www.theatlantic.com/health/archive/2020/02/covid-vaccine/607000/>

I contact you to have a discussion about the effectiveness of the epidemic outbreak preparedness and response measures put in place by governments, particularly in terms of vaccine development.

I would like to know if we could ave a chat on skype. Or, if you prefer, I can send you some questions by email.

I wait for your kind feedback

Regards

Stefano Valentino

Founder
MobileReporter

Special Investigations Contributor
Vox Europ

Fatto Quotidiano

Fullbright Alumni
Berkley School of Journalism

Memberships:

Italian Press Association
European Data Journalism Network
Italian Science Writers Association
Society of Environmental Journalists
Online News Association

Tel: [REDACTED] (b) (6)

Whatsapp: [REDACTED] (b) (6)

Skype: globalreporter

Twitter: @MOBILEREPORTER

info@mobilereporter.info

www.mobilereporter.info

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 10:58:29 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Possible Interview via FaceBook

fyi

From: Brendan Taglianetti <btaglianetti@milford.nh.gov>
Sent: Thursday, April 2, 2020 6:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Possible Interview via FaceBook

Dear Dr. Anthony S. Fauci,

My name is Brendan Taglianetti; I am a Full-Time Advanced EMT provider for Milford Ambulance Service in Milford, NH. I want to help relay your message of COVID-19 information for state of New Hampshire, by conducting a Facebook Live chat with myself to project information and messages to the citizens of New Hampshire. This is a chance for us to chat for around 10 minutes and talk with a first responder to the general public.

I have seen you do interviews with the media/ daytime talk shows, a Facebook live chat with Mark Zuckerberg, and even an Instagram live video with Stephen Curry from the Golden State Warriors.

I run the social media aspect of the department, and I would love to do a 10-15 minute discussion (with information to the public, as well as some question and answer) with you on Facebook (live) to have the general public watch us talk about the pandemic and the next steps, and also maybe take some questions asked of the public watching when they comment. I also will be reaching out to the New Hampshire State Governor Chris Sununu and Dr. Benjamin P. Chan (who is the state's epidemiologist). I would love to have them chat with me, and have you join in on the discussion as well. I have no confirmed with them if they are available yet, but I am putting things in motion.

I know that if I was able to set up a time and date that would work around your busy and important schedule, then I could with ample time promote it. I would love to not only get the town on Milford to watch this, but have the state of New Hampshire and other states nearby tune in. I know this is a long shot and that you have way more important aspects of your job to complete, but I think this an important time to have the public hear you talk.

Please let me know if this could be possible and I would love to set this up, I don't expect to take too much of your time if this can happen. Sometimes in life you just need to ask and see what happens and this is a time where that risk is worth it to have a conversation with you about this pandemic we are facing, especially as we ramp up for starting to "peak" in the number of people affected.

Please let me know if this is possible and tell me if you are interested in doing this with us for the greater good of the general public to keep them informed.

Sincerely,

Brendan J. Taglianetti

Full-Time Advanced EMT/ Field Training Officer

Milford Ambulance Service

66 Elm Street, Milford, NH 03055

Phone: (603) 249-0610 (ext. 275)

Email: btaglianetti@milford.nh.gov

From: (b) (6)
Sent: Wed, 1 Apr 2020 22:15:42 -0400
To: McNeil Jr, Donald G
Subject: Re: Heads Up - Dr. Fauci Bobblehead with a Cause

Yikes!!!

On Apr 1, 2020, at 9:55 PM, McNeil Jr, Donald G <meneil@nytimes.com> wrote:

I'm ordering one for my office desk and maybe another for (b) (6)

----- Forwarded message -----

From: **Phil Sklar** <phil.sklar@bobbleheadhall.com>
Date: Wed, Apr 1, 2020 at 3:35 PM
Subject: Heads Up - Dr. Fauci Bobblehead with a Cause
To: <meneil@nytimes.com>

Hi Donald,

I hope you are staying well during these unprecedented times! I wanted to give you a heads up that we will be unveiling a bobblehead of Dr. Anthony Fauci this Friday, April 3rd. Dr. Fauci has become America's voice of reason as one of the lead members of the White House Coronavirus Task Force. The National Bobblehead Hall of Fame and Museum will be donating \$5 from every Dr. Fauci Bobblehead sold to the American Hospital Association in support of the [100 Million Mask Challenge](#). The bobbleheads will be available for pre-order on our website beginning on Friday.

Bobbleheads are the ultimate honor, and we think Dr. Fauci deserves it given what he has done and continues to do for our country and the world in the battle against COVID-19. The bobblehead will join a growing number of items including donuts, socks and t-shirts featuring Dr. Fauci. We received a lot of requests for a bobblehead of Dr. Fauci and are excited to be able to use the bobblehead to raise funds for a vital organization that is helping limit the spread of the Coronavirus while making people smile during these unprecedented times.

Let me know if you would like the press release, pictures and graphics in advance of Friday's release. Please hold off on publicizing anything related to the bobblehead until Friday—any time on Friday is okay. Please also let me know if you would like a sample when they arrive or if you have any questions.

Thank you,

Phil

Phil Sklar
Co-Founder and CEO
National Bobblehead Hall of Fame and Museum
Phil.Sklar@bobbleheadhall.com
414-519-2625
www.bobbleheadhall.com

This email was sent to mneil@nytimes.com
National Bobblehead Hall of Fame and Museum, PO Box 0982, Milwaukee, WI
53201-0982, US
[Unsubscribe](#)

--
Donald G. McNeil Jr.
Science Correspondent
The New York Times

Tel: (b) (6)
mneil@nytimes.com

Articles: <https://www.nytimes.com/by/donald-g-mcneil-jr>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 1 Apr 2020 19:59:55 +0000
To: Awwad, David (NIH/NIAID) [C]
Attachments: message., Re message.oft, Re message1.oft, u r hypocrite.oft, Call the National Guard in.oft, message,

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Wed, 1 Apr 2020 17:51:34 -0400
To: Duchin, Jeff
Subject: Re: FEMA Test Kits

Jeff:

Thanks for your note. It was very helpful to me to speak with your group last night. I caused quite a stir at the Task Force meeting when I reported on our telephone conversation. I believe that this fixed the FEMA issue.

Best regards,

Tony

On Apr 1, 2020, at 5:43 PM, Duchin, Jeff (b) (6) > wrote:

Tony,

Thank you for taking some precious time to hear from some of the folks on the ground confronting COVID-19 around the country. I can't tell you how much we all value your engagement and leadership on behalf of the nation. I'd love to get your take on whether you think the types of things described in the recent AEI report are realistic. I have serious doubts.

Quick question – I mentioned the problem we had with FEMA test kits being recalled from us because we did not want to use their call line and lab because too slow, – just wondering if that came up in your meeting today because I just heard the kits were released to us without restrictions on how we use them. So either way, apparently resolved.

Stay well and best regards,

Jeff

Jeffrey S. Duchin, MD
Health Officer and Chief, Communicable Disease Epidemiology & Immunization Section
Public Health - Seattle and King County
Professor in Medicine, Division of Infectious Diseases, University of Washington
Adjunct Professor, School of Public Health
401 5th Ave, Suite 1250, Seattle, WA 98104
Tel: (b) (6); Direct: (b) (6); Fax: (206) 296-4803
E-mail: (b) (6)

From: (b) (6)
Sent: Wed, 1 Apr 2020 16:54:57 -0400
To: Kadlec, Robert (OS/ASPR/IO)
Subject: Fwd: (b) (5)

Bob:
See email below. (b) (5)

Thanks,
Tony

Begin forwarded message:

From: "Mascola, John (NIH/VRC) [E]" (b) (6) >
Date: April 1, 2020 at 4:40:39 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6), "Erbelding, Emily (NIH/NIAID) [E]" <(b) (6)>, "Marston, Hilary (NIH/NIAID) [E]" (b) (6) >
Subject: (b) (5)

Tony,

(b) (5)

John





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 1 Apr 2020 16:02:51 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]
Subject: [REDACTED] (b)(5) - PCP

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 1 Apr 2020 16:01:03 +0000
To: Gallo, Robert
Cc: Barasch, Kimberly (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: information

I got it. I will have my staff try to set something up.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gallo, Robert (b) (6)
Sent: Wednesday, April 1, 2020 11:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: information

TONY—this is from me—Bob Gallo

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, April 1, 2020 11:08 AM
To: Gallo, Robert (b) (6)
Subject: RE: information

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 1 Apr 2020 14:04:37 +0000
To: Berkowitz, Avrahm J. EOP/WHO;Gidley, Hogan H. EOP/WHO
Subject: RE: Quick call

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Berkowitz, Avrahm J. EOP/WHO (b) (6)>
Sent: Wednesday, April 1, 2020 9:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Gidley, Hogan H. EOP/WHO (b) (6)>
Subject: Quick call

Dr Fauci – can you please jump on a quick call with Hogan about a press inquiry we received at the White House? He is at (b) (6)
(and I am at (b) (6)).
Thank you!
Avi

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 1 Apr 2020 13:22:58 +0000
To: (b) (6)
Subject: RE: FW: Wpost: Fauci socks, Fauci doughnuts, Fauci fan art: The coronavirus expert attracts a cult following

It is not at all pleasant, that is for sure.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Wednesday, April 1, 2020 9:14 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: FW: Wpost: Fauci socks, Fauci doughnuts, Fauci fan art: The coronavirus expert attracts a cult following

Completely surreal (b) (6) Dizzying, even. Can't imagine what it is like for you, especially in the midst of all this.

On Tue, Mar 31, 2020 at 10:58 AM Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:

Truly surrealistic. Hopefully, this all stops soon.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] <[REDACTED]>
Sent: Tuesday, March 31, 2020 10:43 AM
Subject: Wpost: Fauci socks, Fauci doughnuts, Fauci fan art: The coronavirus expert attracts a cult following

Fauci socks, Fauci doughnuts, Fauci fan art: The coronavirus expert attracts a cult following



Doughnuts bearing the likeness of Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, rest on a plate at Donuts Delite in Rochester, N.Y., on March 25. (Shawn Dowd/Rochester Democrat & Chronicle/AP)

By

[Antonia Noori Farzan](#)

March 31, 2020 at 5:15 a.m. EDT

Early last week, Nick Semeraro wanted to find a way to honor Anthony S. Fauci. As the owner of a small doughnut shop in Rochester, N.Y., he had been closely tracking the latest news about the [coronavirus](#) pandemic. And night after night, he'd been impressed by how Fauci, the director of the National Institute of Allergy and Infectious Diseases, approached the crisis in a calm, knowledgeable manner.

So, as a tribute, Semeraro put the renowned immunologist's face on a doughnut. Expecting to sell a few hundred, he was shocked when the store [sold out](#) day after day, with [thousands flying off the shelves](#). Donuts Delite was besieged with requests to ship the buttercream-frosted creations all over the country, and one Fauci fan [drove](#) three hours just to pick up a dozen. Soon, bakeries in [Wisconsin](#) and [Pennsylvania](#) followed suit, using edible paper to decorate pastries with Fauci's likeness. "We had no idea it was going to blow up this big," Semeraro told [CNN](#). "We didn't know everyone else felt the same way we did."

While Fauci was already a [respected scientist](#) before the outbreak, his appearances during White House press briefings have made him a household name and an unlikely celebrity. With his

straightforward demeanor and willingness to contradict President Trump, he's begun to develop the same kind of cult following as Supreme Court Justice Ruth Bader Ginsburg and former special counsel Robert S. Mueller III, who inspired countless "Plank like RBG" tank tops and a bizarre illustrated children's book, respectively.

Even as whole swaths of the global economy collapse, the pandemic has created a robust cottage industry of Fauci-themed merchandise, including bottle openers, magnets and mugs. On Etsy, you can buy "Honk for Dr. Fauci" bumper stickers, prayer candles depicting "St. Fauci" and socks printed with Fauci's face. Graphic T-shirts bear slogans such as "I Need a Hero" and "In Dr. Fauci We Trust."

If so inclined, you can even decorate your home with an "I Heart Dr. Fauci" throw pillow, or purchase a replica of Fauci's jersey from the time he captained the basketball team at Manhattan's Regis High School. Lingua Franca, which sells cashmere sweaters embroidered with resistance-friendly slogans for \$380 and up, recently began taking orders for an army-green "Dr. Fauci Fan Club" knit.

In honor of Fauci's Italian heritage, a clam bar in Long Island named a linguine dish after him this week. (Available for pickup only, "the linguine with white clam sauce shares origins with Fauci, as the sauce itself was invented in the Fauci Family's native Sciacca, Italy," the restaurant claimed in a statement.)

As countless Americans remain glued to the news while trying to stay indoors, a robust Fauci fandom has flourished online. On Facebook, the "Dr. Anthony S. Fauci Fan Club" has over 32,000 members. Thousands more congregate in groups with names such as "Dr. Anthony S. Fauci, the Man, the Myth, the Legend," "Dr. Fauci Speaks, We Listen" and "Dr. Fauci Memes for Social Distance Teens."

An unassuming 79-year-old public servant who has advised six presidents, Fauci has become a "reliable constant in a time of uncertainty," The Washington Post's Ellen McCarthy and Ben Terris reported. But his admirers — and there are a lot of them — worry that it's only a matter of time before he's sidelined by Trump.

When Fauci missed a White House news conference earlier this month, panic erupted on Twitter, along with speculation that he could be sick. There was palpable relief when he resumed his regular position at the podium the following day and appeared to hide some exasperation as Trump referenced "the deep state."

Fauci later explained that he had simply been trying to dislodge a lozenge from his throat. But the much-analyzed "Fauci facepalm" had already become a meme, deployed by liberal members of what's known as the resistance.

Fauci's newfound fame can be partially attributed to his willingness to engage with all forms of media — in recent weeks, he's gone on a Barstool Sports podcast, chatted with basketball star Steph Curry on Instagram Live as Barack Obama listened in, and appeared on "The Daily Show With Trevor Noah." But it also undoubtedly helps that his fans tend to take social distancing seriously and consequently have ample spare time to produce fan art or perform songs written (or modified) in his honor.

On social media, Fauci's virtual fan clubs peruse old photos of the infectious disease expert in search of "comfy turtleneck vibes," stitch his face on embroidery hoops and discuss erecting statues as tribute. They frost his name on cookies and joke about constructing shrines in his honor. Prominent activists and entertainers confess to wanting to marry him, or have him tuck them into bed.

Fauci has remained characteristically modest about his new status as a cult figure. "Well, that's very nice," he responded when McCarthy and Terris mentioned that people all over the country were praying for him. Of course, that means that his fan base has only continued to grow.

"I never met a guy that, worldwide, he is so loved," Semeraro, the Rochester doughnut shop owner, told CNN. "And a month ago, we never knew his first and last name."

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: (b) (6)
Sent: Wed, 1 Apr 2020 06:26:32 -0400
To: DMID Word Nerds
Subject: Fwd: Covid-19 comments on UK response
Attachments: image001.png, ATT00001.htm, Covid19, UK pharmavaccine response.pdf, ATT00002.htm, Covid19, UK Urgent Action response.pdf, ATT00003.htm, VACCINEarticle.pdf, ATT00004.htm

Sent from my iPhone

Begin forwarded message:

From: Karl Simpson <(b) (6)>
Date: April 1, 2020 at 5:46:14 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: Covid-19 comments on UK response

Dear Dr Fauci

I was just re-reading your January 23 Viewpoint article in JAMA. So little time has passed, but so much has changed, and your comments seem prescient.

I have been working on emergent/re-emergent infectious agents for some time, and authored a 2018 report for the UK government on vaccine responses that was summarised in a Vaccine publication last October attached. As almost everyone else, my attention has been redirected to Covid-19, although monkeypox remains a focus of my interest.

You and your colleagues may be interested in two short documents I produced for the UK government on the 20th and 22nd of March. That also seems long ago now!

As fellow citizen of our planet, I thank you and colleagues for your unstinting efforts to control infectious disease and Covid-19 in particular.

Warmest wishes

Karl

J. Karl Simpson CBIol FRSB
CEO, JKS Bioscience Limited



NIH-000101



JASoloscience

2 Midanbury Court, 44 Midanbury Lane

Southampton SO18 4HF, UK

Tel: (b) (6)

Mobile: (b) (6)

Mail: (b) (6)

Website: <http://www.jksbioscience.co.uk>

Skype: (b) (6)

Company Number: 10051396

VAT number: 238 0528 12

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 31 Mar 2020 21:07:00 +0000
To: NIAID OD AM
Subject: FW: Additional data on masks
Attachments: MacIntyre BMI.pdf, Figure 3.jpg

Adding everyone since it was discussed in am meeting. thx

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, March 31, 2020 5:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E]
<(b) (6) Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Doepel, Laurie
(NIH/NIAID) [E] (b) (6)
Subject: Additional data on masks

Dr. Fauci,

In addition, I found the attached review on masks that addresses use in the community settings. Attached are the paper and figure 3, which summarizes the data from 9 very diverse RCTs (overlapping with what I had sent earlier).

Bottom line: generally there were not differences in ILI/URI/or flu rates when masks were used, although when early use and compliance was taken into account, a few times a difference was seen.

In addition:

This case control study noted that, among SARS patients in Hong Kong without a known source of infection, cases (27.9%) were less likely than uninfected controls (58.7%) to report wearing a mask frequently in public, for what that's worth.

https://wwwnc.cdc.gov/eid/article/10/4/03-0628_article

Andrea

From: (b) (6)
Sent: Tue, 31 Mar 2020 07:25:55 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Harvard Business School / Wharton Business School

Sent from my iPhone

Begin forwarded message:

From: Arash Farin <arash@arash.tv>
Date: March 30, 2020 at 10:32:04 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: Re: Harvard Business School / Wharton Business School

Hi Dr. Fauci,

I just wanted to confirm you received this.

I also just read a great story on you in the WSJ, which discussed your amazing basketball and leadership skills when you were in college. Not surprisingly, even then, your teammates were seeking your advice on leading them through difficult times.

Talk to you soon.

Regards,
Arash

On Sat, Mar 28, 2020, at 7:54 AM, Arash Farin wrote:

Hi Dr. Fauci,

I'm a graduate of both Harvard Business School and The Wharton School, and have truly enjoyed watching the leadership you have shown our nation during these challenging times. Your steady hand, calm demeanor, incisive thoughts, and intellectual rigor, have all been quite comforting to us the last few weeks.

I would like to see if you may have a few minutes to participate in a webcast interview with myself and classmates from Harvard and

Wharton this coming week or next week. We would love to hear your thoughts on dealing with the coronavirus, lessons learned from other countries, and how we can prepare for a potential recurrence, as has been discussed in the media, along with other topics you deem important.

I may also be able to get students from Oxford University to join, as I attended there as well, and I know the UK is dealing with its own set of challenges.

I look forward to hearing from you, and can be reached at [REDACTED] (b) (6) [REDACTED] or via email (arash@arash.tv).

God bless you, and thank you for everything you have been doing.

Best Regards,
Arash

From: (b) (6)
Sent: Tue, 31 Mar 2020 07:24:50 -0400
To: DMID Word Nerds
Subject: Fwd: VVIP information for diagnostic and therapy for COVID-19- Kindly do not delete

Sent from my iPhone

Begin forwarded message:

From: "anahar ." <anahar@abgenics.in>
Date: March 31, 2020 at 3:38:38 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Fwd: VVIP information for diagnostic and therapy for COVID-19- Kindly do not delete

Dear Sir

We request you to spare a few minutes to read this email.

Abgenics is a life-sciences company (Abgenics Life sciences Pvt Ltd, www.abgenics.in) based in Pune, India conducting pioneering research in the area of drug discovery using camelid antibody against infectious diseases in the past 10 years. Abgenics Life Sciences was founded in 2010 and is managed by Anil Nahar (Entrepreneur) and Dr Sanjiban K Banerjee (Technical). Dr Banerjee has studied and lived in the USA for more than 7 y and worked in the area of infectious diseases all his life. He has conducted extensive research in the area of camelid antibody technology in USA. After returning to India and with an urge to help the people of India in area of infectious diseases. Dr Banerjee in association with Anil Nahar started this venture. Since then, the company has extensively worked and developed novel camelid antibody technology for various infectious diseases causing bacteria (Multi drug resistant) and fungus like Pseudomonas, Staphylococcus Aureus, Candida Albicans and other

important pathogens. Our company is the only company in India working on Camelid antibody platform. Camelid antibody is a very robust and novel technology and can be used to develop drugs against any kind of antigen generated from bacteria and viruses. The specialty of camel antibody, it occurs in nanosize, high temperature and high Ph stable. It has very high affinity towards any antigen. **A video explaining our technology is attached in the email.**

An Abgenics Life science was awarded twice by [REDACTED] (b)(4)
[REDACTED] USA in the form of research projects to develop technology for



Corona virus is a spiked virus and the spikes are used by the virus to first attach to and then invade into the host cells. Subsequently the genetic materials, RNA are injected where it hijacks the host replication machinery to multiple and re-infect more cells. If the initial attachment or the fusion of the virus and host membranes can be blocked, the virus replication cycle can be stopped, bringing the infection under control. The spike protein consists of two components, a globular head, S1 that helps the initial attachment and a spiral part S2 that is responsible for membrane fusion which forms the channel for the entry of the



--

Regards

Anil Nahar
MD
Abgenics Life sciences Pvt Ltd
Kant Helix
Bhoir Colony
Chinchwad
Pune
India
Ph- [REDACTED] (b) (6)

--

From: (b) (6)
Sent: Tue, 31 Mar 2020 07:23:59 -0400
To: DMID Word Nerds
Subject: Fwd: New biological disinfection automates, also effective against new Corona virus and multi-resistant germs, from a Florida Company
Attachments: PastedGraphic-1.png, ATT00001.htm, MSDS_Saniswiss_biosanitizer_aHP_P_rev_16032018.pdf, ATT00002.htm, br_automate_aHP_HTA_EN.pdf, ATT00003.htm, br_biosanitizer_aHP_C_EN2.pdf, ATT00004.htm, ABSA conclusion Kopie.pdf, ATT00005.htm, SHS_23082019_WEB.pdf, ATT00006.htm

Sent from my iPhone

Begin forwarded message:

From: Alexander Friedrich <a.friedrich@biosanitize.us>
Date: March 31, 2020 at 6:02:53 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Cc: Tayfun Taylor <mr.taylor@mailbox.org>, "ceo@biosanitize.us" <ceo@biosanitize.us>
Subject: New biological disinfection automates, also effective against new Corona virus and multi-resistant germs, from a Florida Company

Dear Mr.Fauci,

I know you're busy, But at this special time for all of us, I just need to write to you. The new Corona Virus is changing the world. It affects all of us in health, social and economic terms. The importance of hygiene and disinfection can be seen especially now in the pandemic.







do not hesitate to contact us.

Yours, sincerely

Alexander Friedrich
Repr. Biosanitize USA

Alexander Friedrich
Repr. Biosanitize USA
contact: a.friedrich@biosanitize.us

Bio-Sanitize USA LCC
12601 New Brittany Blvd
33907 Fort Myers, Florida, USA



Cleaner spaces. Safer places.



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 31 Mar 2020 02:07:49 +0000
To: Moshe Levi
Cc: Graham, Barney (NIH/VRC) [E]
Subject: RE: Question from Georgetown

Moshe:

I am not sure that I can help you with this. I am referring your e-mail to Dr. Barney Graham of the NIAID VRC. Perhaps he can help you.

Best regards,

Tony

From: Moshe Levi (b) (6)
Sent: Monday, March 30, 2020 3:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Question from Georgetown

Dear Tony:

I know that you are busy 7/24 with the current crisis.

BUT I have a question for you or for one of your colleagues.

(b) (4)

Please let me know.

Meanwhile there are not adequate ways to thank you for all you do.

I should have seen that when you were my attending while you were at Cornell as a Visiting Professor Professor around (b) (6)

Moshe

Cell: (b) (6)

—
Moshe Levi, MD
Dean for Research
Professor of Biochemistry and Molecular & Cellular Biology
Georgetown University
3900 Reservoir Road

Med Dent NW 105
Washington, DC 20057

Office: (b) (6)

E-mail: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 31 Mar 2020 02:02:50 +0000
To: David Katz
Subject: RE: COVID-19 -- URGENT (Please do not disregard!)

David:

I know that it is you. I am sorry, but I am getting more than 2000 e-mails pe day. I totally agree with you and this issue is being actively discussed as recently as today at the task Force meeting. I am not sure what you mean by aerial "eradication" procedures that could be practically implemented. There are some data from NIH that indicate that mere speaking without coughing elicits aerosols that travel a foot or two. If that is the case, then perhaps universal wearing of masks in the most practical way to go.

Best regards,
Tony

From: David Katz [REDACTED] (b) (6) >
Sent: Monday, March 30, 2020 5:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Re: COVID-19 -- URGENT (Please do not disregard!)

For God's sake, Tony -- this is me, not simply an unknown "messenger" from the general public! We go back together for many, many years (to our days together at the NIH, remember?). As you may recall, we worked (successfully) during the infamous 1969 "March on Washington", among other historically important events.

Although I am now [REDACTED] (b) (6) I continue to pay careful attention to world events, and this is one that exceeds any others that have occurred in our lifetime!

As I wrote in my previous e-mail, I have become convinced that COVID-19 is behaving as an airborne virus, and, therefore, we should be directing our mitigation efforts toward more comprehensive aerial eradication procedures!

Think about the most recent reports -- namely that imprisoned inmates, and a young baby, have recently been reported as "infected" with this virus.

Person-to-person infection in these circumstances is difficult to explain! But transmission by viable airborne virus could certainly happen!

I look forward to your response, with best wishes,
David

David H. Katz, M.D.
La Jolla, California

On Sun, Mar 29, 2020 at 11:18 AM Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: (b) (6)
Sent: Mon, 30 Mar 2020 16:29:31 -0400
To: (b) (6)
Subject: Fwd: Hello from Canada!

Could you please respond to her for both of us. Thanks

Begin forwarded message:

From: "El-Gabalawy, Nadia (PHAC/ASPC)" (b) (6) >
Date: March 30, 2020 at 2:48:41 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Hello from Canada!

Hi Dr. Fauci,

I thought I would reach out to you amidst this crisis; I respect the work you're doing a great deal. (b) (6) Hani El-Gabalawy, did a research sabbatical at NIH (b) (6)

Amazing work that you're doing. I've been following your discussions and scientific innovation regarding COVID-19. I've been working for the federal government in Intelligence for about thirteen years and recently moved to the Canadian Public Health Laboratory Network Secretariat to support the Emergency Operations Centre at the National Microbiology Lab. I've been with the NML for almost my whole career.

Just a quick hello and deep respect for your work. My colleagues and Director have said that we're on the exact same page as you, in terms of your perspective and assessment of the pandemic. Although there is a border between us, know that we are in agreement with your work and I'm thrilled to see you advising the public. There is no better person to do the job.

Kindest regards,

Nadia El-Gabalawy
Team Lead, Support Services, Canadian Network for Public Health Intelligence
Public Health Agency of Canada/Government of Canada

(b) (6)

Chef d'équipe, Services de soutien, Réseau canadien de renseignements sur la santé
publique

Agence de la santé publique du Canada / Gouvernement du Canada

(b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 30 Mar 2020 12:23:38 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Invitation to be the keynote speaker at an Insurance Medicine Conference in Washington, DC in October.

RSVP sorry no.

From: Pinho, Paulo <Paulo.Pinho@optimumre.com>
Sent: Monday, March 30, 2020 8:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Invitation to be the keynote speaker at an Insurance Medicine Conference in Washington, DC in October.

Dear Dr. Fauci,

I hope this email finds you well. It is abundantly obvious from the countless sifts through data and tallies of cases, interviews and press conferences, social media appearances, etc. that your schedule is crazy these days. As a practicing physician and an American, I am proud to be represented by you and thank you for your efforts on our behalf. I realize with your schedule and with the thousands of emails, this one may not make it, but I wanted to take a shot in the dark.

I am currently the Chief Medical Officer of a reinsurer and am on the planning committee for the American Academy of Insurance Medicine's annual meeting which will be held in DC this year October 18-21. Dr. Michael Osterholm had agreed to speak at the conference back in January as our first keynote speaker on the subject of pandemics, preparedness. I'd heard him speak before at Prudential (I was medical director there and we were a member company of CIDRAP) and his talk mirrored his book which I've also read. Regretfully, 2 weeks ago I received notice from Laurel, his EA, that he is unable to attend the meeting because he needs to travel to London that week for a meeting he is heading. I think that a talk on the topic is a must at any medical meeting and after hearing your pressers and coming to rely on your sage status updates and advice, coupled with the fact that the conference is in DC, I thought I'd give this a shot. Would you be AAIM's keynote speaker this year?

In the midst of the current COVID-19 pandemic, we understand many industry conferences have had to be canceled. We are continuing to closely monitor the trend of the COVID-19 virus, and may have to do the same for the AAIM meeting in October, but if there is an opportunity to gather and learn, we'd like to prepare for it.

The audience is medical directors that work in the life, health, disability and longterm care space. Some are clinically active. Some of them are resources for health emergency planning for their companies. The audience comes mostly from North America, although other countries/continents are well represented.

The purpose of the meeting is really to illustrate novel trends in the industry that will likely impact morbidity and mortality in the near or distant future. We've had talks on CRISPR, marijuana, precision medicine, data analytics. They're not hard core morbidity or mortality focused, but do touch on it.

Given the scope of the meeting and the attendees and industries they represent, I think that a lecture on pandemics, bioterrorism and emerging infectious disease, especially in light of COVID-19, is necessary. I think you would teach new concepts to a team of doctors that would identify with some of the system gaps in our current supply chain and their impact on human health, wellbeing and survival. You'd provide experience and insight on what went wrong and what could be fixed in the future to make us collectively better prepared.

We would be honored to have you speak and I'm glad to continue discussion of logistics with someone else on your team. If you needed more information about scope, I can certainly provide that. We do provide an honorarium and will cover travel and hotel expenses.

Thanks so much in advance for any consideration you might give this request/offer and most of all thank you for your direction, demeanor and dedication at this global time of crisis.

Best,
Paulo

Paulo Bandeira Pinho, MD, FAAP, FACP
Chief Medical Director
OPTIMUM RE INSURANCE COMPANY



+1 214 528-2020, ext. 30984



Paulo.Pinho@optimumre.com



1345 River Bend Drive, Suite 100
Dallas, TX 75247, U.S.A.



optimumre.com



OPTIMUM.
Life Reinsurance

This email and its attachments is confidential and is intended only for the individual(s) to whom it is addressed. Distribution or copying of this email by anyone other than the named recipient is prohibited. If you receive this email in error, please notify us by email and permanently delete this email and its attachments.

From: (b) (6)
Sent: Mon, 30 Mar 2020 06:06:00 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview with Dr Anthony Fauci in The Times of London

Sent from my iPhone

Begin forwarded message:

From: "Rivalland, Monique" <monique.rivalland@the-times.co.uk>
Date: March 30, 2020 at 4:30:39 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: Interview with Dr Anthony Fauci in The Times of London

Dear Anthony,

I'm an editor at The Times of London. I'm getting in touch to discuss the possibility of interviewing you this week for our Saturday Interview slot next weekend. You have an incredibly tricky role in the fight against coronavirus and have spoken with great clarity. We would love to speak to you about your position and predictions for America.

The interview slot in question is the most prestigious in the weekend edition of The Times - a double-page spread reserved each week for the most influential individuals in public life. Former interviewees range from Boris Johnson to Jeremy Farrar.

We would need 40 - 50 minutes of your time before Friday morning, but preferably by Thursday evening. The interview can be conducted over Skype/Google Hangouts/Zoom or whichever method of video chat you prefer.

We would be delighted if you were to consider our request.

Kind regards
Monique

--
Monique Rivalland
Features Editor
THE TIMES

(b) (6)

@MoniqueLouiseR

--

"Please consider the environment before printing this e-mail"

This e-mail and any attachments are confidential, may be legally privileged and are the property of News Corp UK & Ireland Limited on whose systems they were generated. News Corp UK & Ireland Limited is the holding company for the News UK group, is registered in England & Wales under number 81701, has its registered office at 1 London Bridge Street, London, SE1 9GF and is registered with VAT number GB 243 8054 69. If you have received this e-mail in error, please notify the sender immediately and do not use, distribute, store or copy it in any way. Statements or opinions in this e-mail or any attachment are those of the author and are not necessarily agreed or authorised by News Corp UK & Ireland Limited or any member of its group. News Corp UK & Ireland Limited may monitor outgoing or incoming emails as permitted by law. It accepts no liability for viruses introduced by this e-mail or attachments.

News Corp UK & Ireland Limited and its titles are committed to abiding by IPSO's regulations and the Editors' Code of Practice that IPSO enforces.

From: (b) (6)
Sent: Mon, 30 Mar 2020 06:05:28 -0400
To: DMID Word Nerds
Subject: Fwd: Chloroquine is a thromboxane inhibitor: there is a readily available analog

Sent from my iPhone

Begin forwarded message:

From: "Dr. Josh Backon" <backon@mail.huji.ac.il>
Date: March 30, 2020 at 5:52:32 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: **Chloroquine is a thromboxane inhibitor: there is a readily available analog**

Dear Dr. Fauci,

I'm (b) (6) internist.

I have a suggestion for 2 potent antiviral agents, cheap and readily available, that may prevent viral shedding. No viral shedding? No infectivity. The concept is that EVERYONE should take these items.

First a short bio:

Dr. Josh Backon was affiliated with the Hebrew University Faculty of Medicine for over 33 years. He has a good track record (84+ publications quoted by over 750 other researchers in journal articles https://scholar.google.com/scholar?start=0&q=%22backon+j.%22&hl=en&as_sdt=0,5 and in over 250-300 texts as per <https://www.google.com/search?tbo=p&tbm=bks&q=%22backon+j.+%22&num=100>).

In the 1980's he was Consulting Editor of the Journal of Pediatric Endocrinology, Editor of Reviews in Pure and Applied Pharmacological Sciences, and Associate Editor of the International Journal of Adolescent Medicine and Health. From 1990-2004, he was a consultant

on emergency planning and management at Israel's National Police Headquarters with Nitzav Mishneh Danny Fisher.

Chloroquine, an antimalarial drug, is now being used to treat Covid-19. Its mechanism was found in the 1970's to inhibit thromboxane
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=chloroquine+thromboxane&btnG= The problem with chloroquine was that it also elevated levels of prostaglandin F2alpha. In 1980, Srivastava, an Indian biochemist working in Denmark found that GINGER is a potent inhibitor of thromboxane synthetase. I wrote a number of papers in the 1980's on use of ginger:

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=backon+ginger&btnG=

GINGER IS A POTENT ANTIVIRAL

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=ginger+antiviral&oq=ginger

THE SECOND ANTIVIRAL AGENT IS TURMERIC [add black pepper since piperine dramatically increases oral bioavailability of turmeric]

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=turmeric+antiviral&oq=turmeric

Multisite inhibitors for enteric coronavirus: antiviral cationic carbon dots based on curcumin

D Ting, N Dong, L Fang, J Lu, J Bi... - ACS Applied Nano ..., 2018 - ACS Publications
... These results offer theoretical support for the development of CCM-CDs as a hopeful antiviral drug for the treatment of coronavirus infections, including PEDV ... Curcumin (CCM) is a polyphenol compound obtained from turmeric roots...

NAC AND PIPERINE TO INHIBIT INFLAMMATORY CYTOKINES (iNOS, NF KappaB, TNFalpha) INVOLVED IN ARDS

-

Mortality in COVID-19 patients is usually from ARDS (acute respiratory distress syndrome) via inflammatory cytokines. Apart from N-acetylcysteine which was found 3 years ago to elevate atrial natriuretic factor [found by Kiemer in 2001 to zap inflammatory cytokines: iNOS, NF KappaB, and TNFalpha) now piperine in black pepper was found to inhibit inflammatory cytokines [piperine also dramatically increases oral bioavailability of turmeric [which has been used as a potent antiviral]:

N-ACETYLCYSTEINE

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=n-acetylcysteine+%22inflammatory+cytokines%22&btnG=

PIPERINE

https://scholar.google.com/scholar?hl=en&as_sdt=0,5&q=piperine%20inflammatory%20cytokines&btnG=&fbclid=IwAR0kXZxI66JPLFPry2MDTDxOAelgGnmBZdKBw7c1v78Hfi7t0JJnx0Y2zuE

BTW the thromboxane hypothesis explains the increased male to female ratio in infectivity as well as the low incidence in younger people.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1433448/>

Gut. 1987 Oct; 28(10): 1323.
doi: [10.1136/gut.28.10.1323](https://doi.org/10.1136/gut.28.10.1323)

PMCID: PMC1433448
PMID: [18668886](https://pubmed.ncbi.nlm.nih.gov/18668886/)

Ginger and carbon dioxide as thromboxane synthetase inhibitors: potential utility in treating peptic ulceration

Josh Backon

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 30 Mar 2020 02:06:21 +0000
To: Tim Boyd
Subject: RE: You Rock!

Nancy:

Thank you for your kind note.
Best regards,
Tony

-----Original Message-----

From: Tim Boyd (b) (6)
Sent: Sunday, March 29, 2020 8:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: You Rock!


Dear Dr. Fauci,

After reading the article about you on the front of the New York Times this morning, I was distressed to learn that you have recently been negatively targeted via social media by members of a certain US political faction. The unfairness of these personal attacks upon you is shocking, and I cannot imagine something so hurtful happening to someone like you who possesses such a depth of knowledge and unimpeachable integrity. You are the affable, truthful and reassuring centre of calm during this deadly coronavirus storm. Your job is difficult enough without people taking verbal pot-shots every time you speak.

I wish you all the best during this trying time. Stay well (and I hope you don't completely lose your voice, too)! I look forward to seeing and hearing more from you on CNN and other media outlets.

Best wishes,
Nancy Hill
(b) (6)
Canada

Sent from my iPhone



(b)(5) - PCP

From: (b) (6)
Sent: Sun, 29 Mar 2020 11:31:58 -0400
To: Auchincloss, Hugh (NIH/NIAID) [E]; DMID Word Nerds
Subject: Fwd: Intro to Tony Fauci

From party

Hugh- I thought u responded to Carmona the former Surgeon general?

Sent from my iPhone

Begin forwarded message:

From: Richard Carmona <rcarmona@canyonranch.com>
Date: March 29, 2020 at 9:42:33 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: Fwd: Intro to Tony Fauci

Tony, first and foremost.... thank u for ur continued leadership and integrity in the "combat zone".

I know u r drinking from the proverbial fire hose so I would not send anything ur way if I didn't think it may have merit to address our current challenge with Coronavirus.

I e mail introduced u to this group some time ago. Their science has advanced and in particular there seems to be a potential opportunity to address the sometimes lethal "cytokine storm" in some coronavirus patients as described in the attached e mail. So I forward to you for your consideration as an adjunct.

On a daily basis I receive numerous "ideas" to address coronavirus from many well intended people. A few have merit. Is there a Fed innovation review group that some of these potential ideas could be funneled too?

I pray for you and your family

Be well

Rich

Richard Carmon
a
17th Surgeon General of The United States
Chief of Health Innovations
Distinguished Professor University of Arizona
a

CANYONRANCH.

8600 E. Rockcliff Road | Tucson, AZ 85750

O: 520.749.7754

M: (b) (6)
canyonranch.com

Begin forwarded message:

From: James Thacker <jim_thacker@therimunex.com>
Date: March 29, 2020 at 06:04:40 MST
To: Richard Carmona <rcarmona@canyonranch.com>
Cc: Patricia Maxwell <PMaxwell@canyonranch.com>, "dgrange@ospreyglobalsolutions.com" <dgrange@ospreyglobalsolutions.com>
Subject: Intro to Tony Fauci

External Sender

Dear Rich,



I hope you and the family are healthy. As you can tell, I am still kickin ass and takin names. ☐☐

Be well and be safe my Brother! DOLI

Sine Pari,

Jim



James D. Thacker, PhD
President/Founder - Head of Discovery & Science
1250 Sussex TPKE, Unit 647
Mount Freedom, NJ 07970
Cell: (b) (6)
Email: jim_thacker@therimunex.com
URL: www.therimunex.com

Privileged, confidential and/or copyright information may be contained in this e-mail. This e-mail is intended for the sole use of the addressee. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may not copy, forward, disclose or otherwise use this message, or any part of it in any way whatsoever, to do so is prohibited and may be unlawful. If you receive this e-mail by mistake, please advise the sender immediately by using the reply facility in your e-mail software.

From: (b) (6)
Sent: Sun, 29 Mar 2020 11:25:38 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Phone Interview- COVID19

Sent from my iPhone

Begin forwarded message:

From: "mtorres8@myseneca.ca" <mtorres8@myseneca.ca>
Date: March 29, 2020 at 11:06:49 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: RE: Phone Interview- COVID19

Hi Dr. Fauci,

I'm looking to do a quick 10 minute phone interview on COVID-19. I've seen your interviews on CNN and they are very informative so I think you would be perfect for our podcast.

This would be for a podcast available to faculty and students at Seneca Media Department in Toronto.

Thanks,

Monika Torres
www.senecajournalism.ca

From: (b) (6)
Sent: Sun, 29 Mar 2020 11:24:55 -0400
To: DMID Word Nerds
Subject: Fwd: URGENT ATTN DR FAUCI RE: COVID-19 IDEA FROM AUSTRALIAN GP!
Please just read and see it this has the merit I believe it does!!

Sent from my iPhone

Begin forwarded message:

From: Stevie <stevie@empowerme.enterprises>
Date: March 29, 2020 at 11:18:55 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: URGENT ATTN DR FAUCI RE: COVID-19 IDEA FROM AUSTRALIAN GP! Please just read and see it this has the merit I believe it does!!

Dear Sir,

My GP friend, Dr P'ng is a genius. He has a radical idea for fighting COVID-19. Please find his idea, petition, projections and research attached to the petition. I told him he needed to get this in front of you and Bill Gates. Please consider it. I believe it is viable and the best shot we have. I know you are the expert but I think this is a viable way we can help save millions of lives!

Yours sincerely,

Stephanie

Stephanie Russell-Farnham

Founder & CEO

EmpowerME Enterprises

M (b) (6)

E stevie@empowerme.enterprises

https://www.change.org/p/world-health-organisation-help-defeat-covid-19-save-the-world?recruiter=1066780682&utm_source=share_petition&utm_medium=facebook&utm_campaign=share_petition&utm_term=share_petition&recruited_by_id=40795060-71ab-11ea-a9f8-13e6b487f548&utm_content=starter_fb_share_content_en-au%3Av11

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 29 Mar 2020 11:23:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: New Zealand interview request

fyi

From: Pat Brittenden <info@blindfish.media>
Sent: Sunday, March 29, 2020 7:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: New Zealand interview request

Hey Dr Fauci,

Am wondering if you would be interested in having a chat with us in NZ, over Zoom, as we all sit in our houses fighting Coronavirus

I do a podcast which is normally live streamed but we currently have a country wide lockdown and lots of us have moved our gear home to continue providing content for people who are stuck in their homes

the US is like our big brother, we love you guys and would like to connect in solidarity about COVID19 so I'm hoping that maybe you could find us sometime to have a chat over the internet. Some content would also help us give some more content to Kiwi's who have gotten to the end of Netflix ;)

Find out more about the podcast at www.theDOC.nz and more about me at www.patbrittenden.com/about

Can make anytime happen, fingers crossed we'll hear back from 'someone'.

Pat Brittenden
www.theDOC.nz
www.patbrittenden.com/about

(b) (6)

From: (b) (6)
Sent: Sat, 28 Mar 2020 19:01:58 -0400
To: Idonae Lovetruue
Subject: Re: COVID-19 aetiology and treatment for critically ill patients: irinotecan+etoposide

Thank you for your note
AS Fauci

Sent from my iPhone

On Mar 28, 2020, at 6:36 PM, Idonae Lovetruue
<idonae@demiurge.technology> wrote:

Dear Dr. Fauci,

In addition, I'd like to share with you the following clinically relevant genetic differences between patients in the US and in East Asia:



Please find attached dosage recommendation and my team is standing by if you need any further assistance.

Sincerely,
Idonae

Idonae Lovetruue | CEO, Demiurge Technologies AG, Switzerland

www.demiurge.technology

This email and any attachments (hereinafter referred to as "this email") may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto. This email is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. While some information used in this document may have been obtained from

without published and unpublished sources considered to be reliable, Demiurge Technologies AG neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential loss arising from its use. Thank you.

From: Idonae Lovetruue <idonae@demiurge.technology>
Date: Saturday, 28 March 2020 at 15:53
To: [REDACTED] (b) (6)
Subject: COVID-19 aetiology and treatment for critically ill patients: irinotecan+etoposide

Dear Dr. Anthony S Fauci,

This is Idonae, CEO at Demiurge Technologies AG, a Swiss AI-biopharma company making accurate and rapid drug discoveries for diseases with limited available clinical data. We are committed to the non-profit dissemination of our COVID-19 discoveries to the public to facilitate the search for COVID-19 effective treatments.

SARS-CoV-2 is fundamentally different from all the other viruses that the world has hitherto known, so treatments must be rationally designed to avoid fueling the adaptive mutation and the latent infection of SARS-CoV-2.

Demiurge is the world's first company that has discovered the detailed aetiology of COVID-19 that consistently explains the clinical features of COVID-19 and the McA-based scientific rationale of the candidate treatments for COVID-19

(<https://www.preprints.org/manuscript/202003.0341/v1>).

(b) (4)

Thank you for your consideration and my team is standing by for any further assistance.

Sincerely,
Idonae

Idonae Lovetrue | CEO, Demiurge Technologies AG, Switzerland

www.demiurge.technology

—
This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto. This email is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. While some information used on this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge Technologies AG neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Thank you.


<mime-attachment>

From: (b) (6)
Sent: Sat, 28 Mar 2020 17:58:32 -0400
To: Hallett, Adrienne (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Shapiro, Neil (NIH/OD) [E]; Lauer, Michael (NIH/OD) [E]
Subject: Re: Brad Sherman

Thanks to everyone.

On Mar 28, 2020, at 5:32 PM, Hallett, Adrienne (NIH/OD) [E]
<(b) (6)> wrote:

Thanks Francis. I just spoke to his Deputy Chief of Staff (b) (6)



I'll share what I see when I see it.
Adrienne

On Mar 28, 2020, at 2:27 PM, Collins, Francis (NIH/OD) [E]
(b) (6);

Hi Adrienne,

I spoke with Brad Sherman (D-CA) yesterday. He had originally reached out to Tony, and Cliff Lane spoke to him Thursday, but I stepped in to try to lift one task off of Tony's plate.

(b) (5)

He said he is sending a letter to Tony and me, asking what we need to go flat out against COVID-19. He wanted to know who from my office his staff could work with. I said you!

Francis

From: (b) (6)
Sent: Sat, 28 Mar 2020 17:31:25 -0400
To: Jiaxian Zhou Wu
Subject: Re: Thank you for your service!

Many thanks for your kind note.

> On Mar 28, 2020, at 4:40 PM, Jiaxian Zhou Wu (b) (6) wrote:

>

>

> Dear Dr.Fauci,

>

> I am writing this email to personally thank you for your invaluable service to our country. The United States of America. This virus, COVID-19, is really dangerous and I am very scared of it. I am really worried about my country, about the countless deaths . Your advice to the president has proven really important to prevent the spread of the disease, however, in this nation, there is another epidemic based on lies and self-interest , now the people behind the fake news are targeting to you, one example is the post of an email that relates to you with the former Secretary of State, Hillary Clinton. This is why I decided to write a letter of support, I am sick of fake news, personal attacks and violation of the First Amendment , the right to have an opinion, to civil servants serving this country.

>

> I am still young but I still want to live in a United country. I ask you to continue your job, I want you to know that most Americans regardless of ideology are grateful of your service and sacrifice . A virus does not understand boundaries nor ideology . I am not an expert on this topic nor the president and politicians. Please guide us with the truth in these dire and dark days.

From: (b) (6) (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 19:43:52 +0000
To: (b) (6)
Subject: RE: medRxiv: Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients

(b) (6)

Thanks for the note.

(b) (6)

(b) (6)

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) >
Sent: Friday, March 27, 2020 2:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: medRxiv: Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients

Hi Tony,

Thanks for the update. All of this early science is certainly confusing - (b) (6)
(b) (6) Much the same thing that we are hearing from Am College of Cardiology. I appreciate your keeping me informed.

How are you doing? (b) (6)

Best,

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Sent: Friday, March 27, 2020 1:29 PM

To: (b) (6) >

Subject: [EXTERNAL] FW: medRxiv: Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients

** ATTENTION: This email originated from outside the MedStar network.

** DO NOT CLICK links or attachments unless you recognize the sender and know the content is safe.

(b) (6):

See below. The situation continues to get more complicated.

Best,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients

Yingxia Liu, Fengming Huang, Jun Xu, Penghui Yang, Yuhao Qin, Mengli Cao, Zhaoqin Wang, Xiaohe Li, Shaogeng Zhang, Lu Ye, Jingjun Lv, Jie Wei, Tuxiu Xie, Hong Gao, Kai-Feng Xu, Fusheng Wang, Lei Liu, Chengyu Jiang

doi: <https://doi.org/10.1101/2020.03.20.20039586>

This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should *not* be used to guide clinical practice.

- [Abstract](#)
- [Info/History](#)
- [Metrics](#)
-
-
- [Preview PDF](#)

Abstract

Summary Background The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak started at the end of 2019 in Wuhan, China, and spread over 100 countries. SARS-CoV-2 uses the membrane protein Angiotensin I converting enzyme 2 (ACE2) as a cell entry receptor. Indeed, it was reported that the balance of Renin-Angiotensin System (RAS), regulated by both ACE and ACE2, was altered in COVID-19 patients. It is controversial, however, whether commonly used anti-hypertensive drugs Angiotensin I converting enzyme inhibitor (ACEI) and Angiotensin II receptor blocker (ARB) shall be continued in the confirmed COVID-19 patients. This study was designed to investigate any difference in disease severity between COVID-19 patients with hypertension comorbidity. The included COVID-19 patients used ACEI, ARB, calcium channel blockers (CCB), beta blockers (BB), or thiazide to treat preexisting hypertension prior to the hospital were compared to patients who did not take any of those drugs. **Methods** In this multicentre retrospective study, clinical data of 511 COVID-19 patients were analyzed. Patients were categorized into six sub-groups of hypertension comorbidity based on treatment using one of anti-hypertension drugs (ACEI, ARB, CCB, BB, thiazide), or none. A meta-analysis was performed to evaluate the use of ACEI and ARB associated with pneumonia using published studies. **Findings** Among the elderly (age>65) COVID-19 patients with hypertension comorbidity, the risk of COVID-19-S (severe disease) was significantly decreased in patients who took ARB drugs prior to hospitalization compared to patients who took no drugs (OR=0.343, 95% CI 0.128-0.916, p=0.025). The meta-analysis showed that ARB use has positive effects associated with morbidity and mortality of pneumonia. **Interpretation** Elderly (age>65) COVID-19 patients with hypertension comorbidity who are taking ARB anti-hypertension drugs may be less likely to develop severe lung disease compared to patients who take no anti-hypertension drugs. **Funding** National Natural Science Foundation of China, Chinese Academy of Medical Sciences

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

MedStar Health is a not-for-profit, integrated healthcare delivery system, the largest in Maryland and the Washington, D.C., region. Nationally recognized for clinical quality in heart, orthopaedics, cancer and GI.

IMPORTANT: This e-mail (including any attachments) may contain information that is private, confidential, or protected by attorney-client or other privilege. If you received this e-mail in error, please delete it from your system without copying it and notify sender by reply e-mail, so that our records can be corrected... Thank you.

Help conserve valuable resources - only print this email if necessary.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 19:26:52 +0000
To: Real.Francisco
Subject: RE: A thank you note

Paco:

Thank you for your kind note.

Warm regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Real.Francisco <freal@cnio.es>
Sent: Saturday, March 28, 2020 3:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: A thank you note

Dear Tony,

please allow me to call you Tony as I feel somewhat close to you (although there is no reason why you should remember me). In early 1981 I was doing a clinical fellowship in Immunology/Oncology at Memorial Sloan-Kettering Cancer Center and wrote to you (b) (6)

(b) (6) During my period at Memorial I worked extensively on AIDS and Kaposi's sarcoma... and ever since - I moved in 1988 to Spain, my home country - I have followed and admired your work.

(b) (6) I always felt close to you and your amazing work. Now, when I see you taking care of your country's action against Covid-19, I am proud to have been attracted and inspired by your work in biomedical research and I am proud of what we - physician-scientists - can do for your societies and for human beings.

From my very modest end as a human being, thanks for your responsible, honest, scientific leadership.

Best wishes, we need people like you

Francisco X. Real (Paco)

Epithelial Carcinogenesis Group
Molecular Oncology Programme
Centro Nacional de Investigaciones Oncológicas
Melchor Fernández Almagro, 3
28029-Madrid (Spain)
Phone +34 917328000 ext 3660
E-mail preal@cniio.es

www.cniio.es

**HAZTE AMIGO/A
DEL CNIO**

*más INVESTIGACIÓN
menos CÁNCER*

Fb [Hazte Amigo del CNIO](#) | **Tw** [@HazteAmigoCNIO](#) | **Youtube** [canalcnio](#)

****ADVERTENCIA LEGAL****: Este correo electrónico, y en su caso los ficheros adjuntos, pueden contener información protegida para el uso exclusivo de su destinatario. Se prohíbe la distribución, reproducción o cualquier otro tipo de transmisión por parte de otra persona que no sea el destinatario. Si usted recibe por error este correo, se ruega comunicarlo al remitente y borrar el mensaje recibido.

De conformidad con lo dispuesto en el Reglamento (UE) 2016/679 relativo a la protección de los datos personales de las personas físicas, la información personal que nos pueda facilitar a través de este correo electrónico quedará registrada por la Fundación CNIO con la finalidad de tramitar el objeto del presente correo electrónico. El tratamiento de sus datos personales se encuentra legitimado por ser necesario para gestionar el objeto del presente mensaje. Estos datos personales no serán comunicados a ningún destinatario salvo a aquellos que usted nos autorice o así venga exigido por una ley. Ud. podrá

ejercer los derechos de acceso, rectificación, supresión, limitación de tratamiento, portabilidad y oposición en la siguiente dirección: c/Melchor Fernandez Almagro 3, 28029 (Madrid). Podrá ponerse en contacto con el Delegado de Protección de Datos en: delegado_lopd@cnio.es. Para el caso de que Ud. precise conocer información adicional sobre el tratamiento de sus datos personales, puede consultar dicha información adicional en el siguiente enlace dentro de nuestra página web: <https://www.cnio.es/es/privacidad/index.asp>

****LEGAL NOTICE****: This email and any attached files may contain protected information for the sole use of its intended recipient or addressee. Anyone other than the intended recipient or addressee is strictly prohibited from distributing, reproducing or transmitting the email and its contents in any way. If you receive this email in error, please notify the sender and delete the message.

Pursuant to the provisions of EU Regulation 2016/679 regarding the protection of personal data, any personal information you provide through this email will be registered by the CNIO Foundation in order to deal with content of this email. Your personal data must be processed in order to be able to deal with the content and purpose of this message. Your personal details will not be passed on to anyone else unless you authorise us to do so or we are required to do so by law. You may exercise your rights regarding access, rectification, suppression, limitation of processing, portability and opposition by writing to the following address: c/Melchor Fernandez Almagro 3, 28029 (Madrid). You may contact the Data Protection Delegate (Delegado de Protección de Datos) at: delegado_lopd@cnio.es. If you require further information about the processing of your personal data, go to the following link on our webpage: <https://www.cnio.es/es/privacidad/index.asp>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 19:00:32 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] (b) (6); Harper, Jill (NIH/NIAID) [E]; McGowan, Robert (Kyle) (CDC/OD/OCS)
Cc: (b) (6)
Subject: FW: Time-Sensitive OSTP Request - Due 12 pm Monday, March 30
Attachments: 2020-03-28_COVID-19 FOAs-Projects.xlsx

Please respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schwetz, Tara (NIH/OD) [E] (b) (6) >
Sent: Saturday, March 28, 2020 2:57 PM
To: ICDDIR-L@list.nih.gov
Cc: List DEPDIR-L <DEPDIR-L@list.nih.gov>; NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>; NIH P&E Principals and Alternates <NIHP&EOfficers@mail.nih.gov>; Walsh, Elizabeth (NIH/OD) [E] (b) (6) >
Subject: Time-Sensitive OSTP Request - Due 12 pm Monday, March 30
Importance: High

Good afternoon,

We received a time-sensitive request from OSTP that we are asking for your help to complete. Apologies in advance for the short turn-around.

Action – Complete the attached template to provide FOAs and projects on “innovation” and COVID-19, specifically focused on the topics described below. If your ICO has no nothing to report, please let us know.

Requestor – OSTP

POCs and Due Date – Please send the completed template to Elizabeth Walsh (Elizabeth.walsh@nih.gov) by noon on Monday, March 30

Timeline –

NIH Receipt Date	Institute Response to OD Due Date	OD Office Review Date	NIH Final Response Due Date
3/28/20	3/30/20	3/30/20	3/30/20

Additional Instructions –

- I pulled all the COVID-19 FOAs from the Guide; however, I did not sort through which ones are relevant to this request. Please submit only those that your IC is the lead on that meet the criteria listed above. Delete any that do not apply.

Attachments –

- Response template (FOAs tab, Grants-Contracts tab)

Do let me know if you have any questions.

Best,

Tara A. Schwetz, PhD

Acting Director, NINR

Associate Deputy Director, NIH

A: Building 1, Room 138

P: (b) (6) | M: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 18:43:17 +0000
To: [REDACTED] (b) (6)
Subject: FW: Washingtonian: You Can Now Buy Anthony Fauci Swag

Geeez

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Friday, March 27, 2020 6:11 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>; [REDACTED] (b) (6)
Subject: Washingtonian: You Can Now Buy Anthony Fauci Swag

You Can Now Buy Anthony Fauci Swag

T-shirts, mugs, pillows—and, yes, even a Fauci prayer candle.

Written by [Daniella Byck](#)
| Published on March 27, 2020



About Coronavirus 2020

Washingtonian is keeping you up to date on the coronavirus around DC.

[More from Coronavirus 2020](#)

Fauci stans, assemble! **Dr. Anthony Fauci**, director of the National Institute of Allergy and Infectious Disease, has emerged as *the* celebrity of the coronavirus crisis. Like others before him (remember Mueller mania?), his prominence has yielded buttons, t-shirts, and gifts, all flaunting the Fauci.



Fauci face socks

Another reason you won't want to wear your shoes inside. \$9.99, [Etsy](#).



“Dr. Anthony Fauci Fan Club” button

Fauci-fy any look with this pin. \$3.16, [Etsy](#).



"I need a hero" T-shirt

Paying homage to Fauci *and* Bonnie Tyler? This shirt is working overtime. *\$19.99, [Etsy](#).*



"Honk for Dr. Fauci" lawn sign

A social distancing win: Show your support without leaving the house. \$14.95, [Etsy](#).



Fauci Prayer Candle

Praying you washed your hands. \$20.20, [Etsy](#).



“Fauci 2020” T-shirt

Finally, a shirt for those White House coronavirus briefings. \$18, [Etsy](#).



“Hope” sweatshirt

Thanks, Fauci. \$18.99, [Amazon](#).



“Keep calm and wash your hands” mug

A little PSA to go with your morning coffee. \$19.95, [Etsy](#).



Dr. Anthony Fauci T-shirt

A perfectly acceptable day-to-evening look in your self-quarantine. *\$29.00, [Esty](#).*



"I Heart Dr. Fauci" throw pillow

For sweet, scientific dreams. *\$20.66, [Redbubble](#).*

Keep Up on DC's Latest Fashions with Our Shopping Newsletter

Fashion finds and deals, and the latest trends for you and your home.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 18:26:42 +0000
To: (b) (6)
Subject: FW: Wpost: How the Vietnam War may have changed Anthony Fauci's life

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Friday, March 27, 2020 6:15 PM
Subject: Wpost: How the Vietnam War may have changed Anthony Fauci's life

[Opinions](#)

How the Vietnam War may have changed Anthony Fauci's life



Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, speaks with the coronavirus task force at the White House on Tuesday. (Jabin Botsford/The Washington Post)

By Ray Greenberg

March 27, 2020 at 3:34 p.m. EDT

Ray Greenberg is a physician epidemiologist, former executive vice chancellor for health affairs at the University of Texas System and the author of "Medal Winners: How the Vietnam War Launched Nobel Careers."

Americans may have the war in Vietnam to thank for Anthony S. Fauci.

An adviser to six presidents and now the trusted public face of the scientific response to the coronavirus pandemic, Fauci has worked at the National Institutes of Health (NIH) for more than a half-century — beginning in 1968 with a group of doctors cheekily known as Yellow Berets.

During the conflicts in Korea and Vietnam, the U.S. military faced a pressing need for physicians. In 1966, during Fauci's senior year at Cornell University Medical College, a military recruiter came to tell the assembled students: "After you finish medical school, every one of you except the two women will either be in the Air Force, the Army, the Navy, or the Public Health Service." The last option, entering the Public Health Service, entailed assignment at the NIH, the Centers for Disease Control or the Indian Health Service.

Those who were selected to serve at the NIH were known officially as clinical associates, but informally they were referred to as Yellow Berets. Whether the designation was born in jest or derision, it was intended as a foil to the Green Berets of the Army Special Forces. Fauci never liked the label because it implied an unwillingness to serve in harm's way. "As a physician," Fauci said, "I felt if I had to go [to Vietnam], I would gladly do my part to try to help."

The competition for the limited number of Yellow Beret slots was so intense that only the best and brightest young physicians were selected. Fauci, the top graduate in his medical school class, was one of seven chosen from 140 applicants to train in his laboratory of interest. As described in my book "Medal Winners: How the Vietnam War Launched Medical Careers," the class of Yellow Berets that entered with Fauci included four future Nobel laureates: Joseph Goldstein, Michael Brown, Harold Varmus and Robert Lefkowitz.

Each new appointee completed two years of clinical training before arriving at the NIH. Their primary responsibility was learning how to conduct basic research under the guidance of a senior scientist. The second job was to care for patients at the NIH Clinical Center. Fauci and his fellow infectious disease colleagues also helped to care for wounded service members at the nearby National Naval Medical Center.

Fauci, who had some research experience in medical school, trained at the NIH for three years under the tutelage of Sheldon Wolff — a pioneer in the relationship between the immune system and infectious diseases. Following a year of additional clinical training back in New York, Fauci returned to the NIH as a senior scientist conducting pioneering work, first on autoimmune conditions, then transitioning to study the newly emerging disease that would become known as AIDS.

When he entered the clinical associate program, Fauci's ambition was to become a medical school professor. Had the Vietnam War not brought him to the NIH, Fauci probably would have remained in academia and the country never would have benefited from his extraordinary public service.

Instead, from his position as director of the National Institute of Allergy and Infectious Diseases, Fauci has helped shape national policies related to HIV, bioterrorism and a series of pandemic threats including avian influenza, H1N1 (swine) influenza, Ebola and severe acute respiratory syndrome. It is hard to imagine any other physician who has had such a sustained and profound impact on the health of our nation.

While Fauci remained at the NIH for his entire professional career, most of his fellow Yellow Berets left Bethesda after their training was completed and headed for jobs at universities. Across the nation, the former Yellow Berets became medical school scientists, department chairs and deans. More than 60 former clinical associates, including Fauci, were elected to the prestigious National Academy of Sciences, and he also was one of the more than 125 Yellow Beret alumni elected to the Institute of Medicine (now the National Academy of Medicine). In addition, Fauci was one of 10 alumni to receive the National Medal of Science.

For all the scars left by the Vietnam War, we should not overlook the fact that in its absence, 50 years later the country would probably not have Anthony Fauci guiding us through our current crisis. Dr. Fauci, we salute you and your fellow Yellow Berets.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 17:52:04 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Dr. Fauci hits and requests

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Sent: Friday, March 27, 2020 6:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Subject: FW: Dr. Fauci hits and requests

(b) (5)

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Friday, March 27, 2020 6:23 PM
To: O'Malley, Devin M. EOP/OVP <(b) (6) >
Subject: RE: Dr. Fauci hits and requests

Devin – (b) (5)

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Friday, March 27, 2020 6:18 PM

To: O'Malley, Devin M. EOP/OVP (b) (6); Love, Kelly A. EOP/OVP (b) (6); Henning, Alexa A. EOP/WHO <(b) (6)>; Bowman, Lauren K. EOP/WHO (b) (6); Porter, Macaulay V. EOP/OVP (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Hall, Bill (HHS/ASPA) (b) (6); Murphy, Ryan (OS/ASPA) <(b) (6)>
Subject: RE: Dr. Fauci hits and requests

Thanks, Devin. We have declined and scheduled as you advised. Below is an updated list and schedule.

Friday 3/27

- Pittsburgh, PA (also airs in OH and WV) – Bloomdaddy radio - 634 am live hit completed
- Baton Rouge, LA – Morning News w/ Brian Haldane - 7:05 am live hit completed

Saturday 3/28

Showtime Desus and Mero – taping at 2 p.m. scheduled

Sunday 3/29

CNN State of the Union – live hit 9:15 a.m. scheduled

Monday 3/30

- AppleTV+ Oprah – tape 11:30 a.m. scheduled
- Radio – Rantz show Seattle – 8 p.m. live hit scheduled
- Radio – John/Ken show California – 8:30 p.m. live hit scheduled

Tuesday 3/31

- CBS The Late Show with Stephen Colbert – tape 11 a.m. scheduled
- CNN Coronavirus podcast with Sanjay Gupta – tape 12 noon scheduled
- Wall Street Journal The Journal Podcast – tape 1 p.m. ET

Wednesday 4/1

New York Times The Daily podcast – tape 12 noon scheduled

(b) (5)

Thanks,
Jen

Jennifer Routh [E]

News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892

Direct: (b) (6)
(b) (6)

Disclaimer: This information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Malley, Devin M. EOP/OVP (b) (6)
Sent: Thursday, March 26, 2020 6:58 PM
To: Routh, Jennifer (NIH/NIAID) [E] (b) (6); Love, Kelly A. EOP/OVP (b) (6); Henning, Alexa A. EOP/ (b) (6)
Bowman, Lauren K. EOP/WHO (b) (6); Porter, Macaulay V. EOP/OVP (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Hall, Bill (HHS/ASPA) (b) (6); Murphy, Ryan (OS/ASPA) (b) (6)
Subject: RE: Dr. Fauci hits and requests

Yellow means schedule
Green means let's revisit
Crossed out means please decline

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Thursday, March 26, 2020 6:52 PM
To: O'Malley, Devin M. EOP/OVP (b) (6); Love, Kelly A. EOP/OVP (b) (6); Henning, Alexa A. EOP/WHO (b) (6);
Bowman, Lauren K. EOP/WHO (b) (6); Porter, Macaulay V. EOP/OVP (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Hall, Bill (HHS/ASPA) (b) (6); Murphy, Ryan (OS/ASPA) <(b) (6)>
Subject: RE: Dr. Fauci hits and requests

Good evening –

Below is a list of pending hits and requests for Dr. Fauci:

Thursday 3/26

- WTOP – 6:10 a.m. completed
- NPR Morning Edition – 7:07 a.m. completed
- YouTube content creator interviews – 11 a.m. completed.

- The content creators will publish the interviews on YouTube over the next few days. We expect Trevor Noah will publish tonight.
- Instagram Live video with Steph Curry – 1 p.m. completed
- CNN Town Hall – scheduled 8 p.m. live

Friday 3/27

- Pittsburgh, PA (also airs in OH and WV) – Bloomdaddy radio - 634 am live hit scheduled
- Baton Rouge, LA – Morning News w/ Brian Haldane - 7:05 am live hit scheduled

(b) (5)



Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892

Direct: (b) (6)

(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Malley, Devin M. EOP/OVP (b) (6)

Sent: Wednesday, March 25, 2020 9:24 PM

To: Routh, Jennifer (NIH/NIAID) [E] (b) (6); Love, Kelly A. EOP/OVP (b) (6); Henning, Alexa A. EOP/WHO (b) (6); Bowman, Lauren K. EOP/WHO (b) (6); Porter, Macaulay V. EOP/OVP (b) (6)

Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Hall, Bill (HHS/ASPA) (b) (6); Murphy, Ryan (OS/ASPA) <(b) (6)>

Subject: RE: Dr. Fauci hits and requests

(b) (5)

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)

Sent: Wednesday, March 25, 2020 5:07 PM

To: O'Malley, Devin M. EOP/OVP (b) (6); Love, Kelly A. EOP/OVP

(b) (6) Henning, Alexa A. EOP/WHO (b) (6);
Bowman, Lauren K. EOP/WHO (b) (6); Porter, Macaulay V. EOP/OVP

(b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E]
(b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Hall, Bill
(HHS/ASPA) (b) (6); Murphy, Ryan (OS/ASPA) (b) (6)

Subject: RE: Dr. Fauci hits and requests

Good evening –

Below is a list of pending hits and requests for Dr. Fauci. Flagging a few new inquiries:



Wednesday 3/25

- Bob Rose Radio Show - Gainesville FL – 6:33 am live hit – completed
- Bernie and Sid Radio Show – NYC – 7:05 am live hit – completed
- CNN Cuomo – scheduled live hit 9:05 p.m.

Thursday 3/26

- WTOP – scheduled live hit 6:10 a.m.
- NPR Morning Edition – scheduled live hit 7:07 a.m.
- YouTube content creator interviews – scheduled 11 a.m.
- Instagram Live video with Steph Curry – scheduled remote conversation 1 p.m.
- CNN Town Hall – scheduled 8 p.m. live

Podcasts:



Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E]
Sent: Tuesday, March 24, 2020 8:00 PM
To: 'O'Malley, Devin M. EOP/OVP' <(b) (6)>; 'Love, Kelly A. EOP/OVP' <(b) (6)>; 'Henning, Alexa A. EOP/WHO' <(b) (6)>; 'Bowman, Lauren K. EOP/WHO' <(b) (6)>; 'Porter, Macaulay V. EOP/OVP' <(b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Hall, Bill (HHS/ASPA) <(b) (6)>; Murphy, Ryan (OS/ASPA) <(b) (6)>
Subject: RE: Dr. Fauci hits and requests

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it.

from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E]
Sent: Tuesday, March 24, 2020 7:48 PM
To: O'Malley, Devin M. EOP/OVP (b) (6); Love, Kelly A. EOP/OVP (b) (6); Henning, Alexa A. EOP/WHO (b) (6); Bowman, Lauren K. EOP/WHO (b) (6); Porter, Macaulay V. EOP/OVP (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Hall, Bill (HHS/ASPA) (b) (6); Murphy, Ryan (OS/ASPA) (b) (6)
Subject: RE: Dr. Fauci hits and requests

(b) (5)

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Malley, Devin M. EOP/OVP (b) (6)
Sent: Tuesday, March 24, 2020 7:41 PM
To: Love, Kelly A. EOP/OVP (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Henning, Alexa A. EOP/WHO (b) (6); Bowman, Lauren K. EOP/WHO (b) (6); Porter, Macaulay V. EOP/OVP (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Hall, Bill (HHS/ASPA) (b) (6); Murphy, Ryan (OS/ASPA) (b) (6)
Subject: RE: Dr. Fauci hits and requests

(b) (5)

From: Love, Kelly A. EOP/OVP (b) (6)>
Sent: Tuesday, March 24, 2020 7:34 PM
To: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Henning, Alexa A. EOP/WHO (b) (6); Bowman, Lauren K. EOP/WHO (b) (6); Porter, Macaulay V. EOP/OVP (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Hall, Bill (HHS/ASPA) (b) (6)>; Murphy, Ryan (OS/ASPA) <(b) (6)>; O'Malley, Devin M. EOP/OVP (b) (6)>
Subject: RE: Dr. Fauci hits and requests

(b) (5)

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, March 24, 2020 7:26 PM
To: Love, Kelly A. EOP/OVP (b) (6)>; Henning, Alexa A. EOP/WHO (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Hall, Bill (HHS/ASPA) (b) (6)>; Murphy, Ryan (OS/ASPA) (b) (6)>
Subject: Dr. Fauci hits and requests

Good evening –

Below is an updated list of the hits and pending requests for Dr. Fauci. (b) (5)

(b) (5)

Tuesday 3/24

- 7 am firm live hit Chris Stigall Radio Show (Philly) – completed
- WMAL in WDC – completed
- 10 pm live with Laura Ingraham truck from his house - scheduled

Wednesday 3/25

- Bob Rose Radio Show - Gainesville FL – 6:33 am live hit – scheduled
- Bernie and Sid Radio Show – NYC – 7:05 am live hit – scheduled
- WTOP – working to schedule
- NPR Morning Edition – working to schedule

(b) (5)



Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892

Direct: (b) (6)

(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 17:17:12 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Proposta da un medico ricercatore italiano per arginare l'infezione da Coronavirus

Bob:

Can you figure out a way to get this translated so that we can figure out what he wants and whether we can help him.

Thanks,
Tony


Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)


The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: sandragiudici@libero.it <sandragiudici@libero.it>
Sent: Saturday, March 28, 2020 1:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Proposta da un medico ricercatore italiano per arginare l'infezione da Coronavirus
Importance: High

Egregio Professor Fauci,

foreign language





dot.ssa Sandra Liliana Giudici

Oggetto: Proposal from an Italian research doctor to stem the Coronavirus infection

Dear Professor Fauci,

I'm an Italian research doctor, with a qualification in Internal Medicine, who trained at the Polyclinic Hospital of Milan.



(b) (4)



I'm very grateful for the precious time and for the attention that You will want to devote to my "application hypothesis". Trusting in Your kind reply, I send my best regards.

dr. Sandra Liliana Giudici

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 17:15:57 +0000
To: Janet Tobias
Cc: Conrad, Patricia (NIH/NIAID) [E]; (b) (6)
Subject: FW: Update on Film details, Task Force conversations, etc.

Janet:

Thanks for the note to Patty. We can do some of #4 below. Patty will contact you and we can also chat by phone today to update me on details. As you might imagine, things are very hectic and the most important thing is for me to get my job done. And so we will do what we can but may not be able to do everything that you would like. I look forward to speaking with you later.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E]; (b) (6)>
Sent: Saturday, March 28, 2020 7:28 AM
To: Fauci, Anthony (NIH/NIAID) [E]; (b) (6)
Subject: Fwd: Update on Film details, Task Force conversations, etc.

Sent from my iPhone

Begin forwarded message:

From: Janet Tobias <janet@ikanamedia.com>
Date: March 28, 2020 at 7:24:48 AM EDT
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>

Cc: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>, "Routh, Jennifer (NIH/NIAID) [E]" (b) (6)

Subject: Update on Film details, Task Force conversations, etc.

Hi Patty: A few important updates. And a request for this weekend/Sunday.



2) We have been working with John Burklow/Dr. Collins/HHS on access to the Task Force. The Task Force came back to us and asked us for more details about our approach, we gave them a written description of the overall approach of documenting for history the role of the Task Force, it's leadership, NIH, NIAID, and Dr. Fauci. Burklow is working with us on this.

3) Could I have a ten minute phone conversation with Dr. Fauci this weekend, important—I think—to update him on details personally.

4) We would like, if possible to start filming with Dr. Fauci this weekend. Could we film Dr. Fauci exiting his house and going to the live truck for Sunday morning interviews and then going back home or off to the WH. We would then match that in the film with the feed from the truck of him sitting down and get archive from the shows he appears. We are close by. Zac (DP, who Dr. Fauci knows) has been in complete self-quarantine for two weeks before he left New York State and we are now here a week. He is completely good by self-quarantine rules for above filming.

Thanks to the three of you for the work. The communication is life-saving. I have a couple of close friends on the frontline and they asked me to relay how deeply grateful they are for the work you are all doing.

Janet

On Mar 24, 2020, at 3:38 PM, Conrad, Patricia (NIH/NIAID) [E]

(b) (6) wrote:

Hi Janet

I gave him a hardcopy of your email earlier today...he does have it – we had to add some meetings at the WH prior to his Task Force meeting so I know he was a bit distracted..

Will keep trying...

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Janet Tobias <janet@kanamedia.com>

Sent: Monday, March 23, 2020 9:26 PM

To: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >

Subject: Here and working

Hi Patty:

Zac and I are here and situated. I know you are drinking through ten firehoses. I want to preserve sleep and health for Dr. Fauci. But it would be fantastic to have a 15 minute video (with distancing) Q and A in the garden of his house or in the house this week— what he is working on just scientifically—vaccines, treatments, disease understanding. I want to capture the focus and urgency of the real time scientific work on COVID-19. If we need to we can figure out how to do it with audio, but would love to see if we could do this in 15 minutes on video. Again, anytime this week.

Thanks,

Janet

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 17:00:15 +0000
To: Auchincloss, Hugh (NIH/NIAID) [E]; Erbelding, Emily (NIH/NIAID) [E]
Cc: (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: NIAID-NIBIB discussion
Attachments: COVID_ICD_Tromberg.pptx

Hugh/Emily:

Please handle this and respond to Bruce for me.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tromberg, Bruce (NIH/NIBIB) [E] (b) (6)
Sent: Saturday, March 28, 2020 10:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6)
Cc: Heemskerk, Jill (NIH/NIBIB) [E] (b) (6); George, David (NIH/NIBIB) [E] (b) (6)
Subject: NIAID-NIBIB discussion

Hi Tony, Hugh, and Emily

Hope you are doing well and getting a chance to pause (especially Tony!) after another breathless sprint of a week.

The NIBIB community has unique capacity to design, build, and deploy an array of powerful biomedical technologies. Much of our attention over the past year has been on early disease detection and prevention, and the integration of digital/personal health with conventional medicine. The COVID-19 crisis seems to have many challenges that are ideally matched for our capabilities. With the \$60M NIBIB will receive in the supplement, we are in a unique position to make a contribution.

I am hoping we can meet with you to refine ideas and coordinate as we develop mechanisms to marshal these resources. Your insight will play an essential role in helping us move forward wisely. NIBIB has never received anything remotely like this before and we are in unfamiliar territory. I think it reflects, in part, the confidence--and hope, that people have in advanced technologies to change lives. We are determined to convert these dollars into tangible methods and devices and need your help in optimizing our strategy.

I am forwarding my slide from the science presentation on Wednesday and my follow up email to Francis and Larry to give you a sense of our direction (apologies for the information blast!). We have also been drafting a NOSI with several topic areas that I am adding below...note that we are in the process of condensing and refining these to simplify and more closely resemble our pay plan. I had a great conversation with Francis in a follow up call Thursday and he suggested (b) (5)

[Redacted]

I look forward to your thoughts/comments and hope we (cc'd NIBIB leadership Jill Heemskerk and David George) can schedule a time to talk. Thank you for considering this, I know you are overflowing with emails and requests! If it's easier to just give me a call, my cell is (b) (6), I can give you the quick "cliff notes" summary.

Best,
Bruce

[Redacted]

From: "Tromberg, Bruce (NIH/NIBIB) [E]" (b) (6) > on behalf of "Tromberg, Bruce (NIH/NIBIB) [E]" (b) (6) >
Date: Thursday, March 26, 2020 at 7:22 AM
To: "Collins, Francis (NIH/OD) [E]" (b) (6) >, "Tabak, Lawrence (NIH/OD) [E]"

(b) (6)


Subject: Summary thoughts

Hi Francis and Larry,

Thanks for the opportunity to present yesterday.

(b) (7)


(b) (5)






Best,
Bruce

Bruce J. Tromberg, Ph.D.
Director
National Institute of Biomedical Imaging and Bioengineering
National Institutes of Health
Building 31, Room 1C14
Bethesda, MD 20892-2281
(b) (6)
301-480-0679 - FAX
(b) (6)
<http://www.nibib.nih.gov>





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 16:19:28 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: What's new for 'fauci as' in PubMed

thanks

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, March 28, 2020 11:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: What's new for 'fauci as' in PubMed

Will see to that these are on your cv

From: NLM/NCBI efbck <efbck@ncbi.nlm.nih.gov>
Sent: Saturday, March 28, 2020 6:17 AM
To: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: What's new for 'fauci as' in PubMed

This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.

Sender's message: Search: fauci as

Sent on Saturday, 2020 March 28
Search: **fauci as**

[View complete results in PubMed](#) (results may change over time).

[Edit saved search settings](#), or [unsubscribe](#) from these e-mail updates.

PubMed Results

Items 1 - 2 of 2

1 [Covid-19 - Navigating the Uncharted.](#)

Fauci AS, Lane HC, Redfield RR.

N Engl J Med. 2020 Mar 26;382(13):1268-1269. doi: 10.1056/NEJMe2002387. Epub 2020 Feb 28. No abstract available.

PMID: 32109011 [PubMed - indexed for MEDLINE]

[Similar articles](#)

2 [Role of T-cell trafficking in the pathogenesis of HIV disease.](#)

Cicala C, Arthos J, Fauci AS.

Curr Opin HIV AIDS. 2019 Mar;14(2):115-120. doi: 10.1097/COH.0000000000000529. Review.

PMID: 30601238 [PubMed - indexed for MEDLINE]

[Similar articles](#)

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 14:18:32 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Updates, in DC

Email below from Janet Tobias.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

-----Original Message-----

From: Janet Tobias <janet@ikanamedia.com>
Sent: Saturday, March 28, 2020 7:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Updates, In DC

Dear Tony: I sent a note to Patty with updates. Task Force in progress (asked for more information) and we have finalized plans for distribution/release of the film for when this is over next year and we all feel good about being together in a theater. Will now push to do tiny bits of filming and audio a couple of times a week.

Thanks for everything and thanks yesterday for talking to the frontline. Close friends there have asked me to pass on their gratitude.

See you soon and follow Chris' advice about taking care of yourself.

Janet

> On Mar 22, 2020, at 10:19 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:
>
> My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov <<http://www.coronavirus.gov>> for the latest information and guidance related to COVID-19.
>
> Thank you, and best regards.
>
> Anthony S. Fauci, M.D.
>
>
>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 12:29:31 +0000
To: Burklow, John (NIH/OD) [E]
Subject: RE: Great videos!

Thanks, John!

From: Burklow, John (NIH/OD) [E] (b) (6)
Sent: Friday, March 27, 2020 6:32 PM
To: Myles, Renate (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6); Akinso, Woleola (NIH/OD) [E] (b) (6); Olander, Alyson (NIH/OD) [E] (b) (6); Cox, Todd (NIH/CIT) [E] (b) (6); Rosado, Andrew (NIH/CIT) [E] (b) (6); Collins, Scott (NIH/CIT) [E] (b) (6); Chen, Josephine (NIH/CIT) [E] (b) (6); Welch, Will (NIH/CIT) [E] (b) (6); Diane Baker (b) (6); Awwad, David (NIH/NIAID) [C] (b) (6); Rice, David (NIH/OD) [E] (b) (6)
Cc: Collins, Francis (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6); Norris, Andrea (NIH/CIT) [E] (b) (6); Alboum, Stacie (NIH/CIT) [E] (b) (6); Johnson, Alfred (NIH/OD) [E] (b) (6); Prince, Scott (NIH/OD) [E] (b) (6); Chew, Debra (NIH/OD) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Great videos!

Congratulations to all of you who made today's COVID-19 videos a tremendous success! I know there were a lot of quickly moving, intricate parts and it went off flawlessly—all remotely, to boot! Everyone worked as a team, under very tight timelines, and thanks to Renate, who orchestrated the FC Home Edition! I know NIH staff will greatly appreciate the videos—they're chockful of content! And special thanks to Dr. Fauci, who took time out of his "leisurely" day to devote more than an hour to the taping—incredible!

You all make us very proud!

John

From: (b) (6)
Sent: Fri, 27 Mar 2020 17:51:23 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Reaching out from Frame/Urgent

Begin forwarded message:

From: Ben Moe <ben@frame.media>
Date: March 27, 2020 at 5:47:50 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: Re: Reaching out from Frame/Urgent

Dear Dr. Fauci,

I hope all goes well. I wanted to quickly follow up and see if you might be free for a quick interview on Monday — it would mean so much to include your voice in the piece.

Is there a time on Monday that might work for you? We can jump on the phone for a 5 - 10 minute call if that works better for you.

Best,

Ben

On Thu, Mar 26, 2020 at 5:10 PM Ben Moe <ben@frame.media> wrote:
Dear Dr. Fauci,

I hope this finds you well and thank you for all the work you are doing. I run the digital magazine, Frame, which publishes interactive documentaries made for mobile phones. We are working on a story about the current effort to create a coronavirus vaccine and would love to interview you for the piece.

We've interviewed Regeneron's Chief Scientific Officer, George Yancopoulos, and the piece will tell the story of Regeneron's push to create a coronavirus vaccine in record time. I was hoping you could speak to the broader issue of the often undercovered global threat of diseases and the lack of funding going toward infectious diseases.

Would you potentially be available for a short video interview sometime between 10am - 7pm EST tomorrow? Alternatively, would you be free sometime between 12pm - 2pm or 5pm - 7pm EST on Monday?

Look forward to hearing back and we'd be honored to have your voice in the story.

Here's a brief overview of Frame:

Frame is a newsmagazine that publishes interactive documentaries made for mobile phones. Every Frame story tells a compelling, human story that helps shine a light on a major social or political issue.

Frame stories include interactive features throughout, from maps to timelines, that allow viewers to engage more deeply with the piece. Our stories are delivered through a messaging platform that allows subscribers to have conversations with our journalists and subscribe to news updates on topics they want to follow, all through SMS. Frame has been covered by TechCrunch, Poynter, and Journalism.co.uk, and our investors include Snap Inc.'s Yellow Accelerator.

The very best,

Ben Moe

--

Founder and CEO, Frame
ben@frame.media
[@beneliasmoe](https://twitter.com/beneliasmoe)

--

Founder and CEO, Frame
ben@frame.media
[@beneliasmoe](https://twitter.com/beneliasmoe)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 27 Mar 2020 17:48:31 +0000
To: Hirsch, Vanessa (NIH/NIAID) [E]
Subject: RE: appreciation

Thanks, Vanessa. I appreciate your note.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hirsch, Vanessa (NIH/NIAID) [E] (b) (6)
Sent: Friday, March 27, 2020 10:28 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: appreciation

Hi Tony,

I just wanted to express my appreciation for your sane voice during the Covid-19 crisis. Keep up the good work. I know it has to be exhausting.

Best regards,

Vanessa Hirsch
NHPVS, NIAID, NIH

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 27 Mar 2020 15:57:33 +0000
To: Morens, David (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: [REDACTED] (b) (4)

David:

Provided you [REDACTED] (b) (6), if you could do this within the next 2 to 3 weeks, that would be great.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Morens, David (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Friday, March 27, 2020 11:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: [REDACTED] (b) (4)

Tony, [REDACTED] (b) (4), so I will start to think about what might work.

Do you have a hoped-for timetable? We are both overwhelmed, but I will try to do at least a bit daily as long as [REDACTED] (b) (6). david

From: Morens, David (NIH/NIAID) [E]
Sent: Friday, March 27, 2020 11:24 AM
To: Narasimhan, Sri Devi (ELS-CMA) <srnarasimhan@cell.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>
Subject: RE: Subject: [REDACTED] (b) (4)

Dear Sri, thank you and we wish you and colleagues well too. These are certainly difficult times for all.

I will discuss again with Tony. [REDACTED] (b) (4). We'll ponder that some more and get back to you later. Thanks, again, and stay safe



David M. Morens, M.D.

CAPT, United States Public Health Service
Senior Advisor to the Director
Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Building 31, Room 7A-03
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520



(b) (6) assistants: Kimberly Barasch; Whitney Robinson)




Disclaimer: This message is intended for the exclusive use of the recipient(s) named above. It may contain information that is PROTECTED, PRIVILEGED, and/or CONFIDENTIAL, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. All sensitive documents must be properly labeled before dissemination via email. If you are not the intended recipient, any dissemination, distribution, or copying is strictly prohibited. If you have received this communication in error, please erase all copies of the message and its attachments and notify us immediately.



From: Narasimhan, Sri Devi (ELS-CMA) <>
Sent: Thursday, March 26, 2020 9:23 PM
To: Morens, David (NIH/NIAID) [E] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: Subject: (b) (4)

Dear Tony and David,

Thank you for writing back. Firstly I would like to say thank you for all that you are doing. On



I hope you, your families and colleagues stay safe and healthy through this. Please take care.

I look forward to staying in touch.

Best wishes,
Sri.

Sri Devi Narasimhan, PhD
Deputy Editor, Cell
Cell Press/Reed Elsevier
50 Hampshire St., Cambridge, MA 02139
snarasimhan@cell.com

From: Morens, David (NIH/NIAID) [E] (b) (6)
Sent: Thursday, March 26, 2020 4:53 PM
To: Narasimhan, Sri Devi (ELS-CMA) <snarasimhan@cell.com>
Subject: Subject: (b) (4)

Dear Sri, we're responding, at long last, to your invitation to Tony Fauci several weeks back, to

(b) (4)

First, apologies are in order. We tried to meet about this and get you a quick response the day after you and Tony emailed, but then coronavirus chaos ensued. We had to cancel 5 successive meetings to go over this; in one case minutes before we were to start he got an urgent call to go down to the White House asap, and that was that. Few of us in the office have even seen Tony in recent weeks as he is down at the White House daily from early morning until late at night.

Finally this morning we sat down and had a relaxed discussion. Assuming you are still interested,





(b) (4). Crazy times, for sure.

Thank you, I look forward to hearing from you,

<< OLE Object: Picture (Device Independent Bitmap) >>

David M. Morens, M.D.

CAPT, United States Public Health Service
Senior Advisor to the Director
Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Building 31, Room 7A-03
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520

  (b) (6) stants: Kimberly Barasch; Whitney Robinson)





Disclaimer: This message is intended for the exclusive use of the recipient(s) named above. It may contain information that is PROTECTED, PRIVILEGED, and/or CONFIDENTIAL, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. All sensitive documents must be properly labeled before dissemination via email. If you are not the intended recipient, any dissemination, distribution, or copying is strictly prohibited. If you have received this communication in error, please erase all copies of the message and its attachments and notify us immediately.

<< OLE Object: Picture (Device Independent Bitmap) >>

From: Narasimhan, Sri Devi (ELS-CMA) <srnarasimhan@cell.com>

Sent: Monday, January 27, 2020 4:00 PM

To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]>

Subject: [REDACTED] (b) (4)

Dear Tony,

I hope all is well. I had the great pleasure of meeting you in person when you were the keynote speaker at our Cell Symposium on Emerging and Re-emerging Viruses in 2017. You then gave a wonderful talk that covered AIDS to Zika and your experiences across different outbreaks, administrations and the challenges you encountered.



My best wishes,
Sri.

Sri Devi Narasimhan, PhD
Deputy Editor, Cell
Cell Press/Reed Elsevier
50 Hampshire St., Cambridge, MA 02139
srnarasimhan@cell.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 27 Mar 2020 15:56:36 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Offering help to fight the Covid-19
Attachments: Presentation Doc-line.pdf

Please check it out and respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Peter Lermen (b) (6)
Sent: Friday, March 27, 2020 11:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Offering help to fight the Covid-19

Dear Dr. Fauci,

I don't want you to waste too much time in this stressful situation.

As the doctor in charge of the hygiene of the Berner clinic in Crans-Montana in Switzerland, as well as being in contact with my colleagues in private practice, I see every day how important the need for information and consultation of the population in this situation of insecurity is. At the same time, we are under threat of a shortage of doctors if we have to strictly apply the federal swiss guidelines (Art. 10b and 10c, regulation 2 COVID-19) or if the wave of illness reduces the number of colleagues available for consultations.

(b) (4)


Thank you for your time

Good luck

Best regards,



Peter Lermen
MD internal medicine, internal oncological rehabilitation
Co-President oncoreha.ch

 (b) (6)
www.doc-line.ch

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 27 Mar 2020 13:30:18 +0000
To: Mascola, John (NIH/VRC) [E]
Subject: FW: Vir update
Attachments: Vir Barda TechWatch_05Mar20_vF.pptx

Please take a look at this and respond if appropriate.. Too long an e-mail for me to tackle. I have 745 others.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)


The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Skip Virgin (b) (6) >
Sent: Tuesday, March 10, 2020 11:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Vir update

Tony

My apologies for the slow update. You asked that I get back to you after (b) (4) and so here I am. Notes in sections.





Any advice welcome

Happy to talk (b) (6)

Be well and thanks for all of your public work to help us prepare. I wish they listened more.

Skip

Herbert W. 'Skip' Virgin M.D., Ph.D.
Executive Vice President, Research
Chief Scientific Officer
Vir Biotechnology
499 Illinois Avenue
San Francisco CA 94158
he/him/his

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 16:19:31 +0000
To: Giroir, Brett (HHS/OASH)
Cc: Kadlec, Robert (OS/ASPR/IO); Birx, Deborah L
(b) (6); Lerner, Andrea (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Redd, Stephen (CDC/DDPHSIS/OD)
Subject: FW: Draft of email for ASF to send to Brett Giroir cc'ing Kadlec
Attachments: IMG_2072.mov

Brett:

The proposal below was sent to my office by David Margulies (Harvard/Boston Childrens) who is part of a group of prominent physicians and healthcare executives in Boston developing this idea (David Martin of the Brigham, Gary Gottlieb of Partners and others). See this op-ed they wrote in the Boston Globe yesterday regarding their proposal <https://www.bostonglobe.com/2020/03/25/opinion/mass-needs-comprehensive-care-response-coronavirus/>).

(b) (5)

Can you take a look at this and let me know what you think? (b) (5). David Margulies can be contacted directly at (b) (6) or (b) (6) if you need additional information.

Thanks,
Tony

(b) (4), (b) (5)



David Margolies, M.D.

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 13:25:30 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR TASK FORCE Consideration -- Some sound thinking on COVID-19

We have been discussing each and every one of these suggestions and they are all on the table for consideration of implementation.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Thursday, March 26, 2020 9:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: FOR TASK FORCE Consideration -- Some sound thinking on COVID-19
Importance: High

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Wednesday, March 25, 2020 6:31 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: FW: FOR TASK FORCE Consideration – Some sound thinking on COVID-19
Importance: High

From: Pierce, William <wpierce@apcoworldwide.com>
Sent: Wednesday, March 25, 2020 4:24 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: FOR TASK FORCE Consideration – Some sound thinking on COVID-19
Importance: High

Patty:

I know Tony is the expert, but I thought this memo would be of interest and perhaps of help to him in his battles.

The attached memo is from Dr. Paul Offit (U of Penn) and a colleague of his David Rubin. Tony may know him, I would not be surprised.

But for you, Paul is one of the country's top vaccinologists and virologists. Paul developed a vaccine for a deadly disease. I know him well and he's the real deal. Next to Tony he is my go to science source.

Paul in particular is a highly credible, well known national expert.

They wrote this memo on the 19th of March and it has many suggestions that are incredibly smart and I thought tony would want to see this immediately. Paul and David are obviously available to talk asap.

Let me know.

Bill

William Pierce
Senior Director

APCO Worldwide
1209 Pennsylvania Ave, N.W.
Suite 300
Washington, DC 20004

(t) +1 202 659 7931 (m) [REDACTED] (b) (6)

wpierce@apcworldwide.com
[@apcworldwide](#)

::::: [Learn more about APCO resources available during the COVID-19 outbreak](#) :::::

CONFIDENTIALITY

This email may contain material that is confidential, privileged and/or work product for the sole use of the intended recipient. Any review, reliance or distribution by others or forwarding without express permission is strictly prohibited. If you are not the intended recipient, please contact the sender and delete all copies.

William Pierce
APCO Worldwide
(t) +1 202 659 7931 (m) (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 12:44:24 +0000
Bcc: Crew, Page (NIH/NIAID) [E]; Davey, Richard (NIH/NIAID) [E]; Doepel, Laurie (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]; Higgs, Elizabeth (NIH/NIAID) [E]; Kuriakose, Safia (NIH) [C]; Lerner, Andrea (NIH/NIAID) [E]; Nason, Martha (NIH/NIAID) [E]; Seam, Nitin (NIH/CC/CCMD) [E]; Singh, Kanal (NIH/NIAID) [E]; [REDACTED] (b) (6); Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE); Pau, Alice (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: Memo to NIH/CDC/VA Support Staff for the HHS Panel on COVID-19 Treatment Guidelines

Dear colleagues,

The purpose of this email is to thank-you for agreeing to provide support to the HHS COVID19 Treatment Guidelines Panel. As you are aware clinicians are doing their best to navigate a complicated landscape with little to guide them. I realize everyone is very busy and I appreciate you taking on this additional work at a difficult time.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 10:42:30 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Awwad, David (NIH/NIAID) [C]
Subject: FW: BBC News

Let us see if we can do this from my NIH office today during the day.

From: Chris Foote <chris.foote@bbc.co.uk>
Sent: Thursday, March 26, 2020 5:02 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: BBC News

Hello Dr Fauci

I'm the programme editor of The Nine, a nightly news and current affairs programme on the BBC. I was hoping you could spare ten minutes at some point today (March 26) to speak to us over Skype or FaceTime about the US response the Coronavirus pandemic.

If that's possible, I'll ask one of my producers to arrange it at a time convenient for you.

Chris Foote
Senior Journalist
BBC News

+ [REDACTED] (b) (6)

<http://www.bbc.co.uk>

This e-mail (and any attachments) is confidential and may contain personal views which are not the views of the BBC unless specifically stated.

If you have received it in error, please delete it from your system.

Do not use, copy or disclose the information in any way nor act in reliance on it and notify the sender immediately.

Please note that the BBC monitors e-mails sent or received.

Further communication will signify your consent to this.





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 02:27:28 +0000
To: Joubert, Bonnie (NIH/NIEHS) [E]
Subject: RE: Thank you

Bonnie:
Thanks for the note. Much appreciated.
Best regards,
Tony

From: Joubert, Bonnie (NIH/NIEHS) [E] (b) (6)
Sent: Wednesday, March 25, 2020 9:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Thank you

Dear Dr. Fauci,

I just want to say THANK YOU for all that you are doing for the country to address the COVID-19 pandemic. As an epidemiologist at NIEHS, it is inspiring and encouraging to be part of NIH and to have leaders like you involved in the national and global response during this critical time.

Regards,
Bonnie

Bonnie Joubert, MPH, PhD
Population Health Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
Research Triangle Park, NC 27709
Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 17:20:55 +0000
To: Friedmann, Theodore
Subject: RE: George Church interview

Thanks, Ted. I appreciate your note.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Friedmann, Theodore <tfriedmann@health.ucsd.edu>
Sent: Tuesday, March 24, 2020 4:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: George Church interview

Dear Tony: I sent a brief note to my friend Jon Cohen to congratulate him on what I thought was his fine interview with you. In his response, he suggested that I should send a copy to you. I've been a little reluctant to do that because of what I assumed must be a flood of comments and advice that you are getting in your role on the task force. I attach the message to Jon below and I hope that some of the thoughts are useful and maybe a little comforting for you. With my very warmest regards and best wishes,

Ted

Begin forwarded message:

From: Theodore Friedmann <tfriedmann@health.ucsd.edu>
Subject: Re: George Church interview
Date: March 24, 2020 at 12:09:20 PM PDT
To: Jon Cohen <jcohen@aaas.org>

Dear Jon: Greetings from La Jolla. Congratulations on your interview with Tony Fauci. I have to admit that, until a couple of weeks ago, I have been quite critical of Tony's apparent acquiescence with so much dangerous, incorrect and politically motivated misinformation from the administration. I feared that the upside-down explanations from the administration had the effect of destroying the concepts and tenets of epidemiology and even rationalizing a completely wrong concept of communicable disease that holds that it is unnecessary to screen for carriers in an epidemic but only important to screen symptomatic people. That is upside-down from what we all know about dealing with epidemics and has even been endorsed by Trump, Pence and other members of the COVID-19 task force. It seems to have become a new normal concept of communicable disease management. Like so many things in the Trump era, facts and history are thrown out the window and replaced by governmentally espoused but obviously wrong concepts. We assume to be preparing to completely deny established concepts of communicable disease - screen only the prime suspects or the afflicted. In conversations with colleagues here I wondered "where is Tony Fauci?" They suggested that he must be quietly and heroically working hard being the scenes and at his personal peril to educate our leaders rather than correcting them publicly. But I thought that, in desperate times, the public must hear and see clear truth and denials of lies. My concept of heroes are people who act at their personal peril - Rosa Parks, Martin Luther King, Martin Niemöller, Dietrich Bornhoffer, Thankfully, I think that the real Tony Fauci has emerged, obviously to his peril. I wish him good luck and survival. I find myself wondering what the responses will be to Trump's likely premature lifting of isolation and quarantining procedures and if the concept of disobeying illegal and unethical orders will survive the times.

In any event, good interview! By the way, [REDACTED] (b) (6)
[REDACTED]
[REDACTED]. All the best regards,

Ted

On Dec 6, 2018, at 11:17 AM, Jon Cohen <jcohen@aaaas.org> wrote:

So good to hear from you and do tell Carl to contact me.

Yes, George has received ample criticism, but my job is to air his views, regardless of what I think. And I like his independent, damn the torpedoes approach. He speaks his mind. As for He, everything about this is bizarre, from ethics to science to PR to regulation.

Best,

Jon

On Dec 6, 2018, at 1:19 PM, Friedmann, Theodore
<tfriedmann@ucsd.edu> wrote:

Hello Jon - Greetings from (b) (6). It has been a long time since
we last connected and talked about gene therapy, etc. and

(b) (6)
(b) (6)
(b) (6)

I was very interested to read George Church's troublesome responses in your interview with him in Science and to see his ethical evaluation of He's CCR5 editing experiment in China. I'm not as generous to He as George seems to be and I think that this work is clearly unethical. George inexplicably conjures up the sad history of Jess Gelsinger and the effect of his death on the evolution of the field of gene therapy. Happily, he's right about the fact that gene therapy is now proving itself in a growing list of intractable diseases (underscored by the 2015 Japan Prize). That has happened because studies are now much more carefully designed and carried out. But sadly, we are in an environment in which some people conclude that human medical manipulations - gene therapy, genome editing, stem cell therapy - are ethical as long as they "work". The rationale is, "let's do the study and if it works and doesn't kill or otherwise harm, it's OK". It's not a post-factor evaluation that determines if an instance of human experimentation is ethical and permissible - it is the design of a study that determines if it is ethical or not. George should be reminded of that fact and should re-read the Helsinki declarations or similar codes of human experimentation.

In any event, your interview was fascinating. Best regards,

Ted Friedmann

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 16:59:20 +0000
To: (b) (6)
Subject: FW: Developing Control Charts for Covid 3 24 20 with graphs.docx
Attachments: Developing Control Charts for Covid 3 24 20 with graphs.docx

Please take a look at this. What do you think?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Steve Sternberg (b) (6)
Sent: Wednesday, March 25, 2020 8:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Developing Control Charts for Covid 3 24 20 with graphs.docx

Tony,

Here are reconfigured charts which factor in the guidance from mathematicians at Rockefeller. As you can see, the trend in the U.S. is visibly worse. If this pattern holds, we're going to see many more deaths before things get better.

We would be grateful for a comment. Could you offer a perspective? We're going to try to publish today.

Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 15:01:21 +0000
To: DELFRAISSY Jean-francois
Cc: (b) (6)
Subject: RE: France situation COVID-19

Jean-Francois:

Thank you for your note. I do not see Yazdan copied on your e-mail, and I please forward this e-mail to him. The NIH position is that we should preferably make drugs available on randomized, controlled clinical trials and not freely distribute them. There is a strong push in the USA, favored by the President, to make certain of these drugs more widely available outside of an RCT using mechanisms such as "compassionate usage". In the USA, as you know, HC (plaquenil) is an approved drug for malaria as well as for certain autoimmune diseases such as SLE. Thus, physicians can prescribe the drug on an "off label" usage. This likely will be the major modality of distribution of this drug in the USA, at least for the foreseeable future.

I am copying Cliff Lane on this e-mail. Please include him on any further correspondence on this subject.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: DELFRAISSY Jean-francois (b) (6) >
Sent: Wednesday, March 25, 2020 10:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: DELFRAISSY Jean-francois (b) (6) >
Subject: France situation COVID-19

Hello,

I am once again in service since the global sanitary crisis COVID-19 hit France a couple of weeks ago. I am now leading the Scientific Council for COVID-19, composed of 10 persons, serving the French President, Emmanuel Macron.

The Council was created on March the 10th and we were heavily involved in advisory activities in relation to the President's decision to put the generalized quarantine into force, because we didn't have any better choice.

Firstly

We have a limited number of diagnosis tests, this prevents us from taking up a Korean-like strategy within the next few days. However, by the end of the quarantine (within the following six weeks), we will be able to have a generalisation of the diagnosis test and develop korean-like apps, as well as a strategy for testing and treatment if we have any drugs available by this time. Before this, we will go through a difficult phase in the following weeks, because we won't have enough beds in our care units in some part of France ...

Secondly

On the therapeutic level, Yazdan Yazdanpanah has taken my place and who is now leading REACTing.

Tomorrow morning a french-european medical trial will begin, under the control of the WHO, with 5 arms (placebo/kalatra/kalatra +interferon béta / product of Guilead / hydroxychloroquine alone or in combination for next week).

As you may know, we are currently facing a press buzz since the announcement made by Dr. Raoult about the effectiveness of hydroxy-chloroquine. His data is not particularly convincing. We can distinguish a slight positive signal but it must be confirmed by a well made randomised trial. We also started a monkey-model study with HC and we should have the results by the end of next week. Also a cohort of severe COVID+ patients have been created and some will be treated with HC : we will analyse those results with all the consciousness needed. It will also be possible to do a prevention trial for healthcare

professionals and aging people with HC. I have an enormous political pressure to release HC and to give it to everyone but I am currently resisting...

How is the situation in the USA, especially after Trump's announcement ? What is the NIH position ? What will be put into force ?

Thanks for your answer.

I put Yazdan Yazdanpanah in a copy of this email.

Best regard

Pr. Jean-François Delfraissy

Président | *President*

Comité consultatif national d'éthique pour les sciences de la vie et de la santé

National Ethical Consultative Committee for life sciences and health

Ancien Directeur de l'ANRS | *ANRS former Director*

M [REDACTED] (b) (6)

T [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 13:57:28 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [REDACTED] (b) (4)
PANTHEON

Agree. Skip this and please try to get David back on my morning schedule to start working on the original paper that we had agreed upon.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Wednesday, March 25, 2020 9:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: [REDACTED] (b) (4)

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 12:08:27 +0000
To: (b) (6)
Subject: RE: with love from Italy

Rita:

Many thanks for your kind note. It is much appreciated.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: rita.apgar@alice.it (b) (6)
Sent: Wednesday, March 25, 2020 7:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: with love from Italy

Dear Doctor Fauci. My name is Rita Apgar and if by chance you noticed my last name, as my father said many years ago, "(b) (6)" I have lived in Italy for almost 50 years and the sagacious finger of destiny pointed my way to Italy, the true home of my heart, although not a drop of Italian blood flows through it. But the love of Italy and the Italians pumps through my heart every second of my existence.

That sagacious finger of destiny pointed the way, and I followed it in faith to (b) (6) where I had lived. As soon as I set foot for the first time in the house in this funky ghost town of a medieval village, I felt that we belonged together. And, practically speaking, at the time, it was the perfect solution to some weighty personal problems. Heart and mind were in peaceful agreement.

I have a dear friend who is an infectious disease specialist at the hospital in Asti. She is, obviously, extremely busy these days but she took the time to call me Sunday evening and we talked about you. She said to me, "you know, when I was just a graduate student, I was a secret groupie of Dr. Fauci, and once when he was at a meeting or a conference or something (I'm not sure where or when) I was able to ask him a few questions." I was thrilled, of course, since I also try to watch every appearance you make on TV. I will not add anything in this regard.

But I did say to Maria, Doctor Maria Degioanni, "Maria, I want to invite Dr. Fauci to come and visit us for a few days when this crisis is over, God willing and maybe he would come together with (b) (6) who has promised to come and visit again after 20 years. We can put them up in the fancy Relais San Damian above Isolalunga where I live and take them out to dinner at Gente di Mare. Dear Doctor Fauci, I like to joke when people ask how we are doing in this time of Covid-19 by saying : A Name, a guarantee: ISOLAlunga= ISOLAtion! Legend says that the Benedictine monks who got into mischief centuries ago were sent here as punishment to work in the olive groves: long isolation. Today it's the perfect place to be with a view of the Mediterranean as well as the Maritime Alps from the kitchen window and hardly a soul to practice social distancing with! Grazie per esistere as an Italian song goes, "thank you for being you! I would adore getting a reply from you, but realize how miraculous that would be! We would be over the moon if you accepted our invitation, at any time and at the drop of a hat!

Sincerely, Rita Apgar

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 10:27:40 +0000
To: Jon LaPook
Subject: FW: Serology for the novel coronavirus

Try Barney Graham at the NIAID VRC. You have interviewed him more than once.

-----Original Message-----

From: Jon LaPook (b) (6) >
Sent: Tuesday, March 24, 2020 2:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: Serology for the novel coronavirus

Sigh. Who would you suggest I try to interview?
Thanks,
Jon

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, March 24, 2020 1:57 PM
To: Jon LaPook (b) (6) >
Subject: Re: Serology for the novel coronavirus

Lots of talk. Not sure about progress

> On Mar 23, 2020, at 6:27 PM, Jon LaPook (b) (6) > wrote:
>
> Tony,
> Any progress? Obviously, if we had widespread serologic testing, we could identify people with likely immunity, and put them on the front lines.
> Thanks,
> Jon
>
> Jonathan LaPook, M.D.
> Chief Medical Correspondent, CBS News
> Professor of Medicine
> NYU Langone Health
> Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 02:26:42 +0000
To: (b) (6)
Subject: FW: Serology for the novel coronavirus

Cliff:

Who is the most knowledgeable about serologies for COVID-19? If you know, could you please respond to Jon.
Thanks,
Tony

-----Original Message-----

From: Jon LaPook (b) (6) >
Sent: Tuesday, March 24, 2020 2:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Serology for the novel coronavirus

Sigh. Who would you suggest I try to interview?
Thanks,
Jon

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, March 24, 2020 1:57 PM
To: Jon LaPook (b) (6)
Subject: Re: Serology for the novel coronavirus

Lots of talk. Not sure about progress

> On Mar 23, 2020, at 6:27 PM, Jon LaPook (b) (6) > wrote:

>

> Tony,

> Any progress? Obviously, if we had widespread serologic testing, we could identify people with likely immunity, and put them on the front lines.

> Thanks,

> Jon

>

> Jonathan LaPook, M.D.

> Chief Medical Correspondent, CBS News

> Professor of Medicine

> NYU Langone Health

> Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 01:53:06 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: COVID-19 West Virginia Phenomenon

From: Daniel Ries (b) (6) >
Sent: Tuesday, March 24, 2020 8:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: COVID-19 West Virginia Phenomenon

Dear Dr Anthony Fauci

(b) (6)

Best regards

Daniel Ries
PhD Food Technology
Massey University
NEW ZEALAND

(b) (6)



From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 17:48:57 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: COVID reagent allocation issue

Email response from Jeremy Berg

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Berg, Jeremy (b) (6)
Sent: Tuesday, March 24, 2020 1:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Subject: Re: COVID reagent allocation issue

You are welcome, Tony. We appreciate anything that you can do with regard to the reagent allocation issue. The view from the trenches is pretty stark.

Keep up the good work and do not hesitate to reach out to me if I can be helpful in any way.

Best, Jeremy

Jeremy M. Berg, Ph.D.
University of Pittsburgh
Associate Senior Vice Chancellor for Science Strategy and Planning
in the Health Sciences
Professor of Computational and Systems Biology
Scaife Hall, S304
3550 Terrace Street
Pittsburgh, PA 15213
(b) (6)

(cell)

From: Anthony Fauci [REDACTED] (b) (6) >
Date: Tuesday, March 24, 2020 at 1:44 PM
To: Jeremy Berg [REDACTED] (b) (6) >
Cc: "Lerner, Andrea (NIH/NIAID) [E]" [REDACTED] (b) (6) >
Subject: Re: COVID reagent allocation issue

Thanks, Jeremy

On Mar 23, 2020, at 9:00 PM, Berg, Jeremy [REDACTED] (b) (6) > wrote:

Dear Tony: I am sure you are overwhelmed, but I think it is important to share the attached with you (which will be sent to you directly through regular channels). [REDACTED] (b) (6) is a pathologist who is in charge of testing in a large medical system in Rochester, New York, who has been extremely concerned and frustrated by the lack of access to reagents for the Roche coronavirus testing platform. They have the platform but cannot use it because of a lack of reagents (which were apparently pre-purchased by Quest, LabCorp, and other national groups). The turnaround time for Quest is approximately 5 days and this is completely useless for making clinical decisions about admission compared with local testing with 24 hour per around time.

Thank you for your attention and for everything that you are doing to help our country through this great challenge.

Best, Jeremy

P.S. I enjoyed the interview with you in *Science* and admire your clarity of purpose.

Jeremy M. Berg, Ph.D.
University of Pittsburgh
Associate Senior Vice Chancellor for Science Strategy and Planning
in the Health Sciences
Professor of Computational and Systems Biology
Scaife Hall, S304
3550 Terrace Street
Pittsburgh, PA 15213

[REDACTED] (b) (6)

(b) (6) (cell)
(b) (6)

<Fauci-Rochester-Reagents.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 16:27:17 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: You may be able to help

Linda is a former NIH Institute Director. Please figure out what she is talking about and respond to her on my behalf

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birnbaum, Linda (NIH/NIEHS) [V] (b) (6)>
Sent: Tuesday, March 24, 2020 12:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: You may be able to help

Hi Tony,

Thank you for your tireless efforts to clearly communicate about the pandemic, including correcting the President when necessary. You do it in such a non-threatening and respectful style. I think everyone appreciates it.

(b) (6) runs a home health care company in NC and many other states in the nation. He has managed to get some of the largest home care companies as well as the Home Care Association of America (their trade organization) to sign off on this call for guidance for their industry which provides professional care givers, largely CNAs, to those needing assistance with daily living throughout the nation.

I am reaching out hoping that you might know to whom this message should really go.

Thanks again for all you do – and take care of yourself! The nation needs you.

Sincerely, Linda

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S
Scientist Emeritus (Retired)
Former Director, National Institute of Environmental Health Sciences
and National Toxicology Program
phone: (b) (6)
cell (b) (6)
e-mail: (b) (6)
personal email: (b) (6)

From: (b) (6)
Sent: Monday, March 23, 2020 10:45 PM
To: Linda Birnbaum (b) (6) >
Subject: Message to Dr. Fauci

Dear Dr. Fauci,

The home care industry cares for tens of millions of our most vulnerable citizens in their homes every day. We provide assistance with activities of daily living and instrumental activities of daily living, which keeps our clients in their homes and in the lowest risk setting. **Our professional Caregivers are able and willing to continue to provide care to clients who test positive for COVID-19 or have been exposed to the virus.**

But we need your help so that home care companies do not face unreasonable liability for providing such care. To that end, we ask for your support in getting a bill through congress like the Public Readiness and Emergency Preparedness Act (PREP Act), 42 USC 247d-6d, that will insulate providers like us from claims related to the care we will be providing in these extraordinary times.

We also ask that you support creating a fund that will provide appropriate personal protective equipment to our caregivers. Our clients should not have to bear the additional burden of the added cost of PPE.

Additionally, we would like you to encourage the CDC to clarify its guidance on caring for COVID-19 patients (found [here](#), [here](#) and [here](#)) that the guidance is applicable to "professional, licensed and insured, home based care agencies."

This clarification will give the industry a workable standard to protect caregivers caring for COVID-19 clients. In essence, it would establish that facemasks and gloves are sufficient PPE to care for COVID-19 clients in the home, and not require its caregivers to comply with the healthcare setting requirements of wearing N95 respirators, eye protection (goggles or face shields) or gowns. This is important as a practical matter because respirators and gowns are not readily available at this time. Moreover, most home care workers are not trained in the proper use of respirators.

Finally, we need your help in pressuring congress to provide day care for the children of our caregivers. If they cannot find adequate care for their children, then our clients will suffer. This is a vital step to keep our clients in their homes.

With your help, home care companies will be able to:

1. Relieve the burden on the healthcare system by keeping our clients out of the hospital; and
2. Adhere to shelter-in-place measures which will flatten the curve of COVID-19's spread.

Warmly,

(b) (6)

On behalf of:

Michael Cocco, Chief Operating Officer and General Counsel, Synergy Home Care

Emma Dickson, Chief Executive Officer and President, Home Helpers

Lisa Foster, Chief Clinical Officer, MGA Homecare

Daniel Gottschalk, Co-owner and President, Genova Health

Margaret Haynes, Chief Operating Officer, Right at Home

Vicki Hoak, Executive Director, Home Care Association of America

Peter Ross, Chief Executive Officer and Co-Founder, Senior Helpers


Timothy Ryan, General Counsel, AccentCare, Inc.


Shelly Sun, Founder, BrightStar Care


(b) (6)

www.nursecarenc.com

www.livhome.com







From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 15:33:11 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: The global health leaders call, Wednesday 25 March at 13:00 CET
Attachments: (b) (4) Swisscom Call code.pdf

Please print this out for me for possibility doing the call tomorrow. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. (b) (6)
Sent: Tuesday, March 24, 2020 10:59 AM
To: SHOC <shoc@who.int>; Office of the Director-General <DGOoffice@who.int>; Redfield, Robert R. (CDC/OD) (b) (6); David Heymann (b) (6); Felicity Harvey (b) (6); (b) (6); Chris Elias (b) (6); (b) (6) J. Farrar (b) (6); (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); (b) (6) GREIN, Thomas (b) (6); COX, Paul Michael (b) (6); SCHWARTLANDER, Bernhard F. (b) (6); MINHAS, Raman (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); MAHJOUR, Jaouad (b) (6); FALL, Ibrahima Soce (b) (6); Thomas R. Frieden (b) (6); Lynn Banks (b) (6); President | Resolve to Save Lives <president@resolvetosavelives.org>; (b) (6); AL-SHORBAJI, Farah (b) (6); Robynn Leidig (b) (6); DRURY, Patrick Anthony (b) (6); Dr VAN KERKHOVE, Maria (b) (6); cherylc (b) (6); GRAAFF, Peter Jan (b) (6); POOLE, Marcia <(b) (6)>; Tarik Mohammed (b) (6); Carlos Navarro Colorado (b) (6); Ryan Morhard (b) (6)

(b) (6) BRIAND, Sylvie (b) (6); MORGAN, Oliver
(b) (6); Harries, Jenny (b) (6); Awwad, David (NIH/NIAID) [C]
(b) (6); SIMONSON, Stewart (b) (6); SINGER, Peter Alexander
(b) (6) Jayatunga, Wikum < (b) (6)
>; Julie.HALL (b) (6); Amelie RIOUX < (b) (6);
KABIR, Sophia (b) (6)
(b) (6); SHIN, Young-Soo (b) (6);
(b) (6); Feng Ding (b) (6)
(b) (6)
Cc: SHOC <shoc@who.int>; Office of the Director-General <DGOoffice@who.int>; SCHWARTLANDER,
Bernhard F. (b) (6); MAHJOUR, Jaouad (b) (6); FALL, Ibrahima Soce
(b) (6); GREIN, Thomas (b) (6); MINHAS, Raman (b) (6); COX, Paul
Michael (b) (6); AL-SHORBAJI, Farah (b) (6); POOLE, Marcia
(b) (6); DRURY, Patrick Anthony (b) (6); GRAAFF, Peter Jan
(b) (6); Dr VAN KERKHOVE, Maria (b) (6); KABIR, Sophia
(b) (6); FARES, Christine Youssef (b) (6); AYLWARD, Raymond Bruce J.
(b) (6); SMITH, Ian Michael (b) (6)

Subject: The global health leaders call, Wednesday 25 March at 13:00 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted on Wednesday, 25 March at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email: kabirso@who.int; mobile no. (b) (6)

The agenda and background documents will be shared ahead of the call.

Best,

Mike

Dear participant

To join the upcoming teleconference, please call:

From inside WHO

(b) (4)

From others countries please call:

Country	Number	Access Code
Argentina	+54 115 984 12 00	(b) (4)
Australia	+61 280 147 967	
Austria	+43 720 880 876	
Belgium	+32 280 835 50	
Brazil	+55 213 958 07 18	
Bulgaria	+35 924 917 399	
Canada	+1 613 686 43 59	
Chile	+56 225 95 28 26	
China	+86 105 789 7457	
Croatia	+38 51 777 63 03	
Cyprus	+35 72 503 02 78	
Czech Republic	+42 024 601 95 32	
Denmark	+45 699 182 15	
El Salvador	+50 32 113 37 10	
Estonia	+37 26 68 12 68	
Finland	+35 894 270 50 03	
France	+33 1 77 69 68 25	
Germany	+49 696 991 47 25	
Georgia	+99 57 067 773 41	
Greece	+30 211 198 00 81	
Hong Kong	+85 258 084 851	
Hungary	+36 180 881 90	
Ireland	+35 314 845 940	
India	+91 11 712 79 153	
Israel	+97 237 219 661	
Italy	+39 02 479 211 40	
Japan	+81 345 209 476	
Kazakhstan	+771 727 274 71	
Lathvia	+37 16 765 25 76	
Lithuania	+37 052 05 89 83	
Luxembourg	+352 208 801 72	
Malaysia	+603 921 220 20	
Malta	+35 62 778 01 98	
Mexico	+52 554 624 02 27	
Netherlands	+31 106 920 271	
New Zealand	+64 99 25 03 39	
Norway	+47 210 189 41	
Panama	+507 836 51 38	
Peru	+51 17 08 54 83	
Philippines	+632 231 22 15	
Poland	+48 221 168 469	
Portugal	+351 308 800 872	
Puerto Rico	+17 879 05 73 62	
Russia	+749 540 220 27	
Romania	+40 318 107 181	
Singapore	+65 315 813 05	
Slovakia	+42 123 300 69 18	
Slovenia	+38 61 600 49 18	
South Africa	+27 10 590 11 04	
South Korea	+82 707 488 31 02	
Sweden	+46 840 309 949	
Switzerland (English)	+41 58 262 07 22	
Switzerland (Italiano)	+41 58 262 07 44	
Switzerland (Deutsch)	+41 58 262 07 11	

Switzerland (Français)	+41 58 262 07 33
Spain	+34 931 816 661
Tadzhikistan	+99 242 782 22 70
Turkey	+90 21 290 025 60
United Kingdom	+44 203 370 57 19
United States	+1 646 381 08 89

(b) (4)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 15:32:02 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: interview request

Tell them no.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

—Original Message—

From: Raphael De Montferrand <rdemontferrand@rttv.fr>
Sent: Tuesday, March 24, 2020 11:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: interview request

dr Faucy,

Hello, my channel is doing a section of its news tonight (at 3:45pm your time) on the coronavirus situation in New York. I wondered if we could interview you over skype. Do you think that might be possible at 3:45pm today your time?

We have a simultaneous translator as we operate in french from our studio in Paris.

Looking forward to hear from you,

Raphaël de Montferrand
RT France
0033608662642

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 14:30:50 +0000
To: [REDACTED] (b) (6)
Subject: FW: Boston Globe: In order to save Dr. Fauci, we must destroy him

Yikes! You have to read this. Things are getting unbelievably crazy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Tuesday, March 24, 2020 10:16 AM
To: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>; NIAID COGCORE <COGCORE@mail.nih.gov>
Subject: Boston Globe: In order to save Dr. Fauci, we must destroy him

In order to save Dr. Fauci, we must destroy him

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, is a study of calm and competence in the middle of a pandemic. Which makes him an endangered species, working as he does for a boss who is notoriously insecure and made his name shouting "You're fired!" on a reality TV show.

By [Kevin Cullen](#) Globe Columnist, Updated March 23, 2020, 5:25 p.m.
[209](#)



Dr. Anthony Fauci's

calm, reassuring competence in response to the coronavirus pandemic is placing him at serious risk of hearing the words that made his boss famous: You're fired. Jabin Botsford/The Washington Post

Dr. Anthony Fauci is a bum.

A quack, a snake oil salesman.

He got his degrees online, not from Holy Cross and Cornell.

He watches Wheel of Fortune but not Jeopardy.

He's a Yankees fan.

Such character assassination is unsavory but necessary because Fauci's calm, reassuring competence in response to the coronavirus pandemic is placing him at serious risk of hearing the words that made his boss famous: You're fired.

President Trump is watching and listening to the same thing we are, i.e., Fauci going to the podium to rebut with facts the latest outbreak of paranoid anxiety or the president's regularly reckless statements.

Fauci is an oasis of rigor and reason in a barren desert of confusion and fear.

Which, given who he works for, makes him an endangered species.

During the Vietnam War, some US Army officer supposedly suggested that in order to save a village from the Vietcong they had to destroy it.

And so, to save Dr. Fauci, we must destroy him — at least in Trump's eyes.

Now that might sound crazy, but we're dealing with a crazy president in crazy circumstances.

It's not as if there's no relevant precedent here.

Two words: Bill Bratton.

Two other words: Rudy Giuliani. Who happens to be Trump's BFF.

Before Giuliani grew old, deranged, and more qualified to be a spokesman for Miracle Ear than the president's lawyer, he was the reform-minded mayor of New York City.

Rudy rode into Dodge, which is what Times Square resembled at the time, and vowed to clean it up. His hand-picked sheriff was Dorchester's own Bill Bratton.

As police commissioner, Bratton did much to stem violent crime in the nation's biggest city, but even more remarkably got his cops to reduce the incidence of more minor, so-called quality of life crimes that

had made New York less livable, from the tony sections of Manhattan to the Tony Fauci sections of Brooklyn.

Bratton did his job too well. He ended up on the cover of Time magazine, hailed as the guy who pulled the worm out of the Big Apple. He became more popular than the mayor.

This drove Giuliani nuts. Rudy had to be the smartest guy in the room, had to get all the credit. Sound familiar?

So Bratton had to go.

That wasn't Bratton's first rodeo. Long before he landed in New York, he became the face of progressive, modern policing in his hometown, the youngest-ever Boston Police superintendent. Police Commissioner Joe Jordan resented his overly-ambitious No. 2 so he busted Bratton.

The point is, insecure bosses don't like being shown up by smarter, more competent subordinates. Small men make big mistakes.

It may be too late to save Fauci. He just got the star treatment from Maureen Dowd in The New York Times.

There used to be a thing called the Sports Illustrated curse, that after an athlete appeared on its cover his or her career tanked.

Similarly, being in the Trump administration and getting praised by The New York Times is the kiss of death.

Now, normally, you could print something in the Times and chances were the president wouldn't read it. He routinely dismisses the Gray Old Lady as fake news, except when his and his family's lousy books are mass-bought onto the newspaper's bestsellers list. He is not fond of polysyllabic words and prefers to get his news from "Fox & Friends" or whatever white nationalist website his aide Stephen Miller might recommend.

But Trump reads Mo Dowd because they have known each other forever and she writes about him at a nuanced, personal level that drives him especially cuckoo.

We're way past the theoretical here.

Tony Fauci is in real danger, and by extension so are the rest of us who expect — nay, pray for — one person in the White House to be trustworthy and competent in a time of unprecedented crisis.

So, again, repeat after me, Dr. Anthony Fauci is a bum.

Long live the bum.

Kevin Cullen is a Globe columnist. He can be reached at kevin.cullen@globe.com.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 14:13:33 +0000
To: (b) (6)
Subject: RE: Update #2: Traffic Advisory: Street Closures

Thanks

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Tuesday, March 24, 2020 10:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Update #2: Traffic Advisory: Street Closures

A lot of street closures. I don't think it will interfere with your trip downtown, but just in case

From: AlertDC <noreply@everbridge.net>
Sent: Tuesday, March 24, 2020 7:33 AM
To: (b) (6)>
Subject: Update #2: Traffic Advisory: Street Closures

This is an important message from the District of Columbia AlertDC system.

On Tuesday, March 24, 2020, in coordination with the National Park Service, the Metropolitan Police Department will make several street closures beginning at 7:00 a.m. through approximately 8:00 p.m at the following locations:

- The Memorial Bridge
- Lincoln Memorial Circle
- Potomac River Freeway (all exits to Ohio Drive and Independence Avenue)

- Rock Creek Parkway/Potomac Parkway Drive between Virginia Avenue and Independence Avenue, SW (to include Ohio Drive, SW)
- Independence Avenue between Ohio Drive and 14th Street, SW
- 23rd Street between Constitution Avenue and Lincoln Memorial Circle
- Henry Bacon Drive between Constitution Avenue and Lincoln Memorial Circle
- 17th Street between Constitution Avenue, NW and Independence Avenue, SW
- 15th Street between Constitution Avenue, NW and Independence Avenue, SW
- Maine Avenue between Independence and 12th Street, SW
- All vehicular exits to East Potomac Park and West Potomac Park

All street closures and listed times are subject to change based upon prevailing or unexpected conditions.

The public should expect parking restrictions along the street and should be guided by the posted emergency no parking signage. All vehicles that are parked in violation of the emergency no parking signs will be ticketed and towed.

Individuals and groups will encounter delays in the vicinity of this closure. To help flatten the curve, we strongly discourage any Tidal Basin visits because social distancing has not been possible due to visitor volume.

For more information about the District's coronavirus response, visit coronavirus.dc.gov

[Click Here](#) to update your profile.

To stop receiving future email notifications from this organization [unsubscribe here](#).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 14:12:54 +0000
To: Miller, Katie R. EOP/OVP
Cc: Short, Marc T. EOP/OVP; Conrad, Patricia (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; O'Malley, Devin M. EOP/OVP
Subject: RE: Please advise

I called the reporter and she was very receptive to my corrections of the record and presentation of the facts.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Miller, Katie R. EOP/OVP (b) (6) >
Sent: Tuesday, March 24, 2020 9:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Short, Marc T. EOP/OVP (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) Billet, Courtney (NIH/NIAID) [E] (b) (6) O'Malley, Devin M. EOP/OVP <(b) (6) >
Subject: Re: Please advise

(b) (5)

Sent from my iPhone

On Mar 24, 2020, at 9:27 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:

Marc/Katie:

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Abutaleb, Yasmeeen <Yasmeeen.Abutaleb@washpost.com>
Sent: Tuesday, March 24, 2020 9:05 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Cc: Parker, Ashley <Ashley.Parker@washpost.com>
Subject: Washington Post fact check on Fauci/scientists story

Hi Patty,

Thanks very much for your help yesterday and hope you're doing well. We're working on a story today about Trump's relationship with the scientific and medical experts in the coronavirus response, including Dr. Fauci. We're reporting this out today but wanted to send you what we've been hearing as we get it so there's ample time to fact check everything today. Here are some points we'd love to discuss with the best person in your office or, better yet, Dr. Fauci himself.

- Fauci was apoplectic about Trump's tweet yesterday saying the cure couldn't be worse than the virus and indicating that he wants to reopen businesses soon.
- Fauci has been forceful privately that unproven drugs should not be advertised to Americans as a panacea (and he of course has publicly spoken about these drugs).
- We are also reporting in a separate story that Larry Ellison is building a website for the federal government that will collect data on the efficacy of remdesivir, chloroquine and hydroxychloroquine. Our understanding is Fauci is vehemently opposed to this idea and has pushed back on it, citing patient privacy concerns with the website and collecting data in this way outside of an approved FDA trial.

Again, we'd love to speak with Dr. Fauci and any others in your office who may have insight into these particular issues and other aspects of the coronavirus response. Please feel free to give me a call on my cell at any time at (b) (6)

Thanks very much,


Yasmeen Abutaleb
The Washington Post
Health policy reporter
o: 202-334-8387 c: (b) (6)
@yabutaleb7

From: (b) (6)
Sent: Tue, 24 Mar 2020 07:47:49 -0400
To: Pottinger, Matthew F. EOP/WHO
Subject: Re: regarding masks and Covid-19

Very good point.

(b)(5) - PCP







From: (b) (6)
Sent: Mon, 23 Mar 2020 15:45:21 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Media Request: NPR's 1A Show

Begin forwarded message:

From: Amanda Williams <amandaw@wamu.org>
Date: March 23, 2020 at 3:41:06 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>
Subject: Media Request: NPR's 1A Show

Hello Dr. Fauci,

I'm a producer with National Public Radio's 1A show and we'd like to invite you to join our program to talk about coronavirus in the near future. We've built our show on answering our 4+ million listeners' questions and we know Americans have a lot of questions for you right now. We don't take live calls, but we do curate input from voicemails and social media.

We would love to have you join us. Please let me know if you are available and interested anytime soon. We are very flexible.

A bit more about 1A: We launched in January 2017 and we're ranked among the top 10 public radio programs on a list that includes Morning Edition, All Things Considered and Marketplace. We reach 4+ million listeners every week and air on more than 365 stations across the country. Our major markets include Chicago, LA, NYC, DC, Atlanta, Boston, Philadelphia, San Francisco, Miami, Houston, Minneapolis and Seattle.

Best,
Amanda

Amanda Williams
Across America Producer
1A, from WAMU and NPR

(b) (6) (c) | @amandwms | the1a.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 19:32:28 +0000
To: (b) (6)
Cc: (b) (6)
Subject: Re: USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need
Attachments: image002.jpg

Love you all

On Mar 23, 2020, at 3:07 PM, (b) (6) wrote:

So True!

In a message dated 3/23/2020 2:06:15 PM Eastern Standard Time,
(b) (6) writes:

Lots of a very kind and thoughtful and well-earned words of respect coming your way (b) (6)

On Mon, Mar 23, 2020 at 12:35 PM (b) (6) wrote:

That's a very nice piece about you, (b) (6)

I hope you got some rest this weekend. Sending lots of love.

On Sun, Mar 22, 2020 at 6:34 PM Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

Wow. David Rubenstein (b) (6) used to work for him) was really nice to me.

From: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, March 22, 2020 11:36 AM
Subject: USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

Fauci is the world's leading authority on infectious diseases and the best person in the country to help us deal with the COVID-19 crisis.

David M. Rubenstein

Opinion contributor

Some viewers of the daily White House coronavirus briefings may wonder why everyone increasingly defers to a diminutive, Brooklyn-accented 79-year-old doctor, Tony Fauci.

They do because, as I have learned over many years of talking with and more recently interviewing this man, he is without doubt the world's leading authority on infectious diseases. In any area of human activity or knowledge, there always seems to be one person who is the global gold standard. In the world of infectious diseases that person is Tony Fauci.

So the American people — indeed, people around the globe — should be grateful that Tony has dug into this crisis with the same work-around-the-clock, just-the-facts ma'am style that he has used while serving under and working with six U.S. presidents. He is as apolitical as anyone can be. I have no idea if he is registered with any political party; I suspect though that he is rabidly Independent. His only focus is getting the facts out, providing the best health care treatment and information possible, and saving lives.

A top expert from AIDS to Ebola

Tony Fauci joined the National Institutes of Health in 1968, after completing his medical training at Weill Cornell Medical Center, and he has led the National Institute of Allergy and Infectious Disease since 1984 — 36 years. Hard to believe anyone can run anything that long and still be at the top of his game. But Tony is. During this period, he has dealt with every serious infectious disease challenge — malaria,

Among Tony's best known accomplishments, beyond simply running the institute and training dozens of the world's top infectious disease professionals, has been helping to discover how HIV leads to AIDS and, later, leading the effort to create (at President George W. Bush's direction) the President's Emergency Plan for AIDS Relief (PEPFAR), which has transformed the treatment of HIV/AIDS in Africa, and other parts of the developing world. Millions of lives have been saved by this program alone. More recently, he has been an architect and powerful advocate of President Donald Trump's plan for ending the AIDS epidemic in the U.S. through HIV antiretroviral therapy targeted to disease hotspots.

In his spare time, Tony has been involved with writing or editing more than 1,100 scholarly articles and several textbooks, and, in the process, has become one of the most cited authorities of the entire medical profession.

For these breakthrough activities and his dedicated service (at a government salary) for more than a half century (he worked at NIH for 16 years before assuming his current role), Tony has received, and earned, the Presidential Medal of Freedom and a Lasker Award (called the American Nobel by many).

With this long service and universal acclaim, one might think Tony would let it get to his head, at least a little bit. Not the case, though.

Selfless commitment to public service

He is readily accessible to those who need treatment — he still runs a lab at NIH — or need information. Tony still lives in the same house he bought when he first moved to Washington, and it is there that he and his wife Christine have raised their three talented daughters (though none of them chose to attend medical school).

Until the latest crisis, Tony has often commuted to NIH by Metro, typically after running three miles for his daily exercise. And when he has been invited to make speeches in the Washington area or on Capitol Hill, he invariably turns down a car and driver for the Metro. (This practice has had to change of late for the obvious reasons).

There are, of course, many other dedicated federal servants who also view their commitment to the country and its people over financial rewards. But surely no federal civil servant, in any area, can exceed Tony Fauci's long-term and selfless commitment to this country and the health of its people.

<image002.jpg>

I tried years ago, when Tony was approaching a normal retirement age, to see if he might want after a normal lifetime of federal service, to take some of his considerable skills and knowledge to the private sector. He quickly said no — money did not motivate him, serving the country did. And he stayed at NIH — to the country's good fortune.

If there is any one medical professional who can help the country deal with the COVID-19 crisis, it is Tony Fauci, an example of the best this country has to offer.

He is not a miracle worker. No one is.

But Tony Fauci has the decades of experience needed to understand infectious disease problems and prescribe a treatment that should, in time, provide the requisite comfort, even if, in the short term, the medicine is painful and inconvenient.

David M. Rubenstein is the co-executive chairman of The Carlyle Group.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

(b) (6)

<image002.jpg>





NIH-000275

From: (b) (6)
Sent: Mon, 23 Mar 2020 15:16:17 -0400
To: Barasch, Kimberly (NIH/NIAID) [C]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Meeting on the science of COVID-19, Wed. 3/25, 2 - 5 pm

Please print out for me and have ready in case I do this on Wednesday


Begin forwarded message:

From: "Tromberg, Bruce (NIH/NIBIB) [E]" (b) (6) >
Date: March 23, 2020 at 1:22:18 AM EDT
To: "Collins, Francis (NIH/OD) [E]" (b) (6) >
Cc: "Tabak, Lawrence (NIH/OD) [E]" (b) (6) >, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: Re: Meeting on the science of COVID-19, Wed. 3/25, 2 - 5 pm

Hi Francis,

Thanks, I'm looking forward to the meeting. Probably not directly relevant to this upcoming discussion, (b) (5)





Best,
Bruce

From: "Collins, Francis (NIH/OD) [E]" (b) (6)
Date: Sunday, March 22, 2020 at 9:38 PM
To: "ICDDIR-L@LIST.NIH.GOV" <ICDDIR-L@LIST.NIH.GOV>
Cc: "Tabak, Lawrence (NIH/OD) [E]" (b) (6); "Wolinetz, Carrie (NIH/OD) [E]" (b) (6); "Anderson, James (NIH/OD) [E]" (b) (6); "Parker, Ashley (NIH/OD) [E]" (b) (6); (b) (6); "McManus, Ayanna (NIH/OD) [E]" (b) (6); "Wood, Gretchen (NIH/OD) [E]" (b) (6); (b) (6)
Subject: Meeting on the science of COVID-19, Wed. 3/25, 2 - 5 pm

Colleagues,

I'm glad to hear that most of you are able to join a three-hour virtual meeting on Wednesday March 25 to discuss scientific opportunities in the effort to conquer the COVID-19 pandemic. While NIAID rightly has the lead in this effort for NIH, and is deeply invested in projects in both their intramural and extramural programs, it's clear that a number of other ICs have creative ideas and a strong motivation to try to help with this global crisis. So this certainly seems like a time where we should gather (virtually of course)


to brainstorm together, led by NIAID, and seek to identify any additional areas of contribution that could be subject to acceleration and/or collaboration.

Hilary Marston recently convened a Deputies meeting on this subject, and ICs were then asked to submit examples last Friday of projects they are pursuing in the COVID-19 space. Those were forwarded from Bob Eisinger to me. I have used those submissions, including a detailed list of NIAID projects, to put together a tentative agenda for Wednesday's meeting. That is attached.



There are admittedly a lot of themes and topics here, so this will require some real discipline in the one-slide presentations. I will try to serve as time-keeper – or maybe I'll ask Larry to do that. ☐☐

All IC Directors are invited to have one or two subject matter experts join them for this virtual discussion.

Ashley Parker  (b) (5) will be helping me with the logistics and will have further instructions about how the log in will work.

Here's the specific follow up request that needs your immediate attention:

1. If your IC is pursuing a highly relevant project that's not listed here, and that you want the group to hear about, please send me that information ASAP.
2. If your IC is on the draft agenda to make a presentation, please submit your one slide (except for NIAID, who gets more) to me and Ashley by COB Tuesday 3/24. That way we can put the whole set together as a single ppt file.

Many thanks! This should provide a welcome respite from the many other tasks we are all facing right now.

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 19:06:06 +0000
Bcc: Aberg, Judith;Adaora Adimora;Grund, Birgit;Glidden, David;Daar, Eric;Erica Hardy;Gandhi, Rajesh Tim,M.D.;Jason Baker;Jeff Lennox;Johnson, Steven C - ID;Kim, Arthur Y.,M.D.;Marla Keller;Tebas, Pablo (NIH);Susan Davis;Susan Swindells;Susanna Naggie;Tien, Phyllis;Amy Dzierba;Mitchell Levy;Laura Evans;Craig Coopersmith;Greg Martin;Uyeki, Timothy M. (CDC/DDID/NCIRD/ID);Walker, Robert (OS/ASPR/BARDA);Sheikh, Virginia (FDA/CDER);Anne Collier;Francis, Joe (Contact NLM/OD-External). (b) (6)
Subject: Invitation to join the HHS Panel on Guidelines for The Management of COVID-19

Dear Colleague,

At the request of the Office of the Secretary, HHS and in conjunction with the White House Task Force we are creating a COVID-19 management guidelines panel to provide frequently updated information to the public regarding the treatment of patients with COVID-19.

This guidance will be an HHS document, will be updated frequently and will be modeled to some degree after the ART guidelines. The Panel will include academicians and clinicians currently caring for persons with COVID-19 and representatives from multiple US government agencies (CDC, BARDA, FDA, VA, DoD) and professional societies. Cliff Lane, M.D. Henry Masur, M.D. and Trip Gulick, M.D. will co-chair, and Alice Pau, Pharm.D. will be the exec. sec. for this new panel. Those of you who are appointed to represent your federal agencies will be ex-officio. Other federal employees will be voting members.

I would like to invite you to be a member of this new Panel based on your expertise. We anticipate that work will begin this week and we hope to be able to put out the first guidance in 1-2 weeks. We appreciate your willingness to join this very important effort and your work in caring for patients during this pandemic.

The first meeting (by teleconference) will be Tuesday, March 24 at 11:00AM EDT. More details will be provided soon.

Thank-you for considering this and for all you are doing during this most challenging time.

Sincerely,

Anthony S. Fauci, MD
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 18:38:21 +0000
To: (b) (6)
Cc: (b) (6)
Subject: RE: FW: USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

Love you all.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) >
Sent: Monday, March 23, 2020 12:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: (b) (6)
Subject: Re: FW: USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

That's a very nice piece about you, (b) (6)

I hope you got some rest this weekend. Sending lots of love.

On Sun, Mar 22, 2020 at 6:34 PM Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:

Wow. David Rubenstein (b) (6) used to work for him) was really nice to me.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, March 22, 2020 11:36 AM
Subject: USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

Fauci is the world's leading authority on infectious diseases and the best person in the country to help us deal with the COVID-19 crisis.

David M. Rubenstein

Opinion contributor

Some viewers of the daily White House coronavirus briefings may wonder why everyone increasingly defers to a diminutive, Brooklyn-accented 79-year-old doctor, Tony Fauci.

They do because, as I have learned over many years of talking with and more recently interviewing this man, he is without doubt the world's leading authority on infectious diseases. In any area of human activity or knowledge, there always seems to be one person who is the global gold standard. In the world of infectious diseases that person is Tony Fauci.

So the American people — indeed, people around the globe — should be grateful that Tony has dug into this crisis with the same work-around-the-clock, just-the-facts ma'am style that he has used while serving under and working with six U.S. presidents. He is as apolitical as anyone can be. I have no idea if he is registered with any political party; I suspect though that he is rabidly Independent. His only focus is getting the facts out, providing the best health care treatment and information possible, and saving lives.

A top expert from AIDS to Ebola

Tony Fauci joined the National Institutes of Health in 1968, after completing his medical training at Weill Cornell Medical Center, and he has led the National Institute of Allergy and Infectious Disease since 1984 — 36 years. Hard to believe anyone can run anything that long and still be at the top of his game. But Tony is. During this period, he has dealt with every serious infectious disease challenge — malaria,

Among Tony's best known accomplishments, beyond simply running the institute and training dozens of the world's top infectious disease professionals, has been helping to discover how HIV leads to AIDS and, later, leading the effort to create (at President George W. Bush's direction) the President's Emergency Plan for AIDS Relief (PEPFAR), which has transformed the treatment of HIV/AIDS in Africa, and other parts of the developing world. Millions of lives have been saved by this program alone. More recently, he has been an architect and powerful advocate of President Donald Trump's plan for ending the AIDS epidemic in the U.S. through HIV antiretroviral therapy targeted to disease hotspots.

In his spare time, Tony has been involved with writing or editing more than 1,100 scholarly articles and several textbooks, and, in the process, has become one of the most cited authorities of the entire medical profession.

For these breakthrough activities and his dedicated service (at a government salary) for more than a half century (he worked at NIH for 16 years before assuming his current role), Tony has received, and earned, the Presidential Medal of Freedom and a Lasker Award (called the American Nobel by many). With this long service and universal acclaim, one might think Tony would let it get to his head, at least a little bit. Not the case, though.

Selfless commitment to public service

He is readily accessible to those who need treatment — he still runs a lab at NIH — or need information. Tony still lives in the same house he bought when he first moved to Washington, and it is there that he and his wife Christine have raised their three talented daughters (though none of them chose to attend medical school).

Until the latest crisis, Tony has often commuted to NIH by Metro, typically after running three miles for his daily exercise. And when he has been invited to make speeches in the Washington area or on Capitol Hill, he invariably turns down a car and driver for the Metro. (This practice has had to change of late for the obvious reasons).

There are, of course, many other dedicated federal servants who also view their commitment to the country and its people over financial rewards. But surely no federal civil servant, in any area, can exceed Tony Fauci's long-term and selfless commitment to this country and the health of its people.



I tried years ago, when Tony was approaching a normal retirement age, to see if he might want after a normal lifetime of federal service, to take some of his considerable skills and knowledge to the private sector. He quickly said no — money did not motivate him, serving the country did. And he stayed at NIH — to the country's good fortune.

If there is any one medical professional who can help the country deal with the COVID-19 crisis, it is Tony Fauci, an example of the best this country has to offer.

He is not a miracle worker. No one is.

But Tony Fauci has the decades of experience needed to understand infectious disease problems and prescribe a treatment that should, in time, provide the requisite comfort, even if, in the short term, the medicine is painful and inconvenient.

David M. Rubenstein is the co-executive chairman of The Carlyle Group.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

--
Ali Fauci

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 18:14:25 +0000
To: Barry Albertson
Subject: RE: Pooled Samples

Thanks, Barry.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barry Albertson <barry@fannocreek.com>
Sent: Monday, March 23, 2020 1:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: Pooled Samples
Importance: High

Hi Tony,

I'm forwarding an email I just sent to Paul Cieslak, MD.....one of the lead docs at the Oregon Health Authority (b) (6); he gives my clinic's Internal Medicine docs an 'ID Update' for my CME Grand Rounds each year) ...with this email note from Dr. David Brandon...hope you remember David....he was with Lynn's & Mort Lipsett's group at The Clinical Center.

...I'd bet a coke you know all about pooled samplingbut wanted to pass it along.

You have no idea how many people tell me that your COVID-19 messages on TV, etc. are top flight, enormously helpful and encouraging for them with the best information, in a sea now of poor information.

Andrew Cuomo is also doing a great job informing all of NY (and the rest of us) about what's going on, and his expectations for the public.

Whatever they're paying you ...it's not enough.

You keep your powder dry, and extra flints in your pocket!

Barry

From: Barry Albertson
Sent: Monday, March 23, 2020 9:49 AM
To: 'Cieslak Paul R'
Subject: Pooled Smamples
Importance: High

Good morning, Paul.

Hope you guys at OHA are holding up OK.


I'm fine, family is fine... (b) (6) is doing lots of telemedicine and seeing actual PEDS patients at Westside Hosp. now a few days a week.
My clinic is still open but pretty quiet... we need to stay open at some level no matter what.

One of my colleagues from the NIH (Dr. David Brandon ...he actually published with Tony Fauci back in the late '70s I believe!)..sent me this email on Saturday morning
I suspect you all know about pooled sampling,.....David did it at the NIH for a study that I have long forgotten about. ...thought I'd pass it along to you

" I just looked up to see if pooled sampling has been used to detect viruses in the past, and found that it has been used in a number of cases including during the HIV scare. I am including a link <https://www.israel21c.org/israelis-introduce-method-for-accelerated-covid-19-testing/> to an article in the lay press reporting on an RT-PCR based test that uses swabs from 30-60 individuals to determine if the pooled sample has Covid-19. The study was successful and they are developing it to test workers in the front line work places such as hospitals. There is a body of literature using this method for other mass screenings."

Then I heard that CEPHEID will be getting their Genexpert instrument validated to measure COVID-19. Turns out we have one in my Lab, use it for Chlamydia & Gonorrhea (we have lots of patients here needing this testing). But as you so well know, having the instrumentation without the collection swabs/M4 media, etc. is a bit like biking up a blind alley. I would hope we'll hear more about this.

Give me a shout if I can do anything to help you allbest tack for me, I believe, is to stay out of your way!
Barry



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 18:09:12 +0000
To: O'Grady, Naomi (NIH/CC/CCMD) [E]
Subject: RE: vent rationing

Naomi:

I am not aware of any efforts on rationing ventilators. They speak of making sure the high priority areas such as NYC get what they need, but there is no talk at this time of "rationing"

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Grady, Naomi (NIH/CC/CCMD) [E] (b) (6)>
Sent: Monday, March 23, 2020 1:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: vent rationing

Hi Tony-

I know you are very busy but I wanted to see if you know of any effort on the part of the federal government to issue guidance on the rationing of ventilators when the time comes? Many of my colleagues in critical care across the country have been asking for some such guidance on a federal level. Both for the guidance itself and to protect themselves from legal liability. Are you aware of any such efforts? Thanks for any insights on this. And thanks for all you are doing on the coronavirus effort!
Best regards,
Naomi

Naomi P. O'Grady, MD
Chief, Internal Medicine Services
NIH Clinical Center

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 16:48:31 +0000
To: Dan Hurley
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: 2 questions from NY Times Mag reporter who interviewed you about EV-D68

Dan:

Thanks for the note. The work on an EV-D68 vaccine will continue. The Coronavirus vaccine research is the highest priority. Both come out of Barney Graham's group in our VRC. Best to call Barney about the degree of possible interference. Books are not on my mind right now.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dan Hurley (b) (6)
Sent: Monday, March 23, 2020 11:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: 2 questions from NY Times Mag reporter who interviewed you about EV-D68

Hi Dr. Fauci and Patty: In addition to the two items mentioned in my original email, the NY Times Magazine is also interested in publishing an interview with Dr. Fauci. Thank you, Dan Hurley

On Thu, Mar 19, 2020 at 6:04 PM Dan Hurley <(b) (6)> wrote:

Hi Dr. Fauci: I interviewed you by telephone a few months ago for an article in the New York Times Magazine about enterovirus D68, the putative causal agent of acute flaccid myelitis. At the time you said that NIAID was working hard on developing a vaccine for EV-D68. I have two questions:

1. Is work on developing a vaccine against the novel coronavirus interrupting or slowing work on EV-D68? Hard to believe it wouldn't have an effect.

2. When things calm down with COVID-19, would you consider allowing me to write a biography about you, or helping you write a memoir? This pandemic has kind of turned you into the face of medical science in the United States. I'm the author of four prior science books, and have profiled countless scientists in the Times, The Atlantic, and elsewhere. I know this is not the time for such things. I just want to put the idea out there. I hope and pray you do not find it offensive for me suggest such a thing at this time of danger and stress.

Let me know about that EV-D68 vaccine if you can. I'm also reaching out to Barney Graham. Thank you, Dan Hurley

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 14:51:53 +0000
To: (b) (6)
Subject: FW: Dinarello Proposal
Attachments: Dinarello Proposal for COVID-19.doc

Cliff:

(b) (5)

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: charles dinarello (b) (6) >
Sent: Sunday, March 22, 2020 9:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Dinarello Proposal

(b) (6)

I watch CNN almost constantly to listen to your impressive wisdom. The world listens to you. Shelly would be so proud of you in this world crisis as he was in the HIV-1 crisis. We will not see each other at the National Academy of Sciences meeting end of April, but hopefully next year. I very much enjoyed hearing you place the anecdotal use of chloroquine in its correct context. "Chloroquine is an awfully blunt tool and an indication of our desperation", Peter Libby wrote me recently. Tony, attached is a proposal (b) (4)

I need your guidance. I know you are terribly busy so I am copying Cliff. If there is anyone else who can help me, just forward the attachment.

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 14:48:07 +0000
To: (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 23-3-2020 FAO Dr Birx and Dr Fauci - Covid-19 Task Force RE:- Favipiravir = Avigan

Please have someone handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Monday, March 23, 2020 8:32 AM
To: (b) (6) Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: NST Rogers (b) (6)
Subject: 23-3-2020 FAO Dr Birx and Dr Fauci - Covid-19 Task Force RE:- Favipiravir = Avigan
Importance: High

23-3-2020

Dear Dr Birx and Dr Fauci,

As promised, sorry about the delay.

Please see below two articles relating to Favipiravir which has the brand name Avigan. This appears to have some beneficial effects with regard to the treatment of Covid-19.

I have also included the Wikipedia for Favipiravir.

Good Luck with regard to managing the epidemic/pandemic.

Yours Sincerely

Nicholas Rogers

Favipiravir

Drug

Description

Favipiravir, also known as T-705, Avigan, or favilavir is an antiviral drug being developed by Toyama Chemical of Japan with activity against many RNA viruses. Like certain other experimental antiviral drugs, it is a pyrazinecarboxamide derivative. [Wikipedia](#)

Formula: $C_5H_4FN_3O_2$

ChemSpider ID: 431002

ChemSpider ID: 431002

PubChem CID: 492405


Favipiravir

From Wikipedia, the free encyclopedia

[Jump to navigation](#)[Jump to search](#)

Experimental antiviral drug with activity against many RNA viruses.

Favipiravir



Names

IUPAC name

6-Fluoro-3-hydroxypyrazine-2-carboxamide

Other names

T-705; Avigan; favilavir

Identifiers

CAS Number	• 259793-96-9
3D model (JSmol)	• Interactive image
ChEMBL	• ChEMBL221722
ChemSpider	• 431002
PubChem CID	• 492405
UNII	• EW5GL2X7E0 ✓ ^Y
CompTox Dashboard (EPA)	• DTXSID60948878 ✎

InChI[show]

InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)

Key: ZCGNOVWYSGBHAU-UHFFFAOYSA-N

InChI=1/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)

Key: ZCGNOVWYSGBHAU-UHFFFAOYAM

SMILES[show]

Oc1ncc(F)nc1C(=O)N

Properties

Chemical formula	C ₅ H ₄ FN ₃ O ₂
Molar mass	157.104 g·mol ⁻¹

Pharmacology

ATC code	J05AX27 (WHO)
----------	---------------

Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Infobox references

Favipiravir, also known as **T-705**, **Avigan**, or **favilavir** is an antiviral drug being developed by Toyama Chemical (Fujifilm group) of Japan with activity against many RNA viruses. Like certain other experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. In experiments conducted in animals Favipiravir has shown activity against influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses.^[1] Activity against enteroviruses^[2] and Rift Valley fever virus has also been demonstrated.^[3] Favipiravir has showed limited efficacy against Zika virus in animal studies, but was less effective than other antivirals such as MK-608.^[4] The agent has also shown some efficacy against rabies,^[5] and has been used experimentally in some humans infected with the virus.^[6]

In February 2020, Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 (novel coronavirus disease).^{[7][8]} On March 17, Chinese officials suggested the drug had been effective in treating COVID in Wuhan and Shenzhen.^{[9][10]}

As of 23 March 2020, it seems that Japan and China have issued an export ban on the substance. Japan and China are the only countries in which favirapir is produced and approved as a medical

compound. Some Chinese pharmaceutical companies assure that export rights are still granted via international diplomatic means by the Chinese Ministry of Industry and Information Technology (MIIT).

[1]

Contents

- 1Mechanism of action
- 2Approval status
- 3Ebola virus trials
- 4Coronavirus disease 2019 (COVID-19)
- 5See also
- 6References

Mechanism of action[edit]

The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase.^[11] Other research suggests that favipiravir induces lethal RNA transversion mutations, producing a nonviable viral phenotype.^[12] Favipiravir is a prodrug that is metabolized to its active form, favipiravir-ribofuranosyl-5'-triphosphate (favipiravir-RTP), available in both oral and intravenous formulations.^{[13][14]} Human hypoxanthine guanine phosphoribosyltransferase (HGPRT) is believed to play a key role in this activation process.^[15] Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them.^[11] In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.^[16] However, favipiravir has not been shown to be effective in primary human airway cells, casting doubt on its efficacy in influenza treatment.^[17]

Approval status[edit]

In 2014, Japan approved Favipiravir for treating viral strains unresponsive to current antivirals.^[18] Toyama Chemical initially hoped that Avigan would become a new influenza drug that could replace Tamiflu. However, animal experiments show the potential for teratogenic effects on fetuses, and the approval of production by The Ministry of Health, Labor and Welfare was greatly delayed and the production condition is limited only in an emergency in Japan.^[19]

In March 2015, the US Food and Drug Administration completed a Phase III clinical trial studying the safety and efficacy of Favipiravir in the treatment of influenza.^[20]

On March 15, 2020 the drug was approved in China with the name Favilavir for the treatment of influenza.^[21] The drug was also approved for use in clinical trials for treating coronavirus disease 2019 pneumonia.^[21]

On 22 March, 2020 Italy has approved the drug for experimental use against COVID-19 and has begun conducting trials in 3 regions most affected by the disease.^[22] The Italian Pharmaceutical Agency, however, has reminded the public that the existing evidence in support of this drug is scant and preliminary.^[23]

Ebola virus trials[edit]

Some research has been done suggesting that in mouse models Favipiravir may have efficacy against Ebola. Its efficacy against Ebola in humans is unproven.^{[24][25][26]} During the 2014 West Africa Ebola virus outbreak, it was reported that a French nurse who contracted Ebola while volunteering for MSF in Liberia recovered after receiving a course of favipiravir.^[27] A clinical trial investigating the use of favipiravir against Ebola virus disease was started in Guéckédou, Guinea, during December 2014.^[28] Preliminary results showed a decrease in mortality rate in patients with low-to-moderate levels of Ebola virus in the blood, but no effect on patients with high levels of the virus, a group at a higher risk of death.^[29] The trial design has been criticised by Scott Hammer and others for using only historical controls.^[30] The results of this clinical trial were presented in February 2016 at the annual Conference on Retroviruses and Opportunistic Infections (CROI) by Daouda Sissoko^[31] and published on March 1, 2016 in PLOS Medicine.^[32]

Coronavirus disease 2019 (COVID-19)[edit]

On 17 March 2020, Chinese officials suggested that Favipiravir seemed to be effective in treating COVID-19 in Wuhan and Shenzhen.^{[33][34][35]}

A study on 80 patients comparing it to lopinavir/ritonavir found that it significantly reduced viral clearance time to 4 days, compared to 11 for the control group, and that 91.43% of patients had improved CT scans with few side effects.^{[36][37]}

As of 23 March 2020, it seems that Japan and China have issued an export ban on the substance. Japan and China are the only countries in which favirapir is produced and approved as a medical compound. Some Chinese pharmaceutical companies assure that export rights are still granted via international diplomatic means by the Chinese Ministry of Industry and Information Technology (MIIT).^[*citation needed*]

See also[edit]

- BCX4430
- Brincidofovir
- FGI-106
- JK-05
- REGN-EB3
- TKM-Ebola
- Triazavirin
- ZMapp

References[edit]

- [^] ^{Jump up to: ^{*} ^b} Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD (June 2009). "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections". *Antiviral Research*. **82** (3): 95–102. doi:10.1016/j.antiviral.2009.02.198. PMID 19428599.
- [^] Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (November 2013). "Favipiravir (T-705), a novel viral RNA polymerase inhibitor". *Antiviral Research*. **100** (2): 446–54. doi:10.1016/j.antiviral.2013.09.015. PMC 3880838. PMID 24084488.
- [^] Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL (April 2014). "Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever". *PLOS Neglected Tropical Diseases*. **8** (4): e2790. doi:10.1371/journal.pntd.0002790. PMC 3983105. PMID 24722586.
- [^] Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP (2016). "Zika Virus: Where Is the Treatment?". *Current Treatment Options in Infectious Diseases*. **8** (3): 208–11. doi:10.1007/s40506-016-0083-7. PMC 4969322. PMID 27547128.
- [^] Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (April 2016). "Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis". *The Journal of Infectious Diseases*. **213** (8): 1253–61. doi:10.1093/infdis/jiv586. PMC 4799667. PMID 26655300.
- [^] Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina RE, Enfield KB, Shiferaw M, Gigante C, Condori E, Gruszynski K, Wallace RM (January 2019). "Human Rabies - Virginia, 2017". *MMWR. Morbidity and Mortality Weekly Report*. **67** (5152): 1410–14. doi:10.15585/mmwr.mm675152a2. PMC 6334827. PMID 30605446.
- [^] Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nature Reviews Drug Discovery* 2020 Feb doi:10.1038/d41573-020-00016-0
- [^] BRIEF-Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus. Reuters Healthcare, February 16, 2020.
- [^] NHK World News 'China: Avigan effective in tackling coronavirus'
- [^] Huaxia. "Favipiravir shows good clinical efficacy in treating COVID-19: official." Xinhuanet.com, 17 March 2020

11. ^ Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). "The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase". *PLOS One*. **8** (7): e68347. Bibcode:2013PLoSO...868347J. doi:10.1371/journal.pone.0068347. PMC 3707847. PMID 23874596.
12. ^ Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA (April 2013). "T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro". *Journal of Virology*. **87** (7): 3741–51. doi:10.1128/JVI.02346-12. PMC 3624194. PMID 23325689.
13. ^ Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, et al. (March 2018). "Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques". *PLOS Medicine*. **15** (3): e1002535. doi:10.1371/journal.pmed.1002535. PMC 5870946. PMID 29584730.
14. ^ Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y (October 2009). "Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells". *The Journal of Antimicrobial Chemotherapy*. **64** (4): 741–46. doi:10.1093/jac/dkp274. PMC 2740635. PMID 19643775.
15. ^ Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J (October 2013). "Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)". *Molecular Pharmacology*. **84** (4): 615–29. doi:10.1124/mol.113.087247. PMID 23907213.
16. ^ Koons C (7 August 2014). "Ebola Drug From Japan May Emerge Among Key Candidates". *Bloomberg.com*.
17. ^ Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, et al. (August 2018). "Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses". *Antimicrobial Agents and Chemotherapy*. **62** (8): e00766–18. doi:10.1128/AAC.00766-18. PMC 6105843. PMID 29891600.
18. ^ Hayden, Frederick (2019). "Influenza virus polymerase inhibitors in clinical development". *Current Opinion in Infectious Diseases*. **32** (2): 176–186. doi:10.1097/QCO.0000000000000532. PMC 6416007. PMID 30724789.
19. ^ 条件付き承認で普及に足かせ 富山化学インフル薬の"無念". Retrieved 25 February 2014.
20. ^ "Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316". FDA. Retrieved 17 March 2020.
21. ^ Jump up to: ^a ^b 陈子璇 "Potential coronavirus drug approved for marketing - Chinadaily.com.cn". www.chinadaily.com.cn. Retrieved 2020-03-21.
22. ^ "Coronavirus, il Veneto sperimenta l'antivirale giapponese Favipiravir. Ma l'Aifa: "Ci sono scarse evidenze scientifiche su efficacia"". *Il Fatto Quotidiano* (in Italian). 2020-03-22. Retrieved 2020-03-23.
23. ^ "AIFA precisa, uso favipiravir per COVID-19 non autorizzato in Europa e USA, scarse evidenze scientifiche sull'efficacia". aifa.gov.it (in Italian). Retrieved 2020-03-23.

24. ^ Gatherer D (August 2014). "The 2014 Ebola virus disease outbreak in West Africa". *The Journal of General Virology*. **95** (Pt 8): 1619–24. doi:10.1099/vir.0.067199-0. PMID 24795448.
25. ^ Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (May 2014). "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model". *Antiviral Research*. **105**: 17–21. doi:10.1016/j.antiviral.2014.02.014. PMID 24583123.
26. ^ Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS (April 2014). "Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model". *Antiviral Research*. **104**: 153–55. doi:10.1016/j.antiviral.2014.01.012. PMID 24462697.
27. ^ "First French Ebola patient leaves hospital". *Reuters*. 4 October 2016.
28. ^ "Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea". *AllAfrica – All the Time*. Retrieved 28 December 2014.
29. ^ Fink S (4 February 2015). "Ebola Drug Aids Some in a Study in West Africa". *The New York Times*.
30. ^ Cohen J (26 February 2015). "Results from encouraging Ebola trial scrutinized". *Science*. doi:10.1126/science.aaa7912. Retrieved 21 January 2016.
31. ^ "Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea | CROI Conference". *croiconference.org*. Retrieved 2016-03-17.
32. ^ Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, et al. (March 2016). "Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea". *PLOS Medicine*. **13** (3): e1001967. doi:10.1371/journal.pmed.1001967. PMC [4773183](#). PMID 26930627.
33. ^ "Japanese flu drug 'clearly effective' in treating coronavirus, says China". *The Guardian*. 2020-03-18. Retrieved 2020-03-18.
34. ^ NHK World News "China: Avigan effective in tackling coronavirus"
35. ^ Huaxia. "Favipiravir shows good clinical efficacy in treating COVID-19: official." *Xinhuanet.com*, 17 March 2020
36. ^ Cai, Qingxian; Yang, Minghui; Liu, Dongjing; Chen, Jun; Shu, Dan; Xia, Junxia; Liao, Xuejiao; Gu, Yuanbo; Cai, Qiue; Yang, Yang; Shen, Chenguang (2020-03-18). "Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study". *Engineering*. doi:10.1016/j.eng.2020.03.007. ISSN 2095-8099.
37. ^ Dong, L; Hu, S; Gao, J (2020). "Discovering drugs to treat coronavirus disease 2019 (COVID-19)". *Drug Discoveries & Therapeutics*. **14** (1): 58–60. doi:10.5582/ddt.2020.01012. PMID 32147628.

show

- v
- t
- e

RNA virus antivirals (primarily J05, also S01AD and D06BB)

Hepatitis C NS3/4A • Asunaprevir

protease inhibitors (-previr)	<ul style="list-style-type: none"> • Boceprevir[‡] • Ciluprevir[§] • Danoprevir[†] • Faldaprevir[‡] • Glecaprevir • Grazoprevir • Narlaprevir • Paritaprevir • Simeprevir • Sovaprevir[†] • Telaprevir[‡] • Vaniprevir • Vedroprevir[§] • Voxilaprevir
NS5A inhibitors (-asvir)	<ul style="list-style-type: none"> • Daclatasvir[#] • Elbasvir • Ledipasvir • Odalasvir[†] • Ombitasvir • Pibrentasvir • Ravidasvir[†] • Ruzasvir[†] • Samatasvir[†] • Velpatasvir • Beclabuvir[†] • Dasabuvir[#] • Deleobuvir[§]
NS5BRNA polymerase inhibitors (-buvir)	<ul style="list-style-type: none"> • Filibuvir[§] • GS-6620[§] • Setrobuvir[§] • Sofosbuvir[#] • Radalbuvir[†] • Uprifosbuvir[†]
Combination drugs	<ul style="list-style-type: none"> • Elbasvir/grazoprevir • Glecaprevir/pibrentasvir • Ledipasvir/sofosbuvir[#] • Ombitasvir/paritaprevir/ritonavir[#] • Sofosbuvir/daclatasvir • Sofosbuvir/velpatasvir[#] • Sofosbuvir/velpatasvir/voxilaprevir
Picornavirus Anti-influenza	<ul style="list-style-type: none"> • <i>viral entry</i>: Pleconaril[†] • Baloxavir marboxil

agents

- Pimodivir[†]
- Umifenovir

- *adamantane derivatives/M2 inhibitors* (Adapromine
- Amantadine
- Rimantadine)

- *neuraminidase inhibitors/release phase* (Oseltamivir[#]
- Zanamivir
- Peramivir, Laninamivir[†])

Interferon

- Interferon alfa 2b
- Peginterferon alfa-2a[#]
- Peginterferon alfa-2b[#]
- EICAR[§]
- Favipiravir
- Galidesivir[†]
- Remdesivir[†]
- Mericitabine[†]
- MK-608[§]
- NITD008[§]
- Moroxydine
- Presatovir[†]
- Ribavirin[#]
- Taribavirin[†]
- Triazavirin

**Multiple/genera
I**

**Multiple/unknown
n**

- [#]WHO-EM
- [†]Withdrawn from market
- Clinical trials:
 - [†]Phase III
 - [§]Never to phase III

show

- v
- t
- e

Filoviridae

- *Bundibugyo ebolavirus*
- BDBV
- *Reston ebolavirus*
- RESTV

Ebolavirus

Species



- *Sudan ebolavirus*
 - SUDV
- *Tai Forest ebolavirus*
 - TAFV
- *Zaire ebolavirus*
 - EBOV
- 1976 Sudan outbreak
- 1976 Zaire outbreak
- 2013–2016 West African Ebola virus epidemic
 - Timeline
 - Reported cases and deaths
 - Responses
 - United Nations Ebola Response Fund
 - Operation United Assistance
 - in Guinea
 - in Liberia
 - in Mali
 - in Nigeria
 - in Sierra Leone
 - in Spain
 - in the US
 - in the UK
 - Ouse to Ouse Tock
 - Womey massacre

Outbreaks

Drug candidates

- 2014 DR Congo outbreak
- 2017 DR Congo outbreak
- 2018 Équateur, DR Congo outbreak
- Kivu Ebola epidemic
- BCX4430
- Brincidofovir
- DZNep
- Favipiravir
- FGI-103
- FGI-104
- FGI-106
- JK-05
- Lamivudine
- mAb14
- TKM-Ebola^(failed)
- Triazavirin
- ZMapp

		<ul style="list-style-type: none"> • Vaccines <ul style="list-style-type: none"> ◦ cAd3-ZEBOV ◦ rVSV-ZEBOV • William Close • Jean-Jacques Muyembe-Tamfum • Peter Piot • Selected patients <ul style="list-style-type: none"> ◦ Ameyo Adadevoh ◦ Kent Brantly ◦ Pauline Cafferkey ◦ Thomas Eric Duncan ◦ Salome Karwah ◦ Sheik Umar Khan ◦ Matthew Lukwiya ◦ Mayinga N'Seka ◦ Patrick Sawyer
	Notable people	
	Popular culture	<ul style="list-style-type: none"> • <i>The Hot Zone</i>(1995 book by Richard Preston) • <i>Outbreak</i>(1995 film) • <i>Ebola Syndrome</i>(1996 film) • <i>Executive Orders</i>(1996 novel) • <i>93 Days</i>(2016 film)
	Miscellaneous	<ul style="list-style-type: none"> • Ebola virus disease • Ebola virus disease treatment research • Ebola River • <i>Marburg marburgvirus</i>
	Species	<ul style="list-style-type: none"> ◦ MARV ◦ RAVV
	Outbreaks	<ul style="list-style-type: none"> • 1967 Marburg virus outbreak in West Germany • 2017 Uganda Marburg virus outbreak
<i>Marburgvirus</i>	Drug candidates	<ul style="list-style-type: none"> • BCX4430 • FGI-103 • FGI-106
	Popular culture	<ul style="list-style-type: none"> • <i>The Hot Zone</i>(1995 book)
	Miscellaneous	<ul style="list-style-type: none"> • Marburg virus disease • Marburg
<i>Cuevavirus</i>	Species	<ul style="list-style-type: none"> • <i>Lloviu cuevavirus</i> (LLOV)
<i>Dianlovirus</i>	Species	<ul style="list-style-type: none"> • Mengla virus (MLAV)

-  Commons
-  Wikispecies

Retrieved from "<https://en.wikipedia.org/w/index.php?title=Favipiravir&oldid=946951189>"

Categories:

- Anti-RNA virus drugs

- Pyrazines
 - Carboxamides
 - Organofluorides
 - Ebola
 - Hydroxyarenes
 - Experimental drugs
-

<https://www.theguardian.com/world/2020/mar/18/japanese-flu-drug-clearly-effective-in-treating-coronavirus-says-china>

Guardian Newspaper article dated 18 March 2020 regarding Favipiravir = Avigan (which is the Brand Name) with URL <https://www.theguardian.com/world/2020/mar/18/japanese-flu-drug-clearly-effective-in-treating-coronavirus-says-china>

Japanese flu drug 'clearly effective' in treating coronavirus, says China

Patients given the medicine in Shenzhen turned negative in a median of four days Photograph: John Minchillo/AP

Medical authorities in China have said a drug used in Japan to treat new strains of influenza appeared to be effective in coronavirus patients, Japanese media said on Wednesday.

Zhang Xinmin, an official at China's science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.

"It has a high degree of safety and is clearly effective in treatment," Zhang told reporters on Tuesday.

Patients who were given the medicine in Shenzhen turned negative for the virus after a median of four days after becoming positive, compared with a median of 11 days for those who were not treated with the drug, public broadcaster NHK said.

In addition, X-rays confirmed improvements in lung condition in about 91% of the patients who were treated with favipiravir, compared to 62% of those without the drug.

Coronavirus: the week explained - our expert correspondents put a week's worth developments in context in one email newsletter

Fujifilm Toyama Chemical, which developed the drug – also known as Avigan – in 2014, has declined to comment on the claims.

Shares in the firm surged on Wednesday following Zhang's comments, closing the morning up 14.7% at 5,207 yen, having briefly hit their daily limit high of 5,238 yen.

Doctors in Japan are using the same drug in clinical studies on coronavirus patients with mild to moderate symptoms, hoping it will prevent the virus from multiplying in patients.

But a Japanese health ministry source suggested the drug was not as effective in people with more severe symptoms. “We’ve given Avigan to 70 to 80 people, but it doesn’t seem to work that well when the virus has already multiplied,” the source told the Mainichi Shimbun.

The same limitations had been identified in studies involving coronavirus patients using a combination of the HIV antiretrovirals lopinavir and ritonavir, the source added.

In 2016, the Japanese government supplied favipiravir as an emergency aid to counter the Ebola virus outbreak in Guinea.

Favipiravir would need government approval for full-scale use on Covid-19 patients, since it was originally intended to treat flu.

A health official told the Mainichi the drug could be approved as early as May. “But if the results of clinical research are delayed, approval could also be delayed.”

<https://asia.nikkei.com/Business/Pharmaceuticals/China-says-Japan-developed-drug-Avigan-works-against-coronavirus2>

Nikkei Asian Review article dated 18th March 2020 regarding Favipiravir = Avigan (which is the Brand Name) with URL <https://asia.nikkei.com/Business/Pharmaceuticals/China-says-Japan-developed-drug-Avigan-works-against-coronavirus2>

China says Japan-developed flu drug works against coronavirus - . Fujifilm Toyoma Chemical developed favipiravir, sold under the brand Avigan.

Coronavirus

China says Japan-developed flu drug works against coronavirus

Fujifilm group member's Avigan to be recommended for treatment

SHIN WATANABE, Nikkei staff writer March 18, 2020 07:50 JST



The Chinese government has been conducting clinical research on a treatment for COVID-19.

© AP



DALIAN, China -- An influenza medicine developed by a Fujifilm Holdings group member is effective against the novel coronavirus, the Chinese government said Tuesday.

The government plans to officially recommend the drug's use for treatment. Fujifilm Toyoma Chemical developed favipiravir, sold under the brand Avigan.

"It has a high degree of safety and is clearly effective in treatment," said Zhang Xinmin, director of the science ministry's China National Center for Biotechnology Development, in a news conference. Fujifilm Toyoma Chemical developed the drug in 2014, and it has been provided to patients in Japan as treatment for the novel coronavirus since February.

Zhejiang Hisun Pharmaceutical signed a patent-licensing agreement for favipiravir with Fujifilm in 2016. The drugmaker received clearance to produce the drug from Chinese authorities in February and can ramp up output of a generic version.

The clinical trial was conducted at hospitals in Wuhan and Shenzhen, with 200 patients participating. Test results for those receiving the drug turned negative in a shorter period, and their pneumonia symptoms improved at a higher rate.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 14:47:18 +0000
To: Beigel, John (NIH) [E]
Cc: (b) (6)
Subject: FW: IFN treatment for COVID-19
Attachments: Manuscript and Supplement.pdf

John:

Please handle this.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Young, Howard (NIH/NCI) [E] (b) (6)>
Sent: Monday, March 23, 2020 9:57 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Beigel, John (NIH) [E]
(b) (6)>
Cc: Eleanor Fish (b) (6)>
Subject: IFN treatment for COVID-19

Dear Drs. Fauci and Beigel

Dr. Fish has asked me to share with you this manuscript that has been submitted (b) (4)

(b) (4)

Regards,
Howard

From: Eleanor Fish [REDACTED] (b) (6) >
Sent: Saturday, March 21, 2020 5:25 PM
To: Young, Howard (NIH/NCI) [E] [REDACTED] (b) (6)
Subject: IFN treatment for COVID-19

Dear Howard,
I wanted to share with you our findings from a clinical study [REDACTED] (b) (4)

[REDACTED]

Please keep this confidential.
The manuscript has been submitted for consideration for publication.

*Eleanor N. Fish, PhD, FAAS
UHN Emerita
Professor & Associate Chair
International Initiatives & Collaborations
Dept. Immunology, University of Toronto*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 13:40:42 +0000
To: Casseti, Cristina (NIH/NIAID) [E]
Subject: FW:

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schur, Peter H., M.D. <(b) (6)>
Sent: Monday, March 23, 2020 9:33 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject:

Dear Dr Fauci

I am looking for help and informagtion.

I am still working fulltime at Brigham and Women's Hospital (BWH) as a Rheumatologist--although with the pandemic I am currently working from home

I am also the Medical Director of the BWH Clinical Immunology Lab.

We are looking for a company that can provide us with kits to assess IgG and IgM antibodies to COVID-19. Can you, or one of your staff help us find those companies

When I was at WRAIR many years ago (b) (6) they had a walk in -70C freezer with

(b) (6)

Thank you for your help. Applaud what you are doing on TV. Applaud what you are doing for this pandemic

Trust you are well

Peter H Schur MD
Senior Physician Brigham and Women's Hospital
Professor of Medicine Harvard Medical School
Boston MA
Tel: 617-732-5350

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at <http://www.partners.org/compliance> . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.


From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 13:02:15 +0000
To: Stephen Hahn
Subject: FW: Quick Review: Press Conference Open - March 23
Attachments: Press Conference Open - March 23 - with Fauci edits.docx

Here it is

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(3) - PCT



From: (b) (6)
Sent: Mon, 16 Mar 2020 14:53:22 -0400
To: Adams, Jerome (HHS/OASH); Brett Giroir
Subject: Fwd: Revised social distancing documents - word and powerpoint versions
Attachments: US Social Distancing Recommendations - CDC 1151am_3_16_2020 clean.docx, ATT00001.htm, US Social Distancing Recommendations - CDC 1151am_3_16_2020 track changes.docx, ATT00002.htm, Social Distancing v5 3 16 2020.pptx, ATT00003.htm

FYI

Begin forwarded message:

From: "Schuchat, Anne MD (CDC/OD)" (b) (6)
Date: March 16, 2020 at 12:04:14 PM EDT
To: "Birx, Deborah L. EOP/NSC" (b) (6), "Azar, Alex (OS/IOS)" (b) (6), "Giroir, Brett (HHS/OASH)" (b) (6), "Harrison, Brian (HHS/IOS)" (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" (b) (6), "Kadlec, Robert (OS/ASPR/IO)" (b) (6)
Cc: "Redfield, Robert R. (CDC/OD)" (b) (6), "McGowan, Robert (Kyle) (CDC/OD/OCS)" (b) (6), "Schuchat, Anne MD (CDC/OD)" (b) (6), "Green, Hugh (CDC/OD/OCS)" (b) (6), "Hoo, Elizabeth (CDC/OD/OCS)" (b) (6)
Subject: Revised social distancing documents - word and powerpoint versions

On behalf of Dr Redfield, I am forwarding a revised word document (clean and track changes) and a revised powerpoint with two slides.

These drafts incorporate feedback that Dr Redfield received from the WHTF as well as the emerging evidence-base. Thus we have combined prior advice on yesterday's version that

Anne Schuchat, MD
Principal Deputy Director
Centers for Disease Control and Prevention
Rear Admiral, US Public Health Service (Retired)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 14 Mar 2020 12:37:15 +0000
To: Howard Bauchner;Butler, Jay C. (CDC/DDID/OD);Preeti Malani;Eli Perencevich;Phil Fontanarosa
Cc: Edward Livingston
Subject: RE: Testing - JAMA - Important

Howard/Jay:

I liked Jay's answers to Howard's questions even though there were still some open issues. I will have to leave it to Jay and the CDC to continue with the discussion since I am really swamped. Sorry.

Thanks,
Tony

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Saturday, March 14, 2020 7:48 AM
To: Butler, Jay C. (CDC/DDID/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Preeti Malani <pmalani@med.umich.edu>; Eli Perencevich <Eli-perencevich@uiowa.edu>; Phil Fontanarosa <Phil.Fontanarosa@jamanetwork.org>
Cc: Edward Livingston <Edward.Livingston@jamanetwork.org>
Subject: Re: Testing - JAMA - Important

Thanks Jay

Have also copied Ed –

This is going to become very very important – (b) (4)

This is crossing my desk 4-5 times per day now – and will only get more important (and sadly confusing) – in the weeks to come.

Some questions would focus on public others on HCW (where I am sure general guide; talk with your CMO).

I do love the mention of monopoly – (b) (6)

What you think?

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my [chats with authors](#)

From: "Butler, Jay C. (CDC/DDID/OD)" <(b) (6)>

Date: Saturday, March 14, 2020 at 6:42 AM

To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>, Tony Fauci <(b) (6)>, Preeti Malani <pmalani@med.umich.edu>, Eli Perencevich <Eliperencevich@uiowa.edu>, Phil Fontanarosa <Phil.Fontanarosa@jamanetwork.org>

Subject: Re: Testing - JAMA - Important

[Warning External Email]

Good morning, Howard—some answers and non-answers. As is the case for most answers, the most accurate is "it depends", but I realize that is not helpful in busy clinical settings:

No symptoms – get test positive – can you work

At this point in the pandemic, no. While we do not know what role asymptomatic infection may play in transmission and it is plausible that someone who is NOT coughing and sneezing (or any other respiratory droplet self-generating acts) is going to be less infectious than someone who is, persons known to be infected should self-isolate. This, of course, is particularly important for someone who has closed contact with someone at greater risk of severe illness and health care providers.

Symptoms – test negative – can you work – or do you need 2 negatives – or the test has to be done 2-3-4 days after you develop symptoms

Even before COVID-19, working while ill with a respiratory illness puts others at risk. Particularly during when flu activity is high. Not toughing it out and going into work while sick is more important now than ever and is an important component of social distancing—this is one of the foundational ways that we distribute the impact of the pandemic over as long of a period as possible. (We are all getting good at drawing the two pandemic curves in the air on imaginary x- and y-axes.). One of the critical areas where we need more data is on when someone who is infected becomes test-positive. Presumably, test-positivity would correlate with viral load in the respiratory tract and a + would indicate greater likelihood of infectiousness. But the real challenge of the return-to-work issue lies in your next question:

Test positive – back to work when – do you need negative tests – or just time - ? 2 weeks after first symptoms, first test positive.

Ah, there is the rub—currently, the recommendations vary—CDC has gone with 2 negative swabs 24 hours apart, but we do not believe that positivity during recovery necessarily proves infectiousness. This is a crucial question. We are reviewing the available data, examining at how PCR positivity, cycle threshold, and viral culture line up—the goal is to develop good,

clinical parameters to justify ending precautions, rather than requiring microbiological tests. A Get Out of Isolation Free card, if you will. The hypothesis we are testing to 2 weeks after onset and >72 hours without symptoms. Currently the published recommendations are not satisfying:

<https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html>

I may have more information on this topic later today.

Finally, in all complex epidemics, there is a tendency to search for a silver bullet—that one thing that will solve all of our problems. When an intervention is in short supply, the bullet turns platinum—“if only we could do x, the problem would be solved”. This was vaccine in 2009 H1N1, naloxone in the opioid crisis, and now testing in coronavirus. Increased access to testing is desperately needed to control the COVID-19 pandemic. However, it is going to take a scientifically and wholistic and systemic approach to mitigate the impact. You have nicely outlined some of the “next questions” that are raised when testing is more widely available.

More to follow.

Best regards,
Jay

Get [Outlook for iOS](#)

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Saturday, March 14, 2020 5:53 AM
To: Butler, Jay C. (CDC/DDID/OD); Fauci, Anthony (NIH/NIAID) [E]; Preeti Malani; Eli Perencevich; Phil Fontanarosa
Subject: Testing - JAMA - Important

Jay/Tony

Some very complicated questions around testing have come up and will only increase.

No symptoms – get test positive – can you work

Symptoms – test negative – can you work – or do you need 2 negatives – or the test has to be done 2-3-4 days after you develop symptoms

Test positive – back to work when – do you need negative tests – or just time - ? 2 weeks after first symptoms, first test positive.

As tests become more widely available this will be devil folks.

Any ideas who can write about this.

Jay – does CDC have specific recommendations.

Sorry to bother on Saturday morning -but would like to get up a VP as soon as Tuesday.

HCB

Howard Bauchner, MD

Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my [chats with authors](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 23:06:12 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Antibody Tests and Follow-on Use of 'Survivors'

From: Estes, Franklin J (Frank) LTC USARMY 335 SIG CMD (USA) (b) (6)
Sent: Sunday, March 22, 2020 12:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Antibody Tests and Follow-on Use of 'Survivors'

Dr. Fauci,

I apologize in advance for bugging you but please read and pass along to the appropriate person, if useful.

In the coming weeks, an antibody test for COVID-19 should be available (I suspect). As 'survivors' are identified in the general population and are determined to be largely 'immune' to COVID-19, I think those people should be given the opportunity to administer testing to others in the general population. The employment of VOLUNTEER survivors in the administration of tests would allow immune individuals to quickly learn how to collect samples and deal with potential infected patients face-to-face without fear of jeopardizing their own health or the health of the communities in which they live. This would free up highly trained nurses and doctors from testing and have an exponential benefit as survivors administer tests for infection and tests for antibodies and, thus, identify additional survivors. This would support more aggressive testing to bring about the eventual end of this virus when we try to identify every last infected individual who needs to be quarantined.

Note: I understand we haven't yet determined whether survivors can be re-infected. So early volunteers may be subjected to further sickness. But the rate of re-infection should be less as a percentage than the rate of infection among the general population. And re-infection would likely be less severe.

Note2: Creating a VOLUNTARY REIGSTRY of survivors (those with sufficient antibodies) may have a secondary benefit to businesses. It would allow businesses to quickly hire employees who could come in contact with the general public (thinking of current food delivery, grocery stores, daycare...and later...teachers, anyone in the medical or dental field, other retail businesses).

I do understand my recommendations would generate HIPAA concerns but these are extraordinary times which call for out-of-the-box ideas...and this would all be voluntary.

Thank you for taking a couple of minutes to read this and thank you for managing a very difficult crisis. You and others on your team have saved a lot of lives and we are eternally grateful.

Respectfully,

Frank Estes
(b) (6)
(cell)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 11:17:11 +0000
To: (b) (6) USAR MEDCOM (USA)
Subject: RE: Recommendation

(b) (6)

Thank you for your note.
Best regards,
Tony

From: (b) (6) USAR MEDCOM (USA) (b) (6) >
Sent: Tuesday, March 17, 2020 6:52 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Recommendation

Dr. Fauci,
I am a Nurse Practitioner (b) (6) for the US Army. I have a recommendation as we move through this terrible time in the US as well as the world. To preserve the healthcare workforce why not give 25% of all health workers in the military the trial vaccine? Keep these workers away from patients until which time that the body can build immunity. Let's not expose the entire medical workforce to the COVID-19. The idea is that this 25% can take care of the population (post-vaccine) without worry of getting ill and causing further spread of the disease. If there is possibility of the vaccine, trial age cohorts and demographics could play a crucial part in testing. Thank you for all you are doing to protect the health of our Nation.
Respectfully,
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 23:47:21 +0000
To: Hahn, Stephen
Cc: Redfield, Robert R. (CDC/OD); Birx, Deborah L. EOP/NSC; Lane, Cliff (NIH/NIAID) [E]; (b) (6); Rom, Colin (FDA/OC)
Subject: RE: Treatment Document

Sounds good to me.
Thanks,
Tony

From: Hahn, Stephen (b) (6) >
Sent: Friday, March 20, 2020 7:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Redfield, Robert R. (CDC/OD) (b) (6); Birx, Deborah L. EOP/NSC (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6); (b) (6); Rom, Colin (FDA/OC) (b) (6) >
Subject: Re: Treatment Document

Tony,
Looks like (b) (6). The group wants to make some more edits and then send out this evening for review. We would like to meet up prior to or after the task force meeting tomorrow. Sound OK?
Steve

Sent from my iPad

On Mar 20, 2020, at 7:06 PM, Hahn, Stephen (b) (6) > wrote:

I have a couple of comments

(b) (6)

I'll await for other comments.

Thanks
Steve

Sent from my iPad

On Mar 20, 2020, at 6:45 PM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6) wrote:

Team:

As per my discussion with Steve a few minutes ago, I have made some changes in the document. (b) (5)

(b) (5)

(b) (5) I am

attaching a tracked version of the document that was your FINAL as well as a clean copy with all of the changes accepted. Please take a look and Steve said that he would like to set up a quick call to discuss after you have had a look. I am very sorry to come in with these changes at this late point, but I really did not get a chance to have a good look at the document as I was in a car.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

<dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked changes showing.docx>

<dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked Clean copy.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 12:58:59 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Respiratory Protection Program: Temporary Suspension of Fit Testing

For my clinical center Certification folder.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Wu, Sarah (NIH/OD/ORS) [E] (b) (6)
Sent: Monday, March 23, 2020 8:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Respiratory Protection Program: Temporary Suspension of Fit Testing

Respiratory Protection Program Participants:

Due to the recent COVID-19 outbreak and supply chain shortage, we are temporarily suspending annual fit tests for employees at this time. You will still be required to complete fit testing if:

- you have experienced significant physical changes likely to impact the fit of your respirator such as:
 - substantial weight loss/gain
 - dental surgery
 - cosmetic surgery including the neck area and above
 - an accident
 - a new medical diagnosis
- you are directly involved in the COVID-19 response and are expected to be in close contact with potential COVID-19 patients
- you are emergency response personnel (police, fire department, etc.) required to be on-site throughout this pandemic

If you do not meet these criteria, you are not required to complete your fit test at this time. Please be advised that you will still need to complete the online training despite the suspension of fit testing. *Regular fit testing will resume once the COVID-19 emergency has subsided.*

Any questions concerning the HealthRx website should be directed toward support@healthrx.com. Please visit the manufacturer's websites for details on your particular respirator model. If you have questions about N95 respirators in general, feel free to email nihrespirator@mail.nih.gov. Thank you for your efforts and consideration during this event.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 12:58:16 +0000
To: Karen Backman
Subject: RE: Your Unprecedented Leadership and Professionalism

Karen:

Many thanks for your kind note.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Karen Backman (b) (6)
Sent: Monday, March 23, 2020 8:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Your Unprecedented Leadership and Professionalism

Good morning Dr. Fauci,

I am not one to write emails to our leaders in government as I am sure that the message doesn't get to where it always needs to go. At the risk of you possibly seeing this email, you need to know that you are doing an incredible job.

I doubt you will be broadcasting this note but you should know that my husband and I take great comfort in seeing you up on the podium next to our country's leadership on the COVID-19 pandemic. You are a steady voice of reason and the right person for the job. Even when the President doesn't get it quite right, you manage to be professional in your delivery, information and steadfast manner. We can easily look past the President but we listen when you speak.

From the first time I heard you say on a Sunday morning talk show, "If you think we are overacting then we are probably doing the right things." I live in Maine and we are a rural state so we probably won't see the numbers that are elsewhere but we are listening and acting on your words of caution.

I can't imagine how much pressure you are under doing your job but we need more leadership such as yours. How you choose your words so carefully without getting flustered is a gift. I can only hope that you will continue to be the voice to get this country through this unprecedented event.

Stay healthy and keep doing what you're doing as it matters so much to this nation.

Sincerely,

Karen L. Backman

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 12:46:08 +0000
To: (b) (6)
Subject: Confidential
Attachments: Press Conference Open - March 23 - with Fauci edits.docx

Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 12:25:31 +0000
To: info@mail.mblists.com
Subject: RE: Fill the baseball void: Trivia, A-Rod clinic, classic games

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [REDACTED] (b) (6)
Sent: Mon, 23 Mar 2020 07:32:09 -0400
To: DMID Word Nerds
Subject: Fwd: COVID-19- NOVEL DRUG
Attachments: [REDACTED] (b) (4) 3_17_2020.pdf, ATT00001.htm

Sent from my iPhone

Begin forwarded message:

From: Radka Milanova [REDACTED] (b) (6) >
Date: March 23, 2020 at 1:43:46 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)
Subject: COVID-19- NOVEL DRUG

Dear Dr. Anthony Fauci:

I am involved with a US-based Company Bioxytran [REDACTED] (b) (4)

[REDACTED] (b) (4)



I look forward to hearing from you.

Kind regards,

Radka Milanova, Ph.D.
Office: + 604 488 8380
Moblie: (b) (6)
Email: milanova@shore.ca

This message and any attachments are intended only for the use of the addressee and may contain information that is privileged and confidential. If the reader of the message is not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any dissemination of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by e-mail and delete the message and any attachments from your system.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 01:37:39 +0000
To: David Rubenstein
Subject: FW: USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

David:

You were so very kind to me in this article. Thank you so much.
Warm regards,
Tony

Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need Fauci is the world's leading authority on infectious diseases and the best person in the country to help us deal with the COVID-19 crisis.

David M. Rubenstein
Opinion contributor

Some viewers of the daily White House coronavirus briefings may wonder why everyone increasingly defers to a diminutive, Brooklyn-accented 79-year-old doctor, Tony Fauci.

They do because, as I have learned over many years of talking with and more recently interviewing this man, he is without doubt the world's leading authority on infectious diseases. In any area of human activity or knowledge, there always seems to be one person who is the global gold standard. In the world of infectious diseases that person is Tony Fauci.

So the American people — indeed, people around the globe — should be grateful that Tony has dug into this crisis with the same work-around-the-clock, just-the-facts ma'am style that he has used while serving under and working with [six U.S. presidents](#). He is as apolitical as anyone can be. I have no idea if he is registered with any political party; I suspect though that he is rabidly Independent. His only focus is getting the facts out, providing the best health care treatment and information possible, and saving lives.

A top expert from AIDS to Ebola

Tony Fauci [joined the National Institutes of Health](#) in 1968, after completing his medical training at Weill Cornell Medical Center, and he has led the National Institute of Allergy and Infectious Disease [since 1984](#) — 36 years. Hard to believe anyone can run anything that long and still be at the top of his game. But Tony is. During this period, he has dealt with every serious infectious disease challenge — malaria, Among Tony's best known accomplishments, beyond simply running the institute and training dozens of the world's top infectious disease professionals, has been helping to discover how HIV leads to AIDS and, later, leading the effort to create (at President George W. Bush's direction) the [President's Emergency Plan for AIDS Relief](#) (PEPFAR), which has transformed the treatment of HIV/AIDS in Africa, and other parts of the developing world. Millions of lives have been saved by this program alone. More recently, he has been an architect and powerful advocate of President Donald Trump's [plan for ending](#) the AIDS epidemic in the U.S. through HIV antiretroviral therapy targeted to disease hotspots.

In his spare time, Tony has been involved with writing or editing more than 1,100 scholarly articles and several textbooks, and, in the process, has become one of the most cited authorities of the entire medical profession.

For these breakthrough activities and his dedicated service (at a government salary) for more than a half century (he worked at NIH for 16 years before assuming his current role), Tony has received, and earned, the Presidential Medal of Freedom and a [Lasker Award](#) (called the American Nobel by many). With this long service and universal acclaim, one might think Tony would let it get to his head, at least a little bit. Not the case, though.

Selfless commitment to public service

He is readily accessible to those who need treatment — he still runs a lab at NIH — or need information. Tony still lives in the same house he bought when he first moved to Washington, and it is there that he and his wife Christine have raised their three talented daughters (though none of them chose to attend medical school).

Until the latest crisis, Tony has often commuted to NIH by Metro, typically after running three miles for his daily exercise. And when he has been invited to make speeches in the Washington area or on Capitol Hill, he invariably turns down a car and driver for the Metro. (This practice has had to change of late for the obvious reasons).

There are, of course, many other dedicated federal servants who also view their commitment to the country and its people over financial rewards. But surely no federal civil servant, in any area, can exceed Tony Fauci's long-term and selfless commitment to this country and the health of its people.



I tried years ago, when Tony was approaching a normal retirement age, to see if he might want after a normal lifetime of federal service, to take some of his considerable skills and knowledge to the private sector. He quickly said no — money did not motivate him, serving the country did. And he stayed at NIH — to the country's good fortune.

If there is any one medical professional who can help the country deal with the COVID-19 crisis, it is Tony Fauci, an example of the best this country has to offer.

He is not a miracle worker. No one is.

But Tony Fauci has the decades of experience needed to understand infectious disease problems and prescribe a treatment that should, in time, provide the requisite comfort, even if, in the short term, the medicine is painful and inconvenient.

David M. Rubenstein is the co-executive chairman of The Carlyle Group.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 01:23:55 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; (b) (6)
Subject: FW: Possible agenda for Wednesday
Attachments: COVID-19 TransNIH_032520 hm.docx

Please take the lead in putting together slides for Wednesday. If I can make it (which is uncertain), I will need them to make a presentation.

Thanks, \Tony

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Sent: Sunday, March 22, 2020 7:10 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6); Wolinetz, Carrie (NIH/OD) [E] (b) (6); Anderson, James (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Possible agenda for Wednesday

Thanks for the chance to weigh in. I have it blocked on my calendar and would look forward to the discussion. And I'm happy to pull slides together as outlined.

Here are some minor comments on the agenda, which looks excellent.

Looking forward to it,

Hilary

From: "Collins, Francis (NIH/OD) [E]" (b) (6)
Date: Sunday, March 22, 2020 at 5:09 PM
To: Hilary Marston <(b) (6)>
Cc: "Tabak, Lawrence (NIH/OD) [E]" (b) (6); "Wolinetz, Carrie (NIH/OD) [E]" (b) (6); "Anderson, James (NIH/OD) [E]" (b) (6); Anthony Fauci (b) (6); Henry Lane (b) (6)
Subject: Possible agenda for Wednesday

Hi Hilary,

I've been through the COVID-19 ideas collected from your Deputies meeting, plus reaching out for a few other inputs. What I hope to do is to assemble this into a lively three-hour discussion on Wednesday afternoon (2 - 5 PM). Tony is enthusiastic about our doing this, but his presence is unfortunately doubtful, given all of the other demands he faces. I'm counting on you and Cliff to be there, however – is this etched on your calendars?

Please see attached for my rather rough first attempt at an agenda. It's a lot of topics and the list will probably need to be culled – [REDACTED] (b) (5)

I would want there to be time for discussion in each theme, so that other ideas could be floated.

Please let me know your thoughts, ideally this evening. I'm also asking for input from others who are cc'd here.

Best, Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 00:56:30 +0000
To: Jon LaPook
Subject: RE: Tony, my three minute shpiel on CBS Sunday Morning today.

Very well done as usual.

-----Original Message-----

From: Jon LaPook <(b) (6)>
Sent: Sunday, March 22, 2020 8:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Tony, my three minute shpiel on CBS Sunday Morning today.

<https://www.cbsnews.com/news/coronavirus-covid-19-social-distancing-how-to-reduce-risk-together/>

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 00:51:49 +0000
To: McNeil Jr, Donald G
Subject: RE: big story of mine just posted

Donald:

You not only got it right, but it was an extraordinarily comprehensive, informative and sobering article. I do not agree with everything that is being done by various countries, and you have indicated that many of these approaches are controversial. However, your reporting of them is accurate and well-articulated. Bottom line is that this is an outstanding article.

Best,
Tony

From: McNeil Jr, Donald G <mcneil@nytimes.com>
Sent: Sunday, March 22, 2020 7:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: big story of mine just posted

I would have interviewed you for it, but I know you're busy. I hope you think I got it right....

<https://www.nytimes.com/2020/03/22/health/coronavirus-restrictions-us.html>

—
Donald G. McNeil Jr.
Science Correspondent
The New York Times

Tel: +1 212 556 1142
mcneil@nytimes.com

Articles: <https://www.nytimes.com/by/donald-g-mcneil-jr>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 23:27:37 +0000
To: Murphy, Philip (NIH/NIAID) [E]
Subject: RE: Suggestion

Phil:
Thanks for the note. Very important point.
Best,
Tony


From: Murphy, Philip (NIH/NIAID) [E] (b) (6)
Sent: Sunday, March 22, 2020 7:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Suggestion

Yeoman work, Tony. One suggestion: (b) (5)

(b) (5)
(b) (5)
(b) (5)
(b) (5)

All the best,
Phil

(b) (5)



Phil

From: (b) (6)
Sent: Sun, 22 Mar 2020 17:23:08 -0400
To: Cicala, Claudia (NIH/NIAID) [E]
Subject: Re: Your idea about COVID-19

Thanks, Claudia

On Mar 22, 2020, at 5:17 PM, Cicala, Claudia (NIH/NIAID) [E]

(b) (6)

Dear Tony,

Thank you for taking the time to answer. I want you to know that a huge number of people here and in Italy asked me to pass along a message of support. Thank you for all you are doing.

Take a good care of yourself,
Claudia

Sent from my iPhone

On Mar 22, 2020, at 1:27 PM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6):

Jim:

(b) (5)

Needless to say, this is a overwhelmingly compelling public health and scientific issue. Keep me posted.


Thanks,
Tony


Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 17:29:47 +0000
To: Hallett, Adrienne (NIH/OD) [E]
Subject: RE: Senate Supplemental #3

Thanks!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hallett, Adrienne (NIH/OD) [E] <(b) (6)>
Sent: Sunday, March 22, 2020 1:21 PM
To: icddir-l@LIST.NIH.GOV
Subject: Senate Supplemental #3

NATIONAL INSTITUTES OF HEALTH NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

For an additional amount for “National Heart, Lung, and Blood Institute”, \$103,400,000, to remain available until September 30, 2024, to prevent, prepare for, and respond to coronavirus, domestically or internationally: *Provided*, That such amount is designated by the Congress as being for an emergency requirement pursuant to section 251(b)(2)(A)(i) of the Balanced Budget and Emergency Deficit Control Act of 1985.

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

For an additional amount for “National Institute of Allergy and Infectious Diseases”, \$706,000,000, to remain available until September 30, 2024, to prevent, prepare for, and respond to coronavirus, domestically or internationally:

Provided, That not less than \$156,000,000 of the amounts provided under this heading in this Act shall be provided for the study of, construction of, demolition of, renovation of, and acquisition of equipment for, vaccine and infectious diseases research facilities of or used by NIH, including the acquisition of real property: *Provided further*, That such amount is designated by

1. 2 the Congress as being for an emergency requirement pur-
2. 3 suant to section 251(b)(2)(A)(i) of the Balanced Budget
3. 4 and Emergency Deficit Control Act of 1985.

4.

5. 5 NATIONAL INSTITUTE OF BIOMEDICAL

6. 6 IMAGING AND BIOENGINEERING

7. 7 For an additional amount for “National Institute of
8. 8 Biomedical Imaging and Bioengineering”, \$60,000,000, to
9. 9 remain available until September 30, 2024, to prevent,
10. 10 prepare for, and respond to coronavirus, domestically or
11. 11 internationally: *Provided*, That such amount is designated
12. 12 by the Congress as being for an emergency requirement
13. 13 pursuant to section 251(b)(2)(A)(i) of the Balanced Budg-
14. 14 et and Emergency Deficit Control Act of 1985.

15.

16. 15 NATIONAL LIBRARY OF MEDICINE

17. 16 For an additional amount for “National Library of
18. 17 Medicine”, \$10,000,000, to remain available until Sep-
19. 18 tember 30, 2024, to prevent, prepare for, and respond to
20. 19 coronavirus, domestically or internationally: *Provided*,
21. 20 That such amount is designated by the Congress as being
22. 21 for an emergency requirement pursuant to section
23. 22 251(b)(2)(A)(i) of the Balanced Budget and Emergency
24. 23 Deficit Control Act of 1985.

HEN20279 S.L.C. 78

1. 1 NATIONAL CENTER FOR ADVANCING

2. 2 TRANSLATIONAL SCIENCES

3. 3 For an additional amount for “National Center for
4. 4 Advancing Translational Sciences”, \$36,000,000, to re-
5. 5 main available until September 30, 2024, to prevent, pre-
6. 6 pare for, and respond to coronavirus, domestically or
7. 7 internationally: *Provided*, That such amount is designated
8. 8 by the Congress as being for an emergency requirement

9. 9 pursuant to section 251(b)(2)(A)(i) of the Balanced Budget and Emergency Deficit Control Act of 1985.

11.

12. 11 OFFICE OF THE DIRECTOR

13. 12 For an additional amount for “Office of the Director”, \$30,000,000, to remain available until September 14. 13 30, 2024, to prevent, prepare for, and respond to 15. 14 coronavirus, domestically or internationally: *Provided*, 16. 15 That these funds shall be available for the Common Fund 17. 16 established under section 402A(c)(1) of the PHS Act: *Provided further*, That such amount is designated by the Congress as being for an emergency requirement pursuant to 18. 17 19. 18 20. 19 21. 20 22. 21

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 17:28:59 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Cc: Crawford, Chase (NIH/NIAID) [E]; Selgrade, Sara (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Dr. Fauci: Senate Draft COVID-19 Supp

Thanks. [REDACTED] (b) (5).

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Haskins, Melinda (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Sunday, March 22, 2020 1:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Crawford, Chase (NIH/NIAID) [E] [REDACTED] (b) (6)>; Selgrade, Sara (NIH/NIAID) [E]
[REDACTED] (b) (6)
Subject: Dr. Fauci: Senate Draft COVID-19 Supp

From: (b) (6)
Sent: Sun, 22 Mar 2020 10:58:06 -0400
To: Michela Carluccio
Subject: Re: telmisartan and covid-19

Ms. Carluccio:

Thank you for your note. (b) (6)

Best regards,
AS Fauci

On Mar 22, 2020, at 9:33 AM, Michela Carluccio
(b) (6) wrote:

Dear Professor Fauci,

sorry for the disturb.

My name is Michela, I contacted her from Italy
and I am (b) (6) years old.

I hope you understand my concern, I will
contact you for advice if possible:

(b) (6)

(b) (5)

Sincerely,

Ms. Michela Carluccio

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 05:29:11 +0000
To: guy@vidaldesigncollaborative.com
Subject: RE: ● Suggestion from former Israel Defense Forces member

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 21 Mar 2020 23:02:34 +0000
To: Redfield, Robert R. (CDC/OD)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: TF Agenda for tomorrow (Sunday)
Attachments: White House Coronavirus Task Force Agenda 3.22.20.docx

Bob:

See attached TF Agenda for tomorrow.

(b) (5)

(b) (5)

(b) (5). Many thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Sat, 21 Mar 2020 18:17:02 -0400
To: Auchincloss, Hugh (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]
Subject: Fwd: Positive COVID-19 test result for (b) (6)

Sent from my iPhone

Begin forwarded message:

From: "Holland, Steven (NIH/NIAID) [E]" <(b) (6)>
Date: March 21, 2020 at 4:40:28 PM EDT
To: "McGowan, Colleen (NIH/OD/ORS) [E]" <(b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>, "Lane, Cliff (NIH/NIAID) [E]" <(b) (6)>, "Harper, Jill (NIH/NIAID) [E]" <(b) (6)>, "McGowan, John J. (NIH/NIAID) [E]" <(b) (6)>
Cc: (b) (6)
Subject: Re: Positive COVID-19 test result for (b) (6)

Thanks, Colleen. (b) (6), to bring him into the loop. I am also (b) (6) into this for her knowledge.

Steve

--
Director, Division of Intramural Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960
(b) (6) voice
301-480-4507 fax
(b) (6) email

Assistant lab: Eva Portillo
(b) (6) email
(b) (6) voice

Assistant to SD: Beth Schmidt

(b) (6)

(b) (6) voice

From: "McGowan, Colleen (NIH/OD/ORS) [E]" <(b) (6)>
Date: Saturday, March 21, 2020 at 4:17 PM
To: Steven Holland (b) (6)>, Anthony Fauci
(b) (6) Henry Lane (b) (6)>, Jill Harper
(b) (6), John J McGowan (b) (6)>
Subject: Positive COVID-19 test result for (b) (6)

I'm writing to share that we have received a positive COVID-19 test result of an (b) (6)

(b) (6) These results just came out of the 2pm test run today. The (b) (6) supervisor is (b) (6). The person reported being symptomatic on 3/13/2020, contacted OMS on Monday, but didn't get scheduled for testing till Friday 3/20/20. I'm told (b) (6) continued to work (b) (6) even when feeling ill. I'm not permitted to share PHI, but I am told that OMS has notified the employee, and if they haven't done so already, OMS will contact the supervisor with general information regarding the person's general health status. They will not divulge a positive test result for COVID-19, but rather state a general health condition which precludes the staff member from working.

Since (b) (6) is working in (b) (6), I presume (b) (6) (b) (6), but please let me know if this isn't the case. ORF typically closes down the location for 7 days to allow environmental dissipation of contact surface contamination. I know this area is mission critical, so I will help you contact ORF about prioritizing cleaning procedures. We ask that you take great care in keeping that information as confidential as you can.

Thanks
Colleen

Colleen A. McGowan, MHA, FACHE
Director, NIH Office of Research Services
Bldg 31, Room 4B54
Office Phone: (b) (6)



From: (b) (6)
Sent: Sat, 21 Mar 2020 18:13:55 -0400
To: NIAID Public Inquiries
Subject: Fwd: Jafri_Research Volunteering

Sent from my iPhone

Begin forwarded message:

From: Riaz Jafri (b) (6) >
Date: March 21, 2020 at 5:34:20 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Jafri_Research Volunteering

Hi Dr. Fauci,

Hope you are doing well and thanks for your leadership during this pandemic situation.

I have a medical degree and has experience in basic and clinical research for almost 30 years. Currently in clinical trials, doing studies monitoring. I would like to volunteer during this COVID-19 situations. Please let me know if I can share in anyway.

I appreciate it.

Best regards and be safe..

Dr. Syed R. Jafri

Ph: (b) (6)

Sent from my iPhone

From: (b) (6)
Sent: Sat, 21 Mar 2020 18:13:34 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Fwd: Possible joint collaboration Polish -American Collaboration

Hoping one of you can handle. Taking this out of ASF inbox

If we need to discuss with him let me know.

Sent from my iPhone

Begin forwarded message:

From: Aleksandra Wesolowska (b) (6) >
Date: March 21, 2020 at 6:08:46 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Possible joint collaboration Polish -American Collaboration

Dear Dr Anthony Fauci ,

I am writing in connection to email from Prof Robert Schwartz about possible Polish - American collaboration in the clinical trial focus on treatment patients suffer from COVID-19

As a Polish Medical Research Agency we desire facing this pandemic with NIAID leading vaccine and therapy efforts against SARS-Cov-2.

F. Gray Handley has got in contact with the President of our Agency last week but from that time we have no further information in this pressing issue.

I will be very appreciated if we could discussed with you or your eminent staff any possibility for polish scientists to joint collaboration with NIAID to fight coronavirus for patients all of the world.

I will be personally responsible to hold this topic on behalf of Polish Medical Research Agency.

Thank you for your time and incredible efforts you made to global health and safety.

I remain at your disposal,

Aleksandra Wesółowska, PhD
Senior Research Coordinator



Agencja Badań Medycznych

ul. Moniuszki 1A

00-014 Warszawa

www.abm.gov.pl

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 21 Mar 2020 16:43:19 +0000
To: NIAID OD AM
Subject: FW: Virtual Town Hall with College Students (30+ Schools)?

From: John Monahan <John.Monahan@georgetown.edu>
Sent: Saturday, March 21, 2020 10:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Virtual Town Hall with College Students (30+ Schools)?

Tony --

First of all, thank you for all you are doing to lead our country's response during this crisis.

I hesitate to reach out to you with so much on your plate, but I think this idea might help with the national response.

In light of the continuing challenge of engaging young people in social distancing measures, combined with the fact that so many colleges and universities are now teaching online, Georgetown's Global Health Initiative and Institute for Politics and Public Service are considering a "virtual town hall" in which you could speak directly with students at colleges and universities via Zoom (or some other platform) about the collective challenge of COVID-19 and its risk to their health and to other members of their communities.

This could be a unique forum for you, as the most trusted person in the public dialogue, to make the case directly to young people about their vital role in social distancing to flatten the curve in their communities. We would use social media, of course, to push out key segments and messages from this event more broadly.

While Georgetown would organize this "virtual town hall", we would work closely with a network of more than 30 colleges and universities with which our Institute of Politics and Public Service regularly collaborates. We would also reach out to other schools to ensure a geographic reach and a mix of public and private institutions. Of course, our team would work closely with your staff to manage all logistics so as to use your scarce time as efficiently as possible.

Before we go any further in planning or thinking about this, I wanted to see if you would have time to participate or think this is a good idea.

Best!

John

John T. Monahan, JD

Senior Advisor to the President of Georgetown University
Senior Fellow, McCourt School of Public Policy
Senior Scholar, O'Neill Institute for National and Global Health Law
Georgetown University
3307 M Street NW, Suite 202
Washington, DC 20057
202-431-6556

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:48:05 -0400
To: KEN GLEN
Subject: Re: COVID-19

Thank you for your note.
AS Fauci

Sent from my iPhone

On Mar 21, 2020, at 7:43 AM, KEN GLEN (b) (6) wrote:

Good morning, from Vancouver, Canada.

We hope you are keeping yourself, and your families safe.

Your calm approach, and real life experience being shared during the daily briefings is what everyone looking towards the USA for information needs to see.

As in anything, real knowledge, both sharing and accepting is critical to get everyone focused on overcoming the current situation.

We don't see social distancing between everyone at the news conferences, and that is disappointing, we also don't see Donald Trump acquiring the skills and abilities to truly turn over communication and leadership to people such as yourself and your colleagues on the podium.

While that is also disappointing, it has come to be expected, therefore easy to tune out.

Our Global world needs a Global approach of honesty and transparency, we can't afford to get this one wrong due to our normal tribal tendencies.

Best regards, be safe,

Ken & Cathy Glen (b) (6)

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:44:54 -0400
To: Lerner, Andrea (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: Provider's question!

From Patty

Can one of u pls take this.

Sent from my iPhone

Begin forwarded message:

From: "Rostami, Nahid" <(b) (6)>
Date: March 20, 2020 at 7:25:06 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Cc: "Rostami, Nahid" <(b) (6)>
Subject: Provider's question!

Dear Dr. Fauci,

I am one of the UCSF neonatologist and I have been (b) (6)
I
am (b) (6) now. As you know, in neonatal intensive care unit at least
one parent stays at bedside. Considering the recent coronavirus
outbreak, I am (b) (6) for both potential patient (b) (6)
(b) (6) and staff exposures. I appreciate your advice and
recommendation for (b) (6) who is working
in an intensive care unit. Since I have to go to work, do I need to have
extra percussions besides hand washing? If so, what would you
recommend?

I appreciate your help.

Thanks,

Nahid Rostami

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:42:07 -0400
To: Parks, Donna (djholfmes@uidaho.edu)
Subject: Re: Thank you

Thank you for your note,
AS Fauci

Sent from my iPhone

> On Mar 20, 2020, at 8:49 PM, Parks, Donna (djholfmes@uidaho.edu) <djholfmes@uidaho.edu> wrote:

>

> Dear Dr.Fauci:

>

> I want to thank you and commend you for all you're doing during the COVID-19 pandemic. You are the voice of science and reason - and you seem to be able to get through to President Trump in a subtle way yet with a great deal of integrity. I don't envy you this gig - particularly with an administration that is so hostile to science, reason, and preparedness on the federal level.

>

> I'm still squirming from Trump's latest declarations that hydroxiquinolone could be used for COVID. The more you can explain why this might not be the place to put federal resources right now, the better. Friends of mine are buying it off label in Mexico now, and as a biologist and medical educator I find this alarming.

>

> Thanks. You're the best.

>

> Donna Holmes Parks | djholfmes@uidaho.edu

> WWAMI Medical Education Program

> University of Idaho and University of Washington

>

>

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:39:16 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Coronavirus interview

Sent from my iPhone

Begin forwarded message:

From: "Lindenberger, Isaac D." <lindenberger.9@buckeyemail.osu.edu>
Date: March 21, 2020 at 1:19:57 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: **Coronavirus interview**

Dr. Fauci,

I have Paul Offit coming on my podcast tomorrow to discuss coronavirus, and I would love to have you on after him to talk about your thoughts and what we should do. My friend Nikki Roy recommended you who I have also interviewed for my vaccine show "Straight To The Point." If you're interested we can do an interview at your earliest convenience. My listeners would benefit greatly from it, thank you for your consideration.

Get [Outlook for Android](#)

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:38:39 -0400
To: Friedmann, Theodore
Subject: Re: COVID-19 information for the public

Thank you for your note,
AS Fauci

Sent from my iPhone

> On Mar 21, 2020, at 2:01 AM, Friedmann, Theodore <tfriedmann@health.ucsd.edu> wrote:

>

> Dear Tony: I'm sure that you realize how dismayed and saddened many of us are at the inaccurate and harmful comments coming from our political leaders regarding the COVID-19 pandemic. That feeling hit a new height today with the irresponsible and nonsensical announcement from President Trump regarding his claimed effectiveness of chloroquine and hydroxychloroquine. This announcement and many other untruths were delusional, irrational, unscientific and revealed a profoundly harmful and unethical betrayal by President Trump his responsibility to protect the health of the public that puts the republic in severe danger. I was very glad to hear your public comments that countered this horribly dangerous misinformation. I hope that your message falls on receptive ears in the public and leads to a major change in the kind of public announcements that are currently being foisted on the desperate public who depend on knowing and acting based on the truth. Please continue and even expand your role as the truth teller in the who crowded collection of muzzled officials and sycophants who seem to be more devoted to deceiving the public rather than preparing the public for hard truths and solving the logistics failures of masks, availability of testing kits. Please continue your brave and essential role as honest broker that you play valiantly privately during your policy discussions that the public also deserves to know about the wrong and unethical self-serving propaganda that the public is fed by President Trump and some other members of the Corona Virus task force. It is a deadly governmental game. I wish you good luck in alerting the public to this immoral, unethical and deadly plague of governmental misinformation designed to shape political quandaries rather than public welfare. Please continue speaking out about public misinformation.

>

> Ted Friedmann, MD

>

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:38:11 -0400
To: DMID Word Nerds
Subject: Fwd: hypertensive drug - ACE2- inhibitor related and our work
Attachments: A Combinatorial Antihypertensive Drug (Reserpine and Hydrazine) Does Not Cause Severe Depression.pdf, ATT00001.htm, medrxivcognitionandadelphanel.pdf, ATT00002.htm

Sent from my iPhone

Begin forwarded message:

From: "Dr. Jamuna R Subramaniam" <jamuna17@sriramachandra.edu.in>
Date: March 21, 2020 at 2:04:14 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6), jamuna subramaniam (b) (6)>
Subject: hypertensive drug - ACE2- inhibitor related and our work

Dear Prof. Anthony Fauci,

Good Morning!

I am Dr. Jamuna R. Subramaniam. I did my Ph.D from Georgetown University and postdoc in Johns Hopkins on neurodegenerative diseases. After returning to India I started working on biogenic amine neurotransmitters. One of the major trajectory of my research career was on an FDA approved, antihypertensive drug. Given the current scenario of ACE2 being the receptor for Covid-19, and the widely used antihypertensive drugs also target the same. I thought of sensitizing you on a very effective antihypertensive drug, adelphane and adelphane esidrex made and sold by Novartis This contains a historical VMAT - biogenic amines loading in synaptic vesicles, molecule, reserpine. Here, in India, a well known Nephrologist, has used this to treat a community of close to 3000 patients for almost two decades. From him and others I have heard that it is a very effective, well tolerated antihypertensive. Reserpine is a historical molecule that it had been used in the Indian system of medicine, Ayurveda. But adelphane has the single specific purified molecule, reserpine, an alkaloid. Now Novartis has stopped making it. One of the reasons being given is reserpine's negative publicity when it was used an antipsychotic drug. The reason given was a side effect of severe depression. We did a study on these patients on adelphane and find that it had not caused depression. Further, it seems to be retaining cognition in these patients. I could not publish these in big journals as you can understand. I am enclosing these two papers.

As many lives are at stake, I thought I will sensitize you on this. Hope something good will come out of this. I am telling whomever I come across about the same. That is the best I can do. Hope the current scenario will show the living daylight for reserpine and helps the humanity.

Thank you

With regards
Jamuna

--

Dr. Jamuna R. Subramaniam
Associate Professor
Center for Preclinical and Translational Medicine Research
Central Research Facility
Sri Ramachandra Institute of Higher Education and Research
Porur, Chennai 600 116, India
Extn:8170 ; Tel: 91-44-45928500;
Cell: (b) (6)
www.sriramachandra.edu.in

Academic Editor, PLoS One, Public Library of Science, San Francisco, USA

Website:

Pubmed: <https://www.ncbi.nlm.nih.gov/pubmed/?term=Subramaniam+JR>

Research Gate: https://www.researchgate.net/profile/Jamuna_Subramaniam

Google Scholar:

<https://scholar.google.co.in/citations?user=T4Z2VMAAAAAJ&hl=en>

Quote: "I remain an Optimist. Not that I can give any evidence that right is going to prosper, but because of my unflinching faith that right should prosper in the end" - Mahatma Gandhi

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:37:38 -0400
To: Mr Chiogna
Subject: Re: The Virucidal Efficacy of Blue light (222 nm) UV light with Respect to CoronaVirus

Thank you for your note.
AS Fauci

Sent from my iPhone

On Mar 21, 2020, at 2:46 AM, Mr Chiogna <jchiogna@holycross.bc.ca>wrote:

Dear Dr. Fauci,

My name is John Chiogna. I work as a Physics teacher in Vancouver British Columbia. Attached below is a short write up on a possible inexpensive means of quickly sanitizing private and public locations such as care facilities, hospitals, schools, churches, government workplaces, arenas, etc.

I'm sure that the efficacy of 222 nm light has been considered by some already. However, I have included some numbers that take into account human safety limits, as well as references to peer-reviewed journals that support my claims. It is my hope that this may make this simple idea more plausible.

Please consider the merits of such an idea and implement it as you wish, thank you.

Yours sincerely,
John Chiogna

 [What is the Virucidal Efficacy of Blue light \(2...](#)

*This e-mail is intended only for the individual named above.
Any distribution, use or copying of this e-mail or the information
it contains by other than an intended recipient is unauthorized.
If you have received this e-mail in error, please delete immediately.*

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:35:58 -0400
To: DMID Word Nerds
Subject: Fwd: Note from a NIH "alumnus" re. SARS-CoV-2

Sent from my iPhone

Begin forwarded message:

From: Robert Wiskocil (b) (6) >
Date: March 21, 2020 at 4:30:43 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: Note from a NIH "alumnus" re. SARS-CoV-2

Dear Dr. Fauci,

I used to work in Bob Goldberg's division at the NCI (Bldg 37) from '78-'80. I'm now a rheumatologist in the SF Bay Area.

I'm including a Letter to the Editor (submitted 3.19.20) for the NEJM that proposes a cost-effective therapy for COVID-19. (I've included a slightly longer version with more references):

N-acetyl cysteine for Coronavirus
Robert Wiskocil, MD

Affiliation: Private Practice Rheumatology

Date: March 19, 2020

Telephone Number: (b) (6)

Email: (b) (6)

Abbreviations: N-acetyl cysteine (NAC), porcine epidemic diarrhea virus (PEDV)

In a recent letter to Cell Research, Remdesivir and chloroquine were found to inhibit the SARS CoV-2 (COVID-19) virus activity and replication in Vero cells (1). That study was the basis for current clinical trials involving those medicines.

There might be a more cost-effective treatment for the Coronavirus. I believe it will be sensitive to oral high dose N-acetyl Cysteine

A final common pathway to host destruction (autophagy) in infected cells in both Corona and Rota viral infections involves the PI3K/AKT/mTOR pathway (2,3). This pathway is inhibited by "rapalogues" (like Rapamycin) where the

viral infection is stopped and the host cell survives. N-acetyl-cysteine, a potent anti-oxidant and glutathione precursor, alters the redox state of treated cells and can quench this same pathway (4,5). NAC (N-acetyl cysteine) has been used to rapidly clear Rotavirus diarrheal infections in children (6). Furthermore, the porcine epidemic diarrhea virus (PEDV) coronavirus has been studied in Vero cells. *In vitro*, NAC blocks that particular virus (7), and *in vivo*, NAC blocks intestinal damage caused by this virus (8). NAC likely provides a "redox clamp" on the autophagy pathway this virus exploits.

Since the PEDV coronavirus is effectively blocked in Vero cells by NAC, the SARS-CoV-2 (COVID-19) will likely also be inhibited. This test should be done, and if positive, clinical trials ought to follow.

Doses of 2.4-3.5 g/d of NAC have been used to treat patients with Lupus (4). That dose is well tolerated and inexpensive.

If NAC were effective in symptomatic patients, it could add a cost-effective measure of protection to healthcare workers and exposed individuals.

References:

- 1) Wang, M., Cao, R., Zhang, L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. **Cell Res**
- Y Yin et. al. PI3K-AKT-mTOR axis sustains rotavirus infection via the 4E-BP1 mediated autophagy pathway and represents an antiviral target. **Virulence**, 2018 VOL. 9, NO. 1, 83–98
- 3) J Kindrachuk et. al, Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis **Antimicrobial Agents and Chemotherapy** February 2015 Volume 59 Number 2 p 1088-1099
- 4) Zhi-Wei Lai, et al, N-Acetylcysteine reduces disease activity by blocking mTOR in T cells of Lupus patients, **Arthritis Rheum.** 2012 September; 64(9): 2937–2946
- 5) C. C. Xu, S. F. Yang, L. H. Zhu, X. Cai, Y. S. Sheng, S. W. Zhu, J. X. Xu, Regulation of N-acetyl cysteine on gut redox status and major microbiota in weaned piglets, **Journal of Animal Science**, Volume 92, Issue 4, April 2014, Pages 1504–1511, <https://doi.org/10.2527/jas.2013-6755>

6) C Guerrero et al. N-Acetylcysteine Treatment of Rotavirus-Associated Diarrhea in Children **Pharmacotherapy**

7) Xu X, Xu Y, Zhang Q, et al. Porcine epidemic diarrhea virus infections induce apoptosis in Vero cells via a reactive oxygen species (ROS)/p53, but not p38 MAPK and SAPK/JNK signaling pathways. **Vet Microbiol.** 2019;232:1–12.

8) Wang L, Zhou J, Hou Y, et al. N-Acetylcysteine supplementation alleviates intestinal injury in piglets infected by porcine epidemic diarrhea virus. **Amino Acids.** 2017;49(12):1931–1943.

I hope you find this helpful!

Sincerely,

(b) (6)

Robert Wiskocil, MD

(b) (6)

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:19:19 -0400
To: PITTMAN, RYAN D
Subject: Re: Preparing for COVID-19 in my Neighborhood

Sent from my iPhone

On Mar 21, 2020, at 12:10 AM, PITTMAN, RYAN D
<rpittman@email.sc.edu> wrote:

Good Evening Dr. Fauci,
My name is Ryan Pittman. I live in (b) (6) South Carolina, right outside of (b) (6).
The virus is here. Seeing as this is likely to get worse before it gets better, I want to
be prepared to help people in my neighborhood when they start developing
symptoms and the hospitals are not ready for them.
How do you recommend I go about doing this. I am prepared to acquire a modest
stockpile of supplies to give to those suffering through this, but I am not entirely
sure what would be best. The hope is to take your information and pass it on to
those in other neighborhoods in the area, so we can come together and help as
many people as we can get through this pandemic.
Thank you for your time.
Ryan Pittman, MS
University of South Carolina Department of Statistics

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 21 Mar 2020 02:19:38 +0000
To: Priscilla Kelly
Subject: RE: Thank you from Science

Priscilla:

Thank you for your kind note.
Best regards,
Tony

From: Priscilla Kelly <pkelly@aaas.org>
Sent: Friday, March 20, 2020 9:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Thank you from Science

Dear Tony,

I wanted to send our sincerest thanks from everyone at *Science*, for the superb leadership that you are showing the United States (and the world) during this pandemic. Thank you also for educating the public that the most productive countermeasures will be based on data-driven science. We will continue to do our part here at *Science* to publish the strongest COVID-19 studies to help advance research as rapidly as possible.

All the best,

Priscilla

Priscilla N. Kelly, Ph.D

Biomedicine Editor, *Science*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 22:45:24 +0000
To: Stephen Hahn; Redfield, Robert R. (CDC/OD); Birx, Deborah L.
EOP/NSC: (b) (6)
Subject: Treatment Document
Attachments: dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked changes showing.docx, dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked Clean copy.docx

Team:

As per my discussion with Steve a few minutes ago, I have made some changes in the document. (b) (5)

(b) (5)

(b) (5) I am attaching a tracked version of the document that was your FINAL as well as a clean copy with all of the changes accepted. Please take a look and Steve said that he would like to set up a quick call to discuss after you have had a look. I am very sorry to come in with these changes at this late point, but I really did not get a chance to have a good look at the document as I was in a car.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 21:08:04 +0000
To: (b) (6)
Subject: therapy
Attachments: dbInformation for Clinicians on COVID-19 Therapies3.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 11:52:45 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Modeling of COVID-19 from Mike Levit

It would be a good idea to get a feel for what our modelling people think about this.
Thanks,
Tony

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Sent: Thursday, March 19, 2020 3:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: FW: Modeling of COVID-19 from Mike Levit

Dr. Fauci,

Just re-upping this as your inbox is hopefully less stuffed now. See original email at the bottom from Larry Tabak letting you know about this modeling work.

My summary is below and if you'd like me to ask some NIAID modeling SMEs what they think, let me know.

Andrea

.....
Dr. Fauci—

I took a look at this and here is my impression:



I would defer to our modeling experts at NIAID as to the validity of his model—let me know if you'd like me to reach out to them. (b) (5).
CC'ing Hilary if she has additional thoughts.

Sincerely,

Andrea

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Date: Monday, March 16, 2020 at 10:59 PM
To: "Lerner, Andrea (NIH/NIAID) [E]" (b) (6)>
Subject: FW: Modeling of COVID-19 from Mike Levit

Please take a look and see what you think.

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Friday, March 6, 2020 8:46 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Lauer, Michael (NIH/OD) [E] (b) (6)>
Subject: Modeling of COVID-19 from Mike Levit

Francis, Tony –

Mike Levitt (Nobel prize in Chemistry, 2013) sent the attached modeling of the COVID-19 epidemic to Mike Lauer. I don't know if this will prove useful but wanted to pass it along in case.

He indicated that he was amazed to see how an Excel level analysis could allow him to predict the China epidemic would end as early as 2-Feb and get what he considers the best estimates for case fatality ratio. His first report from 2-Feb is attached as well as his most recent two-part report.

Larry

From: [REDACTED] (b) (6)
Sent: Fri, 20 Mar 2020 06:56:52 -0400
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: Fwd: COVID-19 multidisciplinary FAQ article
Attachments: COVID Question_v2.docx, ATT00001.htm

Begin forwarded message:

From: Andreas Kronbichler [REDACTED] (b) (6)
Date: March 20, 2020 at 3:50:20 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6); [REDACTED] (b) (6)
Subject: COVID-19 multidisciplinary FAQ article

Dear Prof. Fauci,

May I briefly introduce myself: My name is Andreas Kronbichler, I am nephrologist based in Austria, and do have an interest in renal autoimmune disease. As such, I know your landmark study about cyclophosphamide use in GPA published in 1971; and I have learned that you were involved in the management of David Fajgenbaum MCD, whose story is so impressive.

I am contacting you and asking you for your help regarding a multidisciplinary FAQ article we would like to write and which does make sense in our eyes, given the rapid spread of this devastating infectious disease.

We would like to invite experts in the field to comment on a selected topic and then summarize this as a paper with hopefully high impact in the field.

If you agree, can you answer this question (around 400 words max.):

Can you describe the pathophysiology and some of the immunological aspects of SARS-CoV-2 infection and COVID-19 disease?

I would be personally very honored to work together with you. A selection of topics is attached to this e-mail.

With best regards,

Andreas Kronbichler M.D. Ph.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 10:42:16 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Folkers, Greg (NIH/NIAID) [E]; Myles, Renate (NIH/OD) [E]
Subject: RE: COVID-19 science brainstorm at NIH, and town meeting

Thanks, Francis.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Friday, March 20, 2020 5:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Myles, Renate (NIH/OD) [E] (b) (6)
Subject: RE: COVID-19 science brainstorm at NIH, and town meeting

Thanks, Tony. The town meeting runs from 1 to 2. If your press conference runs late, I'd be glad to have you call in at any other time during that hour – we would squeeze you in!

Francis

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Thursday, March 19, 2020 10:54 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)
Subject: RE: COVID-19 science brainstorm at NIH, and town meeting

Francis:

I was just told by the VP's office that I will have to be at the press conference between 11:00 and 12:30 PM. And so I definitely cannot be at NIH physically at 1:00 PM and if the press conference starts and finishes late, I may not even be able telephone in. My guess is that it will end before 1:00 PM and so I will likely be able to phone in. Let us see how tomorrow unfolds. Regarding the session of IC Directors, this would be fine with me.

Best,
Tony

Patty:

Please let us discuss the phone in logistics if I cannot physically get there.
Thanks,,
Tony

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Thursday, March 19, 2020 9:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Subject: COVID-19 science brainstorm at NIH, and town meeting

Hi Tony,

Nice Facebook session with Zuck! And I heard you were just on CNN, but I missed that one. I did an interview with Sheila Kaplan late this afternoon – and she greatly appreciated your message of apology. I don't think (b) (5).

When we spoke yesterday, you were enthusiastic about the convening of a 2 – 3 hour session of IC Directors and SMEs from their ICs, to brainstorm about additional scientific efforts that could be mounted at NIH to address COVID-19. It looks as if this can be arranged for an early afternoon next week. Obviously there would be nothing better than to have you there in person for this. While I know your schedule is not exactly under your control, is there any 2 – 3 hour period next week that might have a chance of being open for you? If not, who would you want to be the presenter of the current portfolio of NIAID investments? (b) (5)

We have the NIH virtual Town Meeting at 1 PM tomorrow. Is there any chance you can come to Wilson Hall in person for that? If not, is there a chance you can call in? I will serve as moderator, and after a few minutes of opening remarks, would hope to turn this over to you for ten minutes or so of the unique Fauci perspective. After that, Larry and Alfred will talk for a few minutes about the NIH COVID Response Team, and Jim Gilman will talk about what's happening at the CC. Then we'll open it up to questions, which we can accept in real time from the estimated 20,000 staff who will be logged in. But you wouldn't need to stay for all that – if we could somehow have your participation (either in person or on the phone) from about 1:10 to 1:20, that would be really wonderful. Please let me know if that will be possible.

Sorry about the long e-mail. Get some sleep!

Best, Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 03:01:09 +0000
To: Besser, Richard
Subject: RE: Checking in

Rich:

Thanks for the note. Much appreciated. I hope that all is well with you.
Best regards,
Tony

From: Besser, Richard <rbesser@rwjf.org>
Sent: Thursday, March 19, 2020 3:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Checking in

Hi Tony:

I hope you are well. I want to applaud you and thank you for your incredible leadership in communicating about this pandemic. I wish CDC were standing with you but I know that is not likely to happen. I hope that you will continue to talk about all that is being done to learn what works to mitigate the impact of the pandemic. Your absence these two days has been quite noticeable. If there is anything I can do to support you, please let me know.

Best regards,

Rich

Richard E. Besser, MD, President and CEO
Office [REDACTED] (b) (6) rbesser@rwjf.org
Connect with me on [Twitter](#) | [LinkedIn](#) | [Facebook](#)

Robert Wood Johnson Foundation
Building a Culture of Health in America. Learn more at rwjf.org.
Follow the Foundation [Twitter](#) | [Facebook](#) | [YouTube](#)

***Please note:** In light of the requests made for increased social distancing related to the coronavirus (COVID-19), we have closed all three RWJF campuses in Princeton, New York City, and Washington until further notice. All RWJF employees are now working remotely, and all in-person meetings are either cancelled or will be conducted virtually. For the most up-to-date information regarding COVID-19 please see resources on [CDC](#), [NIH](#) as well as your state health department websites.*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 02:39:21 +0000
To: Jonathan E. Shoag
Cc: Elemento, Olivier
Subject: RE: Specimens

Would be much more useful [REDACTED] (b) (5)

From: Jonathan E. Shoag [REDACTED] (b) (6)
Sent: Thursday, March 19, 2020 9:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Elemento, Olivier [REDACTED] (b) (6)
Subject: FW: Specimens

Hi Dr. Fauci,

[REDACTED] (b) (5)

All the best,

Jonathan Shoag MD

From: [Denny, Joshua \(NIH/OD\) \[E\]](#)
Sent: Monday, March 16, 2020 6:17 PM
To: [Jonathan E. Shoag](#)
Cc: [Olson, Janet E., Ph.D.](#); [Cicek, Mine](#); [Olivier Elemento](#); [Thibodeau, Steve](#); [Gebo, Kelly \(NIH/OD\) \[G\]](#)
Subject: [EXTERNAL] Re: Specimens

Jonathan -

Thanks for the thoughts and the offer to help. This is indeed something we have discussed [REDACTED] (b) (5)

[REDACTED] I'm copying our chief medical & science officer, Kelly Gebo.

Best,
Josh

On Mar 16, 2020, at 2:16 PM, Jonathan E. Shoag [REDACTED] (b) (6) wrote:

Hi Dr. Denny,

(b) (5)

All the best,

Jonathan Shoag MD

On Mar 16, 2020, at 12:47 PM, Thibodeau, Stephen N., Ph.D.

(b) (6) wrote:

Dear Jonathan

I am one of the Co-PI's of the Biobank for the All of Us Research Program.

Although samples are store here at Mayo,

(b) (5)

(b) (5)

Sorry, the situation is evolving quite rapidly, so no additional information at this point.

Hope this helps.

Steve

From: Jonathan E. Shoag (b) (6)]

Sent: Monday, March 16, 2020 3:35 AM

To: Biobank

Subject: [EXTERNAL] Specimens

To Whom it May Concern,

I imagine someone has thought of this already- but do you know

if

(b) (5)

(b) (5)

I study prostate cancer epidemiology at Weill Cornell, and in discussing this idea with the head of our precision medicine initiative, was informed that the AllofUs specimens reside at Mayo.

All the best,

Jonathan Shoag MD

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 22:16:02 +0000
To: (b) (6)
Subject: RE: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

(b) (6)

All of the therapy stuff is anecdotal. We are trying to get randomized clinical trials done instead of just compassionate use for all of these unproven drugs. (b) (6)

Best regards,
Tony

From: (b) (6) >
Sent: Thursday, March 19, 2020 4:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

Fascinating - thanks for sharing with me. The question that I have is whether COVID 19 adheres and infects epithelial cells through the same mechanism as SARS did. Why the increased lethality and how to we decrease likelihood of infection?

Just saw today that antiretroviral therapy and malaria agents are being touted as potential therapies - how well founded is this - anything more than anecdotal data to support this?

Hope you are getting a few moments of rest. (b) (6) and do not hesitate to call me if I can help.

Best,
Ken

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, March 18, 2020 7:09 PM
To: (b) (6) >
Cc: Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: [EXTERNAL] FW: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

**** ATTENTION: This email originated from outside the MedStar network.**

**** DO NOT CLICK links or attachments unless you recognize the sender and know the content is safe.**

The situation gets confusing. See attached brief commentary and e-mail string. As you can see, I was too tired to make any sense of it. However, my deputy (Cliff Lane) notes that this

paper argues the opposite, i.e. that ACE inhibitors might have a benefit and counters the argument to stop ACE inhibitor.s Bottom line is that we really do not know what the effect will be clinically with respect to COVID-19. In any event, (b) (6)

Best,

Tony

From: Lane, Cliff (NIH/NIAID) [E] <(b) (6)>
Sent: Wednesday, March 18, 2020 5:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

A 2005 paper post-SARS advocating for use of ACE inhibitors to increase ACE2. The opposing argument to stopping ACE inhibitors.

From: Anthony Fauci (b) (6)
Date: Wednesday, March 18, 2020 at 5:22 PM
To: "Lane, Cliff (NIH/NIAID) [E]" <(b) (6)>
Subject: FW: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

I cannot make heads or tails of this. Please take a look and let me know what you think. Thankjs.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ste McCon (b) (6)
Sent: Wednesday, March 18, 2020 5:09 PM
Subject: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

"Clearly, the potential therapeutic utility of recombinant **ACE2 and angiotensin II receptor-inhibitors. [ARB's ?]**—**already in clinical use for control of blood pressure**—for acute lung injury resulting from viruses and other causes will be a productive field for investigation. This is particularly relevant as we prepare to **confront a potential avian flu pandemic, [COVID-19 ?]** armed with only a limited number of therapeutic options."

Regards,

Stephen D. McConnell, BS, MSc-CCP, CIS

Lipidemiologist - Clinical Application Specialist

Medicare-CMS ACO/MSSP/Direct-Contracting Consultant

Medical Science Liaison

Mobile: (b) (6)

(b) (6)

Sent from my iPhone

MedStar Health is a not-for-profit, integrated healthcare delivery system, the largest in Maryland and the Washington, D.C., region. Nationally recognized for clinical quality in heart, orthopaedics, cancer and GI.

IMPORTANT: This e-mail (including any attachments) may contain information that is private, confidential, or protected by attorney-client or other privilege. If you received this e-mail in error, please delete it from your system without copying it and notify sender by reply e-mail so that our records can be corrected... Thank you.

Help conserve valuable resources - only print this email if necessary.

From: (b) (6)
Sent: Thu, 19 Mar 2020 08:30:51 -0400
To: Holland, Steven (NIH/NIAID) [E]
Subject: Re: Link to Wash post article re: Kim Hasenkrug

He is a good guy, but this is the second time for him

On Mar 19, 2020, at 8:20 AM, Holland, Steven (NIH/NIAID) [E]

(b) (6)

https://www.washingtonpost.com/health/trump-ban-on-fetal-tissue-research-blocks-coronavirus-treatment-effort/2020/03/18/ddd9f754-685c-11ea-abef-020f086a3fab_story.html

Just making you aware of the WP article this morning. This was a surprise to us and I have to believe that Kim was unaware of its preparation or release.

Steve

Director, Division of Intramural Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960

(b) (6) voice

301-480-4507 fax

(b) (6) email

Assistant lab: Eva Portillo

(b) (6) email

(b) (6) voice

Assistant to SD: Beth Schmidt

(b) (6)

(b) (6) voice

From: Karyl Barron (b) (6) >
Date: Thursday, March 19, 2020 at 7:35 AM
To: Amy Agrawal (b) (6)
Subject: Link to Wash post article re: Kim Hasenkrug

https://www.washingtonpost.com/health/trump-ban-on-fetal-tissue-research-blocks-coronavirus-treatment-effort/2020/03/18/ddd9f754-685c-11ea-abef-020f086a3fab_story.html

From: (b) (6)
Sent: Thu, 19 Mar 2020 08:29:22 -0400
To: Verma, Seema (FDA/CDER) (CTR)
Subject: Fwd: Long term care facilities

See below. As per your prior discussion

Begin forwarded message:

From: Dorothy Franklin (b) (6)
Date: March 19, 2020 at 8:22:24 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Long term care facilities

Based on studies at Kirkland care facility indicating staff were spreading the coronavirus to multiple facilities sharing staff, is there or will there be guidance to require these facilities to retain a dedicated staff only?

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:33:41 +0000
To: Redfield, Robert R. (CDC/OD); Stephen Hahn; Birx, Deborah L. EOP/NSC
Cc: (b) (6); Troye, Olivia EOP/NSC; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Hicks, Hope C. EOP/WHO; kellyanne conway
Subject: FW: NEJM: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 <http://bit.ly/2x9Uj0>

As per my prior e-mail. The medical people likely are aware of this. It just came out tonight.

(b) (7)

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, March 18, 2020 10:14 PM
Subject: NEJM: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
<http://bit.ly/2x9Uj0>

Access provided by NIH Library

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

List of authors.

- Bin Cao, M.D., et al.

Abstract

Background

No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.

Methods

We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (SaO_2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (PaO_2) to the fraction of inspired oxygen (FiO_2) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir–ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first.

Results

A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir–ritonavir group, and 100 to the standard-care group. Treatment with lopinavir–ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.24; 95% confidence interval [CI], 0.90 to 1.72).

Mortality at 28 days was similar in the lopinavir–ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, –5.8 percentage points; 95% CI, –17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir–ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir–ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir–ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events.

Conclusions

In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308. [opens in new tab.](#))




Figure 2. Time to Clinical Improvement in the Intention-to-Treat Population.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:20:05 +0000
To: sheila.kaplan@nytimes.com
Cc: Collins, Francis (NIH/OD) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Coronavirus interview with Dr. Collins

Sheila:

I do not recall getting a request from you. I am completely swamped and so it may have just gotten buried in a pile and I did not see it. I apologize. I am mostly locked into the White House where we must give up our phones and so it makes it very difficult for me to return calls. I talk to Francis all the time and he is very well versed in these issues. He will do a fine job of providing you with the information you need. If you would still like to speak with me later on, we can try to make that work. Again, I am sorry if you felt snubbed.

Best regards,
Tony

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>
Sent: Wednesday, March 18, 2020 4:10:58 PM
To: Myles, Renate (NIH/OD) [E] (b) (6)
Cc: Burklow, John (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6)
Subject: Re: Coronavirus interview with Dr. Collins

Hi Renate,
Thank you.... We appreciate it. SK

On Wed, Mar 18, 2020 at 3:56 PM Myles, Renate (NIH/OD) [E] <(b) (6)> wrote:

Hi Sheila:

The questions you shared with Amanda were really for Dr. Fauci; he's our spokesperson on all research specific questions. I know he's really backed up and NIAID is doing the best they can with his incredibly packed schedule. The interview with the Atlantic was really intended as a profile, but ended up covering a lot of COVID questions. We can check in with NIAID to see what we can do.

Thanks,

Renate

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>

Sent: Wednesday, March 18, 2020 3:27 PM

To: Myles, Renate (NIH/OD) [E] (b) (6)>; Burklow, John (NIH/OD) [E] (b) (6)>; Fine, Amanda (NIH/OD) [E] <(b) (6)>

Subject: Re: Coronavirus interview with Dr. Collins

Hi there,

Why were we told we could not do an interview, when, after our request, he did one with The Atlantic. You referred us to Dr. Fauci but he isn't talking, either. This doesn't seem fair to us. Can we really not speak to either of them for a story this weekend?

Thanks, SK

On Sun, Mar 15, 2020 at 4:00 PM Kaplan, Sheila <sheila.kaplan@nytimes.com> wrote:

Dear Renate, John and Amanda:

Sheri Fink and I would like to interview Dr. Collins as soon as possible for a story on coronavirus.

Can you please let me know when he might be available.

Thank you,

Sheila

—

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: (b) (6)

—

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 852-0312

Cell: [REDACTED] (b) (6)

—
Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:13:35 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Coronavirus interview with Dr. Collins

Francis:

Go for it. We need all the help we can get. I do not remember getting a request from Sheila. I will write and apologize.

Best,

Tony

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Wednesday, March 18, 2020 9:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Myles, Renate (NIH/OD) [E] (b) (6) >; Burklow, John (NIH/OD) [E] (b) (6)
Subject: FW: Coronavirus interview with Dr. Collins

Hi Tony,

I could use your guidance on press interviews. I understand that only Task Force members are supposed to do television events – and I declined the NewsHour tonight to be consistent with that. But what is your preference for printed press pieces, when you can't do them all? Would it help the cause for me to accept some of those, or is it better to hold off? If I were to engage, I would certainly seek to provide answers that are 100% with what you are doing.

An example is the thread from Sheila Kaplan of the New York Times. I have declined so far – but is this the kind of query that you would like some help with?

Francis

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>
Sent: Wednesday, March 18, 2020 4:10:58 PM
To: Myles, Renate (NIH/OD) [E] (b) (6)
Cc: Burklow, John (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6)
Subject: Re: Coronavirus interview with Dr. Collins

Hi Renate,

Thank you.... We appreciate it. SK

On Wed, Mar 18, 2020 at 3:56 PM Myles, Renate (NIH/OD) [E] (b) (6) > wrote:

Hi Sheila:

The questions you shared with Amanda were really for Dr. Fauci; he's our spokesperson on all research specific questions. I know he's really backed up and NIAID is doing the best they can with his incredibly packed schedule. The interview with the Atlantic was really intended as a profile, but ended up covering a lot of COVID questions. We can check in with NIAID to see what we can do.

Thanks,

Renate

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>
Sent: Wednesday, March 18, 2020 3:27 PM
To: Myles, Renate (NIH/OD) [E] (b) (6)>; Burklow, John (NIH/OD) [E] (b) (6)>; Fine, Amanda (NIH/OD) [E] (b) (6)>
Subject: Re: Coronavirus interview with Dr. Collins

Hi there,

Why were we told we could not do an interview, when, after our request, he did one with The Atlantic. You referred us to Dr. Fauci but he isn't talking, either. This doesn't seem fair to us. Can we really not speak to either of them for a story this weekend?

Thanks, SK

On Sun, Mar 15, 2020 at 4:00 PM Kaplan, Sheila <sheila.kaplan@nytimes.com> wrote:

Dear Renate, John and Amanda:

Sheri Fink and I would like to interview Dr. Collins as soon as possible for a story on coronavirus.

Can you please let me know when he might be available.

Thank you,

Sheila

--

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: (b) (6)

—

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: (b) (6)

—

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:12:30 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: typo, etc. fixed, (b) (6)

Too long for me to read

From: Erik Nilsen <enilsen@bio-signal.com>
Sent: Wednesday, March 18, 2020 10:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: typo, etc. fixed, (b) (6)

Hi Dr. Fauci,

I'm now back in my office. I typed the original message on phone. I just noticed a bunch of typos. Below is a better version.

Regards,

Erik

Dear Dr. Fauci,

You're beyond busy but I hope you read this message.

(b) (4)
I'm only mentioning this so you don't think I'm a paranoid freak. I'm convinced you already know the outbreak is way past the point of containment, and, unfortunately, herd immunity will soon ensue. Then, outbreak 2 will happen shortly after, and, hopefully, not ad infinitum.

I'm writing to make sure you already know or at least suspect everything I'm about to tell you. I need to clear my conscience

because it's possible (albeit unlikely) that some of what tell you is new and possibly useful in, at least, saving lives in the USA.

I'm a physicist and have been modeling this outbreak since January. My panic started minutes after I learned ~5M people left Wuhan around January 22 a few days before the CCP starting locking the country down. The 5M people scattered to 13,000+ cities in China to visit family & friends for the Lunar Festival (Chinese New Year). I've been communicating with quite a few people around the world including an NYU epidemiologist (b) (6). We've both been warning our families, to mostly deaf ears at first, since January. It's been frustrating and exhausting, but, finally, most are as prepared as possible for what's about to happen.

I have lots of information about China due to my business, scientific, friendship, and other ties with many there, including immunologists & virologists at top-tier institutions and laboratories. My WeChat account (like Skype / Whatapp) was blocked by the CCP for 3 days late February / early March, but, after a warning message, it is now unblocked. I'm willing to share with you everything I know, think I know, or seriously suspect.

Here are a few examples:

I'm confident that China stop counting dead COVID-19 infected bodies since ~January 7, 2020. They've been adding fabricated data daily to show (to save face) the world and their own people an impressive flattening of China outbreak curve. It's easy to prove this via data analysis because, for example, improbable coincidences occurred in much of the data. My suspicions were eventually confirmed by at least two of my sources in China ((b) (6)). The data posted by China is not only garbage, it has misled the world into a false sense of security wrt death rate, age vs death, and other things; that is, if people analyzed the world's data including China, the

results are heavily biased towards nonsense, because China's number of cases accounted for the majority of cases worldwide (until a day or so ago).

I want to emphasize that I do not believe China intentionally did this to harm the world. I sincerely believe it was done for saving-face reasons. Saving face is possibly the most powerful motivating force in China. It is the key to understanding how most Chinese think and why they do what they do. China wanted the world to believe that their Herculean quarantining efforts contained the outbreak. However, I don't think this is true, even after spraying ~billions of gallons of "Clorox" all the country. The number of body bags my contacts told me about, even after short 15-minute walks to/from grocery stores in one city during CCP-authorized time slots, suggest the number of deaths is several orders of magnitude larger than what China's posted data indicates. Also, everyone I know in China continues to be in lock down (~6+ weeks now), and several went "silent" since about a week ago. This greatly troubles me because those who went silent live in Wuhan. And, yesterday, the CCP revoked permits/licenses for several foreign reporters who were trying to learn about the situation in Wuhan and other parts of China. Several of my sources have told me, in coded language, that the situation in at least Wuhan is not under control at all. In my opinion, China continues to be extremely concerned about saving face (first) and their economy (second). Their economy is already suffering terribly, and they can't afford to lose the many large manufacturing and other business agreements with foreign countries. This is why I believe they're trying, and succeeding to convince many, to convince most of their population that the outbreak is under control, and it will soon be ok to return to work -- even though it will not be safe, because of current outbreak and outbreak # 2 that will likely start soon. Citizens are not allowed to travel beyond a few stores and, in special cases, their work office, so even people who live there have no idea what's really going on especially in Hubei province including Wuhan. Also, an H15N outbreak seems to have recently started in

humans in Hunan province (which neighbors Hubei/Wuhan area).

I also have lots of information about USA.

Here is some:

I believe that many COVID-19 deaths were incorrectly labelled as 2019-2020 flu deaths. The spreading in the USA is almost certainly already homogeneous, because it's been going on since last year without any containment whatsoever. Once massive testing finally starts, this truth/reality will, unfortunately, become obvious. It will manifest itself as hyper exponential (hyperbolic) growth starting a day or two after the millions of testing kits arrive and start being used. The hyper exponential dynamics will eventually evolve to a more accurately calibrated exponential curve once the number of tests is large enough to properly sample the population. I don't think Italy is ahead of us. I think we're ahead and by a large amount.

A few other quick bits of info...

The time between infection and death seems to have decreased from about ~20 days (a few months) ago to possibly as short as ~8 days. And, the incubation period seems to be significantly longer. Both, and other data I've looked at, strongly suggest at least one mutation has occurred. This is extremely concerning to me. Another concern is the distribution of deaths vs. age appears to not be as strongly biased, compared to when China data was included, towards older people and/or people with chronic health conditions.

Over the past 15+ years, I've traveled to China multiple times per year. I'm pretty sure you've known this for a while, but I truly believe the outbreak tsunami in the USA is either already happened or is about to happen. As you know, as soon as a surge is sensed, the Tsunami will immediately follow. I believe we missed the containment boat quite a while ago. I've been

closely listening to your comments on TV, and I'm pretty sure you've already come to the same conclusion but don't want to cause mass panic (I understand that).

I'm 99% sure that SARS-CoV-2 been spreading in the USA since late November / early December last year. I

[REDACTED]

(b) (6) She works at (b) (6) and it's possible that everyone in her office got infected too. Who knows how many people in Alaska got it too, but I suspect many tens of thousands possible much more. (b) (6)

[REDACTED] but it has been impossible to get tested. I've called 5 places in Alaska and none wanted me to come it for the test.

I've instructed my family and, recently (after family), close friends to get some Alvesco (ciclesonide) for emergency use only. I've been told by colleagues on the front-line in Japan, China, and Korea, and found several pre-print papers, that it is an effective treatment for late-stage COVID-19 patients. Some patients on ventilators who were approaching death have fully recovered after treatment with ciclesonide; ciclesonide has much smaller particles than other corticosteroids so it reaches deeper into lungs and alveolis) . Also, the treatment seems to be a potent suppressor of virus replication. Recovered patients have tested negative shortly after the treatment. Of course, data is limited so can't be sure the treatment is effective. However, because Alvesco has been shown to be safe for infant - 100+ year-old patients, I'm ok with my family and I having it for emergency use. That is, only if healthcare facilities are unable to accept them or me as a patient to treat with ventilator,

corticosteroids (or whatever the best available treatment is at that time). Having Alvesco in our emergency kits is a much better option than someone avoidably dying because of an overburdened healthcare facility. The other drug I have, and have told my family and some friends to get, is called hydroxychloroquine -- also seem to be effective and safe. But, I think Alvesco is better because it appears to prevent the virus from replicating so infection is wiped out and no longer contagious. Alvesco seems to be two silver bullets in one.

I don't believe in coincidences and I'm not a conspiracy theorist, but there are many things out of Iran that also concern me greatly. That's all I say right now.

If all of this is old news to you, then I would greatly appreciate a response. It can be as short as "yes". Anyway, I had to share this information with you. Now my conscience is clear. My concern is that it's possible you don't have some of the above info, so I decided to send you this message.

I wrote this quickly, so I apologize in advance for any typos, etc.

I truly appreciated your efforts, and I'm now confident that President Trump, you, and everyone else involved is doing everything possible to ensure the best possible outcomes. I was deeply concerned a few weeks ago, when the gravity of the situation seemed to not be fully recognized by several in DC.

Feel free to call me anytime. My cell # is below. If you do call, I will keep anything we discuss confidential (if necessary).

Sincerely,

Erik

Erik A. Nilsen, PhD

 ^{(b) (6)} | www.bio-signal.com | [Request a demo or quote](#)



Bio-Signal
Technologies

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:07:41 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Coronavirus interview with Dr. Collins

See yellow highlight. Has Sheila Kaplan tried to get to me and has anyone said that I am "...not talking"? I doubt that.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Wednesday, March 18, 2020 9:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Myles, Renate (NIH/OD) [E] (b) (6); Burklow, John (NIH/OD) [E] (b) (6)
Subject: FW: Coronavirus interview with Dr. Collins

Hi Tony,

I could use your guidance on press interviews. I understand that only Task Force members are supposed to do television events – and I declined the NewsHour tonight to be consistent with that. But what is your preference for printed press pieces, when you can't do them all? Would it help the cause for me to accept some of those, or is it better to hold off? If I were to engage, I would certainly seek to provide answers that are 100% with what you are doing.

An example is the thread from Sheila Kaplan of the New York Times. I have declined so far – but is this the kind of query that you would like some help with?

Francis

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>
Sent: Wednesday, March 18, 2020 4:10:58 PM
To: Myles, Renate (NIH/OD) [E] (b) (6) >
Cc: Burklow, John (NIH/OD) [E] <(b) (6)>; Fine, Amanda (NIH/OD) [E] (b) (6) >
Subject: Re: Coronavirus interview with Dr. Collins

Hi Renate,
Thank you.... We appreciate it. SK

On Wed, Mar 18, 2020 at 3:56 PM Myles, Renate (NIH/OD) [E] <(b) (6)> wrote:

Hi Sheila,

The questions you shared with Amanda were really for Dr. Fauci; he's our spokesperson on all research specific questions. I know he's really backed up and NIAID is doing the best they can with his incredibly packed schedule. The interview with the Atlantic was really intended as a profile, but ended up covering a lot of COVID questions. We can check in with NIAID to see what we can do.

Thanks,

Renate

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>

Sent: Wednesday, March 18, 2020 3:27 PM

To: Myles, Renate (NIH/OD) [E] (b) (6); Burklow, John (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6)

Subject: Re: Coronavirus interview with Dr. Collins

Hi there,

Why were we told we could not do an interview, when, after our request, he did one with The Atlantic. You referred us to Dr. Fauci but he isn't talking, either. This doesn't seem fair to us. Can we really not speak to either of them for a story this weekend?

Thanks, SK

On Sun, Mar 15, 2020 at 4:00 PM Kaplan, Sheila <sheila.kaplan@nytimes.com> wrote:

Dear Renate, John and Amanda:

Sheri Fink and I would like to interview Dr. Collins as soon as possible for a story on coronavirus.

Can you please let me know when he might be available.

Thank you,

Sheila

—

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: [REDACTED] (b) (6)

--

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: [REDACTED] (b) (6)

--

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:05:42 +0000
To: Doug Brust
Subject: RE: Please Help

Doug:

Thanks for the note. I have pushed hard on PPEs and as you may know, the POTUS has involved the Department of Defense to provide 5 million N-95 respirators. Hopefully that will alleviate at least a portion of the PPE shortage. Regarding the bars and beaches, I have been screaming on TV 2 to 5 times per night to tell the younger generation to start taking this seriously. I am very surprised that Gov. DeSantis has not completely closed the bars, even if they serve food. Take out only. I will bring this up at the Task Force meeting tomorrow. Please take care of yourself. You are an indispensable front line warrior.

Best regards,
Tony

From: Doug Brust [REDACTED] (b) (6) >
Sent: Wednesday, March 18, 2020 8:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Please Help

Tony-

I know you're ridiculously busy so please do not be upset with me, but I am frustrated and yes angry. Again, I think you have to hear from the front line while formulating policy.

- Today at the RW clinic I dealt with at least 12 URI's with fever.
- We cannot test.
- We have no PPE in clinic.
- We have a case that tested positive for influenza then SARS-CoV-2--this scared me the most given I'm trying to r/o COVID-19 by doing PCR for other respiratory viruses.
- On the drive home just now, the gyms, bar-grilles and restaurants still packed. Yes, bars are closed in Florida--but if they serve food (which they all do).....they're open. Ans. so much for the 50% capacity "suggestion".
- The beaches still full for Spring Break. Look at the pics of St Pete.
- The DOH? This is from the the FL DOH just a few hours ago. Yes, this is **TODAY**.

"If a cluster of confirmed cases were to be discovered in Florida, the department would move quickly to engage with and isolate any infected individuals to prevent further spread," said Alberto Moscoso, the state health department's spokesman.

I don't have to explain to you how ridiculous that statement is.

- I've written to our DOH and Governor DeSantis three times (including speaking with his staff) asking to close restaurants (aside from take-out), gyms, beaches etc. They are "monitoring". I'm the HIV doc here. I'm it. You know how seriously I take caring for my patients. I have [REDACTED] (b) (6) [REDACTED] I am putting my life on the line so folks can go pump iron, drink beer, have a burger and get a tan.

The band is playing on. Again.

Please help.

With tons of respect and admiration,
Doug

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 01:59:12 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus

Please respond to this person.

----- Original Message -----

From: Beth Abramson (b) (6) >
Sent: Wednesday, March 18, 2020 9:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Coronavirus

Wondering whether it has been considered that only the vulnerable population (those over 60 and/or those with underlying health conditions) be isolated? I am a (b) (6) psychiatrist and after contemplating this option was wondering if this could still reduce the risk to healthcare Systems with less disruption to our society. I await your response and appreciate all you are doing. Beth Abramson MD (b) (6)

Sent from my iPhone.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 01:54:06 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Plaquenil Shortage Causing National Health Emergency for Lupus Patients

Please respond.

From: Bruce Wilder [REDACTED] (b) (6)>
Sent: Wednesday, March 18, 2020 9:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Plaquenil Shortage Causing National Health Emergency for Lupus Patients

[REDACTED] (b) (6) When I tried to refill Plaquenil today, I learned that there was a national shortage due to doctors prescribing Plaquenil to their well patients and themselves. Recent news articles have reported its success in preventing and treating the coronavirus. What can you do to protect the life of [REDACTED] (b) (6) and the millions of other Americans who depend on this drug to stay alive?

Brenda Wilder

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 01:53:32 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Please read- idea for Mask Shortage

Please take a look and handle.

From: Dusti Rainey <[REDACTED] (b) (6)>
Sent: Wednesday, March 18, 2020 9:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Please read- idea for Mask Shortage

I have an idea to HELP with the MASK SHORTAGE!

Please don't disregard this, as this could help our whole country!

I know we are concerned as a nation about a mask shortage and I have an idea to what might help.

I Don't know who to go to that can help implement this and want your input if you think this is a viable aid, then maybe you can help me reach the right people to make the biggest impact, maybe even up to the Coronavirus team in the White House.

I have [REDACTED] (b) (6) & when I first heard about China quarantining 43 million people I got worried about masks, I looked up how to sew a mask for myself & family. I found a site that talked about sewing masks for cancer treatment patients and to use 100% quilters cotton for outside & 100% flannel cotton on inside. I started sewing several. I know they aren't the N95, but they are better than nothing IF needed. My Dr just told me yesterday not to go anywhere without a mask because it's too much of a risk for my health. It got me thinking. What if while people across the country were in home quarantine, ALL those who know how to sew, they sew these masks to donate in their communities. Not for use against Coronavirus, but for other things normal masks are used (food prep, non-sickness medical reasons, etc) then they aren't using up the valuable higher rated masks that are needed for doctors, nurses & first responders fighting Coronavirus. These masks can also be washed as needed again and again which will just keep saving other masks.

During the WH Press Release this morning, Seema expresses the need for masks & Dr Birx explained how the virus is being spread from surfaces, but that it can't survive in fabric. Which means maybe these cloth masks will even help against the spread of the virus.

Either way, if you can help ok for these to be used in some manner vs a medical mask being used will help prolong the need for more masks and hopefully 3M can have more made by then so we never have to experience an lack of masks.

What do you think?

Dusti Bacon

[REDACTED] (b) (6)

From: (b) (6)
Sent: Wed, 18 Mar 2020 19:56:42 -0400
To: John Brouse
Subject: Re: Covid19 treatment

Thank you for your note,
A.S. Fauci

Sent from my iPhone

On Mar 18, 2020, at 7:02 PM, John Brouse (b) (6) wrote:

Sent from [Mail](#) for Windows 10

Dear Dr. Fauci

I understand that South Korea has been administering Hydroxi Chloroquine, a treatment for Malaria, to her citizens that have contracted Coronavirus. Is America considering this drug to help lessen the symptoms of this virus? This drug may not prevent anyone from getting ill, but may be a viable treatment to speed the recovery of individual afflicted with this disease.

Respectfully,

John Brouse

From: (b) (6)
Sent: Wed, 18 Mar 2020 19:55:14 -0400
To: Holly Kreutter
Subject: Re: airport screenings

Thank you for your note.
A.S. Fauci

Sent from my iPhone

On Mar 18, 2020, at 7:10 PM, Holly Kreutter (b) (6) wrote:

Dear Dr Fauci,

First of all, thank you for all the hard work you've done to help mitigate the coronavirus outbreak. We're clearly not there yet, but are further along with your efforts.

I'm not sure whom to contact about this, and so am writing you because I'm confident you can get it to the right hands. With regards to the recent closures to Europe and so many Americans coming home, I was at first heartened to hear that all Americans returning would be medically screened and encouraged to/made to quarantine for 14 days. However, I was then disheartened to learn that that hasn't been the case, at least through this past Saturday.

(b) (6) was on business in Amsterdam last week and rushed home last Thursday after hearing on Wednesday evening about President Trump's Friday midnight shutdown. He came in through LAX from Amsterdam, and wasn't asked any medical questions, nor was he asked to quarantine. Then a friend came in through Miami from Paris on Saturday, and was only given a short medical form to fill out, and then let go. No medical check, no temperature screening, no further questions. From touchdown to taxi (plus picking up bags), 45 minutes total.

Having lived in Singapore through SARS, I'm deeply disturbed. We had medical/temperature checks at all airports, and mandatory quarantines for anyone with possible contact with a SARS contact/patient. The virus was quickly and efficiently contained, and the same has been done in Singapore to date with Covid 19.

I was heartened last Friday as I learned that the federal government was onboard, and hearing about significant measures that would be taken *soon*. I must say I've been disheartened as of today, with not enough tests, mask, respirators and ventilators in place. And then hearing of the lack of medical screenings at airports. Please help, as I know you've so desperately been trying to do. And please help to stem any incorrect information going out from our President, information which

gives us hope for a couple of days, and then dashes that and puts many into a frenzied despair. We can cope with what's happening, and will continue to change our behavior per the guidelines, but only with information that's accurate.

Thank you, and keep safe,

Holly Kreutter

Virginia Resident

From: (b) (6)
Sent: Wed, 18 Mar 2020 19:54:24 -0400
To: NIAID Public Inquiries
Subject: Fwd: Volunteer status for current nursing students

Sent from my iPhone

Begin forwarded message:

From: Ivan Bocardo (b) (6) >
Date: March 18, 2020 at 7:16:25 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Volunteer status for current nursing students

Dear Dr. Anthony Fauci,

My name is Ivan Bocardo, and am a (b) (6) U.S. Army Medic (68W) deployed to Afghanistan in 2011-2012. I can send you my resume so you can see my skills and abilities that I can bring to the table. Am currently in nursing school (R.N.) in Rego Park, Queens with a (b) (6)

My school ((b) (6)) has recieved a request from New York Governor Cuomo's office looking for nursing students to help volunteer. However many students like myself are very hesitant to volunteer for the simple fact that it will interfere with our studies and we will still have to comply with class assignments and class exams and especially with final exams this current semester coming up at the middle to end of April 2020. Yet many of my fellow classmates would love a chance to stand up and deliver help during these trying times. However our school will not except any excuses for lateness or absence even though we are now on an online learning as of this moment. So our greatest fear is that we wont finish this semester and will not be able to start next semester (it starts April 28, 2020 for our school)... basically 2 semesters wasted and it will push back our graduation date and furthermore incur more student loans in order to continue with school.

This is why I am writing to your office if an exception can be made and we can have OTJ (on the job training for nursing) and recieve credit and for our current semester and possibly our next semester. Many of the students I speak about already have a Bachelor's degree (I myself have a B.S. in Biology from (b) (6)) and many are or have worked as Nurse aides in many NYC area local hospitals with many years of excellent experience. Imagine if you are able to approve this for many nursing school students in just the New York City area and Long Island Suburbs. This would be virtually an untapped experienced workforce of literally hundreds perhaps maybe thousands of hands on personnel ready to go to help relieve the over burdened health system workers and provide additional reinforcements due to the coronavirus. In not only my area of New York city but possibly all over the country where we can help providing help and additional assistance and reinforcements

Dr. Fauci, I am humbly asking for special permission, we all will need all the help we can get. Please consider this option as this can be a win/ win situation for not only NYC residents but for other areas of the country hit hard by this crisis. I have spoken to many of my fellow classmates and they all understand the risk and would be willing to share the burden with the

extreme pressures put on the health care system at this time. Many of us including myself would be willing to work on site or what ever site you may need us the most, many us fully understand that we could potentially be away from our families for an extensive unknown period of time which we are ready for and prepared for or possibly put our health on the line too.

I implore you to give us a chance and only ask for special permission for OTJ in order to fully finish our R.N. nursing degree.

Thank you for your time in reading this letter.

You are doing one fine heck of job in providing outstanding information and keeping the public informed

Sincerely,

Ivan Bocardo

Personal Cell phone [REDACTED] (b) (6)

From: (b) (6)
Sent: Wed, 18 Mar 2020 19:52:49 -0400
To: Margaret Wilbur
Subject: Re: coronavirus immunity

Thank you for your note.
A.S. Fauci

Sent from my iPhone

On Mar 18, 2020, at 7:25 PM, Margaret Wilbur <(b) (6)> wrote:

Have we reached a time when it might be useful to prove who is immune to Covid-19? I understand that there is an antibody test already available. If we could identify who is already immune, we could then let those people return to daily life, work safely in essential positions, and feed the economy.

I practiced internal medicine in Cleveland, Ohio for (b) (6). I was amazed on a daily basis by the breakthrough that was PCR testing. Right now old-fashioned antibody tests might make a critical difference to us.

Margaret Wilbur, MD

(b) (6)

From: (b) (6)
Sent: Wed, 18 Mar 2020 19:52:29 -0400
To: Ronald Frank
Subject: Re: Dental offices and the coronavirus IMPORTANT

Thank you for your note.
A.S. Fauci

Sent from my iPhone

> On Mar 18, 2020, at 7:28 PM, Ronald Frank (b) (6) > wrote:

>
> Dear Dr Fauci,

>
> Firstly, I would like to commend you on your expertise and leadership.

>
> As we develop a comprehensive plan to tackle the coronavirus pandemic, I believe that we have failed to address a critical piece of the puzzle to contain the virus.

>
> I am a physician and urologist, but I am astutely aware of the dental profession. I have a older brother who is a practicing dentist and I have voiced my concerns to him.

>
> Each and everyone of us who has had an appointment with a dentist knows the procedure of pressure irrigation in the mouth resulting in a mist and aerosol of secretions and saliva depositing on the faces of patients, the dentist and on all the surfaces in the treatment rooms. While the dentist wears a face mask, the spray of secretions, in a potential coronavirus carrier, widely contaminates surfaces, other employees and patients.

>
> I pose the question, should dental offices be actively treating patients during this critical phase in the Coronavirus pandemic? Everything which I have mentioned is corroborated by several practicing dentists. Is the he CDC and the NIH obligated to set guidelines and restrictions on dental care during this critical time as we try to get control of increasing numbers of cases. Should the ADA take a stronger stance during this crisis?

>
> I respectfully reserve these decisions and recommendations to you and your colleagues. Thank you

>
> Sincerely,

>
> Ronald G. Frank, M.D.
> 1500 Pleasant Valley Way
> Suite 201
> West Orange, New Jersey 07052
> o. 973-731-6600

>
>
> Sent from my iPhone.

From: (b) (6)
Sent: Wed, 18 Mar 2020 19:51:14 -0400
To: dalt222
Subject: Re: Plaquenil for Covid 19

Thank you for your note.
A.S. Fauci

Sent from my iPhone

On Mar 18, 2020, at 7:41 PM, (b) (6) wrote:

Dr Fauci,

I hope all is well with you. I am a Dermatologist practicing in the Metropolitan Detroit area. I have done some literature searching on potential treatments for the novel coronavirus and stumbled across a few case reports from China in 2005 at the time of the SARS outbreak. They detailed some successes in treatment of severe cases with chloroquine. I saw a more recent study showing hydroxychloroquine had better in vitro efficacy than chloroquine. Have you heard of this? Plaquenil is so innocuous, I wonder if we shouldn't just try it.

I think you are doing phenomenal work and really presenting a level, measured and realistic view of this epidemic to the world. Please keep up the great work. It is much appreciated

David A. Altman MD FAAD
Assistant Clinical Professor
Division of Internal Medicine
Michigan State University College
Of Human Medicine

Sent from my Verizon, Samsung Galaxy smartphone

From: (b) (6)
Sent: Wed, 18 Mar 2020 19:50:23 -0400
To: DMID Word Nerds
Subject: Fwd: Interest in collaboration on COVID-19 antibody development

Pls handle

Sent from my iPhone

Begin forwarded message:

From: Dea Shahinas <(b) (6)>
Date: March 18, 2020 at 7:41:40 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Cc: (b) (6)>
Subject: Interest in collaboration on COVID-19 antibody development

Dear Dr. Fauci,

We learned about your research on COVID-19 at NIAID and are interested in collaborating with you in order to fast-track our efforts in developing antibodies against this infection.

We have two decades of experience with single domain antibody (nanobody) technology.

I will provide below a brief summary about our company:

Virotek is a private Canadian biotech with focus on the development of novel biologics for the treatment of viral infections. Our primary focus area has been in the areas of infectious diseases and immuno-oncology in animal and human verticals. (b) (4)



We are also proposing [REDACTED] (b) (4)

[REDACTED] Please let us know if you are interested and we are happy to arrange for a time to discuss in further detail with you.

Best regards,

Dea Shahinas
Director, R&D
Virotek Inc.

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 23:09:32 +0000
To: (b) (6)
Cc: (b) (6)
Subject: FW: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf
Attachments: Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Annotated-YELLOW Nicholls S Peiris M NATURE-Med 9-2005.pdf

(b) (6)

The situation gets confusing. See attached brief commentary and e-mail string. As you can see, I was too tired to make any sense of it. However, my deputy (Cliff Lane) notes that this paper argues the opposite, i.e. that ACE inhibitors might have a benefit and counters the argument to stop ACE inhibitors. Bottom line is that we really do not know what the effect will be clinically with respect to COVID-19. In any event, (b) (6)

Best,
Tony

From: Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, March 18, 2020 5:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

A 2005 paper post-SARS advocating for use of ACE inhibitors to increase ACE2. The opposing argument to stopping ACE inhibitors.

From: Anthony Fauci (b) (6)
Date: Wednesday, March 18, 2020 at 5:22 PM
To: "Lane, Cliff (NIH/NIAID) [E]" (b) (6)
Subject: FW: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

I cannot make heads or tails of this. Please take a look and let me know what you think. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ste McCon (b) (6) >

Sent: Wednesday, March 18, 2020 5:09 PM

Subject: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

"Clearly, the potential therapeutic utility of recombinant **ACE2 and angiotensin II receptor-inhibitors**. [ARB's ?]s—**already in clinical use for control of blood pressure**—for acute lung injury resulting from viruses and other causes will be a productive field for investigation. This is particularly relevant as we prepare to **confront a potential avian flu pandemic**. [COVID-19 ?] armed with only a limited number of therapeutic options."

Regards,

Stephen D. McConnell, BS, MSc-CCP, CIS

Lipidemiologist - Clinical Application Specialist

Medicare-CMS ACO/MSSP/Direct-Contracting Consultant

Medical Science Liaison

Mobile: (b) (6)

(b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 23:03:32 +0000
To: SWAMINATHAN, Soumya
Cc: Collins, Francis (NIH/OD) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Confidential and urgent request regarding

Thanks, Soumya.

From: SWAMINATHAN, Soumya (b) (6)
Sent: Wednesday, March 18, 2020 6:49 PM
To: Collins, Francis (NIH/OD) [E] <(b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: Re: Confidential and urgent request regarding

Dear Francis

I am sure you have seen the results which came out today, and are inconclusive. The DG announced the launch of the WHO Solidarity trial, which will hopefully provide a definitive answer to all these questions. Many thanks to NIAID for their support.

Warm regards
Soumya

Sent from my iPhone

On 17 Mar 2020, at 18:50, Collins, Francis (NIH/OD) [E] (b) (6) > wrote:

Hi Soumya,

See below. Is it possible for WHO to (b) (4)

Thanks for any help you can give.

Francis

From: Hudson, Thomas J (b) (6) >
Sent: Tuesday, March 17, 2020 10:15 AM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID)

[E] (b) (6); Hudson, Thomas J (b) (6)>

Subject: RE: Confidential and urgent request regarding

Dear Francis,

I have not received any response from Dr. Swaminathan to my message sent yesterday

(b) (6)

I expect that we are not the only group trying to get to WHO leaders. A call from Tony or you may be more successful.

In addition to my contact information below, I can be reached via my cell phone: (b) (6)

Tom

THOMAS HUDSON

Senior Vice-President, R&D

Chief Scientific Officer



AbbVie, North Chicago

1 North Waukegan Rd

R473, Building AP9-1

N Chicago, IL 60064

TEL (OFFICE) (b) (6)

EMAIL (b) (6)

abbvie.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Monday, March 16, 2020 8:43 AM
To: Hudson, Thomas J <(b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: [EXTERNAL] RE: Confidential and urgent request regarding

Tom,

Thanks again for reaching out. I can only imagine (b) (4)
(b) (4)

A large rectangular area of the email body is redacted with a solid grey fill. The redaction covers the majority of the text in the paragraph following the opening sentence.

The best contacts would be the WHO Chief Scientist Soumya Swaminathan (b) (6) and potentially Director General Tedros (b) (6)

Let me know if you hit a roadblock with WHO. I might then want to weigh in too.

Francis

From: Hudson, Thomas J <(b) (6)>
Sent: Monday, March 16, 2020 9:16 AM
To: Collins, Francis (NIH/OD) [E] <(b) (6)>
Subject: RE: Confidential and urgent request regarding

Thank you.

THOMAS HUDSON

Senior Vice-President, R&D
Chief Scientific Officer



AbbVie, North Chicago
1 North Waukegan Rd
R473, Building APS-1
N Chicago, IL 60064

TEL (OFFICE) (b) (6)

EMAIL (b) (6)

abbvie.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Monday, March 16, 2020 8:14 AM
To: Hudson, Thomas J (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] <(b) (6)>
Subject: [EXTERNAL] RE: Confidential and urgent request regarding

Hi Tom,

Got your message, am looking into it, hope to get back to you later today.

Best, Francis

From: Hudson, Thomas J (b) (6)
Sent: Monday, March 16, 2020 9:10 AM
To: Collins, Francis (NIH/OD) [E] (b) (6) >; Collins, Francis (NIH/OD) [E] (b) (6) >
Subject: RE: Confidential and urgent request regarding

This follow-up message is a duplicate that I am sending to another e-mail address that I have on file.

Dear Francis,

I am sending this brief note as a request for guidance on an evolving situation with

(b) (4)

(b) (4)

I am reaching out to you to see if you have any suggestions or individuals that we should contact.

Best wishes,

Tom

THOMAS HUDSON

Senior Vice-President, R&D
Chief Scientific Officer



AbbVie, North Chicago

1 North Waukegan Rd
R473, Building AP9-1
N Chicago, IL 60064

TEL (OFFICE) (b) (6)

EMAIL (b) (6)

abbvie.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

(b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 20:09:47 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Covid-19

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ann Beloten (b) (6)
Sent: Wednesday, March 18, 2020 4:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Covid-19

Dear Dr. Fauci,

I am writing to you because I have a question regarding Covid-19. How come you do not tell the complete truth to the American people regarding this virus? All I hear is the bad facts about it. Why not give people some help and tell us the good facts about it? Good facts such as the number of actual patients is very small compared to the whole population, most people who get it make a full and complete recovery. Are you enjoying the senseless panic you made? Panic where people are hoarding food/goods, stealing full shopping carts from the elderly, losing their jobs/wages, inadequate education now that schools are closed.

The number of people who will actually be sickened by the virus will be dramatically dwarfed by the people who lose their jobs, receive a poor education despite their teachers best efforts and miss out on once in a lifetime events such as weddings, graduations, communions.

What you are doing is not right for the American people!! You need to stop playing GOD and tell the people the complete truth!! The country and the people need to get back to our normal lives NOW!!

Sincerely,

Ann Beloten

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 20:07:28 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Rapid diagnostic support for Covid-19

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tony Lemmo (b) (6) >
Sent: Wednesday, March 18, 2020 3:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Rapid diagnostic support for Covid-19

Hi Dr Fauci,

Hello from (b) (6)

I'm sure you are swamped. I'll be brief. I am CEO of the world's leading provider of dispensing equipment for the diagnostics market, BioDot Inc. We have been around for 25 years and provide enabling technology to virtually every rapid immunoassay and molecular diagnostics company in the world. We are actively involved today with companies around the globe to help commercialize lateral flow point of care products to help fight Covid-19. If there is anybody in your organization or on the task force that could help facilitate getting us involved with companies looking to produce tests - we are here to help! For example we are actively working with Biomedomics to get their LFD test into the community as fast as possible.

We will move heaven and earth to help the country in any way we can.

Thank you for all you have done and best of luck in fighting this pandemic

(b) (6)

Tony

Anthony V. Lemmo, Ph.D
CEO and President

BioDot Inc.
2852 Alton Parkway
Irvine, CA 92606
P [REDACTED] (b) (6)
F 949-440-3694
www.biidot.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 20:05:50 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Fabric Face Masks

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: AmiSimms (b) (6) >
Sent: Wednesday, March 18, 2020 4:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Fabric Face Masks

Dr Fauci,
Thank you for your guidance and expertise at this difficult time.

My friend and I are quilters. She lives in (b) (6) and I live in (b) (6). She has created a pattern for a fabric face mask. We read Dr. Tufekci's op ed in the NYT yesterday and have been brainstorming together ever since on ways we can help.

<https://www.nytimes.com/2020/03/17/opinion/coronavirus-face-masks.html>

Several years ago I mobilized quilters throughout the US and we raised more than \$1.1 million for Alzheimer's Disease research. All grass roots, all volunteer. There are 7-10 million quilters in the US.

My friend and I would like to make a fabric face mask pattern available at no charge so that quilters, sewers, and crafters can make face masks. We understand these are nowhere near medical grade, but they would be better than nothing at all. (See research cited in link above.) They would be made from fabric scraps and supplies on hand; no trips to the fabric store would be necessary.

At this time there are no masks available to the public at all. Sewing for a cause would give purpose to those of us staying home. Wearing a mask on rare occasions when we do venture outside has the benefits signaling others to step back even if the masks do not protect against transmission of the virus.

We are just two individuals wanting to help. I've been advised by an attorney that sharing this free pattern might open us up to scrutiny from regulatory agencies or possible law suits. We don't want to step on any toes, nor do we want any legal entanglements.

Could the NIH make this pattern available? Or the CDC? There are millions of sewers who would be delighted to step up and help right now. It would be great for morale, and even though it's one step up from nothing, IT IS SOMETHING. This could even be scaled beyond individuals making fabric face masks for themselves. Masks could be sewn for others.

Could we please work with you?

Thank you for your consideration,
Ami Simms (b) (6) and Emanuela D'Amico (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 19:07:06 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Covid-19 symptoms outside of China

Point this person in the right direction

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

—Original Message—

From: W W (b) (6) >
Sent: Wednesday, March 18, 2020 3:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Covid-19 symptoms outside of China

Dear Dr. Fauci,

Many insist on coughs as one of the requirements for self-isolation or testing for covid-19. However, I have read about instances where coughs were not experienced by those who tested positive.

Is it possible to share a list of covid-19 symptoms that *exclude* the patients in China and perhaps France due to their fairly high number of smokers? Does coughing remain a symptom? I am concerned about the health of our nursing home residents, as well as the financial well-being of service sector workers.

Thank you,
Winnie

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 18:27:08 +0000
To: Redfield, Robert R. (CDC/OD); Stephen Hahn; Birx, Deborah L. EOP/NSC
Cc: (b) (6); Troye, Olivia EOP/NSC; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Hicks, Hope C. EOP/WHO; kellyanne conway
Subject: Follow-up of today's conversation

Folks:



(b) (5). Happy to discuss.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not

accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 15:09:54 +0000
To: (b) (6)
Subject: FW: Bloomberg: 99% of Those Who Died From Virus Had Other Illness, Italy Says

Look at the hypertension percentage

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, March 18, 2020 9:52 AM
Subject: Bloomberg: 99% of Those Who Died From Virus Had Other Illness, Italy Says

[99% of Those Who Died From Virus Had Other Illness, Italy Says](#)


By [Tommaso Ebhardt](#), [Chiara Remondini](#), and [Marco Bertacche](#)
March 18, 2020, 8:56 AM EDT

More than 99% of Italy's coronavirus fatalities were people who suffered from previous medical conditions, according to a study by the country's national health authority.

After deaths from the virus reached more than 2,500, with a 150% increase in the past week, health authorities have been combing through data to provide clues to help combat the spread of the disease.

Prime Minister Giuseppe Conte's government is evaluating whether to extend a nationwide lockdown beyond the beginning of April, daily La Stampa reported Wednesday. Italy has more than 31,500 confirmed cases of the illness.

Italy Coronavirus Deaths By prior illnesses (%)



Source: ISS Italy National Health Institute, March 17 sample

The new study could provide insight into why Italy's death rate, at about 8% of total infected people, is higher than in other countries.

The Rome-based institute has examined medical records of about 18% of the country's coronavirus fatalities, finding that just three victims, or 0.8% of the total, had no previous pathology. Almost half of the victims suffered from at least three prior illnesses and about a fourth had either one or two previous conditions.

More than 75% had high blood pressure, about 35% had diabetes and a third suffered from heart disease.

The average age of those who've died from the virus in Italy is 79.5. As of March 17, 17 people under 50 had died from the disease. All of Italy's victims under 40 have been males with serious existing medical conditions.

While data released Tuesday point to a slowdown in the increase of cases, with a 12.6% rise, a separate study shows Italy could be underestimating the real number of cases by testing only patients presenting symptoms.

According to the GIMBE Foundation, about 100,000 Italians have contracted the virus, daily Il Sole 24 Ore reported. That would bring back the country's death rate closer to the global average of about 2%.

— With assistance by Karl Maier

From: Folkers, Greg (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 18:13:38 +0000
To: Fauci, Anthony (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Subject: RE: Covid-19 coverage in Nature Reviews Immunology

Dear Alexandra,

Thank you for your kind words.

Yes, we can send you references of notable papers

My chief of staff, Greg Folkers (cc'd here), will be my conduit/surrogate.

Regards,

AS Fauci

From: Alexandra Flemming <A.Flemming@nature.com>
Sent: Tuesday, March 17, 2020 10:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Covid-19 coverage in Nature Reviews Immunology

Dear Tony,

Thank you again for contributing the fabulous year in review article to Nature reviews Immunology last year!

Given the current pandemic, we can only imagine how incredibly busy you are at the moment. At Nature Reviews Immunology we have decided that we would like to introduce an in-brief section that provides a brief overview of the most notable/important research on SARS-CoV-2, particularly with regards to its immunopathology and vaccine development. To this end, we are recruiting a small number of advisors to point us in the right direction – this would involve no actual writing, just sending us references to the papers as and when they come out. Would you, or a member of your team, be willing to act as an advisor for this project, by sending us between 1-5 references for notable papers per month? We feel that particularly in this fast evolving situation, it is of paramount importance that amongst the deluge of data, scientists are guided towards the most important papers.

I look forward to hearing from you,

With best regards,

Alexandra

Dr Alexandra Flemming

Chief Editor
Nature Reviews Immunology

Nature Research
4 Crinan Street, London N1 9XW, UK
(b) (6)
a.flemming@nature.com
www.nature.com/nri



DISCLAIMER: This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage mechanism. Springer Nature Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of Springer Nature Ltd or one of their agents.

Please note that Springer Nature Limited and their agents and affiliates do not accept any responsibility for viruses or malware that may be contained in this e-mail or its attachments and it is your responsibility to scan the e-mail and attachments (if any).

Springer Nature Limited. Registered office: The Campus, 4 Crinan Street, London, N1 9XW. Registered Number: 00785998 England.

From: (b) (6)
Sent: Tue, 17 Mar 2020 10:42:33 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]; Lane, Cliff (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: Fwd: Invitation: BIO Coronavirus Collaboration Initiative
Attachments: INVITATION_Fauci BIO COVID19 Virtual Summit 15Mar2020.pdf, ATT00001.htm

Let us discuss and decide one way or another.

Begin forwarded message:

From: Hannah Dorsey <hdorsey@bio.org>
Date: March 16, 2020 at 3:51:02 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, "Marston, Hilary (NIH/NIAID) [E]" <(b) (6)>, Phyllis Arthur <parthur@bio.org>
Subject: Invitation: BIO Coronavirus Collaboration Initiative

Dear Dr. Fauci,

On behalf of BIO, I would like to invite you to participate in our multi-stakeholder COVID-19 Collaboration Virtual Summit which will take place March 24-25. We are hosting this summit in order to facilitate near-term collaboration among industry, government, academic and non-governmental experts to help confront this growing and unpredictable public health crisis.

We would like you to be a speaker during the Plenary session on March 24th. We would like you to give 5-10 minutes of opening remarks to the Summit participants. Please note that the plenary session of the event will be open to the press, while the remaining sessions will be closed to just invited guests to ensure a robust discussion and maximum collaboration. You are welcome to attend any of the subsequent Breakout sessions scheduled over the two days.

This virtual meeting will take place over two days:

- March 24th: 10:00am – 11:45am - Plenary Session
- March 24th: 12:00pm – 2:30pm – Treatment Break Out Session
- March 25th: 10:00am – 12:30pm – Prevention Break Out Session
- March 25th: 1:00pm – 3:30pm – Diagnostics Break Out Session

Attached is the full invitation to our event from our CEO Jim Greenwood, the full agenda will be to follow. Please let us know if you would be available as a speaker for the Plenary session on March 24th.

Best,
Hannah Dorsey
Coordinator, Health Policy
Biotechnology Innovation Organization (BIO)
1201 Maryland Ave. SW, Ste. 900
Washington, DC 20024
Office: (202) 962-6644
hdorsey@bio.org
www.bio.org

From: (b) (6)
Sent: Tue, 17 Mar 2020 07:30:48 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Updates

Sent from my iPhone

Begin forwarded message:

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: March 17, 2020 at 7:14:00 AM EDT
To: Janet Tobias <janet@ikanamedia.com>
Subject: RE: Updates

Thanks, Janet. Please continue to work with Patty to make this happen.
Best regards,
Tony

From: Janet Tobias <janet@ikanamedia.com>
Sent: Tuesday, March 17, 2020 7:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Updates

Dear Tony:

Quick updates, we have partnered with Story Syndicate/John Hoffman (who was in charge of First In Human and Alzheimer's and Obesity projects) on the film about your life. This will help us make sure that next year this film has maximum impact and we carry the message widely of "men serving men" and public health. NIH Communications head John Burklow, and the main office, knows and is very supportive and excited about the potential impact. They have worked super closely with John in the past.

We are putting in the request for filming with the Vice President's office and we will work with Patty to figure out how to film your work and NIAID's work on COVID-19, which is important. But safety and

modelling appropriate behavior always first and foremost. Crews on my side tiny and all from Unseen Enemy.

Thanks for everything, every day, and stay healthy,

Janet

PS The Aids project, and the educational partnership with Howard Hughes Medical Insitute continues in good state, just on hold as it should be.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 03:04:31 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Question about COVID-19 Mechanism of Transmission

Please respond.

From: EDWARD EITZEN (b) (6)
Sent: Sunday, March 8, 2020 3:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Question about COVID-19 Mechanism of Transmission

Hi Tony:

Thank you for what you are doing for our country to try and limit the consequences of COVID-19. Many Americans are hanging on your every word, as they should be, and that includes me.

A question about COVID-19 mechanism of spread: The reported reproductive number from China of about 2.6 indicates a likelihood of large droplet spread as the mode of transmission from person to person. My question is - could there be a component of airborne spread (droplet nuclei) with this virus? If super spreaders exist with COVID-19, is airborne spread possible? Knowing the answer to this question would help to inform decisions about PPE and Decontamination in settings such as Emergency Departments. If this is not already known definitively, could NIOSH and some key partners possibly study it in current quarantine settings?

Thanks, Tony. God bless you and your important work!

Best, Ed

Edward Eitzen, M.D., M.P.H.
Senior Partner, Biodefense and Public Health Programs
Martin-Blanck and Associates
2034 Eisenhower Avenue, Suite 27D
Alexandria, VA 22314-4678

Office Phone: 719-548-9207
Cell Phone: (b) (6)

Email: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 03:02:00 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Flu statistics

Please respond for me.

----- Original Message -----

From: Candace Gunn [REDACTED] (b) (6)
Sent: Sunday, March 8, 2020 10:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Flu statistics

Dear Dr. Fauci,

First of all, thank you so much for the wonderful job you are doing regarding the information on the coronavirus. You were excellent with Chris Wallace!

Is it possible to give facts on the FLU - number of people who have had it and how many have died - during the past month? I wonder if that might perhaps slow down the media frenzy.

Many thanks for your consideration of my question.

Best regards,

Candace Gunn

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 03:00:44 +0000
To: Anderson, Roy M
Subject: RE: Lancet Commentary on COVID-19

Roy:

Thank you for your kind note. Very nice article! I hope that all is well with you.
Best,
Tony

From: Anderson, Roy M [REDACTED] (b) (6) >
Sent: Saturday, March 7, 2020 5:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Lancet Commentary on COVID-19

Dear Tony,

I thought the attached may be of interest to you.

You have been doing a very good job in communicating the important issues around this epidemic – well done.

Kind regards,

Roy

Professor Sir Roy Anderson FRS FMedSci
Director
London Centre for Neglected Tropical Disease Research (LCNTDR)
Department of Infectious Disease Research,
Faculty of Medicine
Imperial College London Praed Street
London W2 1PG

Te [REDACTED] (b) (6)
[REDACTED] (b) (6)

Assistant – [REDACTED] (b) (6)
Project Manager – [REDACTED] (b) (6)
Manager LCNTDR – [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 02:59:48 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Modeling of COVID-19 from Mike Levit
Attachments: 1.Analysis_of_Coronavirus-2019_Data_Michael_Levitt-v1.pdf,
1.The_Corona_Chronologies_Part_II_-_Rest_of_the_World_Michael_Levitt,Stanford.pdf,
30.The_Corona_Chronologies_Part_I_-_China_Michael_Levitt,Stanford.pdf

Please take a look and see what you think.

From: Tabak, Lawrence (NIH/OD) [E] (b) (6) >
Sent: Friday, March 6, 2020 8:46 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >
Cc: Lauer, Michael (NIH/OD) [E] (b) (6) >
Subject: Modeling of COVID-19 from Mike Levit

Francis, Tony –

Mike Levitt (Nobel prize in Chemistry, 2013) sent the attached modeling of the COVID-19 epidemic to Mike Lauer. I don't know if this will prove useful but wanted to pass it along in case.

He indicated that he was amazed to see how an Excel level analysis could allow him to predict the China epidemic would end as early as 2-Feb and get what he considers the best estimates for case fatality ratio. His first report from 2-Feb is attached as well as his most recent two-part report.

Larry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 02:54:15 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Community-Spread Covid-19 Contact Tracking

Take a look and handle.

From: John G. Boland <[REDACTED] (b) (6)>
Sent: Thursday, March 5, 2020 10:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Community-Spread Covid-19 Contact Tracking

Dear Dr. Fauci:

Without success, for more than a week, I have tried to reach any techie CDC person about the problem of community-spread Covid-19 contact tracking.

Though your workload is unimaginable, I thought you might personally know and could provide contact information of an appropriate CDC or NIH epidemiologist.

Brief Summary of Conceptskip to End, if obvious***

Had I been to a doctor or ER with a virulent disease, they would immediately have asked where I had been, with whom, and for what duration. With that information, epidemiologists can notify and test those contacts... and their contacts... before their symptoms are evidenced.

This manual contact tracking process is workload intensive, calendar-day wasting, data-poor, and inaccurate.

"Location tracking" can provide the raw data needed to identify potential contacts automatically, early, and thoroughly, from information routinely collected by network providers.

The location, at a date and time, of a vast number of anonymous cell phones, over the preceding two weeks, would be very useful for identifying the index case and subsequent contacts of an individual.

As an illustration, the New York Times published, on 19 December 2019, "Twelve Million Phones, One Dataset, Zero Privacy" about the commercial location tracking industry:

<https://www.nytimes.com/interactive/2019/12/19/opinion/location-tracking-cell-phone.html>

End of Summary

Ignoring the techie and legal details, can you suggest an appropriate contact, while Covid-19 infections in the United States are few?

Your continuing dedication, candor, and data-driven focus are refreshing and very much appreciated, Dr. Fauci.

Best,

John G. Boland

(b) (6)

(24 hr. text or leave msg if no answer)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 02:53:27 +0000
To: Tom Frieden
Subject: RE: FYI

I tried to call you this evening but got voice mail that said you were not accepting calls. Let us try to connect soon.

-----Original Message-----

From: Tom Frieden [REDACTED] (b) (6)
Sent: Wednesday, March 4, 2020 11:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: FYI

<https://thehill.com/policy/healthcare/485604-meet-the-federal-governments-coronavirus-expert>

I know you don't read the papers but "super smart, super able to communicate very clearly, with a very deep ethical commitment to doing the right thing" is exactly what I think, not just what I'm telling the media.

All the best,

Tom

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 02:48:31 +0000
To: Pardis Sabeti
Subject: RE: Planning for a hearing on Global Health Security Team

Pardis:

Sorry that I did not respond sooner. I am getting over 1500 emails per day and this one got lost in the pile. Anything that you can do to help would be welcome.

Best,
Tony

From: Pardis Sabeti <[REDACTED]> (b) (6)
Sent: Tuesday, March 3, 2020 9:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: Fwd: Planning for a hearing on Global Health Security Team

Dear Tony,

I hope that all is well given our current circumstances. I am sure you are very busy, so apologize for the intrusion, but would love your insight if you have a moment.

I just had a very interesting talk today with Wendy Ginsberg on the House Committee on Oversight and Reform, with an opportunity to testify at a hearing next Wednesday (email attached).

While I am very excited for an opportunity to advocate for further funding and operational support for pandemic preparedness, I also recognize that this format may not be the right one to do so. Moreover, I may not be the right person to do so, as I think you, Francis, or Eric Lander would do far better than me.

I imagine they have already asked you to participate, and would just love any insight you might have as to whether I should consider doing this, and if so, how I should proceed. I really only would want to do so if it is a place where I can help the larger infectious disease community and make a positive nonpolitical impact.

Thanks so much for your consideration,

Pardis

----- Forwarded message -----

From: Ginsberg, Wendy <[REDACTED]> (b) (6)>
Date: Mon, Mar 2, 2020 at 8:54 AM
Subject: Planning for a hearing on Global Health Security Team
To: [REDACTED] (b) (6)>

Richard Preston pointed me in your direction, saying you would be the right person to help me think through a potential hearing on codifying the global health security team on the National Security Council.

The hearing (as of right now in my mind) would

1. Examine the lessons learned from the Ebola and other previous outbreaks about how federal government design and operations can facilitate or hinder global health and stemming pandemics;
2. Analyze how eliminating the global health security team has put us several steps behind where we need to be in fighting coronavirus; and
3. Argue for codifying the team and its leadership as part of the larger national security apparatus and avoid kowtowing to outbreak fatigue.

I'm hoping you might be willing to speak with me about your expertise and thoughts in this area. I'm definitely not the expert and I would love someone with your background to ensure I'm getting this story right – and that I have the right people at the witness stand to tell it.

Would you have time to talk today or some time very soon? We are hoping to have this hearing next week.

Yours,
Wendy



Wendy Ginsberg, Ph.D.
Staff Director
House Committee on Oversight and Reform
Subcommittee on Government Operations

(b) (6)

--
Pardis Sabeti, MD, DPhil
Professor, Harvard University & Harvard School of Public Health
Broad Institute of MIT and Harvard
Howard Hughes Medical Institute

Assistant: [REDACTED] (b) (6)

Phone: [REDACTED] (b) (6)

Website: www.sabetilab.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 01:46:44 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Wall Street Journal request

Please decide if we can do this.

From: Willick, Jason <jason.willick@wsj.com>
Sent: Monday, March 16, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Wall Street Journal request

Dear Dr. Fauci,

My name is Jason Willick with the Wall Street Journal. I was wondering if you would be willing to talk to me for the WSJ weekend interview section on pandemics and the coronavirus—the US response but also the broader challenges from infectious disease. I know you are beyond busy, but I thought I'd ask. Let me know if this is a possibility and I can discuss more details.

Jason

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 00:27:13 +0000
To: Michael liu
Subject: RE: Great advice from Chinese expert

Michael:

Thank you for your note. We indeed have learned much from our Chinese colleagues. I appreciate your bringing these issues to our attention.

Best regards,
Tony

From: Michael liu [REDACTED] (b) (6) >
Sent: Monday, March 16, 2020 8:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Great advice from Chinese expert

Dear Dr. Fauci,

Dr. Wenhong Zhang, has become very famous in China's war against COVID-19 because of his great excellence in anti-virus. Dr. Zhang is the Director of the Infectious Disease Department of Huashan Hospital in Shanghai. He is very good according to my observation all long. Another great doctor in China is Dr. Nanshan Zhong.

According to Dr. Zhang's video at https://www.thepaper.cn/newsDetail_forward_6537248, COVID-19 can really be prevented with 3 key measures, i.e. to keep social distancing, wash hands frequently and **wear masks**. I strongly suggest American people should wear masks like Chinese, South Korean people, etc., because even China's highest leader, Mr. Jinping Xi, wears masks. If it is difficult for all the US people to do this now, I suggest working staff in airports, supermarkets and other public places should wear masks firstly in order to avoid crossing infection.

Further, Dr. Zhang said, if a person is still infected though he/she takes the above 3 measures carefully, the person must be infected by his/her family members. So I propose the **concentrated isolation** of mild confirmed cases should be considered as I advised yesterday.

I strongly suggest American government should learn precious experience of anti-COVID-19 from and cooperate with the mainland China, Taiwan, South Korea with an open mind. If you need any help to contact with Dr. Zhang, I will do what I can.

I am very confident that the US government will lead American people to win the anti-COVID-19 war by you and other great experts. Science, expertise and great learning are best medicines.

God bless you! God bless America, China and the whole world!

Best regards,

Michael Liu

发件人: Fauci, Anthony (NIH/NIAID) [E] [mailto: (b) (6)]

发送时间: 2020年3月15日 13:28

收件人: Jingming Liu (Michael) < (b) (6)>

主题: Re: Great Advice on How to Avoid Family Spread of COVID-19

Thank you for your note
A.S. Fauci.

Sent from my iPhone

On Mar 15, 2020, at 1:26 PM, Jingming Liu (Michael) (b) (6) > wrote:

Dear Dr. Fauci,

My name is Michael Liu. My family are living in (b) (6) now. I have been following spread of COVID-19 (Corona Virus) closely because such virus is very contagious and dangerous.

If a person is mildly sick with COVID-19, the CDC now suggests the person should "stay home except to get medical care", i.e. home-isolation, according to <https://www.cdc.gov/coronavirus/2019-ncov/downloads/sick-with-2019-nCoV-fact-sheet.pdf>

However, the home isolation may result in family spread of COVID-19 in certain kinds of families, e.g., parents are infected but their kids are too young to take care of them, adults are infected but their parents are too old and risky to look after them (if they live together), an old husband/wife is infected but the spouse is too vulnerable to take care of him/her, etc. In such scenarios, the home isolation may increase family spread and even community spread risks in the US.

A great method to avoid home-isolation risks is the concentrated isolation, i.e. to isolate mild symptomatic people in a concentrated place instead of their homes.

The concentrated isolation can avoid the above family spread risks, provide professional medical help to isolated people, reduce mental pressure of other family members, etc., so that it can reduce community spread risks. Such method has been proved to be effective by China's war against COVID-19.

The concentrated place can be a hotel, university dorm building, etc., which should be easily managed for medical surveillance.

The concentration isolation may be voluntarily chosen by relevant families at the beginning, and adjusted to apply subject to different conditions.

Hope the above advice helpful!

Best regards,

Michael Liu

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 00:23:16 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: offer from Mark Zuckerberg

I will write to or call Mark and tell him that I am interested in doing this. I will then tell him that you will get for him the name of the USG point of contact. I agree it should be Bill Hall who could then turf to the White House Comms if he wishes

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Sent: Monday, March 16, 2020 6:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Subject: ASF: offer from Mark Zuckerberg

Per email below, Mark Zuckerberg has extended a few offers to do videos with you that we would be happy to seek clearance on for you to do, if you are amenable. These would have the weight and impact of television – really, more so. Please advise if you want to do and we will seek clearance with VP office and work with Patty to sort out the logistics.

But an even bigger deal is his offer (b) (6)
(b) (6) The sooner we get that offer up the food-chain the better. I gave Bill Hall a heads-up about this opportunity and he is standing by to discuss this with HHS and WH comms, but I didn't want him to do anything without you being aware of the offer. Is it OK if I hand this aspect off to Bill to determine who the best point of contact would be so the Administration can take advantage of this offer, soonest?

Do you plan to call MZ? His cell number is in his message below.

From: Mark Zuckerberg (b) (6)
Sent: Sunday, March 15, 2020 12:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Thanks and ideas

Tony:

I wanted to send a note of thanks for your leadership and everything you're doing to make our country's response to this outbreak as effective as possible. I also wanted to share a few ideas of ways we could help you get your message out, but I understand you're incredibly busy, so don't feel a need to reply unless these seem interesting.

This isn't public yet, but we're building a Coronavirus information Hub that we're going to put at the top of Facebook for everyone (200+ million Americans, 2.5 billion people worldwide) with two goals: (1)

make sure people can get authoritative information from reliable sources and (2) encourage people to practice social distance and give people ideas for doing this using internet tools. This will be live within the next 48 hours.

As a central part of this hub, I think it would be useful to include a video from you because people trust and want to hear from experts rather than just a bunch of agencies and political leaders. This could be done in a number of formats if you're open to it. Probably best would be recording a Q&A where you answer people's top questions, but we'd be open to other formats too.

I'm also doing a series of livestreamed Q&As with health experts to try to use my large following on the platform (100 million followers) to get authoritative information out as well. I'd love to have you do one of these Q&As. This could be the video we put in the Coronavirus Hub or it could be a different thing that we distribute separately, but I think it could be effective as well.

Finally, [REDACTED] (b) (6)

Again, I know you're incredibly busy, so don't feel the need to respond if this doesn't seem helpful. If it's easy to talk live, give me a call anytime on my mobile phone: [REDACTED] (b) (6).

Thanks again for everything you're doing.

Mark

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 00:22:45 +0000
To: Mark Zuckerberg
Cc: Conrad, Patricia (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Thanks and ideas

Mark:

Thank you for your kind note. I tried to call you, but got voice mail. FYI, my cell phone number is (b) (6). Your idea and proposal sound terrific. I would be happy to do a video for your hub. We need to reach as many people as possible and convince them to take mitigation strategies seriously or things will get much, much worse. Also, your idea about (b) (4) is very exciting. I am copying my Special Assistant, Patty Conrad. Her office number is (b) (6) (b) (6). Please have your people contact her to arrange for the video. I am also copying the Director of my Communications and Government Relations group. She can put your people in contact with the best person who could be the US Government point of contact for (b) (4).
Best regards,
Tony

From: Mark Zuckerberg (b) (6) >
Sent: Sunday, March 15, 2020 12:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Thanks and ideas

Tony:

I wanted to send a note of thanks for your leadership and everything you're doing to make our country's response to this outbreak as effective as possible. I also wanted to share a few ideas of ways we could help you get your message out, but I understand you're incredibly busy, so don't feel a need to reply unless these seem interesting.

This isn't public yet, but we're building a Coronavirus Information Hub that we're going to put at the top of Facebook for everyone (200+ million Americans, 2.5 billion people worldwide) with two goals: (1) make sure people can get authoritative information from reliable sources and (2) encourage people to practice social distance and give people ideas for doing this using internet tools. This will be live within the next 48 hours.

As a central part of this hub, I think it would be useful to include a video from you because people trust and want to hear from experts rather than just a bunch of agencies and political leaders. This could be done in a number of formats if you're open to it. Probably best would be recording a Q&A where you answer people's top questions, but we'd be open to other formats too.

I'm also doing a series of livestreamed Q&As with health experts to try to use my large following on the platform (100 million followers) to get authoritative information out as well. I'd love to have you do one

of these Q&As. This could be the video we put in the Coronavirus Hub or it could be a different thing that we distribute separately, but I think it could be effective as well.

Finally, [REDACTED] (b) (4)

Again, I know you're incredibly busy, so don't feel the need to respond if this doesn't seem helpful. If it's easy to talk live, give me a call anytime on my mobile phone: [REDACTED] (b) (6)

Thanks again for everything you're doing.

Mark

From: (b) (6)
Sent: Mon, 16 Mar 2020 19:40:27 -0400
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: Coronavirus antibodies

Please handle

Begin forwarded message:

From: Andrew Sprouse (b) (6)
Date: March 16, 2020 at 4:00:44 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: Re: Coronavirus antibodies

If millennials are spreading the coronavirus should we allow them to be tested with milder symptoms? Otherwise they have no idea they have it.

On Mar 13, 2020, at 5:27 AM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>wrote:

It likely would

On Mar 13, 2020, at 2:58 AM, Andrew Sprouse
(b) (6):

How about human breast milk? Would it have the antibodies as well?


Sent from my iPhone

On Mar 12, 2020, at 7:53 PM,
Andrew Sprouse
(b) (6)>wrote:

Dr. Fauci,

If China is taking patients and using the plasma/antibodies from them to help cure other patients why couldn't we do that to healthy people to give them immunity to the virus?

Andrew





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 23:19:56 +0000
To: Monticone, Giulia
Subject: RE: COVID19 emergency

Your arguments are solid.

From: Monticone, Giulia <(b) (6)>
Sent: Monday, March 16, 2020 7:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: COVID19 emergency

Dear Dr. Fauci,

I am a postdoc researcher working at LSU health sciences center in New Orleans. I would like to communicate my concern about the COVID19 in the US.

I am Italian and my partner is Chinese and we have been carefully following the COVID19 spread first in China and now in Italy and Europe. Based on my scientific and personal knowledge I am confident to say that the US is only few weeks ahead of what is happening in Italy now and this could only be stopped if strict measures will be taken in the entire country as soon as possible.

If you have the power, I ask you to please try to convince the government to apply such measures, even if this means to shut down the entire country for some weeks. I know that the economy and money interests are what often prevents to take such decision, but in this case we are talking about life and death and we cannot risk this high price.

We have a very clear example of how severe the COVID19 can be if we do not act on time and this is unfortunately my country at this time. We also have a good example, China, in which very aggressive measures have been applied and, despite some delay in their application at first, they now have reached a strong regression in the virus spread and they gradually can restart the country. China measures were to close every city borders, close working places and every non essential activity. They asked the population to stay at home and go out only for food and health emergencies. I think this is what we should do in US too.

A recent study from Italy in which they tested every person in one Italian city showed that the 50-70% of the people positive for the virus were asymptomatic. This is such an important information that tells us the only way to prevent the spread is to prevent the people from moving because we cannot really know who is carrying the virus. Also, screening is important and should be ideally extended to everyone. https://www.repubblica.it/salute/medicina-e-ricerca/2020/03/16/news/coronavirus_studio_il_50-75_dei_casi_a_vo_sono_asintomatici_e_molto_contagiosi-251474302/

My lab is based in New Orleans where the number of COVID19 cases is now growing fast. However, there is no sign from the university or my institute to close. We are working as usual with only some mild restrictions even if we have colleagues that are at home sick, or worse, that showed up at work coughing. The city mayor applied some restrictions but the people are still celebrating events on the street. Up to today we were acknowledged that we have a presumptive positive case in the building where we live. We are doing what we can as responsible individuals but tomorrow we will go to work again not knowing if we are spreading the virus.

I thank you for reading this email and I hope my arguments are solid and accurate enough to encourage you to take action.

Best wishes,
Giulia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 21:28:51 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: INTERVIEW QUOTE FOR ESPN FROM YOUR CALL WITH CARLO DEL RIOS

I did not say that they necessarily should actually cancel the tournament, i.e. not play the games. They could still play the tournament and have it televised without having many spectators in the gym. There is a big difference there. And I did not say that all sports should make a similar call

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Monday, March 16, 2020 3:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: INTERVIEW QUOTE FOR ESPN FROM YOUR CALL WITH CARLO DEL RIOS

PLEASE ADVISE

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)>
Sent: Monday, March 16, 2020 3:19 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID Media Inquiries <mediainquiries@niaid.nih.gov>; NIAID FOG <fog@niaid.nih.gov>
Subject: Interview request: ESPN

ESPN
Tisha Thompson
(b) (6)
Tisha.Thompson@espn.com

Deadline: COB today

Hi Patty,

This reporter is writing about the NCAA's reaction COVID-19, and would like confirmation that the following actually occurred:

Dr. Brian Hainline said two members of the NCAA's advisory panel, Dr. Colleen Kraft and Dr. Del Rio, spoke with Dr. Fauci, who said he would back the NCAA in its decision to cancel the tournament. That Dr. Fauci "wholeheartedly" agreed and said to the NCAA reps, "Not only would he back us that this was the right thing to do...he believed that all sports should make a similar call."

The reporter would like a quick call/confirmation this evening, before they publish the story.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 21:17:44 +0000
To: Jon LaPook
Subject: RE: Great news. (b) (6)
(b) (6). Thanks again.

Wonderful!!

-----Original Message-----

From: Jon LaPook (b) (6)>
Sent: Monday, March 16, 2020 4:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Great news. (b) (6). Thanks again.

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 21:17:06 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Treatments that may be useful against the novel coronavirus

Please respond.

From: PEAK (b) (6) >
Sent: Monday, March 16, 2020 4:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Treatments that may be useful against the novel coronavirus

Dear Dr. Fauci:

I am a (b) (6) assistant attorney general of the States of New York and Oregon. I have received some information that may be useful in dealing with the novel coronavirus, but I am not able to evaluate this information personally. It is in an article authored by a former asst. secretary of the US Treasury. I would like to make this information available to you for evaluation, and to that end I am copying it immediately below.

Sincerely,

Robert Roth
Eugene, Oregon

Treatments for Coronavirus That Have Worked in China

[Paul Craig Roberts](#) • March 13, 2020

These are scientific papers showing effective treatments for coronavirus being used in China

Hydroxychloroquine

<https://www.ncbi.nlm.nih.gov/pubmed/32150618>

<https://reader.elsevier.com/reader/sd/pii/S0924857920300820?token=92457EBC4E75F28D02F311F610DB2D48113E501DC04D49C824E6FD819F77BE34A9937B4AEAC0D115710BDB7BCC2175B5>

These research papers show great antiviral promise for both Hydroxychloroquine and Chloroquine. The Chinese have started using them. So should we. The antiviral effects were originally discovered in Europe during SARS, but then forgotten about as SARS was so aggressive it killed the host too quickly and died out. French Prof Raoult and others have helped the Chinese advising them to proceed in this way and they had the good sense to trial it.

Unlike vaccines and costly new antivirals, Hydroxychloroquine and Chloroquine are generally safe, very well tested, cheap and readily available today. They could be a real game changer. Please publish and disseminate. Please also re-refer to the Blaylock cytokine paper to emphasize the importance of vitamin C, D3 etc.

Hydroxychloroquine and Chloroquine

<https://www.ncbi.nlm.nih.gov/pubmed/32150618>

<https://reader.elsevier.com/reader/sd/pii/S0924857920300820?token=92457EBC4E75F28D02F311F610DB2D48113E501DC04D49C824E6FD819F77BE34A9937B4AEAC0D115710BDB7BCC2175B5>

<https://www.ncbi.nlm.nih.gov/pubmed/?term=chloroquine+coronavirus>

(Republished from [PaulCraigRoberts.org](#) by permission of author or representative)

More at Roberts' homepage: https://www.paulcraigroberts.org/wp-content/uploads/2020/03/14_2020.01012.pdf

From: (b) (6)
Sent: Mon, 16 Mar 2020 16:23:09 -0400
To: Luo, Yiming (NIH/NIAMS) [E]
Cc: Kadlec, Robert (OS/ASPR/IO)
Subject: Re: concerns regarding CDC recommendations for COVID-19 prevention in healthcare settings

Yiming:

Thanks for your note. I will forward your email to dr. Robert Kadlec who is in charge of the SNS.

Best regards,
Tony

On Mar 16, 2020, at 2:53 PM, Luo, Yiming (NIH/NIAMS) [E]

(b) (6) >wrote:

Dear Dr. Fauci,

My name is Yiming and I am a clinical fellow in rheumatology at NIH/NIAMS. I have colleagues and friends working in community hospitals fighting against COVID-19 and we are deeply concerned regarding the CDC interim recommendations for COVID-19 prevention in healthcare settings saying that "facemasks are an acceptable alternative when the supply chain of respirators cannot meet the demand". Currently hospitals in New York City are asking their healthcare providers to wear surgical mask while treating COVID-19

COVID-19 is highly contagious in healthcare settings with a large proportion of healthcare professionals being infected reported in early literature [1]. A recent study suggested that asymptomatic patients can transmit SARS-CoV-2 which puts potentially additional threats to healthcare providers [2].

Although surgical mask can effectively prevent droplet transmission, whether and to what degree SARS-CoV-2 can transmit through aerosol approach is still uncertain. Studies with 2003 SARS virus suggest a high level of concerns for aerosol transmission [3], and a recent unpublished study from MedRxiv revealed that SARS-CoV-2 has similar aerosol stability compared to SARS [4].

Healthcare professionals are our frontline force against the coronavirus emergency and we cannot afford even a slight probability of a large scale infections among healthcare workers due to insufficient personal protective equipment. We hope that accessing the Strategic National Stockpile (SNS) and any potential mass production program are actively being considered to protect, and ultimately, save lives for U.S. people.

Sincerely,

Yiming Luo, MD

- [1] Wang et al, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*. 2020 Feb 7. Doi: 10.1001/jama.2020.1585.
- [2] Chang et al, Protecting health care workers from subclinical coronavirus infection, *Lancet Respir Med*. 2020 Mar;8(3):e13. doi: 10.1016/S2213-2600(20)30066-7.
- [3] Jones et al, Aerosol transmission of infectious disease. *J Occup Environ Med*. 2015 May;57(5):501-8. doi: 10.1097/JOM.0000000000000448.
- [4] Doremalen et al, Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. doi: <https://doi.org/10.1101/2020.03.09.20033217> (MedRxiv)

From: [REDACTED] (b) (6)
Sent: Mon, 16 Mar 2020 14:31:15 -0400
To: Redfield, Robert R. (CDC/OD); Deborah Birx
Subject: Fwd: [REDACTED] (b) (4)
Algorithm for addressing people with mild upper respiratory symptoms in the age of Covid-19.

This is a [REDACTED] (b) (5)

Begin forwarded message:

From: Jon LaPook [REDACTED] (b) (6)
Date: March 16, 2020 at 1:52:57 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (4)
Subject: [REDACTED] (b) (4)
Algorithm for addressing people with mild upper respiratory symptoms in the age of Covid-19.

Hi Tony,

Thank you so much for calling me this morning, and for your terrific help last night trying to think through the issue [REDACTED] (b) (4), (b) (6)

[REDACTED]

Given our discussion this morning, I think it would be very helpful if the task force on coronavirus came up with a clear algorithm for addressing issues related to people having symptoms that could be from a cold, flu, or other virus - and not related to the virus that causes COVID-19.

Let's say there's a hypothetical patient with some combination of sore throat, aches and pain, low grade fever in the 99's by mouth, and cough; there's no shortness of breath. Let's say they are now proactively self-quarantined at home and are in the process of evaluation. Questions include:

1. Who, if any, of the person's contacts within the previous days should be contacted?
2. If it's only "close contacts" - those who were within 6 feet of the person for an extended period of time:
 - a. What's the definition of extended period of time?
 - b. Does any physical touching - such as a hug or handshake - immediately mean there is significant contact?
 - c. How far back from the onset of the person's illness do we need to check for "close contacts?" This gets to the issue of how long before symptoms begin can asymptomatic shedding occur.
3. If no Covid-19 testing is available or the person has been told they are not sick enough for testing: how do we think about the potential risk to that person's contacts, for example, at home or work?

4. If Covid-19 testing is available; before the result is back, what is the advice for a corporation or other entity where the person being tested may have infected others through asymptomatic shedding of virus? Should the possible exposure, even if relatively "low risk", set off any protocol that deals with trying to minimize possible spread of the virus?

Obviously, there are many other specific questions. (b) (4), (b) (6)

Thanks!

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: (b) (6)
Sent: Mon, 16 Mar 2020 14:23:32 -0400
To: Billet, Courtney (NIH/NIAID) [E]
Subject: Fwd: coronavirus vaccine using cow pox-small pox example

Niaid inquiries

Begin forwarded message:

From: nishit sawal <(b) (6)>
Date: March 16, 2020 at 1:39:58 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>, "Auchincloss, Hugh (NIH/NIAID) [E]" <(b) (6)>, "Barasch, Kimberly (NIH/NIAID) [C]" <(b) (6)>, "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, "Lerner, Andrea (NIH/NIAID) [E]" <(b) (6)>, "Mascola, John (NIH/VRC) [E]" <(b) (6)>, "Graham, Barney (NIH/VRC) [E]" <(b) (6)>
Subject: coronavirus vaccine using cow pox-small pox example

hi sir,

currently an effective vaccine for covid-19 appears 12-16 months away. in view of rampant spread of disease , we can use the cow pox-small pox idea to minimize the disease mortality.

if general population at large was purposefully infected with human coronavirus strains which classically cause mild URTI's , the chances of them getting infected or more probably getting severely ill with covid-19 would be definitely reduced. we do not need to make a vaccine of these strains - classically they cause mild, self-limiting URTIs.

we have these resources and can do this in a very short period.

think over it - time to innovate like Edward Jenner did.

regards ,

Dr Nishit sawal,

Consultant Neurologist

Government Medical College and Hospital

Chandigarh,India

From: (b) (6)
Sent: Mon, 16 Mar 2020 13:45:28 -0400
To: Jethro Pen
Subject: Re: Steven Hilton of Fox News' Covid19 Question to Dr Fauci et al.

Stay tuned

On Mar 16, 2020, at 1:40 PM, Jethro Pen (b) (6) wrote:

Dear Dr Fauci:

Apologies for further burdening your staff at this time of Covid19 crisis, by submitting this question.

Fox News' Host Steven Hilton posed a question to you on his March 15th program: my understanding of it - which my wife and I, (b) (6), believe to be a "good" question - is as follows:

"Given the relative safety of all but the elderly and those whose immune systems are compromised, and that they are far fewer than the rest of the population, why not quarantine only them?"

Mr Hilton says he believes there to be an answer, but it's not yet been given to the public. For what it's worth, I too believe there's an answer. I'm less certain that it's not been given. Below is the link to this matter on the Fox website.

<https://www.foxnews.com/opinion/steve-hilton-on-coronavirus-dr-fauci-officials-must-answer-the-big-question-americans-are-asking>

Thanks for such attention as this may be given. If in the present circumstances, that means none, I get it; nothing further is necessary or expected.

Happy to try to provide anything further which is needed or helpful.

Sincerely,

/s/ Jethro Pen

From: (b) (6)
Sent: Mon, 16 Mar 2020 13:36:16 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: March 26th hearing postponed

Yeah!

Begin forwarded message:

From: "Hallett, Adrienne (NIH/OD) [E]" (b) (6)
Date: March 16, 2020 at 1:23:40 PM EDT
To: "Hodes, Richard (NIH/NIA) [E]" (b) (6); "Volkow, Nora (NIH/NIDA) [E]" (b) (6); "Sharpless, Norman (NIH/NCI) [E]" (b) (6); "Fauci, Anthony (NIH/NIAID) [E]" (b) (6); "Bianchi, Diana (NIH/NICHHD) [E]" (b) (6); "Gordon, Joshua (NIH/NIMH) [E]" (b) (6); "Collins, Francis (NIH/OD) [E]" (b) (6)
Cc: "Kelley, Melinda (NIH/NIA/ERP) [E]" (b) (6); "Hobin, Jennifer (NIH/NIDA) [E]" (b) (6); "Holohan, MK (NIH/NCI) [E]" (b) (6); "Haskins, Melinda (NIH/NIAID) [E]" (b) (6); "Kaeser, Lisa (NIH/NICHHD) [E]" (b) (6); "Ampofo, Phyllis (NIH/NIMH) [E]" (b) (6); "Mitchell, Michelle (NIH/OD) [E]" (b) (6)
Subject: March 26th hearing postponed

OMB is putting a hold on sending HHS witnesses to the Hill through the end of March. This will indefinitely postpone our budget hearing.

Thanks for your patience,
Adrienne

Dear Agency Legislative Affairs Teams:

Due to the full Administration mobilization underway, we are placing a temporary hold on sending up government witnesses who are engaged in the coronavirus response. The Executive Branch needs all of its resources directly focused on executing its day-to-day response to coronavirus. We will continue to practice "radical transparency" with Congress

and the American people, but participation in hearings cannot continue to divert resources from our response effort.

This pause is effective immediately. It is intended to last for three weeks, through the end of March, though we will reevaluate if it needs to be extended at a later date.

Importantly, as noted above, this does not only include witnesses for hearings that are explicitly focused on coronavirus, but also, to be determined on a case-by-case basis, witnesses and agencies who are playing vital roles on the Task Force or the broader Administration response, whether or not the hearing topic is coronavirus.

Therefore, please do not accept hearing invitations from Congress for hearings through March if you believe they meet the above criteria. If you already have hearings confirmed that you believe fits this criteria, please notify us immediately. You will likely have to postpone those hearings.

Four corners leadership offices have already been notified of this policy.

Please reach out to OMB if you have any questions, and we will be happy to work with you as we implement this policy.

Thank you.

From: (b) (6)
Sent: Mon, 16 Mar 2020 13:34:42 -0400
To: Billet, Courtney (NIH/NIAID) [E]
Subject: Fwd: A SIMPLE STRATEGY FOR PREVENTING CORONAVIRUS SPREAD

Niaid inquiries

Begin forwarded message:

From: Walter Tengelsen <(b) (6)>
Date: March 16, 2020 at 1:32:43 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: A SIMPLE STRATEGY FOR PREVENTING CORONAVIRUS SPREAD

To: Dr. Anthony S. Fauci, MD, Head of NIAID

From: Walter Tengelsen, Chmn. of MACROSYSTEMS INST.

First, allow me to thank *and congratulate* you for telling the government, and the press, about our nation's *unpreparedness* for the coronavirus spread. But while we wait for Big Pharma to develop a vaccine for this disease, there is something that could be done NOW to prevent the spread of the virus ... and it wouldn't cost the government anything! Allow me to explain.

Decades ago, when I was a designer in Aerospace, and took my drawings up to the blueprint room for copies, I would always notice the 'aroma' of ammonia in the room. Inquiring about the safety of this constant exposure by the blueprinting staff I was told that there are three groups of people who **don't** get colds: 1) those working in salt mines, 2) those working in sewers, and 3) those working in blueprint rooms! A few decades later I was advised, *by an MD*, that the way to avoid colds is to keep saucers of household **ammonia** in my house rooms (and in the office rooms, if allowed), and that one would not even notice the smell after a few days. Since cold virus transmission is by aerosol particles from the already-infected, and the dilute ammonia fumes are able to

'inactivate' them, **might these ammonia fumes be able to protect us against the coronavirus?**

Admittedly, too much ammonia gas can be very irritating (and even fatal, as in WW!), but evidently people seem to survive and thrive at the just-noticeable gas levels being recommended here. If there is some potential lung damage from ammonia gas, that might be prevented by taking (freeze-dried) stinging nettles **leaf**, a widely recognized lung-cleaning supplement that is recommended by Naturopathic Doctors. But it would seem that the potential benefits of limiting the spread of the coronavirus in our entire population far outweighs the risks of lung damage. Since most homes already have bottles of ammonia (in their laundry area), **this preventive strategy could be implemented immediately**, and would provide the public with the satisfaction of feeling *they* are doing 'their part' in combatting this pandemic ...and protecting themselves and their loved-ones.

NOTE: I am NOT a medical doctor, but an electronic systems engineer and scientist (who takes systems engineering as a license to meddle in all things), but I was the first male family member in 4 generations who did NOT become a pharmacist or physician. I'm emailing my (old address) CV separately, but the email and cell phone number -- (b) (6) still reach me as I'm (b) (6), and then plan to return to my new home in (b) (6) (IF there's no travel restrictions in force)! I can be reached via email or cell phone to explain this preventive strategy further. Meanwhile, good luck on all your efforts to contain this pandemic; the next four weeks or so will be critical!

From: (b) (6)
Sent: Mon, 16 Mar 2020 13:33:40 -0400
To: Carlos del Rio
Subject: Re: FYI...

Thanks, Carlos

On Mar 16, 2020, at 1:31 PM, Del Rio, Carlos (b) (6) >wrote:

Dear super-star friends:

I wanted to give you a heads up about a letter (attached) that myself as well as two AAAS Leshner fellows have been working on. Our goal is to send this with as many signatures as possible to the WH. Most of what we ask for is what you are already doing or going to be doing but we are calling for **enforced social distancing measures, including closing or severely limiting all non-essential business and schools nationwide**. I hope this is useful in our efforts.

Sincerely,

Carlos del Rio, MD, FIDSA

Distinguished Professor for Emory Clinical and Academic Affairs at Grady
Professor of Medicine

Executive Associate Dean for Emory at Grady

Emory University School of Medicine

Professor of Global Health and Epidemiology

Rollins School of Public Health

Co-Director, Emory CFAR

Tel: (b) (6)

Tweeter: (b) (6)

Pronouns: he/him/his

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the recipient of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

<Open letter from the Infectious Disease scientific and medical community on COVID-19.docx>

From: (b) (6)
Sent: Mon, 16 Mar 2020 13:19:42 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Can existing SARS vaccine be used to possibly limit severity of COVID-19 illness?

Please handle

Begin forwarded message:

From: Benjamin Cintz <(b) (6)>
Date: March 16, 2020 at 1:10:48 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Can existing SARS vaccine be used to possibly limit severity of COVID-19 illness?

Dr. Fauci,

I have read that COVID-19 is closely related to SARS.

I am wondering if the existing SARS vaccine be used to possibly limit the severity of COVID-19 illness in highly at-risk populations?

Thanks,

Ben Cintz

Mobile: (b) (6)

From: (b) (6)
Sent: Mon, 16 Mar 2020 13:12:18 -0400
To: Marston, Hilary (NIH/NIAID) [E]
Subject: Fwd: Coronavirus Antidote
Attachments: Zn2+ Inhibits Coronavirus - 14 March 2020.pdf, ATT00001.htm

People respond

Begin forwarded message:

From: FH Mughal (b) (6) >
Date: March 16, 2020 at 1:05:20 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: Fw: Coronavirus Antidote

I'm anxiously waiting for your response. Kindly respond, the soonest - Thank you

----- Forwarded Message -----

From: FH Mughal (b) (6)
To: (b) (6) >
Sent: Sunday, March 15, 2020, 03:54:48 AM PDT
Subject: Coronavirus Antidote

Dear Dr Anthony Fauci and Hilary D. Marston

Kindly enlighten me on the following points:

Can the high temperature (30-35 degrees C) kill the virus?

Can the heatwave (40-49 degrees C) kill the virus?

During last heatwave, the temperature in some cities of Pakistan was 47-49 degrees C.

What is the antidote for coronavirus?

In the following link, Pastor Jim Bakker is suggesting that the silver solution can kill the coronavirus within 12 hours. What are your views:


[Coronavirus 'Cure' Claims Get FTC Warning, So Maybe Don't Drink Silver](#)



**Coronavirus 'Cure' Claims Get FTC Warning, So
Maybe Don't Drink Silver**

Thomas Brewster

Science says drinking silver won't cure coronavirus, but
companies offering the "cure" are trying to capitalize ...



**Coronavirus 'Cure' Claims Get FTC
Warning, So Maybe Don't Drink Silver**

Thomas Brewster

Science says drinking silver won't cure
coronavirus, but companies offering the
"cure" are trying to capitalize ...

In the attached paper, the authors say zinc can inactivate the virus. Your comments on silver and zinc, please.

Could I kindly request for an early response, please.

Thank you,

Kind regards,

F H Mughal (Mr)
Karachi, Pakistan

From: (b) (6)
Sent: Mon, 16 Mar 2020 13:04:59 -0400
To: Billet, Courtney (NIH/NIAID) [E]
Subject: Fwd: Hypothesis for reducing fatalities from Coronavirus

NIAID inquiries

Begin forwarded message:

From: Patrick Hackenberry (b) (6)
Date: March 16, 2020 at 12:59:07 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Hypothesis for reducing fatalities from Coronavirus

Dear Dr. Fauci / to whom it may concern:

I am not a medical doctor but I have an idea. I know you have every expert on earth working on this virus. I am watching the attempts to slow the transmission and "flatten the curve."

What if we could reduce the fatality rate ? Wouldn't that be huge and assist in reducing the panic ?

I am hearing that hospitals are going to be short on respirators and that the virus attacks the lungs. My idea - might help people to breath more efficiently.

Summary:

Here is my idea: Doctors need to utilize methods that endurance athletes have used in the past to **increase their red blood cells in order to increase their body's blood-oxygen carrying capacity.**

Further description:

Athletes like Lance Armstrong used blood doping and other ways to increase their Erythropoietin (EPO). This was called cheating in sports. However, the results gave him an advantage because his body could get more (VO-2 max) oxygen with a single breath compared to others. This helped Armstrong to become more "super human." I agree that this should be illegal in sports. However, I think it would be great if a person was fighting for their life to be super human.

There are natural ways to increase your EPO and there are drugs to trick your body into producing more EPO. One of the best natural ways is high altitude training (think Boulder, CO and Kenya marathon runners). Also, the risks involved in increased red blood cell count obviously include stroke, blood clot, heart attack and many others. But I think that if monitored closely and as a last resort this method might help some people to survive this outbreak.

Sincerely,

Patrick Hackenberry

From (b) (6)
(b) (6) cell

I have NO connections to the website(s) or companies below:
Reference the article below from www.hammernutrition.com

By: William Misner, Ph.D.

From 1996 until his retirement in 2006, Dr. Bill worked full-time as Director of Research & Development at Hammer Nutrition. Among his many accomplishments, both academically and athletically, he is an AAMA Board Certified Alternative Medicine Practitioner and the author of "What Should I Eat? A Food-Endowed Prescription For Well Being". - Dr Bill's Full Bio

What is EPO?

Erythropoietin (EPO) is a naturally occurring hormone that stimulates the production of red blood cells (RBC). Erythropoietin is a glycoprotein hormone produced in the kidneys, containing a 165-amino acids structure. Most erythropoietin is produced by the kidney's renal cortex, but some is also produced in the liver (mainly in the fetus), the brain and uterus.

Why is it important?

Erythropoietin production is stimulated by low oxygen levels in interstitial cells of the peritubular capillaries in the kidneys. Following its production in the kidneys, EPO travels to the bone marrow where it stimulates production of red blood cells

(RBC's) [2]. EPO increases the body's blood-oxygen carrying capacity, but only up to a point. An overabundance may compromise health and hinder blood flow dynamics with performance-limiting implications. In the absence of EPO, only a few RBC's are formed by the bone marrow.

Why are RBC's important?

Red blood cells carry iron-rich hemoglobin for up to 120-days, then they die. Unless there is a continual supply of Iron, Vitamin B-12, Vitamin C and Folacin, anemia and reduced oxygen carrying capacity manifests in two ways:

Low red blood cell count
Malformed red blood cells.

How can one increase their oxygen carrying capacity?

There is a distinct difference between unethical, harmful, EPO-blood doping methods and the safe nutrition that effectively increases individual oxygen-carrying capacity. One can improve their health and oxygen carrying capacity similar to EPO without compromising the athlete's health or integrity. EPO levels up to 48% safely improve performance in males, however beyond this level, the risk of compromised health increases. Look to dietary suggestions below regarding vitamins, minerals, proteins, and avoiding anemia to ensure oxygen carrying capacity.

Can excess EPO can be lethal?

Yes. The margin between effective and lethal quantities of EPO is very narrow. EPO use can be LETHAL. Many athletes seeking to derive its performance-enhancing effects have died from incorrectly-administered EPO. Inappropriate use of exogenous EPO can cause elevated hematocrit levels (i.e. thickened blood that is difficult to pump). Elevated EPO increases the risk of heart attack due to the increase in hematocrit. Choosing sustainable, healthy choices is preferred.

Exogenous EPO is totally cleared from the urine within 48 hours of its administration and is cleared from the blood within 72 hours of its administration but its physiological effects prevail for several months).[3] A look at EPO's complex pathway further illustrates a complex physiological process below, see PATHWAYS[4]. Research followed over 7,000 middle-aged men for more than 12 years, and discovered that the risk of diabetes increases proportionate to hematocrit increase.[19] [20]. Men with hematocrits above 48 percent have a 400% increased risk of non-insulin-dependent-diabetes mellitus. The upper recommended levels for a female is slightly lower at 45%.

This nutritional intervention parallels exercise intensity's effect for increasing EPO. Nutritional and training interventions for resolving low EPO levels during iron

supplementation (only prescribed by a physician who should monitor progress) should not be permitted above a reference range of 48% in males and 45% in females. Similar research confirms this report.[21] [22] [23]

Does exercise intensity increase EPO?

It's complicated. Roberts & Smith measured the effects of exercise-induced hypoxia on the physiological production of erythropoietin. Twenty athletes exercised for 3 min at 106-112% maximal oxygen consumption. The fitness of these athletes provides a physiological environment for increasing EPO naturally from short 3-minute all-out intervals. Estimated oxyhemoglobin saturation was measured by reflective probe pulse oximetry (Nellcor N200) and was validated against arterial oxyhemoglobin saturation by CO-oximetry in eight athletes. Serum erythropoietin concentrations, as measured using the INCSTAR Epo-Trac radioimmunoassay, increased significantly by 19-37% at 24 hours post-exercise in 11 participants who also had an arterial oxyhemoglobin saturation $\leq 91\%$. Decreased ferritin levels and increased reticulocyte counts were observed at 96 hours post-exercise. However, no significant changes in EPO levels were observed in nine non-desaturating athletes and eight non-exercise controls. Good agreement was shown between arterial oxyhemoglobin saturation and percent estimated oxyhaemoglobin saturation (limits of agreement = -3.9 to 3.7). They concluded that a short 3 minutes supramaximal exercise period could induce both hypoxemia and increased erythropoietin levels in well-trained individuals. The decline of arterial hypoxemia levels below 91% during exercise appears to be necessary for the exercise-induced elevation of serum erythropoietin levels. Furthermore, reflective probe pulse oximetry was found to be a valid predictor of percent arterial oxyhemoglobin saturation during supramaximal exercise when percent estimated oxyhemoglobin saturation $\geq 86\%$. [9]

What naturally occurring, nutritional building blocks aid in EPO production?

Protein adequacy is a factor in erythropoietin (EPO) production. Inadequate protein nutrition can reduce the EPO produced. The erythroid response to Erythropoietin (EPO) is highly dependent on dietary protein adequacy and quality. The mouse spleen is an erythropoietic organ, which contains an EPO-responsive cell population that can be easily amplified by administration of the hormone. Researchers determined the effect of a protein-free diet offered freely to mice up to two days after injection of r-Hu EPO (1000mU/200 ul) on the response of the above population. Splenic cell suspensions from control and experimental mice were prepared in microwells containing 400 mU r-Hu EPO and appropriate medium. The response to EPO was evaluated in terms of ³H-thymidine uptake. The results obtained indicate that acutely induced protein restriction suppressed the response of the EPO-responsive splenic cell population to EPO when it was imposed on mice immediately after hormone injection, and suggest the appearance of deficient rates of differentiation of erythropoietic units by protein restriction. [11] Adequate dietary protein intake is 1.4-1.7 grams/kilogram body weight per day for an endurance

athlete.

What other nutritional elements and processes affect the natural production of EPO and the body's oxygen carrying capacity?

Dietary Iron. To ensure oxygen carrying capacity, one should take the recommended daily value of iron. Food sources of iron are red meat, liver, and egg yolks. Most flour, bread, and cereals are iron-fortified. If the diet continues to be iron-deficient, only a physician should prescribe and supervise iron supplementation.

Calories. Calories are needed for EPO production. Calorie sufficiency (in spite of exercise expense) is required for optimal EPO-release. If training is causing weight loss, then EPO loss may be occurring. In order to test the hypothesis that the early cessation of erythropoietin (Ep) production during hypobaric hypoxia is induced by lowered food intake, researchers compared the plasma Ep titer of rats after exposure to continuous hypoxia (42.6 kPa = 7000 m altitude) for 4 days in fed or fasted rats after exposure to discontinuous hypoxia. They found that plasma Ep was rather low after 4 days of continuous hypoxia. Their findings showed that fasting lowers the EPO-response to hypoxia in normal rats [12].

Hormone and Glucose. EPO production also has hormonal-dependant roots complexly related to glucose metabolism, and calorie adequacy. The effect of Thyroid-T3 replacement and glucose supplementation on erythropoietin production was investigated in fasted hypoxic rats. It was found that 48 hr of fasting significantly reduced the circulating levels of thyroid hormones and the production of renal and extrarenal erythropoietin in response to hypoxia. These effects of fasting were completely abolished when the animals had free access to 25% glucose solution as drinking water, despite their lack of protein intake. Replacement doses of T3 (0.5 micrograms/100 gm per day) restored erythropoietin production in the fasted animals but also increased the response of the fed controls. To avoid the effect of endogenous T3, the experiments were repeated in thyroidectomized rats. EPO production in athyroid rats was found to be markedly decreased, with values equivalent to those found in normal fasted animals, and were not affected by fasting or glucose supplementation. Replacement doses of T3 increased EPO production in all three groups, but the fasted animals needed five times as much T3 to obtain a response similar to that observed in the fed group. Glucose supplementation enhanced the effect of T3 in the fasted animals but did not completely restore them. These results indicate that caloric deprivation is primarily responsible for the decreased EPO production induced by fasting and that this effect is probably mediated by both a decreased level of T3 and a decreased responsiveness to it.[13] A calorie deficit therefore requires 500% more Thyroid Hormone (T3) to maintain EPO levels. This is a good reason for monitoring calorie intake during high training calorie expense.

Iron absorption. Dietary interventions significantly advance nonheme iron absorption rate during EPO production. It is very important to include foods to

enhance nonheme iron absorption, especially when an exercise-induced iron loss is high or when no heme iron is consumed, such as in a vegetarian diet. Absorption of heme iron is very efficient; the presence of red meat increases absorption of non-heme iron +400%. Only 1-7% of the nonheme iron in vegetable staples in rice, maize, black beans, soybeans, and wheat are absorbed consumed alone. Vitamin C improves the rate of absorption of nonheme iron from red meats. Diets that include a minimum of 5 servings of fruits and vegetables daily provide adequate vitamin C to boost nonheme iron absorption. Calcium, polyphenols, tannins from tea, and phytates (a component of plant foods), rice, and grains inhibit the absorption of nonheme iron. Some of the protein found in soybeans inhibits nonheme iron absorption. Most healthy individuals maintain normal iron stores when the diet provides a wide variety of foods. However, if the diet contains large amounts of oxalates and phytates from dark green leafy vegetables and whole cereal grains the absorption of iron decreases due to binding with iron in the gut. High absorption of heme iron is further advanced by foods containing vitamin C in an acid environment found of the stomach. The recommended for daily iron intake is between 10-18 milligrams for adult males and postmenopausal females. Most endurance athletes consume too much iron. Iron is added to breads, cereals, and most packaged foods.

From a computer-generated dietary analysis on 16 endurance athletes and 9 non-athletes, iron intake from their reported food intake was assessed.

The results of this data is as follows:

GROUP

PERCENT DAILY IRON (RDI/RDA)

MALE ENDURANCE ATHLETE

279%

FEMALE ENDURANCE ATHLETE

193%

MALE SEDENTARY

158%

FEMALE SEDENTARY

115%

What are some food combinations that increase the absorption of iron?

How foods are combined may affect iron absorption rate. Excess iron overdose is unhealthy and should be avoided. Common side effects of acute iron overload are gastro-intestinal pain, constipation, nausea, and heartburn. Excess iron levels may generate a continuous low-grade infection. Foods are the best source of iron. The best food source of iron is liver and red meats. These foods contain heme iron, which is better absorbed than non-heme iron. Non-heme iron can be found in dark green, leafy vegetables (spinach, chard and kale) and whole cereal grains (bran and whole wheat bread). Include dark green, leafy vegetables and whole cereal grains in the daily diet. Oxalates and phytates found in dark green leafy vegetables and whole cereal grains decrease the absorption of iron because they bind with iron in the gastrointestinal tract. Iron fortified cereals increase iron from the diet. Anemia may develop on a meat-free diet and/or if the iron store or intake is low.

Red meat contains arachidonic acid, an EPO-precursor nutrient, but it also contains high levels of saturated fats and cholesterol suggesting a little (now and then) is good but too much will harmfully compromise cardiovascular lipid levels. Adding iron to the diet in supplemental form is not recommended except under the supervision of a physician who is monitoring blood serum levels for a specific outcome. It has been shown that eating red meat 1-2 per week may contribute to providing substrates known to regenerate EPO as shown in animal research. The ability of Arachidonic Acid (AA), the bisenoic prostaglandin precursor to stimulate erythropoiesis and Erythropoietin (EP) Production in exhypoxic polycythemic mice and the programmed isolated perfused canine kidney was found to stimulate erythropoiesis when administered to exhypoxic polycythemic mice in the lowest dose tested (50 microgram/kg i.p.). Endogenously synthesized prostaglandins, their intermediates and/or other products of AA metabolism, such as prostacyclin and prostaglandins play an important role in the control EPO production.[14] Hematocrit levels are restored through the supplying dietary or supplemental specific substrates to support the body's natural EPO-producing mechanisms during endurance exercise stress.

SUBSTRATES THAT ASSIST EPO METABOLISM[15]

Acidophilus - 15-30 Billion Count Probiotics
Coenzyme Q10 - 150-300 mg daily
Garlic - 2 cloves or 2 capsules up to 3 x day
Kelp - 100-225 micrograms
Vitamin B6 - 50-100 mg
Vitamin B12 - 200-1,000 mcg
Folic Acid - 800 mcg
Proteolytic enzymes - Bromelain & Papain
Selenium - 200 mcg
Vitamin A - 15,000 IU daily or Beta Carotene - 25,000 IU daily
Vitamin B Complex - 50-100 mg
Vitamin C plus Bioflavonoids - 1-3 grams (divided dose)
Vitamin E - 400 IU daily

Copper - 2 mg

Zinc 40 mg daily ---->(Do not take zinc in amounts over 40 mg daily as it may interfere with metabolism of iron and copper)

More Dietary Recommendations

There is a method to improve iron uptake in the absence of oxalate or phytate rich foods previously mentioned above. If hematocrit, hemoglobin, or ferritin blood lab measures are low, the athlete may add 1-gram of vitamin C to a 3-4 ounce lean cut of red meat cooked in an iron skillet one to two times each week. A complete dietary protocol for cancer patients going through chemotherapy and radiation was published and is applicable to over-trained endurance athletes who present low hematocrit levels.[16]

Conclusion

In normal adults, the kidneys produce EPO, which initiates approximately 90% of natural erythropoietin production. Tissue oxygenation exposure regulates the production of erythropoietin. Less oxygen saturation in the air we inhale (either by altitude or hypoxic interval training) stimulates the kidneys to activate the chemical messengers to instruct the bone marrow to increase the production of EPO to resolve the lack of oxygen exposure. Hypoxia or Anemia stimulates the kidney production of erythropoietin to increase production red blood cells. EPO released from the kidneys increases the rate of red blood cell division and differentiation of specific cells in the bone marrow.

Dietary deficiency of specific foods and micronutrients, hormone imbalance, and lack of specific hypoxic training stress inhibit the endogenous (natural) production of EPO. Additionally, nutritional imbalance from caloric restriction (or exercise related expense), dehydration, fluid intoxication, excess calcium, excess inositol, excess oxalates foods, excess phytic acid from cereal grains, or a lack of hypoxic interval training all inhibit the natural production of EPO also. [17] [18].

Manipulating diet for protein and total calorie adequacy, monitoring hydration, using supplements, timing food combinations, adding weekly hypoxic exercise followed by easy or rest days all increases the release of natural EPO for healthy maximal oxygen carrying capacity. Plus, there are many ways to use diet and wellness to ensure that the body's production of red blood cells is sound and that their oxygen carrying capacity is functioning.

[1] Director of Research & Product Development for HAMMER NUTRITION LTD. 1-800-336-1977, Whitefish, Montana.

[2] Courtesy of From Wikipedia, the free encyclopedia @:
http://en.wikipedia.org/wiki/Main_Page

- [3] In-Tele-Health 2002 (from Hyperhealth Pro CD-ROM)
- [4] Courtesy of Biocarta @
http://www.biocarta.com/pathfiles/h_eponfkbPathway.asp
- [5] CLINICAL PHARMACOLOGY OF PROCRIT@:
http://www.procrit.com/profonly/nephrology/what_is_procrit/clinical_pharmacology.html
- [6] Fisher JW. Pharmacologic modulation of erythropoietin production. *Annu Rev Pharmacol Toxicol.* 1988;28:101-22.
- [7] Plasmapheresis is the process of separating certain cells from the plasma in the blood by a machine; only the cells are returned to the person. Plasmapheresis can be used to remove excess antibodies from the blood.
- [8] Roberts D, Smith DJ, Donnelly S, Simard S., Plasma-volume contraction and exercise-induced hypoxaemia modulate erythropoietin production in healthy humans. *Clin Sci (Lond).* 2000 Jan;98(1):39-45.
- [9] Roberts D, Smith DJ. Erythropoietin concentration and arterial haemoglobin saturation with supramaximal exercise. *J Sports Sci.* 1999 Jun;17(6):485-93.
- [10] Brun JF, Bouchahda C, Chaze D, Benhaddad AA, Micallef JP, Mercier J. The paradox of hematocrit in exercise physiology: which is the "normal" range from a hemorheologist's viewpoint? *Clin Hemorheol Microcirc.* 2000;22(4):287-303.
- [11] Depressed response of the erythropoietin-responsive splenic cell population to erythropoietin in acutely protein restricted mice. *In Vivo.* 1995 Jan-Feb;9(1):71-3.
- [12] Jelkmann W, Kurtz A, Bauer C., Effects of fasting on the hypoxia-induced erythropoietin production in rats. *Pflugers Arch.* 1983 Feb;396(2):174-5.
- [13] Caro J, Silver R, Erslev AJ, Miller OP, Birgegard G., Erythropoietin production in fasted rats. Effects of thyroid hormones and glucose supplementation. *J Lab Clin Med.* 1981 Dec;98(6):860-8.
- [14] Foley JE, Gross DM, Nelson PK, Fisher JW. The effects of arachidonic acid on erythropoietin production in exhypoxic polycythemic mice and the isolated perfused canine kidney. *J Pharmacol Exp Ther.* 1978 Nov;207(2):402-9.
- [15] As with any supplement, always confirm with your physician as to the appropriate level and selection prior to use.
- [16] Nutritional Interventions for Reducing the Negative Side Effects of Chemotherapy, Bill Misner, Ph.D. http://www.cancure.org/Chemo_support.htm

[17] Oxalate-rich foods are: Spinach, Cereals, Green Beans (steamed), Potato (raw), Peanut Butter, Tea (brewed), Celery, Chocolate, Ravioli, and White Bread.

[18] Phytate-rich foods are Grains, Corn, Oats, Rice Bran, Wheat Bran, Legumes, Peanuts, Soybeans, and Seeds.

[19] Catalano C, Muscelli E, Natali A, Mazzoni A, Masoni A, Bernardini B, Seghieri G, Ferrannini E. Reciprocal association between insulin sensitivity and the haematocrit in man. *Eur J Clin Invest.* 1997 Jul;27(7):634-7.

[20] Wannamethee SG, Perry IJ, Shaper AG. Hematocrit and risk of NIDDM. *Diabetes.* 1996 May;45(5):576-9.

[21] Sit D, Kadiroglu AK, Yilmaz ME, Kara IH, Isikoglu B. The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients. *Ren Fail.* 2005;27(4):403-7.

[22] Evrengul H, Dursunoglu D, Kaftan A, Kilicaslan F, Tanriverdi H, Kilic M. Relation of insulin resistance and left ventricular function and structure in non-diabetic patients with essential hypertension. *Acta Cardiol.* 2005 Apr;60(2):191-8.

[23] Amoah AG, Schuster DP, Gaillard T, Osei K. Insulin resistance, beta cell function and cardiovascular risk factors in Ghanaians with varying degrees of glucose tolerance. *Ethn Dis.* 2002 Fall;12(4):S3-10-7.

From: (b) (6)
Sent: Mon, 16 Mar 2020 13:00:10 -0400
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: natural course of the coronavirus pandemic

Please handle

Begin forwarded message:

From: Martin Gelbaum (b) (6) >
Date: March 16, 2020 at 12:52:24 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Cc: Martin Gelbaum (b) (6) >
Subject: natural course of the coronavirus pandemic
Reply-To: (b) (6)

2020-03-16

Dear Dr. Fauci,

Thank you very much for courageous and tireless efforts to defeat the coronavirus pandemic.

One of the statements attributed to you puzzled me.

The article

Dr. Anthony Fauci Says He Would Like a 'Dramatic' Reduction of Personal Interactions at Social Gatherings to Fight Coronavirus, by [Donica Phifer, newsweek.com](https://www.newsweek.com/dr-anthony-fauci-says-he-would-like-dramatic-reduction-personal-interactions-social-1492410)

March 15, 2020 02:20 PM

<https://www.newsweek.com/dr-anthony-fauci-says-he-would-like-dramatic-reduction-personal-interactions-social-1492410>

quotes you as saying,

"I've said many times if you just leave it alone and left the virus to its own devices then it'll go way up and it'll come down naturally over a period of several weeks," Fauci said. "Unfortunately for our colleagues in Italy, in France, and certainly in China, that's what happened."

Question: Is the implication that the virus would have stopped spreading rapidly in China even if their government had not instituted drastic measures to curtail the epidemic?

Put another way: Is it not correct that the drastic measures implemented by the Chinese government were very helpful in halting the spread of the virus in China?

From yet another angle: Is it correct that the public health measures adopted in South Korea and Taiwan have proved very effective in controlling the spread of the epidemic?

Thank you very much again for your hard work,
Martin

From: (b) (6)
Sent: Mon, 16 Mar 2020 12:58:37 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: thank you

Please handle

Begin forwarded message:

From: Robyn Cotter (b) (6)
Date: March 16, 2020 at 12:53:29 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: thank you

Hello Dr. Fauci,

(b) (6) I live a very normal life in a Tennessee suburb. We have always kept a modest supply of important survival items in our home, so we are prepared, not panicked. We are carefully following the information and facts regarding the Coronavirus and taking the appropriate safety suggestions.

The reason for my email today is to thank you for your expertise. You must be exhausted from the stress. Not to mention having to continually repeat yourself... and stretch your political diplomacy to the breaking point while walking the fine line between stating facts and debunking myths (or outright lies).

Please know that my family and I thank you for your continued professionalism, swift communication of facts and overall leadership while we ride this rollercoaster with our neighbors and the rest of the world.

Sincerely,
Robyn Cotter

From: (b) (6)
Sent: Mon, 16 Mar 2020 12:56:53 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: [EXTERNAL] Re: Fox News Request for Dr. Fauci

FYI

Begin forwarded message:

From: "Koerber, Ashley" <Ashley.koerber@FOXNEWS.COM>
Date: March 16, 2020 at 12:56:25 PM EDT
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)
Cc: "Deatrick, Elizabeth (NIH/NIAID) [C]" (b) (6), "Routh, Jennifer (NIH/NIAID) [E]" (b) (6), "Oplinger, Anne (NIH/NIAID) [E]" (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Re: [EXTERNAL] Re: Fox News Request for Dr. Fauci

Hi Patricia,
Would Dr. Fauci be available to join Bret Baier in the 6pm hour one night this week?
I understand he is very busy, but we would accommodate him any night that he is available.
Please get back to me when you can - thanks!
-Ashley

Ashley Koerber Moir
Booking Producer
Special Report w/ Bret Baier
Fox News Channel - DC Bureau
(b) (6) (cell)
Sent from my iPhone

On Mar 13, 2020, at 15:32, Conrad, Patricia (NIH/NIAID) [E] (b) (6) wrote:

I am sorry – we cannot make this work. Apologies.

Patricia L. Conrad

Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baier, Bret <bret.baier@FOXNEWS.COM>
Sent: Friday, March 13, 2020 3:30 PM
To: Koerber, Ashley <Ashley.koerber@FOXNEWS.COM>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Oplinger, Anne (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: [EXTERNAL] Re: Fox News Request for Dr. Fauci

Thank you for considering.

I know Dr. Fauci has been a lot... and will be this weekend... but tonight to wrap the week.. after the national emergency declaration....

We'd love to have him

Bret

Bret Baier
Chief Political Anchor, Fox News Channel
Anchor & Executive Editor "Special Report with Bret Baier"

From: Koerber, Ashley
Sent: Friday, March 13, 2020 3:27 PM
To: 'Conrad, Patricia (NIH/NIAID) [E]' <(b) (6)>
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] <(b) (6)>; Oplinger, Anne (NIH/NIAID) [E] (b) (6)>; Baier, Bret

<bret.baier@FOXNEWS.COM>

Subject: RE: [EXTERNAL] Re: Fox News Request for Dr. Fauci

Hi Patricia,

I know this is last minute, but any chance Dr. Fauci can join us in the 6pm hour tonight? Looping in Bret as well.

Please get back to us when you can – thanks!

-Ashley

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, March 12, 2020 8:58 AM
To: Koerber, Ashley <Ashley.koerber@FOXNEWS.COM>
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] (b) (6)>
Subject: RE: [EXTERNAL] Re: Fox News Request for Dr. Fauci

Sorry – will not work.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Koerber, Ashley <Ashley.koerber@FOXNEWS.COM>
Sent: Thursday, March 12, 2020 8:55 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Oplinger, Anne

(NIH/NIAID) [E] (b) (6)>

Subject: Re: [EXTERNAL] Re: Fox News Request for Dr. Fauci

Hi Patricia,

Would Dr. Fauci be available to join Bret tonight in the 6pm hour?

Ashley Koerber Moir
Booking Producer
Special Report w/ Bret Baier
Fox News Channel - DC Bureau
(b) (6) (cell)

Sent from my iPhone

On Mar 10, 2020, at 11:20, Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>wrote:

Oh – tonight is even worse. I don't think it will work

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Koerber, Ashley <Ashley.koerber@FOXNEWS.COM>

Sent: Tuesday, March 10, 2020 11:08 AM

To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Cc: Deatrick, Elizabeth (NIH/NIAID) [C]